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Abstract
In mammals, male and female fetal reproductive tracts are initially indistinguishable with
Wolffian ducts (WD) and Mullerian ducts (MD) present in both sexes. Androgens play a
vital role in masculinisation of the fetus, including WD rescue and development in males;
however, the mechanisms that underlie this process are unknown. The aims of the current
study therefore were to investigate the timing and mechanisms involved in androgen
mediated WD development. The present study exposed pregnant rats to the androgen
receptor antagonist, flutamide (50 or 100 mgkg"1), Di(n-butyl) phthalate (DBP; 500 mgkg"')
which reduces testicular testosterone production, and/or exogenous testosterone during
specific time windows in fetal life in order to establish the key time windows for androgen-
regulated WD development and the possible mechanisms involved.
These studies confirmed the vital role for androgens in WD development and highlighted
their critical involvement in establishing the early patterning of WD development between
el5.5-17.5, prior to any sign of morphological differentiation. At this stage, androgens
receptors (AR) are only expressed in the stroma, not in the epithelium, thus androgens must
regulate WD differentiation via stroma-epithelial interactions. Contrastingly, high levels of
androgens were not required during morphological differentiation of the WD between el 9.5-
21.5 (when coiling occurs). Impaired androgen action during the correct window of
development disrupted WD development as evidenced by reduced coiling of the future
epididymis. This was likely due to a demonstrated reduction in cell proliferation in both
stromal and epithelial compartments, impaired stromal differentiation, reduced epithelial cell
height and ultimately epithelial degradation. These stromal abnormalities were noted prior
to observing any obvious abnormalities in the epithelium, further highlighting regulation of
the epithelium by the stroma. The mechanisms involved in this impaired WD development
include interruption to the basement membrane and extracellular matrix, as evidenced by
altered expression of some intermediate filaments. These were similar to the mechanisms
noted in the regressing female WD but impaired androgen action did not induce apoptosis in
the male WD, which was observed in the regressing WD in females. Maternal exposure to
testosterone during gestation was able to rescue the female WD and even induce some
degree of morphological differentiation, although this was to a lesser degree than that noted
in the normal male.
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In adult males similarly exposed to flutamide in utero, the majority (80%) of WD-derived
tissues were absent, compared to no incomplete WDs at e 19.5 and 11% at e21.5. This
demonstrates that the major impact of flutamide is on epididymal differentiation rather than
its initial stabilisation, as had previously been assumed. This increased prevalence of
epididymal abnormalities was noted after puberty and is likely to be a result of failure to
establish normal patterning of the WD in the fetus.
Further reducing androgen action either in the Tfm mouse, where the AR is inactivated, or
by exposing rats to DBP plus flutamide in utero, resulted in a complete loss of WD tissue by
birth. However, further investigation highlighted that the male WD regressed later in these
models than occurs naturally in females thus suggesting a possible role for a compensatory
mechanism in the absence of androgen action. It is important to note though that this
mechanism is not sufficient alone to maintain the WD long term or to support full
differentiation in the male.
In conclusion, androgens alone appear to be sufficient for WD development but in their
absence, a compensatory mechanism may try to rescue the male WD. Fetal WD
differentiation is far more susceptible to blockade of fetal androgen action than is its initial
stabilisation although these effects appear to be mediated by disruption of stromal-epithelial
interactions during the stabilization period. Persistence of WD-derived structures postnatally
is also affected, however, this is likely to be due to impaired patterning of the fetal Wolffian
duct rather than prevention of initial stabilisation. These findings have identified the critical
window for androgen action in the WD and thus have created an opportunity to study the
elusive mechanisms behind androgen action. Since androgens act on many other systems in
the body with many parallels existing between the male and female reproductive system, the
outcomes of these studies may therefore impact on our understanding of WD development
but also of other androgen-dependent processes such as the development, function and
diseases of other reproductive tissues.
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1 Literature review
1.1 Sex determination
Sexual differentiation is a complex, pre-programmed series of events regulated by both
genetic and hormonal mechanisms to transform and differentiate the indifferent gonads and
the internal and external sex structures into male and female specific structures. In
mammals, the reproductive system consists of the primordial gonad, the two genital duct
systems (namely the Miillerian and Wolffian ducts), and a common opening for genital ducts
and the urinary tract to the outside through the genital folds. Initially, this tract is
morphologically indistinguishable in male and female embryos but is determined by genetic
sex, which is dictated at conception by the inheritance of an X or Y chromosome from the
male gamete. These sex chromosomes promote the differentiation of the indifferent gonad
into a testis or ovary, which subsequently drives differentiation of the internal and external
sex structures via hormone production.
It is important to note that during sexual differentiation, each component of the urogenital
system undergoes various developmental changes to generate a male or a female. The
precise window for this differentiation is distinct for each structure and is highlighted in Fig.
1.1.
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Figure 1.1 Timings of development of male (A) and female (B) reproductive tract in the
fetal rat (adapted from Wilson et al, 1981; and Hughes, 2001).
1.2 Gonadal development
The indifferent gonads form in males and females from a thickening of the medial side of the
genital ridge, which initially developed from the ventrolateral surface of the embryonic
mesoderm. The signals which initiate and regulate this thickening are poorly understood but
several gene pathways have been suggested to be involved including WT-1, SF-1 and IGF-
1R (summarised in Fig. 1.2) (reviewed in Rey and Picard, 1998; Achermann et al, 1999;
Swain and Lovell-Badge, 1999; Capel, 2000; Brennan and Capel, 2004; Barsoum and Yao,
2006).
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Figure 1.2 Summary of genes and pathways involved in sexual differentiation of the
fetal reproductive tract. Several genes are involved in the formation of the bipotential
gonad from the urogenital ridge including SF-1, WT-1 and IGF-1R. Gata4 and WT-1 are
then required to activate Sry expression in the XY gonad which initiates testis formation;
Sox9, FGF9 and Dhh are involved in this testis formation. Conversely, few genes have been
characterised in ovary formation except Wnt4 and Fst.
AMH, Anti-Mullerian hormone; Dhh, desert hedgehog; FGF9, fibroblast growth factor 9; Fst,
follistatin; Gata4, GATA binding protein 4; Hox A9-13, homeobox transcription factors A9-
13; IGF-1R, insulin-like growth factor 1 receptor; SF-1, nuclear receptor subfamily 5; Sox9,
Sry-like HMG-box protein 9; T, Testosterone; Wnt 4, wingless-related MMTV integration site
4; Wnt7, wingless-related MMTV integration site 7; WT-1, Wilms tumour homologue.
(adapted from Brennan and Capet, 2004)
This bipotential gonad can be identified histologically in the mouse by e9.5 (Kaufman,
1992) and is initially composed of somatic cells, which have migrated from the
mesonephros, and primordial germ cells, which have migrated into the genital ridge from the
extraembryonic mesoderm in the yolk sac (Ginsburg et al, 1990). It is believed that, in
eutherian mammals, this process of differentiation of the genital ridge into the testis is driven
by active genetic mechanisms and critically depends on the presence of a Y chromosome,
whereas the absence of this genetic activity results in ovary formation (Welshons and
Russell, 1959). Ovarian differentiation occurs later in fetal life and is independent of the
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number of X chromosomes, thus it was initially thought of as the default pathway
(Mittwoch, 1969).
1.2.1 Testis development
It has been shown that male sexual determination is due to the sex determining gene, Sry, on
the Y chromosome, which is both vital and sufficient to initiate male development (Gubbay
et al, 1990; Koopman et al, 1991). This vital role can be seen in XY mice lacking a
functional Sry gene which develop ovaries whereas addition of the Sry gene to XX mice
results in testis formation (Gubbay et al, 1990; Lovell-Badge and Robertson, 1990;
Koopman et al, 1991). Furthermore, approximately 10-20% of complete sex reversal
patients carry Sry mutations (Hawkins et al, 1992). Sry acts as a transcription factor but as
yet, its targets and the mechanisms involved remain unclear. It has been suggested that Sry
acts in the male to repress a negative regulator which inhibits testis development
(McElreavey et al, 1993). This negative regulator has been identified as Daxl (Guo et al,
1996). Deletion of this gene can prevent the repressor effect on the masculinising genes thus
resulting in testis formation in XX individuals (Guo et al, 1996).
The most critical function of Sry is initiation of Sertoli cell differentiation. It is believed that
Sry induces Sertoli cell differentiation by regulating another transcription factor, Sry-like
HMG-box protein 9 (Sox 9) since Sox9 alone can induce testis formation in mice while
deleting Sox9 prevents testis formation in XY mice (Kanai and Koopman, 1999; Qin and
Bishop, 2005; Barrionuevo et al, 2006). Sox9 is not the only factor involved in Sertoli cell
differentiation, however, as Prostaglandin D2 (PGD2), wingless-related MMTV integration
site 4 (Wnt4), fibroblast growth factor 9 (Fgf9) and Gata 4 have also all been suggested to
play a role, possibly acting parallel to or downstream of Sox9 (Lim and Hawkins, 1998;
Nachtigal et al, 1998; reviewed in Brennan and Capel, 2004; Barsoum and Yao, 2006)
(summarised in Fig. 1.2). Sertoli cell differentiation is a critical event in male sexual
development since these somatic cells are responsible for producing factors that influence
the further differentiation of the testis as well as the differentiation of the internal and
external sex structures (Burgoyne, 1988). In fact, the initiation of the male pathway depends
on the development of a threshold number of Sertoli cells (reviewed in Brennan and Capel,
2004). In the mouse, male and female gonads remain morphologically indistinguishable
until embryonic day (e)l 1.5-12.5 at which time the mesenchymal cells in the male aggregate
and condense and the pre-Sertoli cells align to form early testicular cords, enveloping the
large meiotically inactive germ cells (Bogan and Page, 1994) (reviewed in Brennan, 2004).
A basal lamina then forms around these early cords to separate them from the interstitial
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mesenchyme. Migration of cells from the mesonephros into the XY gonad is vital in cord
formation as blocking this event by culturing the gonad in the absence of a mesonephros
impairs cord formation (Buehr et al, 1993). This migration depends on growth factors
expressed by the Sertoli cells including FGFs, nerve growth factor (NGF) and platelet
derived growth factor (PDGF) (reviewed in Brennan and Capel, 2004). This organisation
into 2 compartments is vital to provide an environment for germ cell maturation as well as to
produce masculinising hormones.
Another key event in testis formation is the development of the testis-specific vasculature.
The initial growth of the vasculature from the mesonephros into the gonad is similar in XX
and XY gonads but subsequently, following Sry expression, endothelial cells are recruited
into the XY gonad to establish the coelomic vessel (Brennan et al, 2002). This arterial
system elaborates to increase blood flow through the early testis to promote testosterone
transport (Brennan et al, 2002). It has been proposed that the vasculature may play an active
role in further development of the testis and may also be involved in Leydig cell
differentiation, however the events in testis development occur rapidly in the mouse and thus
make it difficult to establish the relative timings and regulatory events (reviewed in Brennan
and Capel, 2004).
Steroidogenic Leydig cells differentiate from the interstitial mesenchyme around 24h after
Sertoli cell differentiation in the mouse (Habert et al, 2001). This is believed to be regulated
by paracrine factors from the Sertoli cells, namely desert hedgehog (Dhh) (Yao et al, 2002)
and PDGF (Brennan et al, 2003), as well as SF-1 and aristaless-related homeobox gene
(ARX) expression (Kitamura et al, 2002; Park et al, 2005). This has been extensively
reviewed in the literature and will not be further discussed here (Habert et al, 2001; Brennan
and Capel, 2004; Haider, 2004; Barsoum and Yao, 2006). Fetal Leydig cells begin to secrete
testosterone around el3-14 in the mouse (Pointis et al, 1980), el5 in the rat (Inomata et al,
1989); Sertoli cells subsequently begin to produce Anti-Mullerian Hormone (AMH), at
around e 14-15 in the mouse (Munsterberg and Lovell-Badge, 1991). Both AMH and
testosterone are vital to drive subsequent male differentiation as detailed below.
The gonads are initially located on the lateral edge of the kidney and following
differentiation into a testis, the gonads descend through the abdomen and inguinal canal to
reside in the scrotum. This process is believed to be biphasic involving both androgens and
other factors including Insl3; details of this mechanism are beyond the scope of this review
but have been extensively reviewed by other authors (Hutson et al, 1997; Nef and Parada,
2000; Nef et al, 2000). Contrary to the testis, the ovary does not descend but is positioned
close to the kidney throughout fetal life.
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1.2.2 Ovary development
Unlike the testis, histological differentiation of the ovary occurs after phenotypic
development of the female reproductive tract has been initiated. Initially it was believed that
differentiation of the female gonad and reproductive tract occurred by default and did not
rely on any active gene regulatory events. However, more recently, this belief has been
brought into question (summarised in Fig. 1.2). For example, Wnt 4 has been shown to be
vital for gonadal formation and remains expressed in the fetal ovary after sexual
differentiation has been initiated to act as an anti-testis gene by repressing aspects of male
development in the XX gonad; conversely, expression is lost in the testis (Staack et al,
2003). The role for Wnt 4 is further highlighted in the Wnt 4 knockout (Wnt4"/_) mouse
which has abnormal ovarian development (Vainio et al, 1999). Wnt4 may act by
upregulating Daxl, an Sry repressor (Swain et al, 1998), thus preventing testis development
and resulting in ovary development (Jordan et al, 2001); increased Wnt4 and/or Daxl
expression has been implicated to be involved in XY sex reversal (Bardoni et al, 1994;
Jordan et al, 2001). These Wnt4"/_ mice also highlighted a role for other female specific
genes in ovarian development, namely BMP2 and follistatin, which may act downstream of
Wnt4 (Menke and Page, 2002; Yao et al, 2004). The masculinisation effects observed in the
female Wnt4"" mice are further discussed in section 1.5.3.2.
During fetal life, the ovary remains a relatively small organ and is not believed to be vital for
female urogenital tract development (reviewed in Staack et al, 2003). Ovarian primordial
follicles normally form prior to birth consisting of germ cells surrounded by supporting
granulosa cells; during fetal life however, there is considerable loss of female germ cells
which continues postnatally (human, Baker, 1963; mouse, reviewed in De Felici et al, 2005).
1.3 Reproductive tract development and differentiation
Unlike gonadal sex, which is primarily determined genetically, sexual differentiation of the
reproductive tract depends wholly on hormonal regulation. However, it is not just the
secretion of these key hormones which is vital for normal sexual differentiation, but also the
expression of their appropriate receptors in the target tissues.
The mammalian reproductive tract is composed of the gonads, the internal genital system
and the external genitalia, as summarised in Fig. 1.3. Much of the urogenital system forms
from the intermediate mesoderm, which develops during early embryonic development from
the intra-embryonic mesoderm (Staack et al, 2003). The urogenital ridges can be identified
on the posterior wall of the intermediate mesoderm by e9.5 in mice, and within this ridge
three overlapping kidney structures develop: the pronephros, mesonephros and metanephros
(Staack et al, 2003).
























Figure 1.3 Schematic representation of fetal internal (A) and external (B) genitalia
(Gilbert, 2003).
1.3.1 Internal genitalia differentiation
The internal genitalia develop from two pairs of ducts, the Mtillerian duct (MD) and the
Wolffian duct (WD), both of which are derived from the part of the intermediate mesoderm
that does not contribute to the gonad. Initially, both sets of ducts are present in both male
and female embryos. The pronephros, a transient structure that never functions as an
excretory organ, gives rise to a pronephric duct which terminates at the cloaca. The
rudimentary pronephros regresses early in embryonic development but the duct persists to
form the mesonephric or Wolffian duct by elO in mice, prior to gonad formation (George,
1994; Staack et al, 2003). The cranial end of the WD is connected to the testis via some of
the mesonephric tubules which are retained to form the efferent ducts. The Mtillerian or
paramesonephric ducts are evident later around el2 in mice and form as invaginations of
coelomic epithelium on the surface of the urogenital ridge (Staack et al, 2003). The MDs lie
on the lateral side of the cranial WD but cross to the medial surface of the WD at the caudal
end. Just cranial to the UGS, the left and right MDs fuse by el6 in the mouse (Staack et al,
2003). Jost (1972) demonstrated that masculinisation of the male reproductive tract depends
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on secretions from the fetal testis, unlike the female tract which can differentiate even in the
absence of an ovary. Many researchers have subsequently built on this early finding to show
that these testicular secretions are in fact, testosterone and Anti-Mtillerian hormone (AMH).
Unlike the internal genitalia, the urogenital sinus (UGS) is derived from the hindgut as an
endodermal tube. The hindgut initially terminates as the cloaca, which subsequently opens
to the perineum at the level of the urogenital orifice at the base of the genital tubercle. The
cloaca is the terminal part of the embryonic hindgut, which becomes divided by the urorectal
septum into the UGS, rectum and anal canal. The UGS is then further subdivided to form
the bladder and the definitive UGS by el 3-14 in the mouse with the MD and WD
terminating in this UGS (Staack et al, 2003).
1.3.1.1 Male
Masculinisation of the male reproductive tract is initiated following differentiation of Sertoli
cells and organisation of seminiferous cords in the testis (Wilson et al, 1981). The first step
is the sexually dimorphic process of MD and WD differentiation, which begins around e 15
in the mouse, el6 in the rat (Inomata et al, 1989). In the male, the MD begins to regress in a
cranio-caudal direction at el5 in the mouse, el6 in the rat (Inomata et al, 1989; Staack et al,
2003). This process is mediated by AMH, which is secreted by the fetal Sertoli cells and
binds to a specific receptor (AMHr2) expressed in the mesenchyme around the MD
(Donahoe et al, 1977; Roberts et al, 1999; Allard et al, 2000). The actions of AMH extends
beyond the scope of this review but has been extensively discussed in previous literature
(Donahoe et al, 1977; Wilson et al, 1981; Josso et al, 2001; Roberts et al, 2002; Xavier and
Allard, 2003). MD regression can be characterised by disruption of the basement membrane
allowing direct contact between the epithelium and mesenchyme, thus leading to a decrease
in epithelial cell size and subsequent epithelial degeneration (Dyche, 1979; Ikawa et al,
1984; Inomata et al, 1989; Austin, 1995). This regression is thought to be driven by
paracrine mechanisms originating in the mesenchyme as a result of a loss of extracellular
matrix (ECM), and they induce the formation of an 'epithelial cuff due to condensation of
the periductal mesenchyme (Dyche, 1979; Inomata et al, 1989; Austin, 1995). In mammals,
it is unclear whether the mesenchyme is also lost during regression, as occurs in alligators
(Austin, 1995). Apoptosis is evident in the regressing MD, probably stimulated by the loss
of cell contact with the basement membrane and ECM, but is not believed to be sufficient to
cause complete regression of the male MD (Allard et al, 2000; Xavier and Allard, 2003).
Some epithelial cells remain viable in the regressing MD and are believed to dedifferentiate
into mesenchymal-like cells (Dyche, 1979; Jirsova and Vernerova, 1993; Roberts et al, 1999;
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Allard et al, 2000), possibly even migrating to contribute to the mesonephros in some
species (Hutson et al, 1997).
After the onset of MD regression, testosterone synthesised by the Leydig cells that
differentiate within the interstitium of the fetal testis stabilises and differentiates the male
WD (Dyche, 1979); this process begins around el4 in the mouse (Staack et al, 2003) and el6
in the rat (Inomata et al, 1989). Testosterone is transported from the testis down the WD
lumen to ensure delivery of high levels of androgen directly to the site of action (Tong et al,
1996); it has been postulated that this may occur by passve diffusion or actively transported
from the testis to the WD however, the exact mechanism is not yet understood. Once
rescued, the cranial segment of the WD elongates and convolutes to form the epididymis, the
middle portion remains a straight simple tube to form the vas deferens, and the caudal tip
buds to form the seminal vesicles (George, 1994; Staack et al, 2003). This process begins
around el 8 in the mouse and continues throughout neonatal life. Each of these WD derived
structures can be identified by their differing morphology, gene expression and function.
The future epididymis, the site of sperm maturation in the adult, becomes surrounded by a
concentric layer of mesenchymal cells which ultimately differentiate into smooth muscle
while the vas deferens is surrounded by 3 layers of smooth muscle and transports mature
sperm to the urethra for ejaculation (George, 1994). The caudal segment of the WD distends
and elongates and the lumen becomes complexly folded in order to form the seminal vesicles
at around el7 in the mouse (George, 1994; Staack et al, 2003), and el 8 in the rat (Inomata et
al, 1989); these vesicles produce seminal or ejaculatory fluid in the adult. The mechanisms
involved in seminal vesicle development are beyond the scope of this review but are further
discussed by Marker and colleagues (2003). The differentiation of the WD into these adult-
derivatives is dependent on testosterone action and is vital for the maturation and transport of
sperm in the adult from the testis out of the body, but little is known about the mechanisms
acting downstream of androgen action or the processes involved in patterning the
development of these three very different adult derivatives of the WD (Jost et al, 1973).
Considerable research has been undertaken to investigate the role for stromal-epithelial
interactions, patterning genes and growth hormones in male sexual differentiation, as
discussed in section 1.8.
The prostate develops as branching and budding of the UGS at around el7 in the male
mouse (Staack et al, 2003), and el 8-19 in the rat (Inomata et al, 1989). The prostate is
originally made up of two portions, each of which develops as a series of buds from the
epithelium lining the UGS and cloaca (Gray, 1918). These buds become tubular and meet
and fuse behind the urethra to form the glandular structures of the 2 main prostatic lobes.
Chapter 1 Literature Review 10
Prostate development has been extensively studied and reviewed in the literature and will not
be discussed in detail here (Cunha et al, 1987; Cunha et al, 1996; Thomson et al, 2002;
Marker et al, 2003; Thomson and Marker, 2006).
1.3.1.2 Female
Unlike the male, the female duct system does not depend on hormonal action to initiate or
control its differentiation. Oestrogen synthesis is temporarily activated in rabbit and human
male and female embryos prior to implantation and this ability to synthesise oestrogens from
androgen continues in the ovary but is minimal in the fetal testis (George and Wilson, 1978).
In rabbits, this oestrogen synthesis begins in the ovary prior to histological differentiation,
around the same time as testosterone synthesis onset in the testis (Milewich et al, 1977;
George and Wilson, 1978). This could suggest a possible role for oestrogens in female
development, however, subsequent studies have shown that oestrogen is not vital for female
reproductive tract differentiation (reviewed in Couse and Korach, 1999). The female MD is
programmed to differentiate into the oviducts, uterus, cervix and upper vagina. However, it
is interesting to note that the female MD expresses the AMHR and exposure to exogenous
AMH can induce MD regression in females (Teixeira and Donahoe, 1996). Further details
on female MD differentiation have been extensively reviewed in the literature (George,
1994; Du and Taylor, 2004; MacLaughlin and Donahoe, 2004; Yin and Ma, 2005). Briefly,
the MD epithelium adopts organ-specific cell fates along its length to form each of the adult
derivatives (Kurita et al, 2001; Yin et al, 2006). In some species such as rodents, the mid
potion of the MDs remain separate to form paired uteri while in others they fuse, as in
humans; the reason for this difference and the mechanisms involved are not fully understood
(George, 1994). Vaginal development is believed to be negatively regulated by androgens
since endogenous testosterone in males prevents vaginal formation and results instead in the
budding of the caudal tips of the WD to form the seminal vesicles (Bok and Drews, 1983;
Drews, 2000). It is accepted that the caudal tips of the female MD contribute to the
formation of the vagina but controversy exists over which other structures also contribute;
some researchers believe that, in the absence of androgens, prior to complete regression of
the WD the caudal tips of the WD link the UGS to the MD (O'Rahilly, 1977; Drews, 2000).
As in the male reproductive tract, the morphology and fate of the epithelium in the
developing female UGT is dictated by the adjacent mesenchyme (Cunha, 1976) (discussed
further in section 1.8). It has been suggested that Wnt signalling is involved in regulating
this epithelial-mesenchymal signalling (Sassoon, 1999). Wnt genes are highly expressed
during female development and are involved in growth and differentiation (Heikkila et al,
2001). Exposing animals perinatally to diethy 1 sti 1 bestrol (DES), a synthetic oestrogen,
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permanently alters patterning of the female UGT partly by de-regulating Wnt gene
expression during morphogenesis (Newbold and McLachlan, 1982). Studies in Wnt
knockout animals have further highlighted the critical role for Wnt genes in female
reproductive development (reviewed in Heikkila et al, 2001; Bernard and Harley, 2006; Kim
et al, 2006). For example, the MDs fail to form in both male and female Wnt-4 knockout
embryos (Vainio et al, 1999). Another gene known to be involved in female UGT
development is p63, a homologue of the tumour suppressor gene p53 (Kurita and Cunha,
2001; Ince et al, 2002). p63 knockout female mice have abnormal genital morphogenesis
with hypoplastic genitalia and a lack of urothelial differentiation (Ince et al, 2002). These
mice highlight a role for p63 in determining the identity switch for cell fate in the MD since,
in the absence of p63, the cervicovaginal epithelium wrongly differentiates to a more
uterine-like epithelium (Kurita et al, 2004). It is believed that p63 plays a role in
differentiating the basal regenerative cells and influences the modelling of the UGT by
altering proliferation, apoptosis and cell cycle arrest (Ince et al, 2002).
Due to the lack of androgens, the female WD begins to regress in a cranio-caudal direction.
In the rat, the WD appears morphologically and histologically similar at el5-16 but has
almost completely regressed by el9 (Jirsova and Vernerova, 1993). In the mouse these
events occur at e 14-15 and el 6, respectively (Price, 1965; Dyche, 1979). WD regression can
be identified histologically by the reduction in diameter of the duct and lumen as well as
degeneration of the epithelial lining (Inomata et al, 1989; Jirsova and Vernerova, 1993). It
has been suggested that the epithelium loses its polarity and the epithelial-mesenchymal
boundary becomes irregular. Previous researchers have reported that apoptosis is involved
in female WD regression, but that some non-altered epithelial cells can still be identified late
in WD regression suggesting a possible role for epithelial-mesenchymal transformation
(Jirsova and Vernerova, 1993). However, prior to complete regression of the WD, the
caudal segment of the WD contributes to the formation of vaginal plate, as detailed above
(Bok and Drews, 1983; George, 1994).
1.3.2 Differentiation of the external genitalia differentiation
Unlike the internal genital ducts which develop from different ductal systems in males and
females, the external genitalia develop in both sexes from common primordial structures,
namely the genital tubercle, genital swellings and urethral folds (Wilson et al, 1981)
(summarised in Fig. 1.3). Once again, the development of the male phallus requires a
hormonal stimulus unlike the female external genitalia which develop autonomously without
any direct hormonal influence (MacLaughlin et al, 2001).
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1.3.2.1 Male
After the onset of masculinisation of the internal duct system, the genital tubercle elongates
to form the body of the penis, the urethral folds elongate and fuse to form the penile urethra
while the urogenital swellings fuse to form the scrotum, which will ultimately house the
testes outside the body cavity (Wilson et al, 1981; Yamada, 2003). This is dependent on the
conversion of testosterone to the metabolically active dihydrotestosterone (DHT) by the
enzyme 5-reductase (Wilson et al, 1981). Hypospadias results when the urethra is not
completely enclosed by the urethral folds with the site of fusion failure dictating the position
of the abnormal opeing of the urethra (reviewed in Yamada, 2003). In rodents, the male
external genitalia do not undergo significant differential growth so that by birth, the phallus
size does not differ greatly between males and females (Wilson et al, 1981). Conversely, in
humans sex can easily be determined externally at birth. However, in both rodents and
humans, the distance between the anus and the base of the genital tubercle (anogenital
distance, AGD) increases in males in response to androgens thus at birth AGD is often used
as a measure of fetal androgenisation (reviewed in Swan et al, 2005; reviewed in Edwards et
al, 2006).
1.3.2.2 Female
Differentiation of the female external genitalia begins later than in the male with little
differentiation occurring during fetal life in rodents (Wilson et al, 1981; reviewed in
Yamada, 2003). The genital tubercle differentiates into the clitoris while the genital
swellings give rise to the labia majora and the folds to the labia minora (Wilson et al, 1981).
Contrastingly, in humans the female external genitalia undergo considerable differentiation
by 26 weeks gestation (Ammini et al, 1994).
1.4 Steroidogenesis
Steroid hormones are vital for the normal development and differentiation of the fetal
reproductive tract; in particular the androgen, testosterone, is essential for normal male
development. The pathway and enzymes involved in testosterone biosynthesis in the fetal
testis have been extensively studied and reviewed in the literature (Sharpe, 1990; Huhtaniemi
and Toppari, 1995; Stocco and Clark, 1996; Miller, 1998) and will only be briefly discussed
here. The main enzymatic steps in steroidogenesis are outlined in Fig. 1.4. One of the key
steps is the rate limiting conversion of cholesterol into pregnenolene and the subsequent
formation of DHEA. This step is controlled by the steroidogenic acute regulatory protein
(StAR) which transfers cholesterol from the outer to the inner mitochondrial membrane, and
two enzymes namely p450 side chain cleavage (P450scc), which cleaves the side chain from
this cholesterol, and p450cl7, which converts pregnenolene into DHEA (Miller, 1998;
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Handelsman, 2003). Many of these early enzymatic reactions are common to the production
of glucocorticoids, mineralocorticoids and sex steroids. Within the gonads, DHEA is
converted into testosterone or oestradiol by the actions of 3p-hydroxysteroid dehydrogenase
(3p-HSD), aromatase and 17P-HSD.
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Figure 1.4 Pathway of steroidogenesis. The key stages in steroidogenesis are highlighted
in red while the key enzymes are coloured blue (Adapted from Holmes et al, 2004).
1.4.1 Testicular testosterone biosynthesis
Testosterone is the main steroid hormone in the male reproductive tract, both during fetal life
and postnatally. Testosterone biosynthesis takes place in the fetal and postnatal testis in the
Leydig cells, with its further metabolism into oestradiol by aromatase or dihydrotestosterone
(DHT) by 5a-reductase occurring mainly in the testes or within the target tissues such as the
prostate or seminal vesicles, respectively (Huhtaniemi and Toppari, 1995; Carreau et al,
2006). Postnatally, testosterone production is driven by luteinising hormone (LH) which acts
via the LH receptor expressed on Leydig cells (Warren et al, 1975; Huhtaniemi, 1994;
Huhtaniemi and Toppari, 1995; Majdic et al, 1998). LH action on the Leydig cells can be
modified by various paracrine and autocrine factors including prolactin and growth factors,
thus regulating testicular testosterone biosynthesis (reviewed in Huhtaniemi and Toppari,
1995; Hedger and de Kretser, 2000; Haider, 2004; O'Shaughnessy et al, 2005). The onset of
testicular testosterone biosynthesis occurs at around el5 in rats, almost as soon as the fetal
Leydig cells have differentiated and peaks around el8.5 (Warren et al, 1972; Tapanainen et
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al, 1981; Habert and Picon, 1984). In humans, testosterone is produced by the fetal testis
around week 7 gestation, approximately 1 week after sexual differentiation of the gonad
(reviewed in Habert et al, 2001). Testicular testosterone production precedes biosynthesis of
pituitary gonadotrophins suggesting that, unlike postnatal testosterone biosynthesis, it is
independent of LH stimulation in the fetus, at least initially (El-Gehani et al, 1998; Majdic et
al, 1998; O'Shaughnessy et al, 1998; Habert et al, 2001); it is presumed that locally-
produced factors drive fetal testosterone synthesis but these factors remain to be defined.
Studies in fetal rats have shown that plasma testosterone levels are at least 4 times higher in
the male than in the female, in which levels remain very low throughout fetal life (Habert
and Picon, 1984).
Testosterone is secreted from the fetal testis into the bloodstream, where it binds to sex-
hormone binding globulin (SHBG) in humans or albumin in rodents, and reaches structures
distal to the testis at relatively low concentrations (reviewed in Grishkovskaya et al, 2000;
reviewed in Handelsman, 2003). Alternatively, testosterone can be transported, via unknown
mechanisms, directly into the WD lumen to reach the cells of the developing WD in
relatively high concentrations, especially at the cranial end (Tong et al, 1996). Once
released from the testis, testosterone can be further metabolised in target tissues into the
more potent androgen, DHT by the enzyme 5a-reductase (Fig. 1.5) (Jaffe, 1969; Wilson and
Lasnitzki, 1971; Cooke and Robaire, 1987; Russell and Wilson, 1994; Tsuji et al, 1994;
Berman et al, 1995). Two isoforms of 5a-reductase exist, type I which is expressed in the
liver and skin, and type II which is expressed in the UGT and liver (Thigpen et al, 1993). In
the fetal male, DHT metabolism occurs in peripheral tissues, rather than in the testis where
DHT levels are barely detectable (Habert and Picon, 1984). Expression of 5a-reductase in
different tissues is further reviewed in section 1.6.1.2.
Studying patients with androgen biosynthesis deficiencies can provide a great deal of insight
into the role of androgens in masculinisation (Zhu et al, 1998; Brinkmann, 2001; Hannema
et al, 2004; Hannema et al, 2006). It is interesting to note that the variation in phenotypes
observed in these patients depends upon the cause of the deficiency. For example, patients
with a deficiency in 5a-reductase type II have normal WD development but lack
masculinisation of the external genitalia at birth (Imperato-McGinley et al, 1974;
Brinkmann, 2001; Imperato-McGinley, 2002) whereas XY male patients with AR mutations
often completely lack any male reproductive tissue other than testes (Hughes and Evans,
1987). This highlights the differential roles for testosterone and DHT in different tissues and
the dependence of complete masculinisation on local amplification of androgen action by 5a-
reductase expression.










Figure 1.5 Structure of testosterone and dihydrotestosterone (DHT) (adapted from
Brinkmann, 2003).
1.4.2 Steroid Receptors
Steroid hormones can enter almost any cell in the body, but only some cells are capable of
binding the steroid so eliciting a response and therefore altering gene expression; this is due
to the presence of intracellular steroid receptors which are members of a large superfamily of
ligand-activated transcription factors (Evans, 1988; Parker, 1990; Mangelsdorf et al, 1995;
Couse and Korach, 1999; Gelmann, 2002). The androgen receptor (AR) is a member of the
steroid receptor family which also includes the glucocorticoid, progesterone and oestrogen
receptors; each of these receptors is structurally and functionally similar (reviewed in
Gobinet et al, 2002).
1.4.2.1 Steroid receptor structure
Steroid hormone receptors share a common structure and are made up of 4 main functional
domains; the DNA-binding, ligand-binding, hinge and variable domains (Fig. 1.6). All
steroid receptors have a DNA-binding domain which is highly conserved and contains two
zinc fingers (reviewed in Carson-Jurica et al, 1990; Mangelsdorf et al, 1995). The C-
terminal zinc finger is believed to be involved in protein-protein interactions which are vital
in transcriptional activity of the nuclear receptor (reviewed in Freedman, 1992). Studies in
patients with a mutation in exon C of the AR, which encodes the second zinc finger,
highlight the vital role for this zinc finger in DNA-binding since the AR in these individuals
had a reduced ability to bind to DNA; this finding offers some explanation for the occurrence
of complete androgen insensitivity in patients in which the AR is capable of androgen
binding (Quigley et al, 1992). Between the two zinc fingers is an amino acid sequence
which can recognise the specific DNA response element thus making this domain vital for
subsequent DNA transcription (Beato et al, 1996). The ligand binding domain is less
conserved and is situated at the C terminus; it determines ligand specificity as well as
binding heat shock proteins (reviewed in Carson-Jurica et al, 1990; Mangelsdorf et al, 1995).
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The hinge domain lies between the ligand- and DNA-binding domains and controls the
movement of the receptor into the nucleus as well as modulation of transcriptional activation
(reviewed in Carson-Jurica et al, 1990; Mangelsdorf et al, 1995). As the name suggests, the
variable domain at the N-terminus is the least conserved among the nuclear receptors and its
function has not yet been defined; suggestions include a role in interactions with other
domains of the receptor to promote complete transcriptional activation or a role in ligand-
independent transactivation function (Simental et al, 1991).
N-terminus C-terminus








Figure 1.6 Basic structure of steroid receptors
1.4.3 Androgen receptor
Androgens are believed to be able to act through both genomic (direct) and non-genomic
(indirect) mechanisms but it has been thought that the majority of their action is through
direct activation of DNA transcription via high affinity interactions with intracellular AR
expressed in target tissues (Verhoeven and Swinnen, 1999). The AR resides in the
cytoplasm and translocates to the nucleus upon hormonal stimulation. In the rat, withdrawal
of this hormonal stimulation by castration, results in the AR relocating back to the
cytoplasm in the prostate within just 1 day (Van Doom and Bruchovsky, 1978). The AR is
coded for by a single copy gene containing 8 coding exons, which is found on the X
chromosome at Xql 1-12 in humans (Brown et al, 1989). AR mRNA normally codes for a
919 amino acid protein (110-144 kDa) but reports exist of a second smaller AR protein
(87kDa) which arises due to alternative splicing in the 3'-untranslated region and only
contributes to a very small proportion of the total AR detected in tissues; the relevance of
this second AR is unknown (Faber et al, 1991; Wilson and McPhaul, 1996). The rat AR
shows 83% nucleotide homology and 85% amino acid homology with the human AR (Chang
et al, 1988; Tan et al, 1988).
The AR has an activation function (AF-1) region in the N-terminus variable domain, AF-2 in
the ligand binding domain at the C-terminus, and a polymorphic glutamine region with a
variable number of CAG repeats; variation in the number of repeats is believed to alter the
transcriptional efficiency of the AR (Chamberlain et al, 1994). Androgen dependent gene
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transcription is regulated by interactions between the AF domains of the AR and co-regulator
proteins, which can act to either increase or decrease transcription (McKenna et al, 1999;
McEwan, 2004). These include steroid receptor coactivator l(SRC-l), CREB-binding
protein (CBP), transcriptional intermediary factor 2 (TIF-2), and steroid receptor RNA
activator (SRA) (Onate et al, 1995; Berrevoets et al, 1998; Bevan et al, 1999).
To date, hundreds of mutations have been identified in the human AR, with the mutations
occurring throughout the gene. Initially, the majority of these mutations were identified in
the steroid binding domain but this was probably due to a bias selection towards patients
with complete androgen insensitivity rather than an increased prevalence of mutations in this
region (Hiort and Holterhus, 2000). The AR mutations vary from point mutations to
deletions of entire exons (Quigley et al, 1992) and result in varying degrees of androgen
insensitivity including complete inactivation of the AR, presenting clinically as a genetic
male but with no signs of genital masculinisation (Quigley et al, 1992), mutations which
impair AR mRNA stability (Choong et al, 1996) or over-elongation of the polyglutamide
trinucleotide repeat region resulting in mild androgen insensitivity presenting as impaired
spermatogenesis (Tut et al, 1997). These are discussed further in section 1.6.2.2.
1.4.3.1 Mechanism of AR action
Testosterone and DHT bind to the same androgen receptor (AR) but with varying affinity;
testosterone has a two-fold lower affinity for AR than does DHT, and dissociates from the
AR five times faster than does DHT. Unliganded AR is bound to heat shock proteins (HSP)
in the cytoplasm, which stabilise the conformation of the ligand-binding domain and
prevents the receptor associating with its specific hormone response element on the DNA
(Picard et al, 1990; Jenster et al, 1993). Upon ligand binding the HSP is shed and the ligand-
receptor complex is transported into the nucleus (Jenster et al, 1993). The AR is then
phosphorylated; this allows specific regulation of gene expression by cell specific kinases
(van Laar et al, 1990; Orti et al, 1992; Kuiper et al, 1993). Steroid receptors do not possess
intrinsic protein kinase activity however, hormone exposure increases steroid receptor
phosphorylation which has been shown to be important in the acquisition of ligand-binding
activity (Golsteyn et al, 1989; Hoeck et al, 1989; Migliaccio et al, 1989; Orti et al, 1989).
The unliganded AR is constitutively phosphorylated on serine residue 94 but upon ligand
binding, the AR becomes hyperphosphorylated (Gioeli et al, 2002). This hormone-
dependent phosphorylation must occur before or during AR conformational change, but not
after (van Laar et al, 1991). It has been proposed that over 90% of the hormonally regulated
phosphorylation sites in the AR are at the N-terminal transactivation domain and involves at
least serine residues 16, 81, 256, 308, 424, and 650 (Kuiper et al, 1993; Gioeli et al, 2002).
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For example, AR can be phosphorylated at Ser-213 by Akt in the presence of androgens but
cannot be stimulated by anti-androgens or growth factors in the absence of androgens
(Taneja et al, 2005). This process was seen to be tightly regulated in a cell type-specific
manner (Taneja et al, 2005). This phosphorylation of AR at Ser-213 was seen in the
epithelium of the human urogenital sinus early in development when androgen levels are
high but was absent later in development when androgen levels and Akt activation are lower
(Taneja et al, 2005). Furthermore, a tyrosine residue on the AR can be phosphorylated by a
cAMP-dependent protein kinase (Golsteyn et al, 1989).
The AR undergoes a conformational change necessary for translocation; this reveals the
DNA-binding domain necessary for interaction with AREs on target genes (Grino et al,
1987). The AR-androgen complex must dimerise in order to bind to androgen response
elements (AREs) on target genes and thus elicit a transcriptional response (Jones, 1990)
(summarised in Fig. 1.7). The consensus binding sequence for the AR is a 15 b.p sequence
which comprises two imperfect 6 b.p indirect repeats; this sequence is almost identical to the
glucocorticoid response element (Roche et al, 1992). The classical ARE does not
discriminate between binding of the DNA-binding domain of the AR and glucocorticoid
receptor (GR) in vitro, however more recently an androgen specific response element has
been identified which binds the AR but not the GR therefore conferring androgen-specific
transcriptional control (Claessens et al, 1996; Schoenmakers et al, 1999).
Transcriptional
regulation
Figure 1.7 Summary of mechanism of androgen receptor action upon ligand binding.
Androgen response element, ARE; Heat shock protein, HSP. Adapted from in house figure
from Prof. P. Saunders.
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Transcriptional regulation of target genes by steroid hormones is complex and involves
many steps including hormone binding, receptor phosphorylation at serine residue 94,
dissociation of HSP, DNA binding, and activation of transcription, many of which are still
not fully understood (Evans, 1988; McEwan, 2004; Wu et al, 2005; Kishimoto et al, 2006).
It is known, however, that transcriptional regulation by androgens is dependent on the
presence of co-factors which can interact with the AR to increase or decrease transcription
(McKenna et al, 1999). It has been proposed that, once transcriptionally activated, the
steroid receptors transfer to a common compartment or foci within the nucleus where they
interact with co-activators in order to initiate complete transactivation (Saitoh et al, 2002).
These co-regulators can act at many stages within the AR signalling pathway, for example
altering chromatin structure or facilitating N-C terminal interactions and include SRC-1,
TIF-2 and GRIP-1 (reviewed in McKenna et al, 1999; Rosenfeld and Glass, 2001). Some
co-activators can act as histone acetyltransferases, such as SRC-1, thereby relaxing the
chromatin packaging thus allowing gene transcription by steroid hormones; on the other
hand, co-repressors tend to recruit histone deacetylases, thereby condensing the nucleosome
and so repressing gene transcription (reviewed in McKenna et al, 1999; Glass and Rosenfeld,
2000). A growing list of AR co-regulators has been identified suggesting that a complex
network of factors may be involved in regulating AR transcription (reviewed in Heinlein and
Chang, 2002) with many co-regulators that interact with the AR also able to interact with
other nuclear receptors (reviewed in McKenna et al, 1999; Rosenfeld and Glass, 2001). It
remains somewhat of a mystery how androgens signalling through this one AR can induce
such different responses in different tissues at different times: co-regulator expression may
be cell type-specific, therefore their role in AR-mediated transcription may go some way
towards providing insight into this phenomenon. As mentioned above, androgens may also
act in a rapid non-genomic way in the absence of functional ARs to indirectly alter the
expression of genes that do not contain AREs. The mechanisms behind this phenomenon are
not fully understood. However, it is hypothesised that androgens may alter the activity or
concentration of secondary transcription factors, hormones or paracrine or autocrine
mediators to elicit a response in the absence of ARs (Verhoeven and Swinnen, 1999). For
example, growth hormone (GH) exposure can mimic androgen effects in the AR deficient
Tfm mouse (Georgatsou et al, 1993).
There is also evidence of other nongenomic pathways of androgen action in which
intracellular mechanisms mediate their effects, for example activation of Src-Rafl/Shc-Erk2.
Androgens and/or oestrogens induce the assembly of a novel ternary complex comprising the
AR, ER and Src; this activates the protein kinase domain of Src, resulting in downstream
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effects such as cell proliferation (Migliaccio et al, 2000). The androgen-AR and estrogen-
ER complexes bind to separate domains on the Src protein, which can be blocked by steroid
receptor antagonists (Migliaccio et al, 2000).
1.4.3.2 Regulation of AR expression
Levels of expression of AR protein are regulated at both the transcriptional and post-
transcriptional level. AR is capable not only of regulating transcription of other genes but
also of autoactivation of its own gene to make more ARs (Bentvelsen et al, 1994; Bentvelsen
et al, 1995). AR mRNA stability is essential in the regulation of AR protein expression:
studies have shown that RNA-binding proteins bind to a highly conserved UC-rich element
in the 3' untranslated region of the AR mRNA, which alters AR protein expression
(reviewed in Yeap et al, 2004). Studies undertaken by Kemppainen have shown that
androgens can decrease AR mRNA levels but can still increase AR protein half-life
(Kemppainen et al, 1992). AR expression is regulated differentially in different tissues and
at different stages of development. For example, it has been shown in rats that withdrawal of
androgen results in involution of the prostate and reduced prostatic AR levels (Cain et al,
1994); testosterone therapy can regenerate the prostate and its AR expression (Prins and
Birch, 1993). However, it is worth noting that AR protein stability is enhanced upon ligand
binding and thus more AR protein may be detected despite reduced transcription of the
mRNA (Bentvelsen et al, 1994).
Oestrogens can also regulate AR expression. Exposure of neonatal rats to oestrogens induced
a loss of AR immunoexpression in association with abnormalities in the pre-pubertal testes
and reproductive tract (Williams et al, 2001). However, it should be noted that these adverse
effects are due to the combined effect of high oestrogen and low testosterone as neither high
oestrogen in the presence of high androgens or low testosterone in the absence of oestrogens
could induce these changes (Williams et al, 2001). Furthermore, exposure of neonatal rats to
oestradiol did not alter AR mRNA expression in the ventral prostate but did permanently
decrease AR protein expression (Woodham et al, 2003). This reduction in AR protein levels
appears to be due to an increase in receptor protein degradation due to increased
ubiquitination, rather than due to transcriptional modifications (Woodham et al, 2003).
AR expression is regulated post-translationally by ubiquitination and proteasome activity;
this process is not just a typical protein degradation event caused by proteasomes but is
believed to be more complex (Jaworski, 2006). This mechanism is highlighted in
experiments which have shown that AR N-terminal interacting protein (ARNIP) can function
as a ubiquitin-protein ligase and reduce AR N-C terminal interactions in Cos cells thereby
reducing AR activity (Beitel et al, 2002). The role for proteasomes in AR regulation
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however is still not fully understood. Previous studies suggest that the ability of the ligand
bound AR to recruit polymerase II and co-regulators to the promoter of the androgen
responsive gene involves proteasomes (Kang et al, 2002). Transcriptional activation by
steroid hormones is a cyclical event with AR only transiently binding to the ARE and co-
regulators; hormone binding to the steroid receptors increases ubiquitination and
degradation of the nuclear receptors and it has been suggested that this degradation of the
AR and/or co-regulators is vital for subsequent rounds of transcription to take place (Ferdous
et al, 2001; Kang et al, 2002). This process of degradation has been suggested to be
mediated by proteasomes since proteasome inhibitors can suppress AR transactivation in
LNCap cells, possibly by inhibiting AR nuclear translocation and/or preventing AR
interaction with co-regulators (Lin et al, 2002). Furthermore, transcriptional complexes are
not recruited if the AR is bound to an antagonist, such as bicalutamide, thereby preventing
phosphorylation and ubiquitination of the AR and so inhibiting gene transcription (Kang et
al, 2002). Recent studies have also suggested a role for sumyolation in regulating AR
activity since it has been shown that SUMO-1 and 3 can both regulate AR activity in prostate
cancer cell lines but as yet this is not fully understood (Zheng et al, 2006).
1.5 Role for androgens in male reproductive development
1.5.1 Normal androgen action and AR expression
1.5.1.1 Differential effects of testosterone and DHT in the fetal
reproductive tract
In some cells, testosterone can be converted to the more potent androgen, DHT by the
enzyme 5a-reductase (see section 1.4.1). Two isoforms of 5a-reductase exist in mammals,
type 1 and 2, which are coded for by 2 genes located on different chromosomes (Andersson
and Russell, 1990; Labrie et al, 1992). Type 1 is expressed in the skin and liver whereas
type 2 is expressed in the fetal and adult male reproductive tract and is the isoform believed
to be responsible for male pseudohermaphroditism (Andersson et al, 1991; Thigpen et al,
1993; Imperato-McGinley and Zhu, 2002). 5a-reductase mRNA expression is regulated by
testosterone (Andersson et al, 1989). This can bee seen from studies in castrated rats in
which the reduced 5a-reductase expression can be recovered by exposure to exogenous
testosterone (Andersson et al, 1989). More recently, it has been suggested that this
androgen-mediated regulation of 5a-reductase activity may be due to paracrine/autocirne
induction of IGF-1 production in the skin (Horton et al, 1993).
Testosterone and DHT regulate the differentiation of different structures during male fetal
development: testosterone is known to regulate WD development whereas differentiation of
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the UGS and external genitalia is controlled by DHT (summarised in Fig. 1.8) (Wilson et al,
1981). However, it is important to highlight that testosterone can mediate differentiation of
the external genitalia if it is present in sufficient concentrations, thus suggesting that the
differential effects of testosterone and DHT on different structures in the male reproductive
tract are due to concentration gradients rather than due to different mechanisms of action.
Considerable variation is seen in the ability of different tissues to convert testosterone to
DHT (Wilson and Lasnitzki, 1971). For example, the male UGS and urogenital tubercle are
able to convert testosterone to DHT before they undergo sexual differentiation to the
prostate, external genitalia and urethra, whereas 5a-reductase activity is not detected in the
WD until after sexual differentiation has begun, thus suggesting its early differentiation
depends on testosterone rather than DHT (Wilson and Lasnitzki, 1971; Siiteri and Wilson,
1974; Thigpen et al, 1993; Tsuji et al, 1994). It is interesting to note that the el 7 rat female
urogenital sinus also expresses 5a reducatse (Berman and Russell, 1993). It is important to
note that 5a-reductase is expressed in the WD later in development, during its morphological
differentiation, and is abundantly expressed in the adult epididymis, thus it cannot be stated
that DHT has no role in WD development or adult function (Siiteri and Wilson, 1974;
reviewed in Robaire and Henderson, 2006). The production of DHT in WD derived
structures is especially pertinent in the caudal tips which differentiate into the seminal
vesicles and much higher levels of 5a-reductase activity are notable in this region. For
example, by post-natal day (pnd) 2 in mice, 5a-reductase activity is much lower in the
prospective epididymis than in the seminal vesicles or UGS (Tsuji et al, 1994; Berman et al,
1995). Locally high levels of testosterone are achieved during WD development as it
diffuses from the nearby testis and this may compensate for its lower potency compared with
DHT. Conversely, structures more distal to the testis depend on circulating testosterone
exposure thus amplification of the testosterone signal to the more potent androgen, DHT is
required. It is interesting to note that 5a-reductase activity is much higher in the
mesenchymal compartment than in the epithelium in both the UGS and seminal vesicles in
pndO mice, further highlighting the dependence of androgen action on stromal-epithelial
interactions (Tsuji et al, 1994; Berman et al, 1995). Further investigation has revealed that
5a-reductase type II, but not type I, is expressed in the developing UGT mesenchyme (Tsuji
et al, 1994; Berman et al, 1995).







Figure 1.8 Summary of androgen action in fetal male reproductive development
(Adapted from Brinkmann, 2003).
Further evidence for the differing roles of T and DHT in different structures in the male
reproductive tract has been gained from patients with a deficiency in the 5a-reductase
enzyme. Evidence for this disorder was first highlighted in 1974 (Imperato-McGinley et al,
1974) and is now known to be due to a mutation in the gene coding for 5a-reductase type II
(Andersson et al, 1991). This causes pseudohermaphroditism by preventing normal
masculinisation of the prostate and external genitalia, but has no obvious impact on the
differentiation of the WD into its adult derivative structures (Imperato-McGinley et al,
1974; Imperato-McGinley, 2002).
Furthermore, studies undertaken in animal models exposed to the 5a-reductase type II
inhibitor, finasteride (Russell and Wilson, 1994) have confirmed the role for DHT in
development of the prostate and external genitalia but have shown it is not essential for WD
differentiation (George, 1997; Bowman et al, 2003). It is worth noting that inhibition of 5a-
reductase does not cause such severe prostate involution as does complete androgen ablation
by castration and that if testosterone levels are increased sufficiently, DHT is not required for
prostate development (Lamb et al, 1992). Together these results suggest that testosterone
can maintain prostate development, and conversion to DHT is merely a means of locally
amplifying the androgen signal from testosterone. High concentrations of testosterone can
interact with the AR in a similar manner to DHT and this allows testosterone to be as
effective as DHT in stimulating AR activity in spite of having a reduced affinity for binding
to the AR (Grino et al, 1990).
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1.5.1.2 AR expression in the fetal male reproductive tract
It has been suggested that the pattern of androgen receptor (AR) expression reflects the
androgen responsiveness of the tissue (Bentvelsen et al, 1995). Several studies have mapped
AR expression in the fetal reproductive tract highlighting, differences in AR expression in
the fetal reproductive tract compared to that observed postnatally (Cooke et al, 1991;
Bentvelsen et al, 1995; Majdic et al, 1995; Sajjad et al, 2004). ARs are initially present in
both the male and female UGS and tubercle, but as they sexually differentiate AR expression
increases in males and decreases in females (Bentvelsen et al, 1994). Early in male
reproductive differentiation, ARs are initially expressed in the mesenchyme of the male
reproductive tract with expression not appearing in the epithelium until later, possibly even
after the initiation of differentiation. This differs from AR expression seen at later stages of
development. This led to the hypothesis that androgens induce epithelial differentiation in
the male reproductive tract by acting on the surrounding mesenchyme (Cunha, 1976)
(discussed further in section 1.7).
AR protein has been shown to be expressed in the rat male reproductive tract from as early
as el4 (Bentvelsen et al, 1995), however exact timings of expression in each tissue varies
between different studies (Bentvelsen et al, 1995; Majdic et al, 1995). These differences
may be due to the use of different antibodies and immunohistochemical methods and/or
different strains of rat. The first tissue to express AR in the rat reproductive tract is the
efferent ducts, which are AR positive from el4 (Bentvelsen et al, 1995) while the fetal rat
testis does not express AR until el7.5 in the interstitial cells and from el8.5 in the
peritubular myoid cells; Sertoli and Leydig cells show no significant nuclear staining for AR
during fetal life (Majdic et al, 1995). AR protein is expressed in the rat WD mesenchyme
from at least el6.5 (Majdic et al, 1995); it is interesting to note that AR was more densely
expressed in the WD mesenchyme on the side furthest from the MD (Bentvelsen et al, 1995).
Controversy exists over the onset of AR expression in the WD epithelium: Majdic and
colleagues (Majdic et al, 1995) detected AR in the epithelium from el8.5 in the rat while
Bentvelsen and colleagues also detected AR in the epithelium at the epididymal head on el8
in the rat but did not detect AR in the epididymal tail or vas deferens until pnd2 (Bentvelsen
et al, 1995). These differences may be due to suboptimal immunohistochemistry techniques
used by Bentvelsen and colleagues (1995). Furthermore, studies in mice using 3H-
dihydrotestosterone steroid autoradiography reported stromal expression from el3 but
epithelial expression was not detected until el9 (Cooke et al, 1991), much later than found
by Majdic and colleagues in rats (Majdic et al, 1995). This difference in timing of expression
may be due to species differences or different methodologies. The mesenchyme of the
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prospective male external genitalia in the rat expresses AR from el4 while the prostate
mesenchyme expresses AR from el6: as in other structures in the urogenital system, AR was
not detected in the prostatic epithelium until later, at pnd 2 in the rat (Bentvelsen et al, 1995).
The male and female MD remains immunonegative for AR whereas the regressing female
WD is immunopositive for AR at el 8 but to a lesser degree than in the male rat (Bentvelsen
et al, 1995).
1.5.2 Impaired androgen action
Further insight into the role for androgens and the mechanisms involved in male
reproductive development can be gained from studying AR mutations and exposure to anti-
androgens.
1.5.2.1 Genetic alterations affecting androgen action
1.5.2.1.1 AR mutations
Mutations in the AR result in abnormal sexual development in males. There have been over
300 mutations reported in the human AR (see the international database at
http://www.mcgill.ca/androgenbd): these mutations are often found at the C-terminus and
impair ligand binding but can be observed anywhere in the AR sequence. The first AR
mutation to be molecularly characterised was that identified in testicular feminisation (Tfm)
mice. Tfm was identified as an X-linked recessive disorder which resulted in genetic males
which had testes and normal testosterone production but whose external genitalia were
phenotypically female (Lyon and Hawkes, 1970). Further examination established that the
MDs regressed normally but that the WD, UGS and external genitalia failed to masculinise
in Tfm mice. Furthermore, although both DHT and testosterone are present, cytosolic AR
protein could not be detected. This provided the insight that the Tfm mutation caused a
complete insensitivity to androgens due to a defect in AR protein, rather than a lack of
androgen production (Attardi and Ono, 1974; Gehring and Tomkins, 1974). The Tfm mice
have a single base deletion in exon 1 at the amino terminus of the AR leading to a frameshift,
introduction of a stop codon and premature termination of AR translation leading to
formation of a truncated AR protein downstream of codon 412 (Fie et al, 1991). In vitro
translation studies have shown that the Tfm AR cannot produce full length AR protein and it
lacks the ability for transcriptional activation since it cannot bind to DNA (He et al, 1991).
A rat model of Tfm also exists in which there is a mutation in the ligand-binding domain,
however controversy exists over the degree of inactivation of the AR (Yarbrough et al,
1990).
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A wide spectrum of AR mutations has been identified in humans all of which result in some
end-organ androgen resistance, a condition known as androgen insensitivity syndrome (AIS).
The first evidence for this came from studies showing decreased androgen binding to
cultured genital skin fibroblasts of affected individuals (Keenan et al, 1974; Wilson et al,
1974). It was later established that this was due to mutations in the AR (Hiort et al, 1993;
Hiort et al, 1996). AIS can manifest as complete (CAIS) or partial (PAIS) absence of
response to androgens in XY males even though formation of a normal testis has occurred
(Quigley et al, 1995; Ahmed et al, 2000). These patients have normal, or even elevated
testicular testosterone production, often associated with increased LH levels (Imperato-
McGinley et al, 1982; Hughes and Patterson, 1994). The high testosterone levels can be
aromatised into oestradiol, which may account for the further lack of masculinisation seen in
XY CAIS patients (Brinkmann, 2001). Many mutations have been reported in the AR and
can result in a complete absence of any functional AR protein or the presence of qualitatively
abnormal AR protein. The clinical observations of AIS vary considerably depending on the
nature of, and location of, the mutation (Saunders et al, 1992; Hughes and Patterson, 1994;
Patterson et al, 1994). Four different types of mutation have been identified in the AR in
AIS patients: single point mutations in the AR coding sequence resulting in altered amino
acid sequences in the ligand-binding or DNA-binding domains, nucleotide insertions or
deletions, complete or partial deletion of the gene and intronic mutations affecting AR RNA
(Lubahn et al, 1989; Ris-Stalpers et al, 1990; Marcelli et al, 1991; Gottlieb et al, 1999). The
latter two types of mutation are much less common. It has recently been suggested that the
severity of the insensitivity phenotype in individuals is highly correlated to the ability of the
AR to shuttle into the nucleus (Wang et al, 2005).
Due to the X chromosome recessive trait of AIS, only genetic males are affected while
females are carriers of the disorder. Wide variation is reported in the phenotype of affected
individuals, with the main focus on the masculinisation of the external rather than the
internal genitalia. Patients with complete AIS (CAIS) fail to respond to androgens at all,
therefore the genetic male has testes but presents with female genitalia, a blind ending
vagina, an absence of WD-derived structures or prostate and gynaecomastia (Hughes, 1997).
PAIS patients have partial impairment of AR action, which varies considerably between
patients, thus explaining the wide variation in phenotypes observed ranging from phenotypic
female genitalia to normal male genitalia but with cryptorchidism and/or oligospermia
(Patterson et al, 1994). In PAIS individuals, WD-derived tissues can range from partially to
fully differentiated depending on the mutation in the AR (Brinkmann, 2001).
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It was assumed that if the external genitalia are not masculinised, the WD might not
differentiate into the epididymis, vas deferens or seminal vesicles (Hannema et al, 2004).
However, it has been noted by several researchers that rudimentary internal genitalia persist
in some AIS individuals (Morris, 1953; Bale et al, 1992; Boehmer et al, 2001) suggesting
that the WD did not completely regress. Furthermore, Hannema and colleagues (2004) have
shown the persistence of well developed epididymides and vas deferens in some CAIS
patients. All of these CAIS patients had single amino acid substitutions in the ligand binding
domain of the AR: ARs from many of these patients were capable of residual transcriptional
activity in vitro, unlike ARs with mutations in the DNA binding domain which completely
lacked transcriptional activity (Hannema et al, 2004). These data suggest that when
mutations in the LBD result in protein capable of mediating some degree of androgen
responsiveness, the availability of locally high concentrations of testosterone in the WD is
capable of rescuing it and even stimulating some degree of differentiation. It is interesting
to note that the external genitalia were feminised in CAIS individuals with persistent WDs
(Hannema et al, 2004), which would be consistent with the action of high local levels of
testosterone secreted into the WD from the adjacent testis, while circulating levels may not
be sufficient to stimulate external genitalia masculinisation. This is consistent with early
experiments undertaken by Jost and colleagues showing that if androgen insufficiency is
induced in fetal rabbits prior to sexual differentiation, a gradient of undermasculinisation is
observed with structures more distal to the testis being more affected (Jost et al, 1953). It is
worth pointing out that the levels of testosterone available during sexual differentiation show
great variation between individuals which may go some way toward explaining the variation
in phenotype of AIS patients (Reyes et al, 1973). Furthermore, no information is available
regarding the ability to convert testosterone to DHT in the AIS patients with persistent WDs
but feminised external genitalia (Hannema et al, 2004). Since 5a reductase enzyme is
induced by testosterone, it is possible that this enzyme is not activated in these patients thus
explaining the lack of masculinisation of DHT-dependent structures. In addition, Hannema
and colleagues (2004) suggest that specific co-factors may be expressed in the WD, which
are not expressed in the external genitalia, and these co-factors could mediate and enhance
androgen action.
Further insight into the role played by androgens in male sexual development can be gained
from sex reversed mice heterozygous for Tfm (Drews and Dieterich, 1978). Sex reversed
mice are XX males due to a translocation of the sex determining region of the Y
chromosome onto one of their X chromosomes (Cattanach et al, 1971). About a quarter of
the XX offspring born will be XTfm/X+(Sxr/+); these mice will have testes, due to the Sry
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mutation, and male sex organs, due to testosterone production by their testes (Drews, 1975;
Drews and Dieterich, 1978). Due to random X inactivation, sex reversed Tfm mice are
mosaics with a mixture of androgen insensitive Tfm cells and androgen sensitive wild type
cells. This can be seen in the WDs, where the Tfm cells cannot respond to testosterone but
they survive as undifferentiated cells due to signalling from the androgen sensitive cells. It
is interesting to note that the epididymis of these offspring differentiate and become
convoluted (Drews and Alonso-Lozano, 1974; Drews and Dieterich, 1978). However, there
are many fewer Tfm cells than wild type cells in the mosaic epididymis, suggesting that
many of the Tfm cells undergo apoptosis (Drews and Dieterich, 1978). Further investigation
highlighted that, upon testosterone withdrawal by castration, both the Tfm and wild type
cells die, indicating that the trophic effect of testosterone arises in the connective tissue of
the epididymis rather than the cells themselves (Drews and Dieterich, 1978). These animals
have feminised external genitalia and vaginas (Drews, 1975).
1.5.2.1.2 Defects in androgen production
It is not only the presence of androgens that is important in male sexual differentiation but
also the level of androgens available at the correct time in development. Any alterations in
the genes that code for LH or for any of the enzymes involved in steroidogenesis can result
in partial to complete sex reversal. For example, defects in the LH receptor can result in
Leydig cell hypoplasia and micropenis (Themmen and Huhtaniemi, 2000) while mutations in
17(3HSD results in complete sex reversal at birth (Lindqvist et al, 2001).
1.5.2.2 Effects of gestational anti-androgen exposure on the male
reproductive tract
Antiandrogens can act in a variety of ways such as by reducing testosterone production (e.g.
phthalates) or by antagonising androgen action by binding to the AR (e.g. flutamide). There
are many examples of antiandrogenic compounds, but the effects of just a few commonly
studied compounds will be discussed below. Maternal exposure to antiandrogenic
compounds during gestation results in varying degrees of impaired masculinisation of the
male offspring, some of which can be observed in the fetus and others are not evident until
puberty/adulthood.
1.5.2.2.1 Flutamide
Flutamide is a non-steroidal competitive AR antagonist which blocks the action of both
testosterone and DHT as flutamide interfers with interactions between the N and C terminals
of the AR thus preventing transcriptional activation of AR in target tissues: flutamide has no
direct effect on testosterone or DHT production (Peets et al, 1974; Schaufele et al, 2005).
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Flutamide was developed by the pharmaceutical industry as a treatment for androgen
sensitive prostate cancer, therefore it was specifically designed as an AR antagonist and its
mode of action is well characterised unlike other anti-androgens (McLeod et al, 1993).
Flutamide is rapidly absorbed after oral exposure and is quickly converted in the liver to the
biologically active metabolite 2-hydroxyflutamide (Katchen and Buxbaum, 1975; Zuo et al,
2002). It is worth noting that flutamide is quickly cleared from the body and excreted in
urine, and has a plasma half-life of just 5-6 h in man (Neri and Monahan, 1972). In male rats
that were orally administered flutamide (5 mgkg"1), highest levels of flutamide were noted in
tissues just 6 h after exposure and had significantly reduced by 18 h after dosing: neither
flutamide nor its metabolites were seen to accumulate in any tissue except the prostate
(www.drugs.com). Even though flutamide is believed to be a relatively strong AR
competitor, exposure to high doses of flutamide is required to ensure sufficient competition
for circulating androgens: studies have shown that flutamide levels 500-1000 fold higher
than circulating testosterone levels are required for sufficient antagonism (Simard et al,
1986).
As well as its role in treating prostate cancer, flutamide also provides a useful tool to study
androgen action in the male reproductive tract. Treatment of pregnant rats with various doses
of flutamide (6-300 mgkg"') between el 2-21, showed that there is a dose dependent effect on
masculinisation of the male fetuses resulting in varying degrees of WD differentiation,
maldescent of the testis, 'feminisation' of external genitalia and missing prostates in
adulthood (Imperato-McGinley et al, 1992; Mclntyre et al, 2001). Exposure to flutamide did
not result in any significant toxicity to the dam and did not alter the sex ratio (Mclntyre et al,
2001). It is interesting to note that the prevalence of WD-derived abnormalities varies
between different studies. For example, incomplete epididymides were only evident at doses
of flutamide above 50 mgkg" in a study undertaken by Mclntyre and colleagues (2001)
whereas earlier investigations by Imperato-McGinley and colleagues (1992) noted this in
males exposed to more than 100 mgkg"1; most adult males who had been exposed to 300
mgkg"1 in utero had no epididymal body or vas deferens evident (Imperato-McGinley et al,
1992). The differences reported in the dose of flutamide required to induce abnormalities in
each of the groups is likely to be due to different routes of administration with exposure via
gavage resulting in more severe effects than exposure by subcutaneous injection. (Imperato-
McGinley et al, 1992; Mclntyre et al, 2001). This is probably due to flutamide being
quickly metabolised to the more potent AR antagonist 4-hydroxy flutamide if exposed orally
(Xu and Li, 1998). In utero exposure to just 12.5 mgkg"1 flutamide resulted in complete
absence of the prostate in adulthood (Mclntyre et al, 2001), suggesting that DHT-dependent
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structures are more sensitive to the effects of flutamide exposure than are testosterone-
dependent structures. This is possibly due to the higher concentrations of androgens
available locally from the testis to compete with flutamide in the developing WD compared
to the UGS (Veyssiere et al, 1982). To the best of my knowledge, no information is
available regarding flutamide's ability to preferentially compete with testosterone or DHT to
bind to the AR. The animal studies described above suggest two possibilities. Firstly,
flutamide competes more easily with DHT for AR binding therefore impairing DHT-
dependent development more readily than testosterone-dependent development. This
appears illogical, however, since DHT has a stronger affinity for the AR than does
testosterone. Secondly, flutamide competes equally with testosterone and DHT for binding
to the AR, but as there are more testosterone molecules than DHT present in the WD to
compete with flutamide, some testosterone is still able to bind to the AR. Since DHT is
more potent, fewer molecules are needed in DHT-dependent structures and so there are
fewer molecules present to compete with flutamide, i.e. it is simply about abundance of
androgen molecules to compete with flutamide for AR binding. Further investigation is
required to distinguish these possibilities. Furthermore, it is not known whether flutamide
exposure prevents testosterone-dependent activation of 5a reductase, therefore further
impairing development of DHT-dependent tissues.
1.5.2.2.2 Linuron
Linuron is a urea-based herbicide which competes with endogenous androgens for binding to
the AR: this binding, however, is with lower affinity than that seen with other AR
antagonists such as flutamide or vinclozolin, thus making it a weaker antagonist (Waller et
al, 1996; Lambright et al, 2000). In vitro, linuron competitively antagonises AR
transcriptional activity induced by DHT (Mclntyre et al, 2000). Experiments in rats to
examine the impact of maternal exposure to linuron (50-100 mgkg"1) during the window of
fetal reproductive development suggest that linuron antagonises androgen-mediated
reproductive development since anogenital distance (AGD) was reduced, nipples persisted in
males, and 7% of adult male offspring had incomplete epididymides (Gray et al, 1999;
Mclntyre et al, 2000). It is worth noting, however, that linuron exposure preferentially
impaired testosterone-mediated reproductive development rather than DHT-mediated events
(Mclntyre et al, 2000). This is in contrast to the impact of other AR antagonists such as
flutamide which affects all androgen-dependent development, but with DHT-responsive
tissue being more easily affected than testosterone-responsive structures (Imperato-
McGinley et al, 1992). Some researchers have suggested that these differences are due to
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differences in metabolism since flutamide is metabolised to the more potent AR antagonist
4-hydroxyflutamide which persists in the body (Xu and Li, 1998) whereas linuron is slowly
metabolised to weaker AR antagonists (Cook et al, 1993). Initial analysis of fetal males
from dams exposed to linuron (50 mgkg"') during gestation showed that fetal serum and
intratesticular testosterone levels were not affected by linuron exposure and these males had
grossly normal WDs, morphologically indistinguishable from controls (Mclntyre et al,
2002); however, subsequent studies by another group showed a decrease in fetal rat testicular
testosterone production after linuron exposure (Wilson et al, 2004). WD abnormalities were
not seen until pnd7, whereas AGD was reduced in males at el9 and e21 (Mclntyre et al,
2002). It is not immediately clear why fetal linuron exposure does not alter epididymal
development until early in postnatal life. The normal rat epididymis continues to coil and
differentiate postnatally, therefore it would seem that antagonism of androgen action during
fetal life can have an impact on subsequent postnatal development, even though exposure
has ceased at birth. Additional studies by the same group reported that in the majority of e21
males there were no obvious WD abnormalities but reduced coiling was seen in around a
quarter of linuron-exposed males and 20% had an incomplete WD (Turner et al, 2003). It is
puzzling why these abnormalities were not detected fetally until the latter study, but the
investigators claim this to be due to improved morphological analysis techniques and
variability between litters (Turner et al, 2003). Taken together, however, these results
suggest linuron-induced abnormalities are atypical of an AR antagonist and more closely
resemble phthalate-induced effects. Why this should be the case is not readily apparent.
Effects of linuron exposure on the male fetal reproductive tract were not as severe as those
seen after exposure to other antiandrogens and vary considerably between different studies
therefore it could be suggested that linuron is not a particularly useful tool for studying
androgen receptor antagonism and the resulting effects on the fetal WD. Turner and
colleagues (2003) went on to examine any changes in gene expression in WDs at e21 from
linuron-exposed male fetuses and showed that AR, Notch 2, IGF-1R and EGFR mRNA were
reduced, while Dlk (a potential ligand for Notch2) was increased. These changes may be
indicative of disruption of the paracrine interactions between stromal and epithelial cells
which subsequently results in impaired WD development.
1.5.2.2.3 Vinclozolin
Vinclozolin is a fungicide commonly used in the fruit industry but has been shown to have
antiandrogenic properties (Kelce et al, 1994). Vinclozolin is capable of binding to the AR
thus competing with androgens and inhibting androgen-dependent gene expression (Kelce et
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al, 1997). Maternal exposure to vinclozolin (200 mgkg"') inhibits masculinisation of the
male fetuses in rats, resulting in reduced AGD, hypospadias, the presence of a blind-ending
vagina and small or no accessory sex glands (Gray et al, 1994). Wolf and colleagues
exposed pregnant rats to vinclozolin during various 2 day windows during the period of fetal
reproductive development and noted that the most sensitive period during fetal life for
exposure to vinclozolin (400 mgkg"1) was between e 16-17: extended exposure between e 14-
19 resulted in more severe, and an increased prevalence of, abnormalities (Wolf et al, 2000).
Exposure to vinclozolin for just 2 days between e 12-13, 14-15, 16-17, 18-19 or 20-21 did not
result in any obvious abnormalities in WD-derived structures in adulthood (Wolf et al,
2000). This is not surprising since Gray and colleagues (1994) saw no epididyma! defects in
rats exposed to vinclozolin (200 mgkg"1) between el4-pnd3.
1.5.2.2.4 Di(n-butyl) phthalate
DBP is a phthalate ester which is widely used in the plastics and other industries: exposure
to DBP impacts on male reproductive health, with neonates more sensitive to the effects than
adults (Foster et al, 1980). Unlike many other anti-androgens, such as flutamide and
vinclozolin, phthalates do not appear to act directly via the AR but cause their effects by
reducing fetal testicular testosterone production (Mylchreest and Foster, 2000; Parks et al,
2000; Fisher et al, 2003). Various studies have shown that maternal exposure to 100 mgkg"1
DBP or above during fetal life (el 2-21) in rats results in undermasculinisation of the fetal
male offspring in a dose dependent manner (Mylchreest et al, 1998; Mylchreest et al, 1999;
Mylchreest et al, 2000; Foster et al, 2001). The most marked effects reported are on
epididymal development, but other adverse effects include cryptorchidism, hypospadias,
reduced AGD, malformed external genitalia and abnormal or underdeveloped prostate,
seminal vesicles and other secondary sexual organs (Mylchreest et al, 1998; Mylchreest et
al, 1999; Mylchreest et al, 2000; Foster et al, 2001). An interesting point to note is that
phthalate exposure interferes with testis descent by inducing regression of the gubernaculum.
Testis descent is believed to be a bi-phasic event which depends on the action of both
testosterone and the peptide hormone insulin-like peptide (insl3) and phthalates are the only
antiandrogen so far found to be capable of reducing both testosterone and Insl3 levels
(Wilson et al, 2004).
1.5.3 The effects of exogenous androgen exposure on fetal reproductive
development
As discussed above, impaired androgen action in fetal life interferes with normal male
reproductive development. However, it is widely accepted that excess androgen exposure
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during fetal life also perturbs normal fetal development, resulting in masculinisation of the
female reproductive tract (reviewed in Abbott et al, 2005). This view has arisen from both
studies in animal models and clinical observations.
1.5.3.1 Clinical observations
The most common cause of female masculinisation in humans is congenital adrenal
hyperplasia (CAH), which results in most cases from an autosomal recessive mutation that
impairs the 21-hydroxylation reaction. This causes a deficiency in Cortisol synthesis in the
fetal adrenal gland such that there is a compensatory increase in adrenal androgen synthesis.
This in turn masculinises the fetal female genitalia in XX individuals resulting in an enlarged
clitoris, partly fused labia majora, and a common urogenital sinus instead of a separate
urethra and vagina. The internal female organs are usually normal and WD-derived
structures are not present (reviewed in Merke and Bornstein, 2005). As discussed above,
masculinisation of the WD in animals requires high levels of local androgen action. In
contrast, the female CAH fetus is exposed to circulating androgens synthesised in the
adrenal, rather than androgens delivered locally from the testis, as occurs in fetal males: this
may explain the masculinisation of the external but not the internal genitalia in CAH
females. To the best of my knowledge, no information is available regarding the ability of
these individuals to convert testosterone to DHT but it is assumed that 5a reductase activity
is evident in these patients. XY males can also be affected by CAH and although they have
no obvious signs of CAH at birth, they undergo early virilisation at 2-4 years old (reviewed
in Merke and Bornstein, 2005).
It is hypothesised from both animal studies and clinical observations, that polycystic ovary
syndrome (PCOS) could be due to excess androgen exposure during fetal life. Symptoms of
PCOS can be seen in adult female rhesus monkeys and sheep that have been exposed in
utero to levels of testosterone equivalent to fetal male levels (Abbott, 1998; Padmanabhan,
1998). These symptoms include hypersecretion of luteinising hormone, abnormal insulin
secretion, enlarged cystic ovaries and anovulation. However, PCOS patients do not present
with masculinised external genitalia suggesting they were exposed to lower levels of
testosterone that were insufficient to masculinise the reproductive tract but which were
sufficient to affect ovarian development.
1.5.3.2 Animal studies
Several studies have been undertaken in animals to examine the effects of exogenous
androgen exposure during fetal life. Exposing pregnant rats to various doses of testosterone
masculinises the female offspring to varying degrees (Swanson and Werff ten Bosch, 1965;
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Ogawa and Nozawa, 1969; Jost et al, 1973; Stinnakre, 1975; Wolf et al, 2002; Wolf et al,
2004). It has been shown that early in gestation, male and female fetuses have similar
plasma androgen levels but as gestation proceeds, androgen levels significantly decrease in
females and rise in males to peak at around el 8-19 in rats (Weisz and Ward, 1980; Baum et
al, 1991). At this age, plasma androgen levels are approximately 60% higher in males than
in females (Baum et al, 1991). It is interesting to note that these studies report a reduction in
plasma androgen levels in male fetuses at e20 resulting in similar plasma androgen levels in
both male and female rat fetuses at e20 and 21 (Weisz and Ward, 1980; Baum et al, 1991).
The authors claim that this short peak in androgens in males is sufficient to sensitise the male
fetus to subsequent androgen exposure and initiates male sexual differentiation. These
authors claim this plasma androgen comes mainly from the placenta in the female fetuses, as
the rat placenta has been shown to be capable of testosterone synthesis from progesterone or
pregnenolone in the second half of gestation (Chan and Leathern, 1975; Gibori and Sridaran,
1981). It has been suggested that this peak in androgens sensitises the developing male in
order that it can respond to androgens during neonatal and postnatal life (Baum et al, 1991).
It is somewhat surprising that females are exposed to low levels of androgens early in
gestation since they also express ARs thus are capable of responding to androgens
(Bentvelsen et al, 1995).
The effects of exogenous androgen exposure on different reproductive structures depends on
the timing and dose of testosterone given. Furthermore, injection of testosterone into the
pregnant dam has less effect on the developing female than does injection directly into the
amniotic sac or into the fetus itself (Swanson and Werff ten Bosch, 1965). Care should be
taken when comparing the levels of testosterone used in these earlier studies as they are often
expressed as testosterone dose per rat rather than by dam weight or as the total testosterone
exposure over the entire dosing period. Prenatal exogenous androgen exposure has no
obvious effect on the male reproductive tract but masculinises the female reproductive tract,
with AGD and the external genitalia most sensitive to these effects (Greene, 1939; Swanson
and Werff ten Bosch, 1965; Ogawa and Nozawa, 1969; Wolf et al, 2002). It is interesting to
note that exposure to low levels of testosterone can masculinise the external genitalia and
stimulate development of the prostate and seminal vesicles in females but does not
compromise normal reproductive function (Greene, 1939; Ogawa and Nozawa, 1969).
Rescue and differentiation of the WD in females requires higher levels of testosterone
exposure than does masculinisation of the UGS or external genitalia and exposure must be
prior to el 8 in the rat (Swanson and Werff ten Bosch, 1965; Ogawa and Nozawa, 1969;
Stinnakre, 1975). As in CAH patients, this is likely to be due to the testosterone being
Chapter 1 Literature Review 35
delivered from the circulation rather than locally as occurs naturally in the WD in males,
therefore testosterone levels do not reach sufficient levels to masculinise the WD. Many
previous studies do not comment on the phenotype of the WD but merely its presence or
absence. However, Greene and colleagues (1939) noted that exposure to high doses of
testosterone (80-90 mg total dose) was able to not only rescue the WD but could even
stimulate some degree of coiling in the epididymal segment, while lower doses (13.5 - 40
mg total dose) could often only rescue the WD unilaterally with the adult derived structures
often incomplete and lacking patent lumens. Unfortunately, images were not provided to
allow visualisation of this coiling. As with other studies, the UGS was well masculinised in
these low dose testosterone-treated animals, again highlighting the increased sensitivity of
these structures to androgen action (Greene, 1939).
A recent study by Wolf and colleagues (2002) showed that exposure to testosterone
propionate (TP) below 0.5 mg/pregnant rat had little effect on the developing reproductive
tract but exposure to 0.5-10 mg/pregnant rat resulted in a permanent increase in female
AGD, absence of a vaginal orifice, masculinised external genitalia, and the presence of a
prostate and seminal vesicles. It is worth noting that they were unable to rescue the WD in
these female offspring, even with 10 mg/rat TP. These organ-specific differences in
masculinisation via TP exposure are probably due to the circulating testosterone being
converted to DHT in the more distal structures such as the prostate and external genitalia
whereas the WD does not express 5a reductase so depends on high levels of local
testosterone to stimulate differentiation. Follow up studies by the same group showed that
combined exposure to testosterone (1 mg/rat) and vinclozolin (200 mgkg"1) resulted in
normal female reproductive development suggesting that this dose of vinclozolin is sufficient
to antagonise the effects of testosterone, but the dose of testosterone was unable to prevent
the effects of vinclozolin on the male fetuses (Wolf et al, 2004). It can be seen from these
studies therefore that testosterone alone is sufficient to rescue the female WD, but there is
considerable variation in the doses and timing of exposure reported to elicit this
masculinisation. Furthermore, little information is available detailing the phenotype of the
rescued WD.
It is worth mentioning that it is not only the reproductive tract which can be masculinised in
female fetuses exposed to exogenous androgens, it can also impact on brain development
resulting in an increase in male-like play behaviour in rats, for example, increased rough
play was noted in juvenile females that had been exposed to testosterone in utero (Meaney
and Stewart, 1981). Testosterone exposure also induces intrauterine growth retardation
(IUGR) (Wolf et al, 2002; Wolf et al, 2004; Steckler et al, 2005; Carlsen et al, 2006;
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Padmanabhan et al, 2006). It is known that inappropriate steroid hormone signalling during
fetal life can affect neonatal growth and examples of this can be seen in humans, as patients
with polycystic ovarian syndrome (PCOS) have an increased prevalence of babies born small
for gestational age (Sir-Petermann, 2005). It is unknown, however whether this is the result
of testosterone action directly in the mother or is the result of testosterone being converted
into oestradiol, since oestrogens are also known to cause a decrease in maternal weight gain
and fetal birth weight, at least in rats (Zimmerman et al, 1991; Padmanabhan et al, 2006).
Further evidence for extraneous testosterone exposure masculinising female fetuses comes
from studies in mice in which the Wnt-4 gene has been deleted (Vainio et al, 1999). In
contrast to Wnt-4 mutant males, which have normal reproductive tracts, Wnt-4 mutant
females do not develop normally but are masculinised (Vainio et al, 1999). It has been
shown that their ovaries synthesise testosterone which, in turn, rescues the WD and even
stimulates coiling in the proximal segment: contrastingly, the external genitalia of these mice
are not masculinised (Vainio et al, 1999). The difference in the structures masculinised in
these mice compared to animals exposed to maternal exogenous testosterone is likely due to
the differences in the source of testosterone i.e. local or circulating. Furthermore, in female
Wnt4 mutant mice, the levels of circulating testosterone are lower than in normal males thus
are presumably insufficient for masculinising structures distal to the source of testosterone
i.e. the ovary. It is not immediately obvious why this would be the case but perhaps the
levels of circulating testosterone are insufficient to induce 5a reductase and so DHT activity.
The Mullerian duct cannot be identified in males or female Wnt4 ''' animals at birth: taken
together with the evidence demonstrating that the Mullerian ducts form from Wnt4
expressing coelemic epithelium and that the mesenchyme underlying the Mullerian duct
expresses Wnt4, this suggests that Wnt4 is necessary for Mullerian duct formation (Vainio et
al, 1999).
1.6 Role for oestrogens in urogenital development
Oestrogen synthesis is temporarily activated in the male and female embryo prior to
implantation in the uterine wall, suggesting oestrogen action is vital for embryo survival
(George and Wilson, 1978). Oestrogen synthesis is later re-initiated in the fetal ovary prior
to histological differentiation suggesting that female reproductive differentiation depends at
least partly on oestrogen action (Wilson et al, 1981). Oestrogen action is mainly mediated
by binding to intracellular receptors, either oestrogen receptor a (ERa) or p (ERp) (Evans,
1988). These receptors are members of the steroid nuclear receptor family (discussed in
section 1.5) and act as ligand dependent transcription factors (reviewed in Evans, 1988;
Couse and Korach, 1999). ERp protein is highly homologous to ERa protein, particularly in
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the DNA-binding domain (Kuiper et al, 1996). The biological significance of the two ER
subtypes is still unclear, but it is likely that they may play different roles in different tissues,
possibly responding to different ligands since they only share around 60% homology in the
ligand-binding domain (Kuiper et al, 1996).
Many studies have been undertaken to examine the expression of ERa and ERP, however,
this review will focus only on their expression in the rodent reproductive tract. Most studies
in the reproductive tract have investigated adult ER expression showing that both receptors
are expressed in most structures in the male. These studies highlighted that ERP is more
abundantly expressed and in more cell types than is ERa in the rat male reproductive tract
(Saunders et al, 1998). For example, little ERa is expressed in the adult rat prostate while
ERP protein was localised to the secretory cells: similarly, ERa was weakly expressed in
adult rat seminal vesicles whereas ERP was detected in both epithelial and stromal cells
(Pelletier et al, 2000). ERa is expressed in the epididymal epithelium and in the stroma of
the vas deferens at pndl8 but this expression is lost by adulthood: contrastingly, ERP is
expressed in the epithelium and stroma of the rat epididymis and vas deferens throughout
postnatal life (Atanassova et al, 2001). Neonatal rat exposure to DES, a synthetic oestrogen,
alters this ER expression pattern which may account for the 'blurring' of the boundary
between the vas deferens and epididymis seen in these animals (Atanassova et al, 2001).
Both male and female fetuses express ERa and p, with all cells that express AR in the
developing rat reproductive tract also expressing one or both of the ERs (Williams et al,
2001): ERP is believed to be more highly expressed in the developing male reproductive
tracts than is ERa (Sharpe, 1998). In the mouse, ERs are present in the WD mesenchyme,
but not the epithelium, from el6 and expression decreases as these mesenchymal cells
differentiate into smooth muscle (Stumpf et al, 1980; Cooke et al, 1991). The efferent ducts
are the first site of ER expression in the epithelium (by el6) with epididymal expression
beginning later at el9: the vas deferens epithelium remains negative for ERs (Cooke et al,
1991). However, these studies did not differentiate between ER a and P as they were prior to
the discovery of ERP and used steroid autoradiography.
As discussed above, it is widely accepted that fetal WD development is dependent on
androgens but there is some evidence for a role for oestrogens in some aspects of
reproductive tract development, especially around the time of puberty. For example,
neonatal exposure to exogenous oestrogenic compounds results in abnormal development or
even atrophy of the epididymis (Orgebin-Crist et al, 1983; Robaire, 1988; Williams et al,
2001). However, although neonatal exposure to DES results in structural abnormalities in
the testis and reproductive tract prepubertally, these can largely be prevented by co-
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administration of testosterone (Williams et al, 2001). It was hypothesised therefore that the
adverse changes induced by DES exposure are the result of a disturbed androgen-oestrogen
balance, and that rather than the absolute hormone levels being the determining factor, it is
the relative levels of androgens and oestrogens that is important in determining whether such
abnormalities develop (Williams et al, 2001). It is worth noting that DES-induced
abnormalities are always associated with reduced AR expression, therefore highlighting the
possibility that DES is acting effectively as an anti-androgen (Williams et al, 2001; Williams
et al, 2001).
Further insight into the role for oestrogens in the male reproductive tract has been gained
from studies in mice lacking ERP ((3ERKO) or a (aERKO) (Lubahn et al, 1993; Krege et al,
1998). Oestrogens are believed to play a role in the adult male reproductive tract (Hess et al,
1997; Hess et al, 2001), however, as yet there is no direct evidence for a role in the
development of this tract. Male aERKO mice are infertile whereas male PERKO are fertile
(Lubahn et al, 1993; Krege et al, 1998). Epididymides from young aERKO mice have
abnormal cell organisation and impaired fluid reabsorption by the efferent ducts, which may
explain the abnormal sperm maturation observed in these mice (Eddy et al, 1996; Hess,
2000; Hess et al, 2000). It is unlikely, however, that oestrogens play a role in WD rescue or
morphological differentiation since both aERKO and aromatase knockout (ArKO) mice have
normal looking epididymides present at birth (Fisher et al, 1998; Robertson et al, 1999; Hess
et al, 2000). A role for oestrogens in WD functional differentiation cannot be completely
ruled out, however, since adult efferent ducts and epididymides do not appear to function
normally in aERKO mice (Hess et al, 2000).
1.7 Stromal-epithelial interactions
Stromal-epithelial interactions are believed to be vital in mediating the steroid-dependent
regulation of reproductive tract development. In both fetal and adult life, the organs of the
male and female reproductive tract are composed of epithelial parenchyma and surrounding
supporting fibromuscular stromal or mesenchymal cells (Fig. 1.9). Communication between
cells is vital in multicellular organisms to coordinate differentiation, growth, motility and
immunity and interactions between epithelial and mesenchymal cells are known to play vital
roles in embryonic development and in adulthood in both normal and abnormal tissues (e.g.
cancer) (Cunha, 1976; Cunha et al, 1985).
For the purpose of this review, the term "stroma" will refer to both the fetal mesenchymal
cells as well as the postnatal stromal cells.
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Junction
Figure 1.9 Schematic representation of the spatial organisation of stromal and
epithelial cells in reproductive structures.
1.7.1 Epithelium
The epithelium is the basic tissue of early embryos in which cells are tightly bound together
with specialised junctions between them connecting them into a sheet of epithelium: these
sheets line all the cavities and free surfaces of the body and serve several fundamental
purposes including acting as a barrier to the external environment, regulating pattern
formation and providing mechanical integrity (summarised in Alberts, 1994). Epithelial cells
have little ECM between them but rest upon an underlying basement membrane: this is a
specialised layer of ECM which provides the interface between the stromal and epithelial
compartments and plays a role in maintaining tissue integrity (discussed in section 1.8).
Furthermore, cytoskeletal fdaments cross the cytoplasm between cells, and along with
junctions, give the epithelium strength and structure: these fdaments are discussed further in
section 1.8.
1.7.2 Stroma
Mesenchymal cells, the embryonic equivalent of stromal cells, firstly arise in the embryo by
migrating from the primitive streak (reviewed in Hay, 1995; Shook and Keller, 2003).
Definitive embryonic mesenchyme often arises by epithelial-mesenchymal transformation
(EMT) from the mesodermal epithelium (reviewed in Hay, 1995; Shook and Keller, 2003).
This cell type transformation can occur in either direction and plays a considerable role in
normal developmental processes that require migration and ECM invasion as well as in
disease development such as cancer (reviewed in Shook and Keller, 2003; Singh et al, 2003).
For example, epithelial cells can turn off epithelial markers such as cytokeratin, activate
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stromal master genes and gain motility thus allowing them to interact with the ECM and gain
stromal-like properties. Alternatively, stromal cells can de-differentiate to re-express
epithelial regulatory genes such as E-cadherin, turn off motility machinery and regain
polarity (reviewed in Hay, 1995; Thiery, 2002; Rang and Massague, 2004).
The stromal compartment is thought of as a loose fibrous connective tissue which is made up
of a variety of different cell types including fibroblasts, endothelial cells, smooth muscle
cells and neuroendocrine cells. These cells are surrounded by a structural ECM, which plays
a vital role in its function. The ECM and its role in stromal-epithelial interactions is further
discussed in section 1.8.
1.7.3 Stromal-epithelial interactions in the reproductive tract
The development of the fetal reproductive tract depends on reciprocal interactions between
the epithelial and stromal cells and if either component is removed or altered, tissue
morphogenesis is disrupted (reviewed in Franks et al, 1970; Marker et al, 2003; reviewed in
Cunha et al, 2004). Classical experiments carried out by Cunha and colleagues have
highlighted the direct role for the stroma in inducing epithelial differentiation in the male and
female reproductive tract (reviewed in Cunha et al, 1985; reviewed in Cunha et al, 2004). In
the fetus, paracrine signals from stromal cells specify the identity of, and induce
differentiation of, epithelial cells as well as dictating the morphological pattern of the
epithelium, thus controlling whether the epithelium forms a highly branched network such as
in the prostate or a simple unbranched tube such as in the WD (Donjacour and Cunha, 1991;
Cunha, 1998). The stroma is also able to regulate the timing, pattern and rate of epithelial
proliferation and apoptosis as well as the functional differentiation of the epithelium in the
developing reproductive tract (Cunha and Young, 1992; Kurita et al, 2001; Marker et al,
2003). Much of this evidence comes from studies undertaken by Cunha and colleagues
which examined the effects of recombining stroma from one reproductive organ with
epithelium from another, highlighting that the fetal stroma can dictate the phenotypic
differentiation of the epithelium (Cunha et al, 1985; Cunha and Young, 1991; Cunha et al,
1992; Cunha and Young, 1992; Cunha et al, 1992; Cunha et al, 1997; Cunha et al, 2004).
For example, epithelia from the upper and middle portions of the WD develop into seminal
vesicles, rather than epididymides and vasa deferentia, when recombined with neonatal
seminal vesicle stroma (Higgins et al, 1989). This mesenchyme was able not only to
regulate cytodifferentiation of the epithelium but even induced the secretion of seminal
vesicle secretory proteins showing induction of functional differentiation (Higgins et al,
1989).
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These observations raise the question of whether this fetal specification and differentiation of
the epithelium is permanent or whether adult epithelium remains susceptible to re-
specification by changes in the signals from the mesenchyme. In adult organs, the
epithelium is generally thought of as stably differentiated but these cells are continually
cycling and being replaced, therefore epithelial morphology and function must be maintained
and cell proliferation tightly regulated in order to sustain organ integrity. It is likely that this
occurs by similar mechanisms to those operating in the fetus involving stromal-epithelial
interactions. Previous studies have shown that adult epithelia remain responsive to
signalling from the surrounding stroma. For example, fetal UGS stroma can stimulate adult
prostate epithelium to produce new ducts (Chung and Cunha, 1983; Cunha et al, 1983).
Similarly, adult mammary epithelium initiates morphogenesis in response to fetal mammary
stroma (Sakakura et al, 1979).
Earlier studies showed that adult epithelia are not only responsive to signalling from the
stroma but that they are not irreversibly committed to their phenotype and can be re-
specified to another phenotype by the underlying stroma. For example, adult vaginal
epithelium can be differentiated into prostatic epithelium by fetal UGS stroma (Cunha et al,
1985). However, it is not just fetal stroma that can alter epithelial morphology but adult
stroma can also elicit major changes in the epithelium. This has been shown in experiments
using adult vagina stromal cells which can induce both the morphological and functional re-
differentiation of neonatal uterine epithelium into vaginal epithelium (Cunha, 1976). These
results are not surprising since adult epithelium continues to be renewed and replaced
throughout life, therefore it needs to retain its plasticity and ability to respond to its
environment.
It has therefore been well documented that epithelial differentiation, growth and
morphogenesis, in both adults and fetuses, depends upon interactions with the underlying
stroma. However, studies highlight that the interactions between these two cell types are
reciprocal and that the epithelium can signal to the stroma and facilitate its capacity to
respond to subsequent hormonal stimulation. For example, in males prostatic epithelial
differentiation depends on androgen action on the stroma but stromal differentiation into
smooth muscle depends on reciprocal androgen-dependent signalling from the epithelium
(Cunha et al, 1996). Further evidence for this phenomenon comes from recombination
studies whereby uterine, but not vaginal, epithelium is able to promote uterine stromal
proliferation in response to oestrogen and progesterone (Bigsby, 2002), and if uterine
epithelium is ablated in vivo, the stroma is no longer capable of decidualising in response to
hormones (Lejeune et al, 1981).
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1.7.4 Role of stromal versus epithelial steroid receptors in stromal-epithelial
interactions
The studies discussed above highlighting the vital interaction between stromal and epithelial
cells suggest that hormone receptors expressed in either the stromal or epithelial
compartment may play a differential role in hormone signalling during reproductive
development and/or function. This can be seen during prostate development: initially ARs
are only expressed in the developing stroma prior to bud development, thus suggesting that
androgens act on the stroma which then signals to the epithelium to regulate its
differentiation (Cooke et al, 1991). This has been further studied in recombination studies in
vitro using stroma and epithelium from mice lacking steroid receptors or from wild type
mice (Cunha et al, 1987; Cooke et al, 1997; Buchanan et al, 1998; Kurita et al, 1998). For
example, studies recombining Tfm stroma with wild type epithelium did not result in
prostate formation in response to androgens in vitro whereas wild type stroma grown
alongside Tfm epithelium resulted in prostate development and differentiation (Cunha et al,
1987) (summarised in Fig. 1.10). These studies therefore highlight that androgen-responsive
prostate development is mediated through ARs in the stroma which can then stimulate the
epithelium to proliferate and differentiate, even if the epithelium has no AR.




















Figure 1.10 Summary of a typical recombination experiment carried out by Cunha et
al. Wild type (WT, blue) tissue expresses androgen receptor whereas testicular feminised
(Tfm, pink) tissue does not.
Furthermore, studies have been carried out to investigate whether androgen-dependent
effects on the prostate epithelium continue to be mediated via the stroma in the adult, as
occurs in the fetus. Wild-type UGS stroma was combined with wild-type or Tfm fetal
bladder epithelium and transplanted under the kidney capsule in adult male host mice (Cunha
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and Chung, 1981). Both types of recombination resulted in the growth of mature prostatic
buds which degenerated in response to castration (Cunha and Chung, 1981). Subsequent
testosterone replacement was able to restore prostate morphology and stimulate epithelial
proliferation, thus highlighting that, even in the recombinants in which the epithelium was
AR negative, the prostate could respond to androgens and elicit epithelial proliferation
(Sugimura et al, 1986). As in the fetus, this must be mediated via the ARs in the stroma,
further highlighting the vital role for steroid receptors and stromal-epithelial interactions.
However, care must be taken in interpretation of these experiments as they could suggest that
direct steroid hormone action on the epithelium is not essential during reproductive
development. This does not appear to be true as further investigations have revealed that
epithelial steroid receptors are required for functional differentiation. For example, epithelial
AR expression is necessary for expression of AR-dependent secretory proteins in seminal
vesicle epithelium (Cunha and Chung, 1981) and ERa expression in both the epithelium and
stroma is vital for epithelial stratification and cornification in the vagina (Buchanan et al,
1998).
1.7.5 Role for stromal-epithelial interaction in disease
Stromal-epithelial interactions have also been highlighted in several disease states including
cancer (Cunha et al, 2002). In adulthood, homeostasis of organs is believed to be maintained
by interactions between the stroma and epithelium to regulate proliferation and apoptosis
(Cunha et al, 1985; Arnold et al, 2001) and disruption of these interactions can result in de-
differentiation of prostatic cells, de-regulation of proliferation and apoptosis and thus
development of cancer (Cunha et al, 1996; Cunha et al, 2002). Once again, recombination
experiments have highlighted the role for steroid receptors and stromal-epithelial interactions
in disease states. In some cases, receptors were required in both the stroma and epithelium
to induce metaplasia: for example, in the prostate oestrogens acting through ERa cause
squamous metaplasia of the epithelium, however ERa must be expressed in both the
epithelium and the stroma for this to occur (Risbridger et al, 2001). In this system, it is
hypothesised that the stromal ERa mediates proliferation of the epithelium while epithelial
ERa regulates epithelial differentiation. This differs from the mechanism seen in the
development of cervicovaginal adenosis which depends only on epithelial receptors, DES
exposure acting through ERa in the epithelium to induce cervicovaginal adenosis (Kurita et
al, 2004).
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1.7.6 Potential mediators of stromal-epithelial interactions
It is unknown whether stromal-epithelial interactions rely on direct contact between the
stroma and epithelium or whether some soluble diffusible factor such as growth factors may
be responsible. Early cell culture studies showed that epithelial cells could not survive in
vitro in the absence of stromal cells, but that extracellular matrices could be used in place of
cells to support epithelial cells and promote proliferation (Cunha et al, 1985). However,
direct contact with stromal cells was required to stimulate epithelial differentiation and
morphogenesis suggesting that the ECM plays a role in these stromal-epithelial interactions
but some stromal-specific factors are required for more complex epithelial differentiation.
These factors are obviously stromal factors and are likely to be tissue specific since different
stroma can promote different epithelial morphology and function.
1.7.6.1 Role for growth factors in stromal-epithelial interactions
One suggestion is that growth factors may be involved in regulating stromal-epithelial
interactions. Many growth factors have been shown to be present in the male reproductive
tract including FGF, epidermal growth factor (EGF), insulin-like growth factor l (IGF-1)
and keratinocyte growth factor (KGF), with several researchers implicating roles for them in
both the adult and developing reproductive tract (Bossert et al, 1990; Cunha et al, 1992;
Alarid et al, 1994; Cunha et al, 1995; Gupta, 1996; Sugimura et al, 1996; Chua et al, 2002;
Wang et al, 2003). The general mechanisms behind growth factor signalling extend beyond
the scope of this review but have been extensively reviewed recently, however as yet, the
exact function, intracellular signalling pathways and mechanisms involved are poorly
understood (Tomsig and Turner, 2006; Tomsig et al, 2006).
The most extensively studied growth factor in male reproductive development is epidermal
growth factor (EGF). Several studies have shown that blocking EGF action results in WD
abnormalities and degeneration of the epithelium, even in the presence of endogenous
androgens, and that EGF is able to mimic some of the effects of testosterone including
partially rescuing the female WD and increasing female AGD (Gupta et al, 1991; Cain et al,
1994; Gupta, 1996). Furthermore, exposure to EGF can partially rescue the effects of
flutamide exposure both in vivo and in vitro (Gupta et al, 1991; Cain et al, 1994). It appears
that the effects of EGF and androgens are reciprocal in that EGF stimulates androgen
binding and modulates AR transcriptional activity in the reproductive tract, possibly by
promoting phosphorylation of the pi60 family coactivator transcription intermediary factor
2/glucocorticoid receptor interacting protein 1 (TIF2/GRIP1) and increasing its interaction
with AR (Gupta et al, 1996; Gregory et al, 2004): on the other hand, androgens stimulate
EGF secretion, induce EGF receptor (EGFR) expression, induce phosphorylation of EGFR,
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and establish the ability to secrete and bind EGF in response to androgens (Traish and Wotiz,
1987; Kashimata et al, 1988; Gupta and Jaumotte, 1993; Johnson et al, 1993). It is
interesting to note that EGF cannot induce AR Ser-213 phosphorylation in the absence of an
AR agonist (Taneja et al, 2005). EGF mRNA levels peak in the male mouse reproductive
tract at el4 and el8, coinciding with the onset of WD stabilisation and differentiation,
respectively, thus highlighting the potential importance of EGF in WD development (Gupta
and Singh, 1996). EGFR protein has been identified in the mouse male reproductive tract
from el8 and appears to increase with age and testosterone exposure, whereas flutamide
exposure can decrease EGFR expression (Gupta, 1996). The EGFR protein is expressed in
the mouse WD epithelium rather than the stroma, while EGF ligand can be detected in both
the stroma and the epithelium suggesting a role for both paracrine and autocrine EGF
signalling (Winters et al, 1993; Gupta, 1997). Together with the fact that early in sexual
differentiation ARs are only expressed in the stroma, this suggests that EGF may be involved
in mediating the androgen signal from the stroma to the epithelium and enhancing AR
transcriptional activity. Complete masculinisation therefore appears to depend on both
testosterone and EGF, possibly due to EGF mediating the effects of testosterone (Gupta and
Jaumotte, 1993; Gupta, 1996; Gupta et al, 1996).
Another growth factor commonly studied in male reproductive development is KGF, which
has been shown to be widely produced by the stromal cells and to act specifically on
epithelial cells (Alarid et al, 1994). Previous studies have indicated a role for KGF in
mediating androgen-driven stromal-epithelial interactions in seminal vesicle development
(Alarid et al, 1994). As with EGF, blocking KGF in organ culture inhibited epithelial
proliferation and differentiation but had no obvious impact on the stroma (Alarid et al,
1994). Furthermore, KGF is believed to mediate androgen action between the stroma and
epithelium in prostate cancer (Planz et al, 1999).
Taken together, these studies all point to a role for growth factors in mediating androgen
dependent stromal-epithelial interactions during male reproductive development. However,
it remains questionable whether growth factors alone can induce the specificity required for
tissue morphogenesis as they are often ubiquitously expressed.
1.7.6.2 Role for Hox genes in stromal-epithelial interactions
The factors regulating stromal-epithelial interactions and specifying epithelial identity are
unlikely to be transiently expressed since the epithelium appears to remain relatively plastic
throughout life and depends on constant signalling from the underlying stroma to maintain
its phenotype. Hox genes may fulfil this role as their expression in the reproductive tract is
patterned in the fetus and persists into adulthood suggesting Hox genes may play a role in
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maintaining tissue patterning postnatally. Hox genes are homeobox containing transcription
factors which regulate patterning and segmentation of the body axis in the fetus (Favier and
Dolle, 1997). These genes are highly conserved and bind to specific sequences of DNA to
modulate gene transcription (Levine and Hoey, 1988). Late in gestation, the 5' members of
the Flox gene family are expressed in the male reproductive tract (Dolle et al, 1991) and this
expression persists in the adult with Hox alO, all, al3, dlO and d 13 expressed in the
epithelium and stroma of the postnatal epididymis and vas deferens (Hsieh-Li et al, 1995;
Podlasek et al, 1999; Bomgardner et al, 2001; Bomgardner et al, 2003). These genes have
been suggested to play a role in patterning the reproductive tract as mice deficient in Hox
alO show reduced budding in their seminal vesicles (Podlasek et al, 1999) while mice
lacking Hox all are infertile with homeotic transformation of the vas deferens to more
closely resemble an epididymal phenotype (Hsieh-Li et al, 1995).
Hox gene expression has been shown to be regulated by sex steroid hormones in the
endometrium with Hox AlO and All both increasing in response to oestrogen or
progesterone (Taylor et al, 1998; Taylor et al, 1999). Furthermore, exposure to the potent
oestrogen, DES, in utero interferes with the normal pattern of Hox gene expression in the
female reproductive tract, resulting in anterior homeotic transformation (Block et al, 2000).
For example, Hox alO is normally expressed in the stroma and epithelium of the whole
uterus but exposure to DES in utero restricts expression to the caudal segment of the uterus
only (Block et al, 2000). These results suggest that one mechanism by which DES alters
female reproductive patterning is by altering Hox gene expression and thus tissue identity.
This raises the possibility that sex steroids may regulate the expression of Hox genes in both
the stroma and the epithelium in the male reproductive tract which in turn will mediate tissue
patterning and morphogenesis in the fetus. Together these data suggest that Hox genes may
play a role in mediating the hormone-dependent stromal-epithelial interactions in the
reproductive tract.
1.8 Extracellular matrix and its role in reproductive development
The extracellular matrix (ECM) surrounds cells and is vital not only to provide mechanical
support but it also plays a role in controlling their behaviour, proliferation and differentiation
by regulating the availability of signals, such as growth factors, reaching the cell surface
(Streuli and Gilmore, 1999). The ECM is composed of fibres, including collagen,
fibronectin and elastin, and ground substance, which includes glycosaminoglycans such as
hyaluronic acid or heparan sulphate. In most connective tissues, the supporting fibroblasts
secrete the majority of the components of the ECM however some are made by the
epithelium such as hyaluronic acid.
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1.8.1 ECM and stromal-epithelial interactions
It has been suggested that the ECM plays a role in mediating the signals between stromal and
epithelial cells and thus plays an important role in inducing and regulating organogenesis and
tissue remodelling. For example, hyaluronic acid plays a role in organ formation by creating
free space for cells to migrate into, thus allowing a structure to change shape (summarised in
Alberts, 1994).
Early attempts at cell culture suggested that epithelial cells could not be maintained in vitro
in the absence of stromal cells as the epithelial cells flattened and de-differentiated when
cultured alone on glass or plastic surfaces (Cunha et al, 1985). However, if these epithelial
cells were cultured on collagen or other biomatrices, they maintained their functional
differentiation and morphology in the absence of stromal cells (Lee et al, 1984). These and
other studies led to the hypothesis that, as well as the stromal effects caused by secreted
paracrine factors (as discussed in section 1.7.6), at least some of the effects of stromal cells
on the epithelium may be due to, or act via, the ECM. Cunha suggested that more complex
morphogenetic processes may require the presence of stromal cells while maintenance and
proliferation of differentiated adult epithelial cells may be mediated by the ECM alone
(Cunha et al, 1985). This can be seen in cultured adult mammary epithelial cells as they
require the presence of mammary stromal cells in order to induce ductal morphogenesis in
vitro: collagen substrates alone are not sufficient to cause morphogenesis but are able to
stimulate epithelial proliferation (Sakakura et al, 1979; Cunha et al, 1985). These data imply
that the integrity of the ECM is fundamental in tissue morphogenesis by playing a vital role
in signal transduction between stromal and epithelial cell compartments both in the fetus and
the adult.
1.8.2 Basement membrane
The basement membrane is a special thin tough sheet of ECM which forms the interface
between the epithelium and the surrounding connective tissue or stroma. The basement
membrane plays an important role in mediating epithelial cell adhesion, polarity, gene
expression, proliferation, migration and differentiation (Danen and Yamada, 2001). Integrity
of the basement membrane is vital to maintain tissue structure and loss of the basement
membrane can result in epithelial cell death and epithelial-stromal transition, as seen in the
regressing Mullerian duct (discussed in section 1.3.1.1) (Dyche, 1979; Ikawa et al, 1984;
Inomataefa/, 1989; Austin, 1995).
The basement membrane is made up of 3 layers: the lamina lucida which lies nearest the
tissue it is supporting (i.e. the epithelium), the middle dark lamina densa, and the lamina
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fibroreticularis which merges with the supporting tissue (i.e. the stroma) (summarised in
Alberts, 1994). The basement membrane is mainly made by the cells that rest upon it (i.e.
epithelia) and is composed normally of type IV collagen, heparan sulphate and structural
glycoproteins (summarised in Alberts, 1994). These structural glycoproteins include
fibronectin, entactin and laminin and bind the basement membrane and the underlying
connective tissue to the cell membrane it is supporting (Erickson and Couchman, 2000).
Laminin is one of the first ECM proteins made in the developing embryo with early
embryonic basement membranes mainly composed of laminin with little or no collagen IV
(Dziadek and Timpl, 1985). Laminin is widely expressed, produced mainly by epithelial
cells and is involved in a variety of processes such as adhesion, migration, embryo
development and wound healing (Aumailley and Smyth, 1998).
Fibronectin is another extracellular adhesion protein however it promotes attachment of
fibroblasts to the ECM, rather than epithelial cell attachment as does laminin. Fibronectin is
secreted by fibroblasts and accumulates along the interface between the epithelium and
stroma and attaches cells to a variety of extracellular matrices, except type IV matrices that
involve laminin as the adhesive molecule (Ruoslahti, 1981). Fibronectin is involved in many
cellular processes, including tissue repair, embryogenesis, blood clotting, and cell
migration/adhesion. Fibronectin sometimes serves as a general cell adhesion molecule by
anchoring cells to proteoglycan substrates or organises cellular interactions with the ECM by
binding to different components of the extracellular matrix and to membrane-bound
fibronectin receptors on cell surfaces (summarised in Alberts, 1994). Like many other
cytoskeletal proteins, fibronectin plays a role in regulating cell structure and behaviour and
redistribution of fibronectin can be associated with epithelial differentiation (Paranko et al,
1983). The importance of fibronectin in cell migration events during embryogenesis has
been documented in several contexts: for example, during vertebrate limb development the
pattern of fibronectin deposition dictates the patterns of precartilage cell adhesion to the
ECM, thus determining limb-specific patterns of chondrogenesis (Tavella et al, 1997).
Changes in fibronectin levels have also been associated with altered epithelial cell
proliferation in response to hormones in the mammary gland (Woodward et al, 2001).
Furthermore, fibronectin has been reported to increase matrix-metalloproteinase 2 (MMP-2)
activity and induce epithelial cell loss in mammary gland involution after hormone
withdrawal (Schedin et al, 2000). Taken together, these results suggest that the basement
membrane and its components are vital in maintaining tissue integrity and interruption to the
basement membrane can result in loss of the epithelium and therefore degeneration of the
tissue.
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1.9 Cytoskeleton
As well as the ECM regulating cell behaviour and hence organogenesis, all mammalian cells
have a cytoskeletal network in their cytoplasm which also plays a vital role in maintaining
cell shape, allowing cell movement and division and mediating intracellular transport
(summarised in Alberts, 1994). This cytoskeleton is composed of microtubules, actin
filaments and intermediate filaments (IF) (summarised in Alberts, 1994). There are 5 types
of IF: Type I & II - Cytokeratins, which are found in epithelial cells; Type III - Vimentin,
desmin, peripherin, which provide mechanical strength to cells; Type IV - neurofilaments,
which strengthen the long axons of neurons; and Type V - lamins, which stabilise the inner
membrane of the nuclear envelope (summarised in Alberts, 1994).
Despite their chemical diversity, IFs all play similar roles providing a supporting framework
within the cell, connecting the membrane and nucleus and thus regulating protein
localisation and transmission of signals (Paramio and Jorcano, 2002). IFs could therefore
play a vital role in organogenesis, more specifically in mediating signals between the stroma
and epithelium, and disruption to the cytoskeleton could result in impaired inter-cellular
signalling and thus lead to degradation of the tissue. IFs interact with proteins which can
regulate their behaviour thus causing IF re-organisation or collapse: these proteins are often
signal transducers and their interaction with IFs can alter the signalling potential and hence
alter tissue morphogenesis (Paramio and Jorcano, 2002).
Expression of the early stromal IF, vimentin, is often transient with its expression preceding
expression of other type III IFs during differentiation: for example, vimentin is expressed in
all fibroblasts and is believed to play a role in cell motility, but it is often subsequently
replaced by desmin as the cells differentiate into muscle cells. However, aberrant expression
of vimentin can result in abnormal cell behaviour. This can be seen in epithelial cells that
have metastasised in which vimentin is re-expressed and cytokeratin expression is lost, thus
explaining the increased invasive capacity of the cells (Singh et al, 2003). This increase in
vimentin and decrease in cytokeratin in epithelial cells is a sign of epithelial-stromal
transformation, as discussed above. During this process, a decrease in cell adhesion
molecules is also often observed, especially E-cadherin (Avizienyte et al, 2002).
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1.10 Conclusions
It is widely accepted that androgens play a role in mediating WD stabilisation and
development, however the mechanisms, the precise timing of events and the downstream
signalling pathways involved in this remain somewhat of a mystery. The experimental work
undertaken in this thesis focuses on the upper segments of the WD and the mechanisms
involved in both its initial rescue in males and its subsequent differentiation into the
epididymis and vas deferens. These adult derivative organs are vital for the maturation and
transport of sperm, therefore normal development of these structures is fundamental for
normal male fertility. It has been shown by many researchers that impaired androgen action
in the fetus interferes with this developmental process. However, most researchers have
examined the effects in adult tissues, rather than in the fetus, and as yet the mechanisms
involved are not understood. It is feasible that stromal-epithelial interactions, possibly acting
via the ECM, are likely to be involved since they play a major role in mediating the
development and differentiation of other tissues in both the male and female reproductive
tract.
Over 20 years ago, Wilson and colleagues (1981) wondered how tissues develop the capacity
early in fetal life to respond to hormonal stimulation later in development and how the same
hormonal signal can be translated into different physiological effects in different tissues.
This phenomenon remains unanswered today but insight into this will help us to understand
the mechanisms involved in male reproductive development and more specifically, WD
development.
This previous research led us to hypothesise that androgens control WD stabilisation and
differentiation by acting on the stroma and mediating the patterning and coiling of the future
epididymis via stromal-epithelial interactions. The primary aim of this thesis was therefore
to investigate the impact on the fetal WD of impaired androgen action. Pregnant rats were
exposed to the anti-androgen flutamide and the WDs from the male offspring were examined
at both the gross and histological level (Chapter 3). Chapter 4 focuses on the further
characterisation of the histological changes in the fetal WD after flutamide exposure using
markers of normal WD development and compartmentalisation. Previous studies have
interfered with androgen action during the entire window of male reproductive development
(el4-21), therefore studies were designed to investigate the precise window of androgen
action in WD development by examining the effect of flutamide exposure either during the
initial window of stabilisation (el4-17) or during morphological differentiation of the WD
(e 19-21) in the rat (Chapter 5). Since the WD naturally regresses in female fetuses, this
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provided a unique opportunity to examine the impact on the WD in the male of artificially
reducing androgen action compared to a naturally occurring model (Chapter 6). These
studies were performed in parallel with an investigation of impaired WD development in
animal models with more complete reduction in androgen action, namely Tfm mice in which
the AR is inactive and rats exposed to DBP + flutamide in which both testosterone synthesis
and action are impaired (Chapter 6). The natural model of female WD regression was
further utilised to examine whether exogenous testosterone exposure was sufficient to rescue
and differentiate the female WD or whether some other testicular factor also plays a role in
male WD development (Chapter 7). Finally, chapter 8 summarises and discusses the main
findings of this research and examines the contribution made to our further understanding of
the mechanisms and timing ofWD development.
1.11 Aims
The main aims of this thesis are:
To examine the role for androgen action in fetal WD development.
To investigate the cellular and molecular mechanisms involved in fetal WD development
and their perturbation by anti-androgen treatment.
To investigate the role for stromal-epithelial interactions in WD development.
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2 General Materials and Methods
The aim of this project was to investigate the role for androgens in the development of the
Wolffian duct (WD). This involved the use of control rats for investigating the timing of
natural WD development and regression as well as for in utero experiments manipulating
androgen action. Details on the sourcing of the biological tissues, their handling and their
experimental processing are provided in this chapter. Where specific procedures were used,
further information is provided in the relevant experimental chapter.
2.1 Animal work
All animal studies were carried out in accordance with the Animal (Scientific Procedures)
Act 1986. Wistar rats were bred and maintained in our own animal facility, the BRF,
provided by the University of Edinburgh. Daily animal husbandry and the majority of the
licensed procedures were carried out by Mark Fisken of the MRC, for which 1 am extremely
grateful. All procedures were undertaken according to UK Home Office regulations, under
project license 60-3045, held by Prof Richard Sharpe.
2.1.1 Welfare conditions
Animals were housed under standard conditions and had access ad libitum to fresh tap water
and a soy-free breeding diet (Type 3, soy free, rat; SDS diets; Dundee, UK). Light was
provided from 7am until 7pm daily, humidity was kept at 55% and the temperature
maintained between 20 -25°C.
Rats were housed in clear cages with solid bottoms, contained bedding, consisting of wood
shavings and corn cob, and a cardboard tunnel for environmental enrichment (BS&S,
Scotland). Up to six females were housed together after mating whereas stud male rats were
singly housed, except during mating.
For experiments that allowed dams to deliver pups and pups to develop postnatally, dams
were individually housed just prior to parturition until weaning of the pups after 21 days old.
2.1.2 Time-matings
Grid bottomed cages were used for mating to allow copulatory plugs to fall through the cage
and so be detected on trays below. Time-matings were set up to allow accurate calculation
of their stage of gestation. One stud male and one female rat were paired together in grid
bottom cages at 08.00 and monitored hourly for the presence of a vaginal plug. Detection of
a copulatory plug was taken as evidence of mating: this was defined as embryonic day 0.5
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(e0.5). Once a positive mating was detected, the female was removed from the male rat. If
mating was not detected by 16.00, males were removed from the mating cage overnight and
pairings set up again at 08.30 the following day. Stud males were derived from the in-house
colony and were between 6-12 months of age at the time of mating. Stud males were retired
from the colony as plugging efficiency decreased, approximately every 3-6 months. Dams
were at least 10 weeks old at mating and where possible, proven dams were used. This
standardisation of husbandry practices helped to maximise the reproducibility of the
experimental work.
2.2 In utero treatments
Pregnant dams were randomly allocated to treatment groups, summarised in Figure 2.1.
Dams were dosed once daily between 08.30-10.00 by either gavage or subcutaneous
injection and control dams were treated daily with the vehicle alone. Dams were weighed
just prior to treatment to enable dosing of accurate bodyweight related volumes. Dams were
checked daily for signs of toxicity and any treatment related changes in animal welfare.
Control litters were dosed alongside each new series of treatments.
Throughout this thesis, offspring from dams exposed to any of the following compounds
during pregnancy will be referred to a treated "in utero" or "flutamide/testosterone/DBP
exposed". This does not mean that the animals were directly exposed but that fetuses were
exposed indirectly via the pregnant dam.











e21.5 birthe13.5 e15.5 e19.5








Figure 2.1 Summary of the maternal treatment regimes used.
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2.2.1 Gavage
Dosing by gavage is a Home Office recognised route and caused minimal discomfort to the
rats. The appropriate volume of test compound was taken up in a disposable plastic 1ml
syringe (B-D Plastipak) and transferred directly into the pregnant adult female rats' stomach
using the attached 10-12cm long 15-16G commercial blunt ended steel gavage cannula
(Medicut, Sherwood Medical Industries Ltd., UK).
2.2.1.1 Flutamide
Flutamide (Sigma, Poole, UK), a competitive androgen receptor antagonist, is a yellow
powder stored at room temperature. Flutamide is insoluble in oil therefore was dissolved in
DMSO (2.5%; Sigma) prior to diluting in pure corn oil (supermarket bought) to 1 mlkg"'
maternal bodyweight. For example, to dose at lOOmgkg"' bodyweight, lOOmg flutamide was
dissolved in 25 pi DMSO then made up to 1 ml with corn oil, and administered at a volume
of lmlkg"' maternal weight. Flutamide was freshly prepared for each experiment and stored
at room temperature between dosing: any excess was disposed of appropriately at the end of
each study.
Flutamide was administered by gavage to pregnant rats on el 5.5-e21.5 at 50 mgkg"' (n=24
dams) or 100 mgkg"1 (n=23) bodyweight. These doses were selected based on results
previously reported highlighting a high incidence of male reproductive tract malformations
without any adverse toxicological effects (Imperato-McGinley et al, 1992). Dosing was
undertaken from el5.5 as this is when the fetal testis begins androgen synthesis (Warren et
al, 1972).
2.2.1.2 DBP
Di-rt-butyl phthalate (DBP), CAS No.: 84-74-2, a viscous pale yellow oil, stored at room
temperature (Sigma D-2270, >99% pure). DBP is lipid soluble therefore was diluted in pure
corn oil to 1 mlkg"1 dam bodyweight. For example: to dose at 500 mlkg"' maternal
bodyweight, 5 ml of DBP was made up to 10ml with corn oil, and administered at a volume
of 1 mlkg"1 maternal bodyweight. DBP solutions were freshly prepared for each experiment
and were stored at room temperature between administrations: any excess was disposed of
appropriately at the end of each study.
DBP was administered by gavage to pregnant rats from el 3.5-e21.5 at 500 mgkg"1
bodyweight (n=22). Previous studies have undertaken dose response studies exposing
pregnant rats to 4, 20, 100 or 500 mgkg"' DBP and have shown that exposure to 500 mgkg"'
did not result in any adverse toxicological effects in the dam or increased fetal mortality but
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did cause a high incidence of male reproductive tract abnormalities (Ema et al, 1997;
Mylchreest et al, 2000; Foster et al, 2001).
2.2.2 Subcutaneous injection
Dosing by subcutaneous injection is a Home Office recognised route and caused minimal
discomfort to the rats. The appropriate volume of test compound was taken up in a
disposable plastic lml syringe (B-D Plastipak) and injected into the pregnant adult female rat
using a 25G needle.
2.2.2.1 Testosterone Proprionate
Testosterone proprionate (TP; T-1875; Sigma) is a solid white powder that is insoluble in
water and is stored at room temperature. TP was dissolved in pure corn oil (supermarket
bought) to 5 or 20 mlkg"'. For example, to dose at 20 mgkg"' maternal bodyweight, 20 mg
TP was dissolved in 0.4 ml corn oil, and administered at a volume of 0.4 mlkg"1 maternal
bodyweight. TP was freshly prepared for each experiment and stored on a Cozee Comfort
heating mat (Burco Dean Appliances Ftd, Burnley, UK) set at setting 1 (29°C) between
dosing to prevent precipitation of the TP out of solution. Any excess TP was disposed of
appropriately at the end of each study.
TP was administered by subcutaneous injection to pregnant rats on el4.5-e21.5 at 5 mgkg"1
(n=8 dams) or 20 mgkg"1 (n=18) maternal bodyweight. These doses were selected based on
results previously reported showing that doses above 1 mg TP (per rat) increased female
fetal T by 80%, increased female ano-gential distance (AGD) and rescued the seminal
vesicles without a high incidence of toxicological effects (Wolf et al, 2002).
2.3 Necropsy
Dams were killed by inhalation of carbon dioxide and subsequent cervical dislocation and
fetuses recovered at el7.5 - e21.5. Neonates were killed by decapitation and postnatal
animals, older than pndlO, were killed by inhalation of carbon dioxide and subsequent
cervical dislocation. Fetal (e21.5), neonates and postnatal animals were weighed and AGD
was measured using digital callipers (Faithfull Tools, Kent, UK) (detailed in section 2.3.3).
2.3.1 Gross dissection
2.3.1.1 Fetuses
Fetuses were removed from the dam using an established gross dissection technique. The
pregnant dam was positioned supine and the abdomen opened to allow removal of the intact
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uterus. Fetuses were removed from their amniotic sac and their umbilical cord was cut prior
to decapitation and immersion of the body in ice-cold phosphate buffered saline (PBS,
Sigma). Fetuses were transported in PBS on ice to minimise degeneration prior to fine
dissection and tissue recovery.
2.3.1.2 Postnatal rats
The abdomen of the supine postnatal male rat was opened and testes and epididymides
pulled out of the scrotal sac by the fat pad. The vasa deferentia were cut midway down and
the testes, epididymides and vasa deferentia removed from the rat. Males were examined for
the presence and morphology of the seminal vesicles and prostate.
2.3.2 Fine dissection
2.3.2.1 Fetal dissections
Gonads and reproductive tracts were recovered from fetuses by microdissection and
examined using a Leica MZ6 dissecting microscope. Gonads were trimmed off the WD or
Mtillerian duct (MD) and reproductive tracts were photographed using a Leica ICA camera.
Reproductive tracts from control and treated males and females were analysed
microscopically, at the time of dissection, for any gross morphological abnormalities.
Considerable variation was seen in the degree of regression of the WDs, therefore careful
note was taken of any macroscopic abnormalities, including the degree of coiling and
interruption of the WD lumen. This was particularly relevant in fetuses at e21.5 when
greater damage and variation was seen than in younger fetuses.
2.3.2.2 Postnatal dissections
Gonads were carefully dissected off the reproductive tracts and epididymides and vasa
deferentia were analysed for any gross morphological abnormalities. Reproductive tracts
were photographed using a D70 camera (Nikon, Surrey, UK) fitted with a Nikon AF Nikkor
24-120mm lens (Nikon).
2.3.3 Measurement of anogenital distance
The distance between the anus and the base of the genital tubercle (anogenital distance,
AGD) increases in males in response to androgens and it is widely believed that AGD
reflects the degree of androgenisation/masculinisation of the animal (reviewed in Swan et al,
2005; reviewed in Edwards et al, 2006). Prior to recovery of reproductive tracts, AGD was
measured in fetal (e21.5) and postnatal animals using digital callipers (Faithfull Tools, Kent,
UK). This involved measuring the distance between the base of the genital tubercle and the
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anus. These measurements were undertaken separately by two independent scientists and
average values were recorded.
2.4 Tissue preservation
Isolated fetal tissue was preserved by snap-freezing or fixed in Bouin's or 4%
paraformaldehyde (PFA) while postnatal epididymides and vasa deferentia were fixed in
Bouin's. All fixatives were prepared by the core histology facility, for which I am very
grateful (section 2.14).
2.4.1 Frozen tissue
Isolated male WDs were snap frozen in 1.5 ml cryovials on dry ice then archived at -80°
until required.
2.4.2 Tissue fixation
2.4.2.1 PFA for whole mounts
Isolated male and female fetal reproductive tracts were fixed in 4% PFA in an airtight
container for 24 h at 4° C prior to dehydration in 25% methanol in PBS, 50% methanol in
PBS, 75% methanol in PBS then 100% methanol. Fixed reproductive tracts were stored in
methanol in air tight containers at -20°C.
2.4.2.2 Fixation in Bouin's
Isolated male and female fetal reproductive tracts were fixed in Bouin's for 1 h at room
temperature in an air-tight container while postnatal epididymides and vasa deferentia were
fixed in Bouin's for 6 h. Bouin's fixed tissue was subsequently transferred into 70% ethanol
and processed for 17.5 h in an automated Leica TP1050 processor (Leica Microsystems,
Milton Keynes, UK). Processed tissue was embedded by hand in liquid paraffin wax and the
cooled wax block was stored at room temperature until required. Fetal and postnatal
reproductive tracts were deliberately orientated in the paraffin wax to lie horizontally thus
standardising the plane of section obtained and allowing complete cross-sections of the
whole epididymis to be obtained. This was carried out in our core histology laboratory by
Mike Millar, Sheila MacPherson and Arantza Esnal, for which I am extremely grateful.
2.5 Histological analysis
Gross histological analysis was performed on WD sections stained with haematoxylin and
eosin, using standard protocols. Note was taken of any histological abnormalities including
abundance of epithelial cross-sections, swollen lumens and epithelial malformation. Harris's
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haematoxylin (section 2.14) stains cell nuclei blue. Slides were immersed in a bath of
haematoxylin for 5 min, rinsed in tap water, briefly immersed in 1% acid alcohol to remove
any non-specific cytoplamsic staining and rinsed in tap water. Slides were immersed in
Scott's tap water for 30 s to allow the blue dye to develop. This was checked using a
standard light microscope. Eosin (section 2.14) was used to stain cell cytoplasm pink. Slides
were immersed in a bath of eosin for 30 s then rinsed thoroughly in tap water. The pink
colouration was checked using a standard light microscope. Following staining, slides were




Immunohistochemistry was performed on isolated reproductive tracts, using standard avidin
peroxidase protocols, to highlight the location of proteins of interest. All immunostaining, or
its absence, was reviewed in the context of the tissue morphology and treatment, alongside
proper experimental control tissue. The principles applied and the protocols used are outlined
below.
• dewaxing and rehydration of sections
• retrieval of the target antigen for detection by the specific primary antibody
• blocking non-specific antigens
• incubation of tissue with specific primary antibody
• detection of the primary antibody by an amplification system
• visualisation of antibody localisation
• counterstaining of non-immunostained tissue
2.6.1.1 Immunohistochemistry on sections
2.6.1.1.1 Sectioning
Wax blocks containing fixed tissue were chilled on ice prior to sectioning to make them
more rigid and thus easier to cut. 5 pm sections were cut using a microtome (Leica, model
RM 2135) and floated in a waterbath (Lamb RA, model E/65) at 45-50°C to smooth out any
wrinkles. Sections were then mounted onto electrostatically charged glass slides (BDH, Cat
No.: 406/0179/00). Slides were stacked in a metal rack and dried overnight in an oven at 50-
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60°C (Lamb RA, model E28.5) to ensure sections were adhered to the glass slides. Slides
were cooled and stored at room temperature in a dust free environment.
2.6.1.1.2 Dewaxing and rehydrating
Sections were deparaffinised in Histoclear (National diagnostics, Hull, UK) at room
temperature for 5 min, x2. Tissue was rehydrated by immersion in 100% ethanol for 30 s x2,
95% for 30 s, 75% for 30 s then washed in water.
2.6.1.1.3 Antigen retrieval
Fixatives induce cross-linking in order to preserve tissue integrity, however, this can often
mask proteins (antigens) and thus prevent their immunodetection. In order to unmask these
antigens, sections were exposed to high temperature and pH change as detailed by Shi and
colleagues (1993). Antigen retrieval was performed using 0.01 M citrate buffer, pH 6.0 in a
domestic pressure cooker (Tefal, Clypso). Sections were immersed in 2 1 of boiling buffer,
pressure cooked for 5 min at full pressure, left to stand for 20 min then cooled under running
water.
2.6.1.1.4 Blocking
Immunhistochemistry can result in non-specific binding due to non-specific affinity of the
primary or secondary antibody or detection reagents to molecules other than the desired
antigen. This non-specific binding was blocked deliberately before the primary antibodies
were added.
Horseradish peroxidase amplification was used (section 2.6.1.1.6) therefore endogenous
peroxidase activity must be blocked to prevent non-specific binding. This was carried out by
immersing sections in 3% hydrogen peroxide in methanol (30% H202, BDH) for 30 min on a
rocker at room temperature. Slides were washed in a rocking bath of tap water for 5 min.
Non-specific binding of the secondary antibody was prevented by incubating sections in a
dilute solution of serum from the species in which the secondary antibody was raised. In
most cases, a goat raised secondary antibody was used therefore slides were incubated in
normal goat serum (NGS; Autogen Bioclear UK Ltd, Wiltshire, UK) diluted 1:4 in TBS
containing 5% bovine serum albumin (BSA; Sigma). Slides were removed from water and
tissue was used to carefully dry around the section to remove excess buffer. Blocking serum
was added to sections and slides were maintained in a humidity chamber at room
temperature, for 30 min.
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Slides were washed well between each step in order to removed residual reagents. All
washes between antibody or reagent incubations comprised two 5 min washes on a rocker
(20-40 rpm) at room temperature in TBS (section 2.14).
2.6.1.1.5 Primary antibodies
Blocking buffer was replaced on the sections with a solution of primary antibody diluted in
blocking serum to an optimised concentration. The slides were incubated overnight in the
humidity chamber at 4°C. The exact conditions (concentration/temperature/duration) were
optimised for each primary antibody used. Table 2.1 below summarises the general
conditions used. Control sections were incubated with blocking peptide when available or
blocking serum alone to confirm antibody specificity.
Table 2.1 Summary of primary antibodies used for immunohistochemistry. Santa Cruz
products supplied via Autogen Bioclear UK Ltd, Wiltshire, UK.
Target Antigen Source Dilution Retrieval Host Species
Androgen Receptor Santa Cruz 1:50 Citrate Rabbit
Smooth Muscle Actin Sigma 1:10000 None Mouse
Pan-cytokeratin Sigma 1:200 Citrate Mouse
Phospho-Histone H3 Upstate Biotechnology 1:1000 Citrate Rabbit
Cleaved
Caspase 3
Cell Signalling 1:200 Citrate Rabbit
Desmin DAKO 1:400 Citrate Mouse
Vimentin DAKO 1:1000 Citrate Mouse
Laminin Abeam 1:100 Citrate Rabbit
E-cadherin BD Biosceinces 1:200 Citrate Mouse
N-cadherin Zymed 1:500 Citrate Mouse
CD45 BD Bioscience 1:50 Citrate Mouse
CD68 DAKO 1:500 Citrate Mouse
Neutrophil Elastase DAKO 1:500 None Sheep
2.6.1.1.6 Secondary antibodies
After washing off the primary antibody, sections were incubated with the appropriate
secondary antibody to amplify the localisation of the primary antibody. The secondary
antibody was raised against a species-specific sequence on the primary antibody. A biotin
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labelled goat secondary antibody was diluted 1:500 in blocking serum and incubated on
sections for 30 min at room temperature.
Table 2.2 Summary of secondary antibodies used for immunohistochemistry




This biotinylated secondary antibody signal was amplified by incubation for 30 min with
avidin-biotin conjugated with horseradish peroxidase diluted in 0.05M Tris-HCl, pH 7.4
according to manufacturers instructions (ABC-HRP; DAKO, Ely, UK). This system takes
advantage of avidin and biotin having a very high and specific binding affinity for each other
(Fig. 2.2).
Figure 2.2 Schematic representation of the principles of the biotin amplification
immunohistochemistry protocol. Proteins are expressed in cells, with particular parts of
them recognised as antigens. Specific primary antibodies then bind to these antigens. A
biotin-labeled secondary antibody binds to the species-specific regions on the primary
antibody and an avidin/biotin/ enzyme complex (ABC) associates itself with the conjugated
biotin. The resulting enzymatic reaction with the chromagenic substrate creates a visible
colour change thus localizing the site of the antigen expression.
2.6.1.1.7 Antigen detection
Antibody localisation was determined using 3,3'-diaminobenzidine (liquid DAB+; DAKO).
DAB chromagen was diluted in the specific buffer, according to manufacturers' instructions,
just prior to use. Sections were incubated with DAB until staining was optimally detected in
control sections: this varied depending on the antibody and target tissue. The reaction was
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stopped by immersing the sections in distilled water. A colour was generated at the site of
the original antigen thus allowing its localisation within the tissue.
2.6.1.1.8 H & E counterstain and mount
Sections were lightly counterstained in Harris's haematoxylin, to stain cell nuclei blue, as
described above (section 2.5). Slides were rinsed in tap water, dehydrated by immersing in
70% ethanol for 20 s, 85% ethanol for 20 s, 95% ethanol for 20 s, 100% ethanol for 20 s x2.
Slides were then immersed in HistoClear™ (R A Lamb Limited, Eastbourne, UK) for 5 min
and finally cleared in Xylene for 5 min. After immunostaining, glass coverslips (VWR,
Lutterworth, UK; 22x32mmxl,Cat No.: 631-0133) were mounted on the sections using
Pertex (Cell Path, Hemel Hempstead, UK), a solvent based glue. Slides were allowed to dry
prior to archiving and storage in a dry, room temperature environment.
2.6.1.1.9 Light microscopy and Provis
Cellular sites of expression of target proteins were determined and slides photographed using
a Provis AX70 (Olympus Optical, London, UK) microscope fitted with a Canon DS6031
camera (Canon Europe; Amsterdam).
2.6.1.2 Automated immunohistochemistry
An automated immunostaining machine was utilised to allow high throughput staining in a
controlled and repeatable manner. The Bond-X automated immunostaining machine (Vision
Biosystems, Newcastle, UK) permitted staining of 30 slides per run. Exact conditions were
optimised for each antibody and all kits were purchased from Vision Biosystems. Sections
were deparaffinised, rehydrated (section 2.6.1.1.2) and antigen retrieval (section 2.6.1.1.3)
performed as detailed above. A specific polymer high contrast programme was used for all
antibodies, which applied the same principles as described above (section 2.6.1). Briefly,
slides were peroxidase blocked for 5 min, incubated for 2 h with the primary antibody
diluted to the optimal concentration in the diluent supplied and then incubated with the post¬
primary reagent for 15 min. Control sections were incubated with diluent alone to confirm
antibody specificity. Sections were then incubated with the polymer reagent for 15 min to
increase sensitivity of detection prior to DAB detection for 10 min. Sections were
counterstained in haematoxylin for 5 min. Slides were then removed from the machine and
dehydrated and mounted as detailed above (section 2.6.1.1.8).
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2.6.1.3 Fluorescent immunohistochemistry
Fluorescent immunohistochemistry allows better visualisation of some antigens and allowed
co-localisation ofmore than one antigen simultaneously.
Sections were dewaxed, rehydrated and antigen retrieval performed as detailed above
(section 2.6.1.1). Sections do not require a peroxidase block as no peroxidase reagents were
used in the detection method. All washes were performed using PBS (Sigma) and serum
block was diluted in PBS/BSA rather than TBS/BSA.
2.6.1.3.1 Primary Antibody
After incubation with blocking serum, sections were incubated overnight at 4°C with the
primary antibody diluted in serum/PBS/BSA.
2.6.1.3.2 Secondary Antibody
After washing in PBS, sections were incubated with a secondary antibody: this varied
between protocols and the fluorescent chromagens used are summarized in Table 2.3. Slides
must be protected from the light once the fluorescent chromagen was added to the slides to
prevent bleaching of the fluorescent signal.
2.6.1.3.2.1 Direct method
This was a single-step process whereby sections were incubated with a secondary antibody
directly labelled with a fluorescent tag. For example, pan-cytokeratin localisation was
detected by incubating sections for 1 h with goat anti-mouse secondary antibody directly
conjugated with alexa fiuor 488 (Molecular Probes, Poort Gebouw, Holland) diluted 1:200 in
PBS to produce green fluorescence.
2.6.1.3.2.2 Indirect method
This was a two-step process allowing amplification of the immunofluorescence. Firstly,
sections were incubated with biotin labelled secondary antibody, raised against a species-
specific sequence on the arm of the primary antibody. This signal was then amplified and
detected using a fluorescently labelled streptavidin complex which bound to the biotin. For
example, AR immunostaining was detected by incubating sections with biotinylated goat
anti-rabbit IgG secondary antibody (DAKO) diluted 1:500 in NGS/PBS/BSA for 30 min
followed by incubation for 1 h with streptavidin-conjugated alexa 546 (Molecular Probes),
producing red fluorescence.
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2.6.1.3.3 Counterstain and mount
Slides were washed in PBS and counterstained by incubation with either To-Pro 3
(Molecular Probes) for 2 min diluted 1:2000 in PBS, or with DAPI (DAPI; Sigma) for 10
min diluted 1:1000 in PBS. Both stains result in a nuclear-specific blue fluorescent label.
Slides were then washed in PBS and mounted in Mowiol mounting medium (Calbiochem;
Lutterworth, UK).
2.6.1.3.4 Fluorescent Microscopy
Fluorescent images were captured using a Zeiss LSM 510 Meta Axiovert 100M confocal
microscope (Carl Zeiss Ltd, Welwyn Garden City, UK).
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To ensure reproducibility of results and allow accurate comparison of immunostaining
between treatment groups, sections from control and treated animals were processed in
parallel on at least three occasions: sections from at least 3 animals in each treatment group
were run on each occasion. Appropriate negative controls were included, whereby the
primary antibody was replaced by blocking peptide when available or normal serum alone,
to ensure that any staining observed was specific: none of the antibodies used showed other
than minor non-specific staining.
2.6.2 Western blots
Western blotting allows the separation of a mixture of proteins according to their molecular
size. This method exploits the protein electro-mobility through a gel with specific sized
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pores. These proteins are transferred onto a membrane, which then are labelled with
antibodies specific to the protein of interest. The antibody binding is then visualised and
quantified, as detailed below. To ensure reproducibility of results, each blot was performed
several times and protein was isolated from at least 3 WDs from 3 different litters each time.
2.6.2.1 Protein extraction
Lysis buffer was used to break open the tissue thus allowing cells to release their proteins.
Whole cell protein was harvested from frozen tissue using RIPA lysis buffer (section 2.14).
In order to prevent degradation, tissue was kept frozen on dry ice until the lysis buffer was
added and protease inhibitors were added to the lysis buffer. SDS was added to break non-
covalent bonds within proteins and to give each protein a negative charge to facilitate their
separation in acrylamide gels. Samples were homogenized in 75 pi RIPA buffer using a
cordless handheld motor driven grinder (Sigma, Z35,997-1) with a pestle designed to fit the
1.5 ml tube (Sigma, Z35,996-3): this disrupted the tissue and thus release of the protein. The
homogenate was then incubated on ice for 1 h prior to centrifugation at 2500 rpm for 10 min.
The protein enriched supernatant was collected in a fresh 1.5 ml Eppendorf™ and stored at -
80°C until required.
2.6.2.2 Protein quantification
In order to correct for differences in amounts of protein recovered from each sample, protein
concentration was quantified for each sample. The protein concentration was determined
using a Biorad BCA protein assay kit according to manufacturer's instructions (Biorad
Laboratories; Hemel Hempstead, UK) using solutions of known concentration of BSA in
RIPA to standardise. Alternatively, protein concentrations were determined using the
Genequant RNA/DNA calculator (Pharmacia Biotech, San Francisco, UK) using solutions of
known concentration of BSA in RIPA to standardise.
2.6.2.3 Electrophoresis in acrylamide gels
2.6.2.3.1 Preparing acrylamide gels
SDS gels were prepared in two parts: a large pored upper stacking gel that contained the
wells and concentrated the sample prior to separation and a resolving gel below it with
smaller pores. Resolving gel (5 ml; section 2.14) was pippetted into a plastic cassette
(Invitrogen, Paisley, UK) and allowed to set at room temperature for 20 min. This was
overlaid with distilled water to block out any air and so allow the gel to set. Once set, the
water was poured off and the stacking gel (2 ml; section 2.14) was pippetted into the cassette
on top of the resolving gel. A 10 or 15 well comb was slid into place, ensuring no air
bubbles were present to interfere with efficient loading and running of the gel. Gels were left
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to set then stored in a humid environment at 4°C. Gels were prepared with 7.5%, 10% or
12% weight/volume acrylamide to allow optimal separation of proteins: larger proteins pass
through lower percentage gels easier and so faster while higher percentage gels allow protein
molecules to run slower thus better separating out proteins that are of similar sizes.
2.6.2.3.2 Preparing samples
Optimally, 15 pg of protein was used but the amount of protein used in each Western blot
was restricted by the sample availability, concentration and the finite volume of the wells in
the gels.
Proteins were denatured by boiling with 5 pi 2x SDS loading buffer (1.0 ml glycerol, 0.5 ml
B-mercaptoethanol, 3.0 ml 10% SDS, 1.25 ml 1.0M Tris-HCL pH6.7 and 1-2 mg
bromophenol blue) for 5 min before loading each protein extract onto a cast polyacrylamide
gel (7.5-12%). Protein samples were carefully loaded into the wells of the cast gel and 5 pi
of a pre-stained multi-coloured standard for SDS-PAGE (Invitrogen, LC5725) was loaded in
at least one lane per gel. This marker included proteins of known molecular weight thus
allowing comparison against the expected position of the target protein.
2.6.2.3.3 Running gels
SDS-PAGE relies on proteins' ability to migrate through polyacrylamide gel pores, from the
cathode to the anode, when under an electrical charge: proteins are treated with SDS to make
them negatively charged. The gel was positioned in the tank with 1 x SDS running buffer
(25mM Tris Base, 250mM Glycine and 0.1% SDS) and subjected to electrophoresis at 100V
under reducing conditions until the pre-stained multi-coloured standard reached the bottom
of the gel, approximately 1-2 h. Care was taken to ensure the proteins were not allowed to
run too far through the gel and so lost off the bottom.
2.6.2.4 Western transfer of proteins
Having separated the proteins according to their molecular weight, they were transferred and
immobilised to a nitrocellulose membrane. The protein gel plates were prised apart and the
protein gel was carefully removed to a petri dish filled with running buffer until the blotting
apparatus was assembled.
The nitrocellulose membrane (Immobilon-P; Millipore, Bedford, MA) was rehydrated in
methanol for 30 s then washed in transfer buffer. The porous pads and 6 pieces of 3mm
Whatman paper were also soaked in transfer buffer to prevent dehydration of the gel when
assembling the blotting apparatus. A gel/membrane sandwich was assembled according to
manufacturers' instructions as shown in Figure 2.3, and placed in a transfer tank. This
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arrangement of the gel and the membrane allows the SDS treated proteins to be transferred
laterally from the gel towards the anode until their migration was stopped by the membrane.
The tank was filled with a methanol transfer buffer (in-house protocol, see below) and




Figure 2.3 Schematic representation of Western blot apparatus
2.6.2.5 Protein detection
The Western blot apparatus was dismantled and the membranes were washed in TBS
containing 0.1% Tween 20 (TBST; Sigma). Antibodies were then used to detect specific
proteins on the membrane.
Two analysis systems were available for detection of the proteins, the Typhoon 9400
variable mode imager (Amersham Bioscience), which utilised a horseradish peroxidase
detection system or the Li-Cor (Li-Cor, Nebraska, USA) which detected the proteins using
fluorescence. The Li-Cor system allows the detection of more than one protein
simultaneously but was not available until my final year, therefore initial Western blot
analysis was carried out on the Typhoon.
2.6.2.5.1 Analysis on Typhoon
2.6.2.5.1.1 Blocking of non-specific binding
As with immunohistochemistry, non-specific binding sites had to be blocked. This was done
by incubating membranes in TBST containing 5% (weight/volume) powder milk (shop
bought) for l h at room temperature.
2.6.2.5.1.2 Primary antibody
Membranes were washed twice in TBST for 5 min then incubated overnight at 4°C with
primary antibody. The same primary antibodies were used as for immunohistochemistry
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(Table 2.1) but were diluted in TBST lOx more than for immunohistochemistry. An anti-B-
tubulin antibody (Sigma) was used as a standardization control, diluted 1:300 in TBST.
2.6.2.5.1.3 Secondary antibody
The secondary antibodies used were directed against the primary antibody host species, as
for immunohistochemistry (section 2.6.1.1.6), and were conjugated with HRP. The HRP
reacted with the chemiluminescent substrate to create light emission at the site of antigen
expression. The specific pattern of light emission was captured by timed exposure to
photosensitive film in a dark room.
After washing off any residual primary antibody with TBST for 5 min (x3), membranes were
incubated for 1 h at room temperature with anti-rabbit horseradish peroxidase or anti-mouse
horseradish peroxidase labelled secondary antibody (Scottish Antibody Production Unit,
Carluke, UK) diluted 1:5000 in TBST/5% milk.
2.6.2.5.1.4 Visualisation of proteins
Membranes were again washed in TBST for 5 min x3 prior to detecting the signal using
Enhanced Chemi-luminescence (ECL plus™, Amersham Biosciences, Buckinghamshire,
UK) Western blot detection reagents according to manufacturers instructions (Amersham
Biosciences). Signals were visualized using high performance chemi-luminescence imaging
film (Amersham Bioscience) and developed using a Xograph compact X4 imaging system
(Xograph, Tetbury, UK). Exposure times were optimised for each experiment according to
the intensity of the signal detected. Antibody specificity was confirmed by the detection of
only one band at the expected size when using each antibody. The intensity of the bands was
then quantified using the Typhoon 9400 variable mode imager (Amersham Bioscience). The
image was analysed using the ImageQuant software (Amersham Life Sciences, UK) and the
area of film exposed to the chemiluminescence was quantified per gel, per antibody and per
sample. The area of exposure equated to the amount of labelled protein present in the
sample. The protein expression level was corrected for loading using B-tubulin and related
to el 9.5 control protein levels.
2.6.2.5.1.5 Stripping of blots
Bound antibodies can be stripped from Western blot membranes, leaving the transferred
proteins intact, to permit hybridisation with another antibody. This allowed quantification of
several proteins on one blot and allowed different protein expressions to be quantified
against each other. This was particularly useful as WDs only yielded small amounts of
protein. Blots could be stripped and re-probed successfully up to 3 times, although care was
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taken to avoid using more than one primary antibody that had been raised in the same
species to minimise background staining. Restore Western Blot Stripping buffer ™ (Pierce;
supplied by Perbio Ltd, Northumberland, UK) was added to the membrane for 1 h at room
temperature. To check for complete stripping, the membrane was then washed in TBST
before incubation with the secondary antibody against the primary antibody being stripped.
The membrane was again washed in TBST then developed using ECL plus™. No bands
should be detected.
2.6.2.5.2 Western blot analysis using the Li-Cor
2.6.2.5.2.1 Blocking
Non-specific binding sites were blocked by incubating membranes for 1 h at room
temperature in Odyssey® blocking buffer (Li-Cor, Nebraska, USA) diluted 1:1 in PBS.
2.6.2.5.2.2 Primary antibody
Membranes were incubated overnight at 4°C with the primary antibody, diluted in Odyssey®
blocking buffer/PBST. Tween was added to the PBS in order to reduce any background.
The same primary antibodies were used as for immunohistochemistry (Table 2.1) but were
diluted lOx compared with the dilution used for immunohistochemistry. An anti-B-tubulin
antibody (anti-mouse, Sigma; anti-rabbit, Santa Cruz) was used as a standardization control,
diluted 1:300.
The Li-Cor allows detection of more than one antibody at a time, therefore 2 antibodies
could be added at once so long as their host species differed so they could be discriminated
by secondary antibodies of different specificities. Before combining 2 primary antibodies,
preliminary blots were performed using each primary antibody alone to confirm the expected
band pattern and eliminate any possible background bands. Both primary antibodies were
diluted, at the appropriate dilution, in the Odyssey® blocking buffer/PBST and incubated
with the membrane simultaneously for 1 h at room temperature.
2.6.2.5.2.3 Secondary antibody
The secondary antibodies used were directed against the primary antibody host species, as
for immunohistochemistry (section 2.6.1.1.6), and were fluorescently labelled. Membranes
and reagents were therefore protected from light from this step onwards.
Residual primary antibody was washed off with PBST for 5 min (x3). Membranes were
incubated for 1 h at room temperature with the appropriate secondary antibody (Table 2.5)
diluted 1:5000 in Odyssey® blocking buffer/PBST. If two-colour detection of two primary
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antibodies was used, both secondary antibodies were added to the membrane simultaneously.
For example, if detecting AR (rabbit) and SMA (mouse) simultaneously, goat anti-rabbit 800
and goat anti-mouse 680 secondary antibodies were added. AR protein would be indicated
by the presence of red bands while SMA would be shown as green bands on the membrane
when visualised with the Li-Cor.
Table 2.4 Summary of secondary antibodies for Western blot detection using the Li-
Cor.





Alexa Fluor ® 680 Donkey anti
goat
Molecular Probes 680/green
Alexa Fluor ® 680 Goat anti
mouse
Molecular Probes 680/green





2.6.2.5.2.4 Visualisation of proteins
Membranes were again washed in PBST for 5 min (x3) then PBS (xl), to remove any
residual Tween, prior to detecting the signal. The membrane was scanned using the Li-Cor,
according to manufacturers' instructions. Antibody specificity was confirmed by the
detection of only one band at the expected size when visualising each antibody. The intensity
of the bands was then quantified, with the area of exposure equating to the amount of
labelled protein present in the sample. If two-colour detection was used, quantification was
carried out for each antibody separately. The protein expression level was corrected for
loading using B-tubulin and related to el9.5 control protein levels.
2.6.2.5.2.5 Stripping the membrane
Bound antibodies were stripped from Western blot membranes after developing to permit
hybridisation with another antibody. Blots could be stripped and re-probed successfully up
to 2 times, although care was taken to avoid overstripping the membrane as this can remove
target proteins. Stripping buffer (25nM glycine pH2.0 + 1-2% SDS) was added to the
membrane for 10-15 min at room temperature. To check for complete stripping, the
membrane was re-scanned to confirm no bands were present. Generally, stripping was not
particularly successful with this detection method and was rarely used.
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2.7 RNA analysis
2.7.1 RNA extraction
RNA was isolated from frozen tissues using the RNeasy Mini extraction kit (Qiagen,
Crawley, UK) according to the manufacturer's instructions. Briefly, samples were
homogenised in the supplied lysis buffer using a cordless handheld motor driven grinder
(Sigma, Z35,997-1) with a pestle designed to fit the 1.5 ml tube (Sigma, Z35,996-3): this
facilitated the disruption of the tissue and thus release of the RNA. Any genomic DNA
contamination was removed from the sample by DNase treatment during extraction using
RNase-free DNase on the column digestion kit (Qiagen) according to manufacturers'
instructions.
2.7.2 RNA quantification
In order to correct for differences in amounts of RNA recovered from each sample, RNA
concentration was quantified using RNA 6000 Nano chips on an Agilent 2100 Bioanalyser
(Agilent Technologies, Wockinghan. UK). This allowed quantification of both RNA
concentration and integrity.
2.7.3 Reverse transcription
Reverse transcription of RNA to cDNA was primed with oligo-dTs or random hexamers,
depending on the final application to be used. Oligo-dTs are specific to mRNAs with a poly
A' tail therefore ensuring amplification from mRNA only, however, they do not always
amplify up the 5' end of long mRNAs. Random Hexamers amplify total RNA therefore they
must be used to amplify ribosomal RNA, vital for Taqman reactions since 18S, a ribosomal
RNA, is used as the internal positive control. Random hexamer primed reverse transcription
will also yield more cDNA.
2.7.3.1 Oligo-dTs
Oligo-dT primed cDNA was amplified using Bioscript Reverse Transcriptase (Bioline,
Germany) according to manufacturer's instructions, as detailed below.
Total RNA l pg
Oligo dT (0.5 pg/pl) (Invitrogen) 1 pi
Water up to 11 ul
Total 12 pi
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Samples were incubated at 70 °C for 5 min then chilled on ice before adding 8 pi of the
following mastermix.
Mastermix:
RNase inhibitor (20units/pl, Promega)
















Total final reaction volume = 20 pi
Samples were incubated at 42°C for 1 h before stopping the reaction by heat inactivating the
enzyme at 70°C for 10 min.
2.7.3.2 Random Hexamers
Random hexamer primed cDNA was prepared using the Applied Biosystems TaqMan ®
reverse transcription kit (Applied Biosystems, Foster City, CA) according to manufacturers'
instructions.
Mastermix:
Actual volume Final Concentration
Water 1.85 pi
1 Ox RT buffer 1 pi lx
25nM MgCl2 2.2 pi 6.25mM
2.5mM dNTP 2 pi 0.5mM
Random Hexamers (50pM) 0.5 pi 2.5pM
RNase inhibitors (20U/pl) 0.2 pi 0.5 U/pl
Reverse Transcriptase (50U/pl) 0.25 pi 1.25 U/pl
RNA (lOOngpl) 2 ml
Total 10 pi
The reagents were added together in a 0.2 ml sterile thin walled PCR tube (Continental Lab
Products, Oxford,UK) and cycled in a thermo-cycler through the following programme:
25°C for 20 min, 42°C for 60 min and 95°C for 5 min.
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2.7.4 Taqman®PCR
Quantitative PCR was performed with the ABI Prism 7900 Sequence Detection System
(Applied Biosystems). TaqMan ® uses a fluorogenic probe to enable the detection of a
specific PCR product as it accumulates during PCR cycles. Expression of specific gene
mRNA was determined using the Assay-On-Demand Gene Expression ™ system (Applied
Biosystems), as detailed in Table 2.5 below. All reagents were obtained from Applied
Biosystems, unless otherwise stated. Samples were run in triplicate on a 96 well MicroAmp
optical reaction plate (Applied Biosystems). The expression level of the specific gene
mRNA was related to an internal control, 18S ribosomal RNA. Appropriate positive and
negative controls were included in each plate. Results shown are the mean of a minimum of
3 WDs per treatment group performed in triplicate on at least 2 occasions.
For each sample the following mastermix was prepared and 25 pi was aliquoted into each
well. The plate was sealed with ABI prism optical adhesive optical cover (Applied
Biosystems) and loaded onto the ABI 7900 HT sequence detection system.
Mastermix:
2x PCR mastermix
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2.7.4.1 Analysis of results
Taqman PCR results are displayed as an amplification plot, which shows the amount of the
reporter dye generated during amplification: this relates directly to the amount of PCR
product formed and thus the amount of target gene expressed in the target tissue. When
analysing the data, the baseline value and threshold must all be considered. The baseline
value refers to basal fluorescence in the reaction plate while the threshold value is the point
at which an increase in signal is associated with an exponential increase of PCR product.
This threshold value should therefore be set in the exponential region of the amplification
plot rather than in the plateau or baseline regions. The ct (threshold cycle) reflects the cycle
number where the fluorescence that is generated in a reaction crosses the threshold. This ct
value reflects the cycle number at which the level fluorescence due to amplification of the





Figure 2.4 A typical amplification curve after a successful Taqman run. a - plateau
phase, b - linear phase, c - expontential phase, d - background, e - baseline. (Adapted from
Applied Biosystems, Relative Quantitation Using Comparative CT - Getting Started Guide).
A relative quantitation assay is used to analyse any changes in gene expression in a given
sample, relative to another reference sample (such as an untreated control sample). This
relative quantification is achieved using the comparative ct method, which utilizes arithmetic
formulas. For each sample the ACT is calculated by subtracting the ct for the internal
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positive control gene from the ct for the target gene; e.g. AR ct - 18S ct. This is then
averaged for the triplicate for each sample and is then compared to a reference sample. This
is calculated by subtracting the ACT for the reference sample from the ACT for the target
sample and is referred to as AACT. An arithmetic formula is then applied to calculate the
fold change in the target gene in the target sample compared to the reference sample: 2-
AACT. Values were expressed as a fold difference relative to uterus, unless otherwise stated.
2.8 Luminal length analysis
Differentiation of WDs was quantified by measuring the luminal length of the epididymal
segment of WDs from control and treated animals: a line was digitally drawn through the
lumen of the WD image taken at time of dissection using the Image J program (National
Institute of Health, USA). This line was drawn from the head of the epididymis, where the
efferent ducts end, to the tail of the epididymal section just prior to the start of the vas
deferens. To ensure reproducibility and to correct for individual variation, luminal length
was measured for WDs from 15-37 animals from at least 3 different litters per treatment
group. Comparisons were then made between control and treatment groups.
Only samples that were analysable were studied: for example, WDs from flutamide-exposed
animals with incomplete lumens (7% of animals at e21.5) were not included in the analysis
of luminal length. Thus, results presented for luminal length are likely to underestimate the
overall effect of flutamide exposure.
2.9 Epithelial height and width measurements
WD sections were immunostained for pan-cytokeratin as detailed above to label clearly all
epithelial cells. Sections were viewed using the x63 objective on an Olympus BH-2
microscope fitted with a Prior automatic stage (Prior Scientific Instruments Ltd, Cambridge,
UK). Image-Pro Plus version 4.5.1 with Stereologer-Pro 5 plug-in software (Media
Cybernetics UK, Wokingham, Berkshire, UK) was utilized to measure epithelial cell height
and width. Using a x63 objective, epithelial cell height and width were measured in every
5th epithelial cell per section. Height measurements were performed separately for the caput,
corpus and cauda regions of the future epididymal portion of the WD. Only epithelial cells
in which the nucleus could be clearly identified were measured, thus excluding from analysis
any epithelial cells from the flutamide treatment groups that were severely flattened or
disintegrating.
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2.10 Apoptosis analysis
Cleaved caspase 3 immunostaining was performed on WDs from control and flutamide
exposed fetuses using standard methods, as detailed above, to stain for apoptotic cells. Very
few cleaved caspase 3 positive cells were detected, therefore a detailed stereological analysis
was not appropriate and all positive cells were manually counted in each WD using an
Axiolab microscope (Carl Zeiss Ltd, Hertfordshire, UK).
2.11 Statistical Analysis
Where appropriate, values were expressed as Means ± S.E.M. Differences between means
were analysed using an unpaired two-tailed t-test (for 2 groups) or one-way Analysis of
Variance (ANOVA) followed by the Bonferroni post-hoc test (for 3 or more groups). The
criterion for significance for all tests was set at p< 0.05. All analyses were carried out using
GraphPad Prism version 4 (Graph Pad Software Inc., San Diego, CA, USA).
2.12 Commonly used solutions
2.12.1 Fixatives
2.12.1.1 Bouin's Soution
Picric acid can no longer be bought except by
to this recipe by Triangle Biomedical Sciences
2.12.1.2 4% (w/v) Paraformaldehyde
Paraformaldehyde (Sigma) 4 g
Distilled water 50 ml
industry so Bouin's solution was made for us
Ltd, Lancashire, UK.
The PFA solution was heated to 60°C until the PFA depolymerised and dissolved: the
solution was not allowed to heat above 70°C 1-2 drops of 1M NaOH was added to clear the
solution. This 8% (w/v) PFA in distilled water was then diluted to 4% in PBS by cooling the
solution to room temperature and adding 50 ml 2M PBS (Sigma). This 4% PFA solution
was filtered and the pH was checked to be between pH7.2 - 7.4.
PFA was used on the day ofmaking or frozen in aliquots at -20°C.
2.12.2 Stains
2.12.2.1 Harris's Haematoxylin
Haematoxylin (2.5g) was dissolved in Absolute Alcohol (25 ml). Aluminium Potassium
Sulphate (50g) was dissolved in 500 ml warm distilled water and the haematoxylin solution
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was added. The solution was brought to the boil and mercuric oxide (1.25g) was added
slowly. The haematoxylin solution was plunged into ice to cool it before filtering it into a
staining dish. Glacial acetic acid (4 ml per 100 ml Haematoxylin) was added.
2.12.2.2 Eosin
An aqueous eosin solution was made by dissolving 1% (w/v) eosin (15 g) in water (1500
ml). An alcohol solution was also made by dissolving 1% (w/v) eosin (5 g) in methylated
spirit (500 ml). Both solutions were mixed together (3 parts aqueous to 1 part spirit eosin
solution) and filtered. Formaldehyde (1 ml) was added to prevent bacterial growth and a
sprinkle of calcium chloride was added.
2.12.2.3 Acid Alcohol
70% Ethanol
1% Concentrated hydrochloric acid
2.12.2.4 Scotts Tap Water
Potassium hydrogen carbonate 10 g
Magnesium sulphate 100 g
Tap water 5 1
2.12.3 Common Buffers
2.12.3.1 Tris buffered saline (TBS) 0.5M
Tris (Sigma) 60.5 g
NaCl 87.6 g
HCl 300 ml
Water up to 10 1
Total 10 1
The solution was corrected to pH7.4 using concentrated HCl.
This lOx TBS solution was diluted to lx TBS using distilled water before use.
2.12.3.2 EDTA0.5M
EDTA (Sigma) 186.1 g
800 mlDistilled water
The solution was corrected to pH 8.0 with NaOH then made up to 1 1 with distilled water.
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2.12.3.3 TE buffer 1x
1M Tris 5 ml
0.5M EDTA 1 ml
Water 494 ml
Total 500 ml
2.12.3.4 Tris-Acetate-EDTA (TAE) Buffer (50x)
Tris (Sigma) 242 g
Acetic acid (BDH) 57.1ml
0.5MEDTA 100 ml
Water up to 1 1
Total Volume 1 1
The pH of the solution was adjusted to pH8.5. This stock solution was diluted to lx with
distilled water before use.
2.12.3.5 RIPA Protein Extraction Lysis buffer
Final Concentration
Triton X-l 00 1%
HEPES-NaOH (pH 7.5) 15 mM
NaCl 0.15 mM
Sodium deoxycholate 1%
Sodium dodecyl sulfate (SDS) 0.1%
Sodium orthovanadate 1 mM
EDTA 10 mM
Protease inhibitor cocktail (Sigma) 0.5%




Distilled water up to 1 1
Total 1 1
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2.12.4 Acrylamide gels





























Total 15 ml 15 ml 15 ml
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3 The impact of androgen action on normal Wolffian duct
development
3.1 Introduction
It is widely accepted that sexual differentiation of the male reproductive tract is dependent
on hormone action (George, 1994). For example, the Wolffian duct (WD) is pre¬
programmed to regress and degenerate unless it receives a signal to initiate rescue and
stabilisation. This signal is believed to be testosterone, which is secreted by the fetal testis
from el5 in rats (Warren et al, 1972). Once stabilised, the male WD begins to differentiate
into its adult derivatives: the cranial portion convolutes to form the epididymis, the central
portion remains a simple straight duct but develops a thick muscular coat to form the vas
deferens, while the seminal vesicles bud off the distal segment (Robaire, 1988). By e21.5 in
rats, this segmentation of the WD is obvious with the future epididymal segment already
highly convoluted at this age (N.Marchetti, unpublished thesis).
Previous researchers have shown that interfering with androgen action during fetal life,
either using androgen receptor mutant animals or exposure to anti-androgenic compounds,
results in abnormal reproductive tracts in adult males (reviewed in Lyon and Hawkes, 1970;
reviewed in Gray et al, 2001; Yeh et al, 2002) (section 1.5.2). Most studies have exposed
rats to anti-androgenic compounds between el3-21, as this encompasses the onset of
testosterone production by the testis and the window of male reproductive development, and
have then examined the effects on the adult reproductive tract. In these adult males, the
epididymis and/or vas deferens is often incomplete or absent altogether: it is generally
presumed that this is due to a failure of the male WD to stabilise early in fetal development,
however, this has not been directly demonstrated since few of these researchers have
examined the morphology of the fetal WD in any detail (Imperato-McGinley et al, 1992;
Mylchreest et al, 1998; Mclntyre et al, 2000). The adult phenotype could in fact be due to
degeneration of the WD-derivatives later in life. Therefore further detailed investigation into
the morphology of the fetal WD is required.
Various compounds have been utilised to examine the effects of reduced androgen action on
WD development including linuron, vinclozolin, phthalates and flutamide (section 1.5.2.2).
Flutamide is one of the most potent anti-androgens as it is a highly competitive androgen
receptor antagonist and it induces a high prevalence of reproductive tract abnormalities in
males without inducing any obvious toxicity (Imperato-McGinley et al, 1992). Flutamide
was developed by the pharmaceutical industry specifically as an AR antagonist therefore its
mode of action is specific and well characterised, unlike many other anti-androgens which
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were developed for other functions such as vinclozolin, a fungicide that happens to have
anti-androgenic properties (section 1.5.2.2). Unlike phthalates, flutamide acts on the AR and
does not reduce testosterone production, therefore any impact on WD development can be
directly correlated with reduced androgen action (Xu and Li, 1998; Fisher et al, 2003).
Administration of flutamide to pregnant rats between el4.5-21.5 has been shown to dose-
dependently impair masculinisation. For example, treatment with 18mgkg"' flutamide
resulted in complete feminisation of external genitalia but normal WD differentiation in male
offspring whereas at doses above 100 mgkg"1 flutamide, the vas deferens was absent
unilaterally or bilaterally and only small remnants of the epididymis were present in adults
(Imperato-McGinley et al, 1992). To the best of my knowledge, no such studies have
examined the phenotype and morphology of the fetal WD or the mechanisms involved in the
degeneration of WD-derived tissues by adulthood.
Whilst it is obvious that androgens play a role in WD development, the molecular and
cellular events that underlie its stabilisation and subsequent differentiation have received
little attention to date. To address this, we have used a model system in which WD
development can be altered, thus enabling the investigation of WD stabilisation and
differentiation with the aim of elucidating the cellular mechanisms responsible for androgen
dependent WD development.
3.1.1 Aims
To establish a model for manipulating androgen action on the fetal urogenital tract in our rat
colony, comparable to models previously published, using maternal flutamide exposure.
To investigate the effect of maternal flutamide exposure on the WD. To establish if
flutamide-induced blockade of androgen action interferes with stabilisation of the male WD,
as occurs naturally in females, and/or its differentiation.
To investigate whether androgens control WD development by altering cell proliferation
and/or apoptosis and if this preferentially targets one cell compartment.
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3.2 Materials and Methods
3.2.1 In utero treatments
As detailed in section 2.2, pregnant dams were randomly allocated to treatment groups and
dosed once daily by gavage with 1 mlkg"1 maternal bodyweight of the various treatments
detailed below. Dams were dosed between el5.5-e21.5, or until the day prior to cull if this is
before e21.5. This window of exposure was selected to encompasses the onset of androgen
action at el5.5 and the period of fetal male reproductive development e 15.5-21.5 according
to (Warren et al, 1972).
Flutamide: 50 mgkg"1 in 1ml com oil/2.5% DMSO (n=24 litters)
100 mgkg"1 in 1ml com oil/2.5% DMSO (n=23 litters)
Control: 1ml com oil/2.5% DMSO (n=68 litters)
These doses were selected based on previous results which reported a high incidence of male
reproductive tract malformations in rats without any adverse toxicological effects (Imperato-
McGinley et al, 1992).
Throughout this chapter, offspring from dams treated with flutamide while pregnant will be
referred to as "flutamide-exposed" or treated "in utero". This does not mean that fetuses
were directly exposed to flutamide but were exposed indirectly via their mother.
3.2.2 Tissue collection
Dams were killed by inhalation of carbon dioxide and subsequent cervical dislocation and
fetuses were recovered at el7.5 - e21.5. Postnatal animals, older than pndlO, were killed by
inhalation of carbon dioxide and subsequent cervical dislocation. Fetuses (e21.5) and
postnatal animals were weighed and anogenital distance measured as described in section
2.3.
Fetuses were killed by decapitation then reproductive tracts were recovered by
microdissection and photographed using a Leica ICA camera (section 2.3.2.1). Reproductive
tracts and gonads were collected from postnatal animals and photographed as described in
section 2.3.2.2. Reproductive tracts were analysed microscopically, at the time of dissection,
for any gross morphological abnormalities. Tissue was either fixed or frozen as detailed in
section 2.4.
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3.2.3 Luminal length analysis
Differentiation of fetal and neonatal WDs was quantified by digitally measuring the luminal
length of the epididymal segment ofWDs from control and treated animals, as described in
chapter 2, section 2.8. Only samples that were analysable were studied: for example, WDs
from flutamide-exposed animals with incomplete lumens (7% of animals at e21.5) were not
included in the analysis of luminal length. Thus, results presented for luminal length are
likely to underestimate the overall effect of flutamide exposure.
3.2.4 Histological analysis
Most histological analyses were performed on WD sections stained with haematoxylin and
eosin, using standard protocols as detailed in chapter 2, section 2.5. WDs were inspected
carefully and note was taken of any abnormalities seen.
3.2.5 Co-immunoexpression of epithelial and stromal compartments
In order to delineate stromal and epithelial compartments, fluorescent immunohistochemistry
was used to co-localise cell-specific proteins in WDs recovered from control and flutamide-
exposed fetuses at el7.5 - e21.5. Sections were deparaffinised, rehydrated and antigen
retrieval performed as detailed in section 2.6.1. All washes between antibody or reagent
incubations comprised two 5 min washes at room temperature in PBS (Sigma). At each
stage, control sections were incubated with blocking serum without antibody in order to
confirm antibody specificity. Non-specific binding sites were blocked by incubating
sections in normal goat serum (NGS; Autogen Bioclear UK Ltd, Wiltshire, UK) diluted 1:4
in PBS containing 5% bovine serum albumin (BSA; Sigma). Sections were incubated
overnight at 4°C with anti-pan-cytokeratin antibody (Sigma) diluted 1:200 in
NGS/PBS/BSA. Pan-cytokeratin localisation was detected by incubating sections for 1 h
with goat anti-mouse secondary antibody directly conjugated with alexa fluor 488
(Molecular Probes) diluted 1:200 in PBS to produce green fluorescence. Sections were
incubated for 30 min with mouse IgG (Sigma) diluted 1:2000 in NGS/PBS/BSA to block any
remaining mouse IgG sites and prevent the second mouse antibody sticking non-specifically.
Non-specific binding sites were blocked again by incubating sections with NGS/PBS/BSA
for 30 min before incubating overnight at 4°C with anti-smooth muscle actin antibody
(SMA; Sigma) diluted 1:500 in NGS/PBS/BSA. Sections were incubated for 1 h with goat
anti-mouse labelled with Cy5 (Amersham Biosciences, Little Chalfont, UK) diluted 1:60 in
PBS, producing blue fluorescent SMA immunostaining. Sections were counterstained for 10
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min with a nuclear-specific blue fluorescent label (DAPI; Sigma) diluted 1:1000 in PBS.
Slides were then washed in PBS and mounted in Mowiol mounting medium (Calbiochem;
Lutterworth, UK). Fluorescent images were captured using a Zeiss LSM 510 Meta Axiovert
100M confocal microscope (Carl Zeiss Ltd, Welwyn Garden City, UK).
3.2.6 Epithelial height and width measurements
WD sections were immunostained for pan-cytokeratin (section 2.6.1) to label clearly all
epithelial cells and epithelial cell height and width were measured in every 5th epithelial cell
in the future epididymal segment, as detailed in section 2.9.
3.2.7 Measurement of WD width
WD sections were stained by H&E (see section 2.5) and viewed using the x63 objective on
an Olympus BH-2 microscope fitted with a Prior automatic stage (Prior Scientific
Instruments Ltd, Cambridge, UK). Image-Pro Plus version 4.5.1 with Stereologer-Pro 5
plug-in software (Media Cybernetics UK, Wokingham, Berkshire, UK) was utilized to
measure the width of the WD in at least 3 evenly spaced places along the length of the
epididymal section.
3.2.8 Frequency of cell mitoses in WDs
In order to determine if cell proliferation in WD compartments was affected by flutamide
treatment, various cell cycle markers and analytical methods were investigated. For
technical reasons, it was considered that determination of the proliferation index was
impractical for the densely packed stromal cell compartment: previous researchers have
commented on the difficulty of counting cellular ratios in the WD (Bowman et al, 2005).
Instead, a method was devised to allow enumeration of the total number of mitotic cells in
each compartment, as outlined below.
3.2.8.1 Immunostaining of mitotic cells
WD sections from control and flutamide exposed fetuses at el9.5 - e21.5 were
immunostained for phospho-histone H3 (Upstate Biotechnology, Dundee, UK), a mitotic
marker, using a Bond-X automated immunostaining machine (Vision Biosystems,
Newcastle, UK) and a polymer high contrast programme. Briefly, after high pressure
antigen retrieval, slides were peroxidase blocked for 5 min, incubated for 2 h with the
primary antibody diluted 1:1000 in the diluent supplied and then with the post-primary
reagent for 15 min. Control sections were incubated with diluent alone to confirm antibody
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specificity. Sections were then incubated with the polymer reagent for 15 min to increase
sensitivity of detection prior to DAB detection for 10 min, counterstained in haematoxylin
for 5 min, dehydrated and mounted.
3.2.8.2 Analysis of mitotic cells
Phospho-histone H3 positive cells were counted in the epithelial compartment and in the
inner and outer stromal layers of the WD (Fig. 3.1) using the x20 objective on an Olympus
BH-2 microscope fitted with a Prior automatic stage.
Figure 3.1 Image of e21.5 WD stained for phospho-Histone H3 (brown) to identify mitotic
cells. Note that examples of the different cellular compartments are delineated by black lines
and mitotic cells (brown) were counted in each compartment individually. Epithelium (arrow),
inner stroma (arrowhead) and outer stroma (*).
Image-Pro Plus version 4.5.1 with Stereologer-Pro 5 plug-in software (Media Cybernetics
UK) was utilized for analysis of the number of mitotic cells. Positive cells were only
counted in the future epididymal portion of the WD, not in the efferent ducts or vas deferens.
Since differences were noted in the degree of coiling along the length of the future
epididymal portion of the WD, phospho-histone H3 positive cells were initially counted in
each region of the future epididymis individually, defined as in the adult epididymis as
caput, corpus and cauda (Robaire, 1988). However, no consistent difference was seen in
phospho-histone H3 staining between the different regions of the epididymal portion of the
WD, therefore proliferation was subsequently analysed in the epididmyal portion of the WD
as a whole.
Variation was noted in the amount of the WD visible in each section as well as the amount of
epithelium visible per section: this was due to both treatment effects and the plane of
sectioning. To correct for this variation, the overall length of the WD and the length of
epithelium visible in each section were measured. The number of phospho-histone H3
positive cells in the epithelial compartment was then divided by the total length of
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epithelium visible in the section to calculate proliferation per micron of epithelium (see Fig.
3.2). Since flutamide exposure reduces coiling and WD luminal length, it was important to
take this into account when analysing cell proliferation. The number of positive epithelial
cells per micron of epithelium visable was therefore multiplied by the luminal length for that
specific WD (measured at the time of dissection, method detailed above) in order to calculate
total epithelial cell proliferation in the whole epididymal portion of the WD, not just cell
proliferation in the section being analysed. Similarly, the number of phospho-histone H3
positive cells in the stromal compartment was divided by the length of WD epithelium
visible in to correct for variation in the length of the WD. This was then multiplied by the
luminal length of the WD to calculate total stromal proliferation in the whole epididymal
portion of the WD. Sections from 8-14 fetuses from 3-5 separate litters were analysed from
both control and flutamide-exposed animals at each age.
Figure 3.2 Diagramatic representation of the proliferation analysis method. Mitotic
cells (orange) were counted in each cellular compartment (E - epithelium, IS - inner stroma,
OS - outer stroma). The length of epithelium visible in each section was measured and the
number ofpositive cells was corrected to this.
3.2.8.3 Epithelial mitotic index
To confirm that this analysis was likely to reflect the cell proliferation/mitotic index, the total
number of phospho-histone H3 positive and negative epithelial cells were counted (500-700
cells) in 3 control and 3 F100 e21.5 WDs, and an epithelial mitotic index was derived
(phospho-histone H3 positive cells/total number of cells xl00%). This was not able to be
calculated for the stromal compartment as it was technically impossible to count individual
stromal cells.
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3.2.9 Apoptosis analysis
Cleaved caspase 3 immunostaining was performed on WDs from control and flutamide
exposed fetuses using standard methods, as detailed in section 2.6.1, to stain for apoptotic
cells. Very few cleaved caspase 3 positive cells were detected, therefore a detailed
stereological analysis was not appropriate and all positive cells were manually counted in
each WD using an Axiolab microscope (Carl Zeiss Ltd, Hertfordshire, UK).
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3.3 Results
3.3.1 Normal fetal Wolffian duct development
Figure 3.3 highlights the positions of the various reproductive organs within an el9.5 male
(A) and female (B) fetal rat reproductive tract. In the male (A), the Wolffian duct develops
lateral to the testis, connected proximally to the tesis via the efferent ducts, while the distal
segment of the WD, the future seminal vesicles (A), connects to the prostate. In the female
(B), the MD connects proximally to the ovary, while the distal end connects to the urogenital
sinus. At this age the female WD has fully regressed so cannot be seen, however, prior to
regression, it would lie medial to the MD.
Figure 3.3 Representative reproductive tracts from e19.5 male (A) and female (B) rats.
Note the male WD (arrow) connects proximally to the testis (T) via the efferent ducts (*) and
distally inserts into the prostatic complex (P), situated above the bladder (B). In the female,
the MD (arrowhead) leaves the ovary (O) and inserts into the urogenital sinus/bladder
complex (US/B).
3.3.1.1 The timing and patterning of normal Wolffian duct development
Figure 3.4 shows images of male WDs isolated at el 6.5 - e21.5. At el 6.5, a remnant of the
regressing MD can still be identified lying lateral to the WD. The MD has completely
regressed by el7.5. The male WD remains a simple straight duct until el9.5, with coiling
first evident at the caput (adjacent to the efferent ducts) and caudal ends of the future
epididymal portion of the WD at e20.5 while the corpus remains relatively uncoiled. By
e21.5, the full length of the epididymal portion of the WD appears highly convoluted,
including the corpus. Distal to the future epididymal segment, the future vas deferens
remains a straight duct throughout life.
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Figure 3.4 Representative WDs recovered from e16.5-e21.5 control fetuses showing an
age-dependent increase in coiling/elongation. The remnant of the male MD is still visible
in the mate at e16.5 (arrowhead), medial to the WD (arrow). Note the appearance of coiling
in the WD caput (Cap) and cauda (Cau) at e20.5 and along the corpus (Co) by e21.5. The
efferent ducts (*) lie at the end proximal to the testis while the vas deferens (V) continues
distally towards the prostate. Scale bar =100 pm. All images are at the same magnification.
This age dependent increase in coiling and development was confirmed quantitatively, by the
demonstration of an increase in luminal length (Fig. 3.5). No significant increase (p>0.05) in
WD luminal length was seen between el7.5-el8.5 or el8.5-el9.5, but a highly significant











el 7.5 el 8.5 el 9.5 e20.5 e21.5 pndO
n=9 n=20 n=33 n=l9 n=51 n=6
Figure 3.5 Age-dependent increase in coiling/elongation of the Wolffian duct (WD)
between e17.5 and pndO. The graph illustrates quantification of coiling (= luminal length) of
the WDs. Note the progressive increase in luminal length of WDs from controls between
e17.5 and pndO. Values are mean ± S.E.M. ***p<0.001, in comparison to respective value
for preceding day.
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3.3.1.2 Normal Wolffian duct histology
The WD is made up of 2 cellular compartments (Fig. 3.6). Simple columnar epithelial cells
line the lumen of the duct with mesenchymal cells surrounding this epithelium: this
histological organisation did not vary along the length of the WD or with age. The
mesenchymal cells can be easily separated into two distinct populations: those directly
surrounding the epithelial cells which are more densely packed, and termed here as inner
stroma, and those that make up the rest of the "body" of the WD, referred to here as outer
stoma. Note that at el 7.5, the remnant of the regressing MD can still be identified.
el7.5 Control ^.e21.5 Control
Figure 3.6 Demarcation of a e17.5 and e21.5 Wolffian duct (WD) stroma into the inner
(IS; *) and outer stromal compartments (OS; arrowhead). Note that the IS (*) can be
identified as the more dense compartment immediately adjacent to the epithelium (arrow).
Note that the MD (MD) remnant can still be seen lateral to the WD at e17.5.
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3.3.2 Normal morphology of adult male reproductive tract
Figure 3.7 shows a normal adult male reproductive tract (pnd 70), highlighting the position
of the WD-derived tissues. The epididymis attaches proximally to the testis via the efferent
ducts then connects distally to the vas deferens to carry sperm out of the body. The vas
deferens remains a simple straight duct throughout life whereas the epididymis, in which
coiling was initiated in the fetus, becomes even more convoluted and highly coiled during
postnatal development.
Figure 3.7 Representative male reproductive tract from a young adult rat (pnd70).
Note that the epididymis (arrowhead) lies alongside the testis (T) then connects distally to
the vas deferens (arrow). Panel C highlights the extensive coiling in the epididymis
(arrowhead).
3.3.3 Effects of maternal flutamide exposure
3.3.3.1 Non-reproductive effects of flutamide
Consistent with previous studies (Mclntyre et al, 2001; Foster and Harris, 2005), exposure to
flutamide (50 or 100 mgkg"1) did not result in any toxicological effects to the dam with no
obvious problems with labour, no increase in fetal death (data not shown) or decrease in
litter number (p=0.38). However, there was a slight decrease in maternal weight gain (Fig.
3.8) by the end of gestation (e21.5) between control dams and flutamide exposed dams (100
mgkg"1) but this was not significant (p=0.4). At e21.5, there was no change in the
bodyweight of female fetuses from flutamide-exposed mothers (50 or 100 mgkg"1) compared
to age matched controls (Fig 3.9). However, there was a significant decrease (p<0.05) in
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male bodyweight at e21.5 between control fetuses and those from litters maternally exposed
to high doses of flutamide (100 mgkg1). This was not evident in fetuses from dams exposed
to low dose flutamide (Fig 3.9).
Bodyweight remained slightly reduced at pndl7 in males from litters exposed to high dose





Figure 3.8 Maternal % weight gain at e21.5, relative to bodyweight at e15.5. Note the
trend for reduced weight gain by e21.5 in dams exposed to flutamide (50 mgkg'1, chequered
bars; 100 mgkg'1, striped bars) during pregnancy, but this was not significant. Values are
means ± S.E.M for 4-8 animals per group.
All fetuses Male fetuses Female fetuses
Figure 3.9 Bodyweight at e21.5 in fetuses from control (solid bars), low dose flutamide (50
mgkg'1; chequered bars) and high dose flutamide (100 mgkg'1; striped bars) litters. Note the
decrease in fetal bodyweight from dams exposed to high dose flutamide (* p<0.05)
compared to age matched controls. This is likely to be due to the reduced bodyweight of
male fetuses (* p<0.05) from these litters as there was no change in female fetal bodyweight.
Values are means ± S.E.M for 9-30 animals per group.
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Control Male F100 Male Control Female
Figure 3.10 Bodyweight of pnd17 animals from control litters and litters exposed to
maternal flutamide treatment during gestation (100 mgkg'1). Bodyweight remains reduced in
pnd17 males exposed to flutamide (100 mgkg'1; striped bar) during gestation compared to
control males (blue bar), but this was less obvious than in fetal rats and was not significant.
Values are means ± S.E.M for 14-16 animals.
3.3.3.2 Effects of flutamide on the reproductive tract
Maternal exposure to either dose of flutamide (50 or 100 mgkg"1,), as expected, had no
obvious effect on fetal female reproductive tract morphology but prevented normal
masculinisation of fetal males. Normally, fetal sex can be determined externally by the
distance between external genitalia and the anus (anogenital distance; AGD), with AGD
significantly larger in fetal males than in females (Fig 3.11, p<0.001). However, maternal
exposure to flutamide prevented normal masculinisation of fetal external genitalia, with
AGD significantly reduced (p<0.001) in e21.5 males from flutamide-exposed litters to a
length similar to that of control females. Exposure to flutamide (50 or 100 mgkg"1) did not





Figure 3.11 Anogenital distance (AGD) in e21.5 male (blue bars) and female (pink bars)
fetuses from control (solid bars), low dose maternal flutamide (50 mgkg'1; chequered bars)
and high dose maternal flutamide (100 mgkg'1; striped bars) litters. Note that AGD was
significantly smaller in control and flutamide-exposed female fetuses (pink bars) than in
males (solid blue bar) AGD in male flutamide-exposed fetuses (50 mgkg'1, blue chequered
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bars; 100 mgkg'1, blue striped bar) was reduced compared to control males and was
comparable to female AGD. Maternal exposure to either dose of flutamide did not alter
female AGD (pink bars, p>0.05). *** p<0.001 compared to control male AGD. Values are
means ± S.E.M.
As shown in Fig 3.12, AGD remained reduced to female values (p<0.001) in pndl7 males
from flutamide-exposed litters (100 mgkg'1) compared to age matched controls.
p>0.05
Control male Ft00 male Control female
Figure 3.12 Anogenital distance (AGD) in pnd17 animals. Note the reduced AGD in
males from litters exposed to flutamide in utero (striped bar; 100 mgkg1) compared to control
males (blue bar): AGD in flutamide-exposed males was reduced to a level comparable with
control female AGD (pink bar) (p>0.05). Values are means ± S.E.M for 6-14 animals. ***
p<0.001, compared to control male AGD.
Maternal exposure to flutamide prevented normal prostate formation in males and resulted in
the presence of a vagina (data not shown). Testis descent was unaffected at e21.5 by
maternal flutamide exposure (data not shown). Consistent with previous reports (Mylchreest
et al, 1999; Mclntyre et al, 2001; Foster and Flarris, 2005), these abnormalities were still
evident postnatally (data not shown).
3.3.4 Gross effects of flutamide on the fetal Wolffian duct and its adult
derivatives
Maternal exposure to either dose of flutamide (50 or 100 mgkg"') had detrimental effects on
the fetal WD, which persisted in the adult WD-derived tissues. These are detailed below.
3.3.4.1 Flutamide induced abnormalities in the fetal Wolffian duct
Maternal exposure to flutamide (50 or 100 mgkg"1) impaired normal WD development but
considerable variation was seen in the degree and phenotype of impairment between
different ages, different doses of flutamide and even between littermates.
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3.3.4.1.1 Effects of maternal treatment with flutamide on fetal Wolffian duct
coiling and differentiation
Maternal exposure to flutamide interfered with the pattern and degree of WD
coiling/development, as seen in Fig. 3.13. Consistent with previous studies (Bowman et a!,
2003) that have interfered with androgen action in utero, considerable variation was noted
between animals in the degree ofWD coiling after maternal exposure to flutamide: this was
more apparent at later fetal ages (e20.5 - 21.5) when WDs are more differentiated in fetuses
from control mothers. To take account of this variability, WDs were analysed from 6-51
animals from at least 3 litters per age/treatment group.
An age-dependent increase was noted in the degree of coiling and hence differentiation of
WDs from flutamide exposed fetuses, but this was reduced compared to age matched
controls (Fig. 3.13). As in controls, no coiling was seen in WDs from flutamide-exposed
animals (50 or 100 mgkg"1) at el8.5 or el9.5 (Fig. 3.13). WD coiling was dramatically
reduced in all e20.5 and e21.5 fetuses from flutamide exposed mothers (50 or 100 mgkg"1,
Fig. 3.13), with some WDs less coiled than others (data not shown). In fetuses from low
dose flutamide exposed dams (50 mgkg"'), the onset of WD morphological differentiation
was not altered, with coiling first evident at e20.5, as in control fetuses (Fig. 3.13).
However, the onset of WD coiling varied in fetuses from dams exposed to high dose
flutamide (100 mgkg"1) with coiling evident in some WDs by e20.5 while some WDs still
showed no sign of coiling by e21.5 (Fig. 3.13). In control WDs, coiling was first evident at
the caput and cauda, with coiling not evident in the corpus until a later age (Fig. 3.13).
However, the patterning of WD coiling was altered by maternal exposure to flutamide (50
mgkg"1) with coiling first evident in the caput and the proximal end of the corpus at e20.5
and appearing to progress along the duct towards the cauda by e21.5 (Fig. 3.13). It was not
easy to distinguish the pattern of WD coiling in fetuses from dams exposed to high dose
flutamide (100 mgkg"1) since coiling was still not apparent in many of these ducts at e21.5.
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el8.5 el9.5 e20.5 e21.5
Figure 3.13 Age-dependent increase in coiling/elongation of the Wolffian duct (WD)
between e18.5 and e21.5. Representative WDs recovered from control fetuses (top row)
and fetuses exposed to 50 mgkg1 flutamide (middle row) or 100 mgkg'1 flutamide (bottom
row) at e18.5 (first column), e19.5 (second column), e20.5 (third column) and e21.5 (final
column) are illustrated. Note the reduced coiling in WDs from flutamide-exposed animals at
e20.5 and e21.5 (arrow) when compared to the age matched control (top row). Scale bar =
100 pm. AH images are at the same magnification. * - efferent ducts
These qualitative observations were quantified by measuring the length of the WD lumen.
At el7.5-el9.5, no difference was noted in the luminal length of WDs from fetuses from
dams exposed to flutamide (50 mgkg"1 or 100 mgkg"1). At e20.5 and e21.5, however,
flutamide-exposed fetuses showed a highly significant reduction (p<0.001) in WD coiling
and luminal length, compared to age matched controls (Fig. 3.14). At e21.5, coiling was
more dramatically reduced in fetuses from dams exposed to 100 mgkg"1 flutamide than those

























Figure 3.14 Quantification of coiling (= luminal length) of e17.5 - pndO WDs from
control and flutamide-exposed litters. Note the progressive increase in luminal length of
WDs from controls between e18.5 and pndO (solid blue bars). There was a significant
reduction in luminal length at e20.5 and e21.5 in WDs from animals exposed in utero to
either 50 mgkg'1 (chequered bars) or 100 mgkg'1 (striped bars) flutamide, when compared to
controls, whereas at e18.5 and e19.5, no difference was evident. Values are mean ± S.E.M,
***p<0.001, in comparison to the respective control value.
3.3.4.1.2 Maternal flutamide treatment does not alter fetal Wolffian duct width
As evident from Fig. 3.15, there was no significant change in the overall width of the WD in
fetuses from dams exposed to flutamide (50 mgkg-1), compared to age matched controls.
This was not measured in WDs from fetuses from dams exposed to 100 mgkg"1 flutamide.
n=9 n=6 n=6 n=ll n=7 n=16
el 9.5 e20.5 e21.5
Figure 3.15 Width of control and flutamide exposed Wolffian ducts at e19.5-e21.5. WD
width did not change significantly with age or in fetuses from dams exposed to flutamide
during pregnancy (50 mgkg'1, chequered bars), compared to age matched controls (solid
blue bars). Values are means ± S.E.M.
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3.3.4.1.3 Flutamide-induced loss of Wolffian duct segments
As well as the reduction in coiling mentioned in section 3.4.4.1.1, some WDs from flutamide
exposed fetuses appeared incomplete at e21.5 with thinning of the epithelium and missing
corpus/cauda segments (Fig. 3.16): this was never seen in control WDs and affected WDs
always had a short lumen apparent at the caput. This phenotype of missing segments was
first noted at e21.5 and was similar in low and high dose flutamide litters, however, there
was an increased prevalence in fetuses from high dose flutamide litters in which 11% of
WDs recovered from animals exposed to flutamide had incomplete lumens compared to a
5% prevalence in fetuses from low dose flutamide litters (Table 3.1). This was not seen in
WDs from flutamide-exposed animals prior to e20.5. This is in contrast to the natural







Figure 3.16 Flutamide-induced interruption to the lumen of the WD at e21.5 in
occasional animals. Note that exposure to both low (50 mgkg'1, A) and high (100 mgkg'1,
B) dose maternal flutamide resulted in lumens only being apparent at the caput end of the
WD (arrow). Both images are at the same magnification.
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E18.5 Control 0 10
Flutamide 50 mgkg"1 0 21
Flutamide 100 mgkg"1 0 21
E19.51 Control 0 37
Flutamide 50 mgkg"1 0 47
Flutamide 100 mgkg"1 0 35
E20.5 Control 0 25
Flutamide 50 mgkg"1 0 68
Flutamide 100 mgkg 1 2 (7%)2 29
E21.5 Control 0 24
Flutamide 50 mgkg"1 2 (5%)2 39
Flutamide 100 mgkg"1 4(11%)2 34
Pndl7 Control 0 16
Flutamide 100 mgkg"1 1 (13%)3 7
Pnd42 Control 0 12
Flutamide 100 mgkg"1 5 (63%)2 3
Adults Control 0 18
Flutamide 100 mgkg"1 10 (83%)3 2
2
1 At el9.5, the Wolffian duct in control female rats has completely regressed
2 Note that these WDs were all from the same litter (e20.5 F100 - 1 of 3, e21.5 F50 -
1 of 6, e21.5 F100- 1 of 3, and pndl7F100 1 of 1)
3 Note that these reproductive tracts were found in males from 2 of 2 litters at pnd42
and 3 of 3 litters in adulthood.
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3.3.4.2 Persistence of maternal flutamide-induced gross abnormalities in
postnatal Wolffian duct-derived tissues
The abnormalities seen in the fetal WD not only persisted in the WD-derived tissue in
postnatal life, but in the majority of postnatal animals abnormalities were more prevalent and
more severe than in the fetus. Considerable variation was noted in the degree of abnormality
seen in WD-derived adult tissues, including underdeveloped or incomplete epididymides,
lack of vas deferentia, and underdeveloped or vestigial seminal vesicles (Fig. 3.17 and 3.18).
As in the fetus, at pndl7 (i.e. before puberty) 13% of males from dams exposed to 100
mgkg"1 flutamide had incomplete WD-derived tissues, with the corpus segment of the
epididymis often absent: the prevalence of this phenotype rose to 63% by pnd42 (Table 3.1).
Similarly, in adult males from dams exposed to 100 mgkg"1 flutamide, 83% of epididymides
and/or vasa deferentia studied were incomplete (Table 3.1). In five adult males, there was
near complete absence of all WD-derived tissues.
Figure 3.17 Wolffian duct-derived tissues in males from control (A) and maternal
flutamide treated (100 mgkg'1, B and C) animals at pnd42. Note the thinning of the
corpus (arrow, B and C) and the vestigial caudal segment (arrowhead, C) in epididymides
from males exposed to maternal flutamide during gestation, compared to age matched
control males (A). All images are the same magnification.
Jr' ■** - J
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Figure 3.18 Adult (pnd70) epididymides from control males (A and C) and males from
litters exposed to maternal flutamide treatment (B and D, 100 mgkg'1). Note the
abnormal caput from the flutamide-exposed animal (arrow, B) compared to the highly
convoluted caput from the control epididymis (A). Furthermore, note the absence of any
obvious corpus in the flutamide male (arrow, D) compared to the normal coiled corpus (C).
All images are at the same magnification.
3.3.5 Flutamide-induced histological abnormalities in fetal WDs
Maternal exposure to flutamide (50 or 100 mgkg"1) did not alter the cellular
compartmentalisation of the fetal WD into epithelial and stromal compartments, as described
in section 3.3.1.2 (Fig. 3.19).
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Figure 3.19 Cellular compartments in e21.5 Wolffian ducts from control (A and C) and
flutamide-exposed (B and D) males. Note that flutamide exposure did not alter the
compartmentalisation of the WD into the epithelium (arrow) and the surrounding stromal
compartments. Note also that the stroma can easily be distinguished into the more densely
compacted inner stroma (*; in panels C and D, immunostained blue for smooth muscle
actin), immediately proximal to the epithelium (arrow; in panels C and D; immunostained
green for cytokeratin), and the outer stroma (arrowhead; in panels C and D, SMA negative,
nuclei are counterstained with DAPI, shown as white). Scale bars =50 urn
3.3.5.1 Gross changes to the epithelial compartment after flutamide
exposure
Examination of WDs revealed no obvious histological differences between WDs from
control and flutamide-exposed fetuses at el8.5 or el9.5 (data not shown). However, as seen
in Fig. 3.20, histological abnormalities became apparent by e21.5 in WDs from fetuses
exposed to flutamide (50 or 100 mgkg-1), including loss of epithelium lining the lumen,
widening or narrowing of the lumen and flattening of the epithelium compared to that of
controls, sometimes even appearing fibroblast-like (Fig. 3.20). The extent of this flattening
varied between WDs but was not seen in controls or flutamide-exposed WDs at any earlier
age.
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Figure 3.20 Representative abnormalities in epithelia of e21.5 WDs from low (50 mgkg'
1, A & B, stained for a nuclear receptor) and high (100 mgkg'1, C & D, stained for
cytokeratin) dose flutamide litters. Note the widened lumen seen in some WDs (A)
compared to the flattened lumen in others (C). There is an apparent loss of epithelium lining
the lumen in several WDs (A-C) while in other WDs, the epithelium was still present but the
cells were reduced in height (D). Scale bars = 50pm
3.3.5.2 Quantification of epithelial cell abnormalities after flutamide
exposure
As noted above, maternal treatment with flutamide induced abnormalities in the epithelial
compartment of the WD. The apparent reduction in epithelial cell height can be seen in Fig.
3.21 and was confirmed quantitatively at el8.5 and e21.5 (Fig. 3.22). At e 18.5, the reduction
in WD epithelial cell height was not as obvious microscopically as in e21.5 WDs: however,
when quantified, there was a trend for reduced epithelial cell height in WDs from el8.5
fetuses of dams exposed to flutamide compared to age matched controls but this was not
significant. By e21.5, maternal flutamide exposure significantly reduced fetal WD epithelial
cell height (p<0.01). This reduction was more dramatic in the corpus and cauda portions of
the WD and was most pronounced in fetuses from dams exposed to 100 mgkg"1 flutamide.
No significant difference was noted in the width ofWD epithelial cells in flutamide-exposed
animals (100 mgkg"1) compared to controls (Fig. 3.23).
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Figure 3.21 Reduced epithelial cell height at e18.5 and e21.5 in flutamide-exposed (100
mgkg-1, D-F) WDs, compared to age matched controls (A-C). Note that the reduced
epithelial cell height (immunostained for cytokeratin) in WDs in the flutamide-exposed animal
is not as apparent at e18.5 (A compared to D) but is obvious at e21.5 (compare B to E and C
to F). Images are all from the caput region of a WD, the segment of the WD where epithelial




Figure 3.22 Quantification of epithelial cell height at e18.5 (A & B) and e21.5 (C & D) in
Wolffian ducts (WDs) from controls (solid blue bars) and animals exposed to 50 mgkg'1
(chequered bars) or 100 mgkg'1 (striped bars) flutamide. At e18.5, there was a trend for
reduced epithelial cell height but this was not significant (p>0.05, A & B). Maternal flutamide
F100
F50 F100 Caput Corpus Cauda
Caput Corpus Cauda
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exposure resulted in a highly significant reduction in epithelial cell height at e21.5 in the WD
as a whole (C; 50 mgkg-1 p<0.01, 100 mgkg'1 p<0.001). However, when each segment of
the epididymal portion of the WD was analysed individually, epithelial cell height was found
to be reduced more in the corpus and cauda portions of the future epididymis after flutamide
treatment (D). * p<0.05, ** p<0.01, *** p<0.001, in comparison to respective control value.
Values are means ± S.E.M for 5-7 animals per treatment, from at least 3 different litters.
Control F100
Figure 3.23 Epithelial cell width at e21.5 in Wolffian ducts (WDs) from controls (solid blue
bars) and animals exposed to 100 mgkg'1 (striped bars) flutamide. Note that no difference
was seen in WD epithelial cell width between control and flutamide-exposed litters. Values
are means ± S.E.M for 3 animals per group.
3.3.6 Prevalence of apoptotic cells in fetal Wolffian ducts
Apoptotic cells were rarely detected (typically 1 cell per section) in either epithelial or
stromal compartments of WDs from either control or flutamide exposed fetuses at any age
examined (Fig. 3.24).
Figure 3.24 Frequency of apoptotic cells (immunopositive for cleaved caspase 3;
black staining) in representative e21.5 Wolffian ducts (WDs) from a control (A) and an
animal exposed in utero to 100 mgkg'1 flutamide (B). Note that few apoptotic cells were
seen in either control or flutamide-exposed WDs (arrow). Scale bar - 100 urn.
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3.3.7 Analysis of cell proliferation in fetal Wolffian ducts
Cell mitosis was evident in all compartments of WDs from control and flutamide-exposed
animals at all ages (Fig. 3.25). Immunostaining for phospho-histone H3 suggested fewer
mitotic cells were present in WDs from flutamide-exposed fetuses compared to controls (Fig.
3.25). This was confirmed quantitatively highlighting a reduction in the number of mitotic
epithelial and stromal cells per WD, compared to age-matched controls, at all ages studied
(Fig. 3.26-3.28). Note that a significant reduction in the number of mitotic cells was
apparent in the stroma at el9.5 and e20.5 (Fig. 3.26 & 3.27) but was not seen in the
epithelium until e21.5 (Fig. 3.28). Furthermore, the reduction in number of mitotic cells
became more apparent at e21.5 and maternal exposure to 100 mgkg"1 flutamide resulted in a
greater reduction in the number of mitotic cells than did 50 mgkg"1 (Fig. 3.28).
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Figure 3.25 Frequency ofmitotic cells (immunopositive for phospho-histone H3; black
staining) in representative e21.5 Wolffian ducts (WDs) from a control (A) and an animal
exposed in utero to 50 mgkg'1 flutamide (B). Note the numerous mitotic cells in the inner
stroma (arrows), outer stroma (arrowhead) and epithelium. Scale bar - 100 um
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Figure 3.26 Total number of mitotic epithelial and stromal cells in the entire
epididymal segment of the WD at e19.5 in controls (solid blue bars) and animals
exposed to 50 mgkg'1 (chequered bars) flutamide. Note the reduction in number of
mitotic cells in WDs from animals exposed to flutamide compared to controls: this trend was
apparent in all cellular compartments but was only significant in the outer stromal
compartment at this age. * p<0.05, in comparison with respective control values. Values are






Epithelium Inner Stroma Outer Stroma
Figure 3.27 Total number of mitotic epithelial and stromal cells in the entire
epididymal segment of the WD at e20.5 in controls (solid blue bars) and animals
exposed to 50 mgkg'1 (chequered bars) flutamide. Note the reduction in number of
mitotic cells in WDs from animals exposed to flutamide compared to controls: this trend was
apparent in all cellular compartments but was only significant in the stromal compartment at
this age. * p<0.05, in comparison with respective control value. Values are means ± S.E.M
for 8-11 animals.
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Figure 3.28 Total number of mitotic epithelial and stromal cells in the entire
epididymal segment of the WD at e21.5 in controls (solid blue bars) and animals
exposed to 50 mgkg'1 (chequered bars) or 100 mgkg'1 (striped bars) flutamide. Note
the reduction in number ofmitotic cells in WDs from animals exposed to flutamide compared
to controls: this was apparent in all cellular compartments and was more dramatic in WDs
from high dose flutamide litters compared to those from low dose litters. *** p<0.001, in
comparison to respective control value. Values are means ± S.E.M for 12-16 animals.
Cell proliferation data was expressed as the overall number of mitotic cells in the complete
epididymal portion of the WD rather than per 100pm epithelium, so as to take into account
the treatment-induced reduction in WD length. If this correction was not applied, a similar
treatment-induced reduction in cell mitosis was evident but was of smaller magnitude.
3.3.7.1 Epithelial mitotic index
Analysis of the epithelial mitotic index, at e21.5, yielded comparable results as the method
described in section 3.2.1.2, with epithelial mitosis reduced (p<0.05) in flutamide-exposed
WDs, compared to control WDs (Fig. 3.29). This suggests that the analytical method used
above reflects the mitotic index.











Figure 3.29 Epithelial mitotic index in the entire epididymal segment of the WD at
e21.5 in controls (solid blue bars) and animals exposed to 100 mgkg'1 (striped bars)
flutamide. Note the flutamide-induced reduction in mitotic index in the epithelial
compartment at e21.5 compared to age-matched controls. * p<0.05, in comparison to
respective control value. Values are means ± S.E.M for 3 animals
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3.4 Discussion
In males, the WD differentiates during neonatal life to form the epididymis, vas deferens and
seminal vesicles (Wilson et al, 1981). In female rats, due to a lack of androgens the WD
naturally regresses between el6.5 and el8.5 (see chapter 6) whereas at this age in males,
androgen action is believed to stabilise the WD, allowing it to differentiate subsequently into
its adult derivatives (George, 1994; Huhtaniemi, 1994). In our rat colony, the male MD has
completely regressed by el7.5, leaving the simple straight WD lying alongside the testis.
Morphological differentiation can be seen by coiling in the future epididymis of the fetal
WD around e20.5 suggesting that the developmental window for WD morphological
differentiation is between el9.5 and birth: this coincides with the peak in testicular
testosterone production in male rats at el9.5 (Warren et al, 1972). These findings agree with
previously published timings (Barlow and Foster, 2003). By e21.5, the WD can easily be
distinguished into its adult derivative organs with the future epididymis already appearing
highly coiled suggesting that the pattern of the reproductive tract is established, probably by
androgens, during fetal life.
There are many anti-androgenic compounds available that interfere with androgen action in
vivo using different modes of action, such as linuron, a weak AR antagonist (Mclntyre et al,
2000), DBP, which reduces fetal testosterone production by the testis (Mylchreest et al,
1999), and flutamide, a competitive AR antagonist (Imperato-McGinley et al, 1992) (see
section 1.5.2.2). Flutamide was selected for these studies as, unlike DBP, its mode of action
has been well characterised as competition with testosterone or DFIT for binding to the AR
(Peets et al, 1974; Zuo et al, 2002; Schaufele et al, 2005). Furthermore, flutamide is
believed to be a more potent AR antagonist than linuron: gestational exposure to linuron
resulted in no epididymal abnormalities in male fetuses (Mclntyre et al, 2002). Furthermore,
gestational exposure to flutamide (100 mgkg"1) resulted in a greater prevalence of epididymal
abnormalities in the adult (100% epididymides absent/partially developed) than from
exposure to DBP (500 mgkg"1; 50% epididymides absent/partially developed) (Mylchreest et
al, 1999).
The doses of flutamide selected for these studies were based on previous studies which also
used flutamide to interrupt male reproductive development (Imperato-McGinley et al, 1992;
Bentvelsen et al, 1995; Mylchreest et al, 1999; Mclntyre et al, 2001; Hotchkiss et al, 2002).
Dose response studies undertaken by Imperato-McGinley and colleagues highlighted that
exposure to just 24 mgkg"1 flutamide completely abolished prostate differentiation but had no
obvious effect on WD development while exposure to 100 mgkg"1 flutamide markedly
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impaired WD differentiation with WD-derived structures often absent in the adult (Imperato-
McGinley et al, 1992). These differential effects on different reproductive structures are
likely to be due to the higher local concentrations of testosterone in the developing WD than
in tissues derived from the urogenital sinus (Veyssiere et al, 1982). Doses above 100 mgkg"1
flutamide (200 or 300 mgkg"') did not markedly increase the prevalence of these epididymal
abnormalities (Imperato-McGinley et al, 1992) suggesting that maternal exposure to 100
mgkg"1 flutamide is sufficient to induce a high prevalence of epididymal abnormalities. In
this thesis, dams were also exposed to 50 mgkg"' flutamide in order to induce less severe
abnormalities without inducing a complete loss of WD tissues therefore allowing
investigation of the effects of partial androgen action inhibition and subsequent gene
expression.
Consistent with previous studies (Mclntyre et al, 2001; Foster and Harris, 2005), flutamide
did not result in any obvious toxicological effects in the dams: for example, there were no
signs of premature labour, no increased prevalence of fetal deaths and no obvious maternal
health issues. Maternal exposure to flutamide, however, did decrease maternal weight gain.
This is probably due to the decrease in male, but not female, fetal bodyweights suggesting
that androgens may play a role in determining male fetal bodyweight. It is unclear whether
this is due to flutamide disturbing androgen signalling in the mother or in the male fetus
itself. Previous studies have highlighted a similar decrease in dam weight gain after
treatment with 50 mgkg"1 flutamide but without any significant change in pup weight
(Mylchreest et al, 1999; Mclntyre et al, 2001): currently there is no literature on pup weight
after exposure to 100 mgkg"' flutamide. The reduction in bodyweight persisted in males
postnatally, suggesting that postnatal bodyweight may be predetermined during fetal life.
This is consistent with reports that exposure to glucocorticoids, especially during late
gestation, alters offspring birthweight and the effect of this persists into postnatal life, even
predicting adult morbidity (Seckl, 2004).
As previously reported maternal exposure to flutamide, at the doses used in this study,
impaired androgen-dependent reproductive tract development in male offspring (Imperato-
McGinley et al, 1992; Mylchreest et al, 1999; Mclntyre et al, 2001). As expected, female
fetuses were unaffected by flutamide exposure thus confirming the accepted hypothesis that
androgens play no role in female fetal development. However, male fetuses from dams
exposed to either low (50 mgkg"1) or high (100 mgkg"1) doses of flutamide, had no prostate,
reduced AGD and impaired WD development. These abnormalities persisted into adulthood
confirming that the patterning and establishment of the reproductive tract is set up in the
fetus and interfering with androgen action during this period permanently alters reproductive
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tissues. This is consistent with previous studies (Imperato-McGinley et al, 1992; Mylchreest
et al, 1999; Mclntyre et al, 2000; Mclntyre et al, 2001) and confirms that we have
established a model of impaired androgen action in our rat colony, comparable with other
groups.
Previous studies have reported that flutamide exposure in utero results in abnormal
epididymides in adults but these studies do not identify whether the WD formed and
stabilised fetally but later degenerated during differentiation or whether it failed to form
and/or stabilise (Mylchreest et al, 1999; Mclntyre et al, 2001; Foster and Flarris, 2005). In
the present studies, WDs from flutamide-exposed males were present at el7.5 - el9.5 and
appeared normal in all animals, with no obvious morphological differences or reduction in
luminal length compared with age matched controls. This suggests that flutamide-exposed
WDs initially form normally and are morphologically stabilised but it is unknown whether
these WDs are functional at the biochemical level therefore this warrants further
investigation. In the female, the WD regresses at least partially due to apoptosis suggesting
that the WD is dying rather than simply not differentiating (discussed in chapter 6) (Dyche,
1979; Jirsova and Vernerova, 1993). In contrast, minimal cell apoptosis was detected in
WDs from flutamide-exposed males at any age studied. Together these findings suggest that
the doses of flutamide administered may not completely block the AR and so may not reduce
androgen action sufficiently to impair WD stabilisation and cause it to degenerate, as occurs
in the female (Jirsova and Vernerova, 1993). This difference could reflect the higher levels
of testosterone reported to be available at el 8.5, when the WD is undergoing stabilisation,
than at e20.5, when the WD is morphologically differentiating thus making it more difficult
for flutamide to block androgen action (Habert et al, 1992). Alternatively, WD stabilisation
may require relatively low levels of androgens, less than that required for differentiation, or
WD stabilisation and differentiation may be regulated by different mechanisms. This
highlights WD development as a 2-phase process, each of which may be differentially
controlled. It is likely that the former hypothesis is true since previous researchers have
reported that it is easier to inhibit androgen dependent growth of immature sex accessory
tissues than it is to initiate degeneration and apoptosis (Lambright et al, 2000). Insight from
patients with complete androgen insensitivity syndrome (CAIS) and Tfm mice might further
elucidate this as androgen receptor signalling is disabled in each case. Reports have shown
that in both instances, adults lack any WD-derivatives (Drews and Dieterich, 1978; Quigley
et al, 1995), however, no definitive evidence is published regarding the status of the fetal
WD. This is further discussed in chapter 6.
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In controls, WDs showed a significant age-dependent increase in coiling, a morphological
sign of differentiation, as determined by quantification of the WD luminal length: this is
believed to be an androgen dependent process. Unsurprisingly, flutamide partially impaired
his differentiation, as seen by the reduced WD luminal length in fetuses from dams exposed
to flutamide (50 or 100 mgkg"1). This confirms the vital role for androgens in differentiation
of the stabilised WD. The reduction in coiling was more pronounced in WDs from pups
from high dose flutamide litters than from low dose litters, suggesting that WD
differentiation is dependent not only on the presence on androgens, but also on the level of
androgen action.
At el9.5, WDs from all flutamide-exposed animals were morphologically intact suggesting
that AR-mediated signalling in the WD was incompletely blocked in the fetus, even at 100
mgkg"1 flutamide, thus allowing the WD to be rescued. This dose of flutamide is
approximately 4-fold higher than that required to prevent prostate development and to
completely feminise the external genitalia (Imperato-McGinley et al, 1992). This difference
is likely due to the much higher local concentrations of testosterone reported in the WD than
in tissues derived from the urogenital sinus (Veyssiere et al, 1982). It is worth noting that
exposure to flutamide does not reduce fetal testicular testosterone levels at e21.5 but actually
causes a slight increase in testosterone production (unpublished data). In adults from dams
that had been similarly exposed to 100 mgkg-1 flutamide, the majority of the WD-derived
tissues were largely absent in 83% of adult males examined. This is in agreement with
previous studies showing that exposure to anti-androgenic compounds in utero results in a
high frequency of epididymal malformations in adult rats (Imperato-McGinley et al, 1992;
Mylchreest et al, 1999; Mclntyre et al, 2001; Turner et al, 2003; Foster and Harris, 2005).
The contrast between the prevalence of flutamide induced WD abnormalities at el 9.5 (0%)
and in adulthood (83%) demonstrates that the major effect of flutamide is on epididymal
differentiation rather than its stabilisation, contrary to suggestions by earlier researchers
(Imperato-McGinley et al, 1992; Mylchreest et al, 1999). This increased prevalence of
epididymal abnormalities with age may be a result of failure to establish normal patterning
of the WD fetally. Interfering with androgen action within a critical window of development
can therefore impair WD patterning and hence differentiation into its adult derivatives,
resulting in irrecoverable malformation of the reproductive tract and likely impairment of
fertility. Further studies were undertaken to investigate this window for androgen action
during WD development and will be discussed in chapter 5.
By e21.5, WDs from flutamide-exposed animals showed abnormalities in both gross
morphology and histology, including shorter, flatter epithelia, occasional missing corpus
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segments of the future epididymis, reduced coiling and incomplete lumens. The widened
lumens seen in some animals at e21.5 may be due to the collapse of the lumen distally,
resulting in blockade of fluid flow down the duct. These abnormalities were not seen until
e21.5, thus the epithelium initially forms normally in flutamide-exposed animals but
degenerates during differentiation, possibly due to interrupted androgen-driven signalling
between the stroma and epithelium. This epithelial flattening was also reported by previous
studies in which animals were exposed to Di-rc-butyl phthalate (DBP; 500 mgkg"1) during
fetal life but flattening of the epithelium was not observed until pndl6 (Barlow and Foster,
2003). Furthermore, castration of fetal rats on day 19 resulted in epithelial cells changing
shape from columnar to more cuboidal cells (Inomata et al, 1989). In multiple organ
systems, it is believed that steroid hormones control the fate of epithelial cells via
interactions with the underlying stroma and hormone withdrawal can result in epithelial-
mesenchymal transformation (Donjacour and Cunha, 1991; Cunha et al, 1992; Cunha and
Young, 1992; Cunha et al, 1996; Aupperle et al, 2004). Since the epithelium in incomplete
regions often appeared flattened with some cells even looking more fibroblast-like, it may be
that a lack of androgen signalling resulted in de-differentiation of some epithelial cells into
mesenchymal-like cells thus contributing to the impaired development of the WD. These
missing segments were only noted in the corpus segment, the region of the WD that coils last
and the segment of the adult epididymis that is least coiled. The 'androgen signal' may be
weaker in the corpus than in the caput or cauda and thus flutamide treatment could have
more impact on its development. The caput is closest to the testis and is therefore likely to
be exposed to high levels of locally delivered androgens, but it is not obvious why the cauda
should be less affected by flutamide treatment than the corpus. It is possible that the cauda
may obtain testosterone from the blood as well as directly from the testis. Flowever, there is
unlikely to be a role for the more potent androgen, DHT, as Wilson (Wilson and Lasnitzki,
1971) and Siiteri (Siiteri and Wilson, 1974) both reported that DHT was not detectable in the
WD until after epididymal differentiation was complete.
The most obvious explanations for the abnormal WD development are an increase in cell
apoptosis and/or a decrease in cell mitosis. Since apoptosis was minimal in WDs from
flutamide-exposed animals, it was considered likely that altered cell proliferation was
responsible. Proliferation was apparent in both the epithelial and stromal cell compartments
in WDs from both control and flutamide-exposed (50 or 100 mgkg"1) litters. However, it
was clear from these studies, that maternal exposure to flutamide resulted in reduced
proliferation in both the epithelial and stromal cell compartments of the WD at all ages
examined, although significant effects on stromal cell mitosis were noted earlier than
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epithelial effects. This highlights the impact of androgen blockade on cell mitosis in the
differentiating WD, showing that androgen regulates both stromal and epithelial cell
proliferation but the consequences of reduced androgen receptor signalling can be noted
earlier in the stromal compartment.
3.5 Conclusion
There is substantial literature on the effects of reduced androgen action on the male
reproductive tract using knockout mice and androgen receptor antagonists, however most
have studied the effects in adult males, and few have looked at how this impacts on
development in fetal life. These studies have utilised a model that allowed manipulation of
androgen action during fetal life, using maternal exposure to 50 or 100 mgkg"1 flutamide.
The results of this maternal treatment were comparable to those previously published
(Imperato-McGinley et al, 1992; Mylchreest et al, 1999; Mclntyre et al, 2001).
The flutamide regime used in these studies interfered with normal WD development;
however, it did not prevent stabilisation of the WD but impaired its subsequent convolution
and differentiation into its adult derivatives. This highlights WD development as a 2-phase
process with WD stabilisation apparently requiring lower androgen action than WD
differentiation. Why WD stabilisation is not affected by administration of high doses of
flutamide, approximately 4 fold higher than levels that prevent formation of the prostate and
induce feminisation of the external genitalia, is something of a mystery, and merits further
study. Flutamide exposure interfered with WD differentiation by reducing cell proliferation
rather than inducing cell apoptosis. This was noted in both the epithelial and stromal cell
compartments at all ages studied.
Future studies will focus on utilising the present model system to investigate possible
mechanisms involved in WD patterning and differentiation.
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4 Impact of interrupted androgen action on normal markers of
Wolffian duct development and its cell compartments and
cytoskeleton
4.1 Introduction
The results in the previous chapter confirmed the essential role for androgens in WD
stabilisation and differentiation, since exposure to flutamide (50 or 100 mgk"1) between
el 4.5-21.5 impaired convolution and differentiation of the WD. Surprisingly, this flutamide
regime did not interfere with the earlier stabilisation of the WD, highlighting WD
development as a bi-phasic process with stabilisation apparently requiring lower androgen
action than does differentiation. The studies presented in this chapter will utilise this model
system to investigate the possible mechanisms involved in androgen-dependent WD
patterning and differentiation and their perturbation by maternal exposure to flutamide.
Sexual differentiation of the reproductive tract is dependent on hormonal regulation but it is
not just the secretion of these key hormones which is vital for normal sexual differentiation,
but also the expression of their appropriate receptors in the target tissue. It has been
suggested that the pattern of steroid hormone receptor expression reflects the ability of the
tissue to respond to that hormone (Bentvelsen et al, 1995). There is no evidence for a role
for either oestrogens or DHT in WD development (discussed in section 1.6 and 1.5.1.1,
respectively) but all evidence points to a vital role for testosterone. Several studies have
mapped AR expression in the fetal reproductive tract, highlighting that ARs are initially
expressed in the rat WD mesenchyme from at least el6.5 with expression not appearing in
the WD epithelium until later, around el8.5, even after the initiation of differentiation.
(Bentvelsen et al, 1995; Majdic et al, 1995) (section 1.5.1.2). This led to the hypothesis that
androgens induce epithelial differentiation in the male UGT by acting on the surrounding
mesenchyme, but the mechanisms behind such paracrine interactions are still only
superficially understood (Cunha, 1976) (discussed in section 1.7).
In both fetal and adult life, the organs of the male and female reproductive tract are
composed of both epithelium and surrounding supporting stromal cells. Differentiation of
the epithelial cells depends on signals received from the underlying mesenchyme. This
patterning and compartmentalisation of reproductive organs varies between different
structures in the male reproductive tract but is dependent on androgen action in all structures.
It is likely therefore that impaired androgen action may interfere with this patterning,
compartmentalisation, and differentiation therefore contributing to the abnormal
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development of the WD. For example, Hayward and colleagues showed that as
mesenchymal cells in the prostate mature and differentiate into smooth muscle cells,
expression of early mesenchymal markers such as vimentin decreased while muscle cell
markers such as smooth muscle actin and desmin increased: this is believed to be dependent
on androgen action (Hayward et al, 1996).
It has been suggested from studies in other reproductive tissues that the extracellular matrix
(ECM) and cytoskeleton are likely to be involved in mediating mesenchymal-epithelial
signalling and thus promote organogenesis and maintain tissue integrity (section 1.8.1 and
1.9) (Cunha et al, 1985). The ECM surrounds cells and plays a role in controlling their
behaviour, proliferation and differentiation by regulating the availability of signals, such as
growth factors, reaching their cell surface (Streuli and Gilmore, 1999). Little is known about
the composition of the ECM and basement membrane in the normal WD or its role in
androgen-dependent WD development though studies have suggested a role for them in the
regressing female MD (section 1.3.1.1). MD regression is characterised by a disruption of
the basement membrane, so allowing direct contact between the epithelium and
mesenchyme, thus leading to epithelial degeneration (Dyche, 1979; Ikawa et al, 1984;
Inomata et al, 1989; Austin, 1995). This is hypothesised to be mediated by the ECM (Dyche,
1979; Inomata et al, 1989; Austin, 1995). It is feasible therefore that the ECM and basement
membrane may play a vital role in preventing degradation of the male WD by mediating
androgen signalling between the stroma and epithelium.
Previous studies have shown that reduced androgen action in fetal life results in a loss of
epididymal and vas deferens tissue by adulthood, but none of these studies have addressed
the mechanisms behind this degradation (Imperato-McGinley et al, 1992; Mylchreest et al,
1998; Mclntyre et al, 2000). Studies reported in chapter 3 have shown that this is not due to
impaired WD stabilisation but is due to a bi-phasic degradation of this tissue late in fetal life
or post pubertally (section 3.3.4.1.3). It is not understood why this degradation occurs or
what mechanisms are involved in mediating this. Studies involving exposure of neonatal
rats to DES may provide some insight into potential mechanisms as DES exposure also
results in a loss of WD-derived tissue in adults and this was shown to be at least partially
mediated by an infiltration of immune cells into the lumen (Atanassova et al, 2005).
Furthermore, matrix metalloproteinases (MMPs) are known to play a role in degradation of
the ECM and have been shown to be involved in MD regression, therefore these enzymes
may also contribute to the degradation of the WD-derivatives (Roberts et al, 2002).
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4.1.1 Aims
To investigate steroid receptor expression in the developing WD and the impact of flutamide
treatment on this expression in the WD and its adult derivatives. To establish if altered
expression of AR plays a role in flutamide-induced inhibition ofWD development.
To investigate differentiation of the specific cellular compartments of the WD and its adult
derivatives, both in normal and flutamide-exposed animals. To establish if the effects of
flutamide treatment are first detectable in the stromal compartment, consistent with the view
that epithelial development is mediated by androgen effects on the stroma.
To examine the extracellular matrix (basement membrane, intermediate filaments and
cytoskeleton) in the developing WD and its integrity after exposure to flutamide.
To investigate possible proteins involved in the loss of segments of the WD and its adult
derivatives after flutamide exposure.
To examine the role for patterning genes in the normal development of the WD and any
alterations to this patterning caused by exposure to flutamide.
Chapter 4 Impact of interrupted androgen action on cellular compartments 119
4.2 Methods
4.2.1 In utero treatments
As detailed in chapter 2, section 2.2, pregnant dams were randomly allocated to treatment
groups and dosed once daily by gavage with 1 mlkg"1 maternal bodyweight of the following
treatments. Dams were dosed between el 5.5-e21.5, or until the day prior to cull if this was
before e21.5.
Flutamide: 50mgkg"' in 1ml corn oil/2.5% DMSO (n=24 litters)
lOOmgkg"1 in 1ml corn oil/2.5% DMSO (n=23 litters)
Control: 1ml corn oil/2.5% DMSO (n=68 litters)
Throughout this chapter, offspring from dams treated with flutamide during gestation will be
referred to as "flutamide-exposed" or treated "in utero". This does not mean that fetuses or
WDs were directly exposed to flutamide but were exposed indirectly via the pregnant dam.
4.2.2 Tissue collection
Dams were killed by inhalation of carbon dioxide and subsequent cervical dislocation and
fetuses were recovered at el 7.5 - e21.5. Postnatal animals, older than pndl 0, were killed by
inhalation of carbon dioxide and subsequent cervical dislocation. Fetuses were killed by
decapitation then reproductive tracts were recovered by microdissection and photographed
using a Leica ICA camera (section 2.3.2.1). Reproductive tracts and gonads were collected
from postnatal animals. Tissue was either fixed in Bouin's or PFA or frozen (section 2.4).
4.2.3 Immunohistochemistry
Immunohistochemistry was performed on isolated reproductive tracts fixed in Bouin's, using
standard avidin peroxidase protocols in order to highlight the location of proteins of interest,
as detailed in section 2.6.1.
4.2.3.1 Non-fluorescent immunohistochemistry
Briefly, sections were cut from paraffin blocks and mounted on glass slides. Sections were
then dewaxed and rehydrated then pressure cooked in citrate buffer if required (Table 4.1).
Non-specific binding was blocked before adding the appropriate primary antibody overnight,
as detailed in Table 4.1. A biotin labelled secondary antibody was used that had been raised
against a species-specific sequence on the primary antibody. This biotinylated secondary
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antibody signal was amplified by incubation with avidin-biotin conjugated with horseradish
peroxidase and the signal was localised using DAB. Sections were counterstained with
haematoxylin and mounted with glass coverslips. Further detailed protocols can be found in
section 2.6.1.
Table 4.1 Summary of primary antibodies used for immunohistochemistry.
Target Antigen Source Dilution Retrieval Host Species
Androgen Receptor Santa Cruz 1:50 Citrate Rabbit
ERa Novocastra 1:20 Citrate Mouse
ER(3 Gift from P.Saunders
5a reductase I Gift from B. Robaire 1:35 None Rabbit
5a reductase II Gift from B. Robaire 1:35 None Rabbit
p63 Santa Cruz 1:500 Citrate Mouse
Smooth Muscle Actin Sigma 1:10000 None Mouse
Pan-cytokeratin Sigma 1:200 Citrate Mouse
Desmin DAKO 1:400 Citrate Mouse
Vimentin DAKO 1:1000 Citrate Mouse
Laminin Abeam 1:100 Citrate Rabbit
E-cadherin BD Biosciences 1:200 Citrate Mouse
Fibronectin Abeam 1:100 Citrate Mouse
MMP-2 In house 1:200 None Mouse
N-cadherin Zymed 1:500 Citrate Mouse
CD45 BD Bioscience 1:50 Citrate Mouse
CD68 DAKO 1:500 Citrate Mouse
Neutrophil Elastase DAKO 1:500 None Sheep
4.2.3.2 Fluorescent immunohistochemistry
Fluorescent immunohistochemistry was used in some cases to allow co-localisation of more
than one antigen simultaneously (see section 2.6.1.3).
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4.2.3.2.1 Triple immunohistochemistry protocol
In order to delineate stromal and epithelial compartments, fluorescent immunohistochemistry
was used to co-localise three proteins in WDs recovered from control and flutamide-exposed
fetuses at el7.5 - e21.5 and in postnatal epididymides (Fig. 4.1). Sections were
deparaffinised, rehydrated and antigen retrieval performed as detailed in section 2.6.1. All
washes between antibody or reagent incubations comprised of two 5 min washes at room
temperature in PBS (Sigma). At each stage, control sections were incubated with blocking
serum without antibody in order to confirm antibody specificity. Non-specific binding sites
were blocked by incubating sections in normal goat serum (NGS; Autogen Bioclear UK Ltd,
Wiltshire, UK) diluted 1:4 in PBS containing 5% bovine serum albumin (BSA; Sigma).
Sections were incubated overnight at 4°C with anti-pan-cytokeratin antibody (Sigma) diluted
1:200 in NGS/PBS/BSA. Pan-cytokeratin localisation was detected by incubating sections
for 1 h with goat anti-mouse secondary antibody directly conjugated with alexa fluor 488
(Molecular Probes) diluted 1:200 in PBS to produce green fluorescence. Sections were
incubated for 30 min with mouse IgG (Sigma) diluted 1:2000 in NGS/PBS/BSA to block any
remaining mouse IgG sites and prevent the second mouse antibody sticking non-specifically.
Non-specific binding sites were blocked again by incubating sections with NGS/PBS/BSA
for 30 min before incubating overnight at 4°C with anti-AR (Santa Cruz) diluted 1:50 in
NGS/PBS/BSA. AR immunostaining was detected by incubating sections with biotinylated
goat anti-rabbit IgG secondary antibody (DAKO) diluted 1:500 in NGS/PBS/BSA for 30
min followed by incubation for 1 h with streptavidin-conjugated alexa 546 (Molecular
Probes), producing red fluorescence. Non-specific binding sites were blocked again by
incubating sections with NGS/PBS/BSA for 30 min before incubating overnight at 4°C with
anti-smooth muscle actin antibody (SMA; Sigma) diluted 1:500 in NGS/PBS/BSA. Sections
were incubated for 1 h with goat anti-mouse labelled with Cy5 (Amersham Biosciences,
Little Chalfont, UK) diluted 1:60 in PBS, producing blue fluorescent SMA immunostaining.
Sections were counterstained for 10 min with a nuclear-specific blue fluorescent label (Dapi;
Sigma) diluted 1:1000 in PBS. Slides were then washed in PBS and mounted in Mowiol
mounting medium (Calbiochem; Lutterworth, UK). Fluorescent images were captured using
a Zeiss LSM 510 Meta Axiovert 100M confocal microscope (Carl Zeiss Ltd, Welwyn
Garden City, UK).
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Figure 4.1 Diagrammatic representation of triple fluorescent immunohistochemistry
protocol
4.2.3.2.2 Co-localisation of vimentin and cytokeratin
Sections were deparaffinised, rehydrated and antigen retrieval performed as detailed in
section 2.6.1. Non-specific binding sites were blocked by incubating sections in
NGS/PBS/BSA for 1 h then incubated overnight at 4°C with anti-pan-cytokeratin antibody
(Sigma) diluted 1:200 in NGS/PBS/BSA. This signal was detected by incubating sections
for 1 h with goat anti-mouse secondary antibody directly conjugated with alexa fluor 546
(Molecular Probes) diluted 1:200 in PBS to produce red fluorescence. Sections were washed
well in PBS before blocking in NGS/PBS/BSA for 1 h. Since the anti-vimentin antibody
(Dako) and the pan-cytokeratin antibody were both raised in mice, Mike Millar from our
histology lab directly labelled the anti-vimentin antibody with Alexa fluor 488 using an
Alexa fluor 488 labelling monoclonal antibody labelling kit (Molecular Probes), for which I
am extremely grateful. This antibody was diluted 1:15 in NGS/PBS/BSA and incubated on
sections for 2 h at room temperature. As no secondary antibody detection was required,
slides were washed well in PBS and counterstained with Dapi and mounted as detailed above
(section 4.2.3.2.1).
4.2.4 Whole mount immunohistochemistry
Whole mount immunohistochemistry allows localisation of target antigens in a 3-
dimensional manner within a whole tissue. This method used similar principles as detailed
in section 2.6.1.
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4.2.4.1 Re-hydration
After fixation in 4% PFA, fetal reproductive tracts were stored in methanol at -20°C as
detailed above (section 2.4.2.1). Prior to immunostaining, the tissue was re-hydrated through
a series of methanols in PBS at room temperature. Tissue was incubated in 75%
methanol/PBS for 20 min, 50% methanol/PBS for 20 min then 25% methanol/PBS for 20
min. Re-hydrated tissue was washed in PBS for 5 min then in distilled water for 48 h, with
several changes. The tissue was then washed in PBS with 0.5% Triton-X (PBSTx; Sigma)
for 5 min.
4.2.4.2 Permeabilisation
Fixatives induce cross-linking in order to preserve tissue integrity, but this can often mask
proteins (antigens) and thus prevent their immunodetection. In order to unmask these
antigens, tissues were permeabilised/digested using 0.05% trypsin (Sigma) in PBS with 0.1%
Calcium Chloride. Tissues were incubated for 30 min in the trypsin solution which was pre¬
heated to 37°C in a waterbath.
4.2.4.3 Non-specific blocking
Tissues were washed in PBS for 5 min prior to incubation for 6 h at room temperature in 2%
normal goat serum diluted in PBSTx (PBSTx/NGS). Any non-specific binding of the
secondary antibody was prevented by incubating sections in a dilute solution of serum from
the species in which the secondary antibody was raised. Triton-X is a detergent therefore
aided the unmasking of the antigens and increased the sensitivity of the immuno-detection.
4.2.4.4 Primary antibodies
Blocking buffer was replaced with primary antibody (Table 4.2), diluted in blocking buffer
to an optimised concentration. Tissues were incubated on a rotator in a 0.5 ml Eppendorf™
overnight at 4°C with SMA diluted 1:7500 in PBSTx/NGS. Control tissues were incubated
with blocking serum only to confirm staining specificity.
Table 4.2 Summary of antibodies used for whole mount immunohistochemistry
Target Antigen Source Dilution Host Species
Smooth Muscle Actin Sigma 1:7500 Mouse
Pan-cytokeratin Sigma 1:400 Mouse
4.2.4.5 Secondary antibodies
Tissues were washed well in PBSTx for 2 h at room temperature on a rotator to remove any
residual primary antibody thus preventing non-specific background staining. The secondary
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antibody was raised against a species-specific sequence on the primary antibody.
SMA/cytokeratin was immunodetected by incubating tissues for 3 h with goat anti-mouse
secondary antibody directly conjugated with alexa fluor 488 (Molecular Probes) diluted
1:200 in PBS to produce green fluorescence. Tissues were washed well in PBSTx for 1 h at
room temperature on a rotator to remove any residual primary antibody
4.2.4.6 Microscopy
WDs were transferred into a 12 well plate (Corning Incorporated, Loughborough, UK) and
visualised using a Leica MZFL III microscope (Leica Microsystems). Cellular localisation
of SMA was determined and WDs were photographed using a Coolsnap camera
(Photometries, Roper Scientific, Buckinghamshire, UK). WDs were not archived since
fluorescence fades within approximately 2 weeks.
4.2.5 Western blots
Western blotting was carried out to separate a mixture of proteins according to their
molecular size, as detailed in section 2.6.2. Briefly, protein was extracted from frozen WDs
(el7.5-e21.5) using RIPA lysis buffer (section 2.6.2.1) and 15ug of each protein was loaded
into an SDS-page gel and subject to electrophoresis at 100 V for l-2h. Proteins were electro-
transferred from the gel and immobilised onto a nitrocellulose membrane. Proteins were
subsequently detected on the membranes using antibodies specific to proteins on the
membrane (Table 4.3) as described in 2.6.2.5. An anti-13-tubulin antibody (Sigma) was used
as a standardization loading control, diluted 1:300 in TBST.
Table 4.3 Summary ofprimary antibodies used for Western blotting
Target Antigen Source Dilution Host Species
Androgen Receptor Santa Cruz 1:300 Rabbit
Smooth Muscle Actin Sigma 1:10000 Mouse
Vimentin Dako 1:4000 Mouse
p-tubulin Sigma 1:300 Mouse
E-cadherin BD Biosceinces 1:2000 Mouse
4.2.6 RNA extraction
RNA was extracted from frozen WDs at el7.5-e21.5 using RNeasy Mini extraction kits
(Qiagen, Crawley, UK) and quantified using RNA 6000 Nano chips on an Agilent 2100
Bioanalyser (Agilent Technologies, Wockinghan. UK), as detailed in section 2.7.1-2.7.2.
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4.2.7 Taqman QRT-PCR
Random hexamer primed cDNA was prepared using the Applied Biosystems TaqMan ®
reverse transcription kit (Applied Biosystems, Foster City, CA) (see 2.7.3.2) and
quantitative PCR was performed using the ABI Prism 7900 Sequence Detection System
(Applied Biosystems). Expression of specific gene mRNA was determined using the Assay-
On-Demand Gene Expression ™ system (Applied Biosystems), as detailed in Table 4.4.
Detailed protocols can be found in section 2.7.5.
Table 4.4 Summary of Taqman ® Assay-On-Demand Gene Expression ™ primes used.





Oligo-dT primed cDNA was amplified using Bioscript Reverse Transcriptase (Bioline,
Germany) according to manufacturer's instructions (section 2.7.3.1). Oligonucleotide
sequences for Hox A10 primers were designed and generously provided by Griet
Vanpoucke: primers were synthesised by MWG-Biotech (Germany). Table 4.5 details the
specific sequences, annealing temperature and product sizes for each primer pair used;
primers were diluted to 5pM before use.





Hox A10 forward AGCGAGTCCTAGACTCCAC 500bp 65°C
Hox A10 reverse AGGCAGAAGGATGGGTACAG 500bp 65°C
4.2.8.1 PCR reaction
In all PCR reactions, Bio Taq (Bioline) was used, according to manufacturer's instructions as
detailed below.




lOx NH4 Buffer 1 pi lx
50mM MgCl2 0.3 pi 1.5mM
2mM dNTPs 1 pi 200pM
Forward Primer 5pM 1 pi 0.5 pM
Reverse Primer 5 pM 1 pi 0.5 pM




Reagents were added together in a sterile 0.2ml thin walled PCR tube (Continental Lab
Products) and thermo-cycled through the following programme.
Denature - 95°C for 5 min
Amplification (30 cycles):
Denature - 94°C for 30 s
Anneal - 50-58°C (depending on primers) for 30 s
Extension - 72°C for 1 min
Extension - 72°C for 10 min
4.2.8.2 Electrophoresis
4.2.8.2.1 Loading Dyes and Ladders
Once the target gene was amplified using PCR, they were analysed using agarose gels. A
loading dye was added to each sample in order to retain the DNA in wells and prevent it
floating away. This dye also allows visualisation of how far each sample has run on the gel.
Different dyes will ran at different speeds due to differences in the size of the molecules,
however, Orange G was used in all experiments. Orange G (50% lx TAE, 20% glycerol,
0.25% Orange G) runs to 50 base pairs (bp) therefore products will still be on the gel if they
are bigger than 50bp. Each sample had 5pi Orange G added to it before being loaded into an
agarose gel (see details below). A DNA ladder was also run on each gel to check that PCR
products were the expected size and confirm amplification of the correct target sequence.
Hyperladder IV (Bioline), a DNA ladder with loading buffer already added, was used. This
allows accurate sizing and quantification ofDNA between lOObp and lOOObp.
Chapter 4 Impact of interrupted androgen action on cellular compartments 127
4.2.8.2.2 Agarose gel
PCR products were electrophoresed on 2% agarose gels (150 ml lx TAE buffer + 3 g
Agarose (Bioline)). This solution was heated in the microwave to ensure agarose was
dissolved. This was allowed to cool slightly then 75pl ethidium bromide (lmgrnf1 at
1/2000) was added to the agarose solution: ethidium bromide intercalates between the DNA
bases and fluoresces under UV light to allow visualization of the DNA bands in the gel. The
agarose gel solution was poured into a case with a comb to form the wells and was then left
to cool and set.
4.2.8.2.3 Electrophoresis and visualisation
The agarose gel was transferred into an electrophoresis tank (Biorad, Hertfordshire, UK)
filled with lx TAE buffer. The DNA ladder and PCR samples were loaded into wells and the
electrodes were connected up to a Biorad power pack 300 (Biorad) and subjected to 75V for
approximately 1 h. Gels were visualized using a transilluminator.
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4.3 Results
4.3.1 Expression of steroid receptors in the Wolffian duct and its adult
derivatives
4.3.1.1 Androgen receptor expression
4.3.1.1.1 Androgen receptor expression in the fetal Wolffian duct
The androgen receptor (AR) was immunolocalised to cell nuclei throughout the WD at all
ages examined (el6.5 - e21.5). AR expression was first detected in a few sporadic cells in
the WD stroma at e15.5 and in most stromal cells by el6.5: epithelial expression did not
switch on until around el7.5 (Fig. 4.2). In all subsequent fetal ages, inner stromal cells
directly surrounding the epithelium showed the most intense immunostaining while the
epithelial cells showed weaker staining at all ages (Fig. 4.2). WDs from flutamide-exposed
animals displayed a similar pattern of AR expression to controls at all ages studied with
more intense AR expressed in the stroma (Fig. 4.3) and epithelial expression switching on in
some cells by el7.5 (Fig. 4.3). This differing expression in the inner stroma compared to the
epithelium can be highlighted by co-staining AR with cytokeratin, an epithelial cell marker,
and SMA, a marker of inner stroma (Fig. 4.4).
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Figure 4.2 Immunoexpression of androgen receptor (AR) in the developing Wolffian
duct (WD) from e15.5-e21.5. AR was not detected in the WD at e15.5 but was expressed
in the WD stroma by e16.6 (immunostained brown, *). AR expression in the epithelium
(arrow) began to switch on around e17.5 and was strongly expressed in the epithelium by
e19.5. AR was intensely expressed in both the stroma (*) and the epithelia (arrow) by e21.5.
Scale bar = 100 urn




Figure 4.3 Expression of androgen receptor (AR) protein in the Wolffian duct (WD)
from control (A-C) and flutamide-exposed (D-F, 100 mgkg'1) rats at e17.5 (A & D), e19.5
(B & E) and e21.5 (C & F). The pattern and timing of AR expression did not vary between
control and flutamide-exposed WDs: stromal AR (*) was strongly expressed at e17.5 with
epithelial AR expression (arrow) switching on at around e17.5 in flutamide-exposed WDs
(D). Scale bar = 100 urn
Figure 4.4 Androgen receptor (AR) expression in the different Wolffian duct (WD)
compartments at e21.5. Note that the inner stroma is demarcated by smooth muscle
immunostaining (SMA; blue) and the epithelium by cytokeratin staining (arrow, green). No
obvious difference was seen in AR expression (red) between WDs from control animals (A)
and animals exposed to 50 mgkg'1 (B) or 100 mgkg'1 (C) flutamide. Image D shows AR only
staining from Fig 5A, highlighting that AR protein is expressed more intensely in the stroma
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than in the epithelium (arrows) of the control WD at e21.5 (D) and flutamide treatment had
no obvious effect on this pattern (B & C). Scale bar = 50pm
Further analysis of AR expression using Western blotting and Taqman QRT-PCR confirmed
that there was no significant difference in either AR protein (Fig. 4.5) or mRNA (Fig. 4.6)
expression in control compared to flutamide-exposed WDs at el8.5-e21.5. Variation was
seen in the levels of AR mRNA and protein within each age/treatment however, this was not
significant and presumably represents variation between individual WDs.
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Figure 4.5 Quantification ofAR protein levels in the Wolffian duct (WD). Panel A shows
a representative Western blot for AR protein expression in WDs at e19.5 - e21.5 (n-3 WDs
per age/treatment) with its loading control below. Panel B shows quantitative analysis (mean
± SEM) of AR protein from Western blots confirming no significant change in AR expression
in WDs at e18.5-e21.5 from control (solid blue bars) and flutamide-exposed (chequered bars
- 50 mgkg'1; striped bars - 100 mgkg'1) rats (n-6 Western blots, each using a pool of 3 WDs
per age/treatment, from at least 3 litters). Protein expression was corrected for loading and
expressed relative to levels in e19.5 control WD (means ± S.E.M, n-3-5 WDs per
age/treatment, each from different litters).
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Figure 4.6 Quantitaive analysis of AR mRNA in the Wolffian duct. No significant
difference was see in AR mRNA expression in WDs at e18.5-e21.5 from control (solid blue
bars) and flutamide-exposed (chequered bars - 50 mgkg'1; striped bars -100 mgkg'1) rats,
as determined by Taqman QRT-PCR (means ± S.E.M, n-3-5 WDs per age/treatment, each
from different litters). mRNA expression was corrected for loading and expressed relative to
levels in the uterus.
4.3.1.1.2 Androgen receptor expression in postnatal WD-derived structures
AR continues to be expressed in the epithelium and stroma in postnatal WD-derived
structures. The expression pattern alters from the fetal WD with epithelial AR expression
becoming more intense than in the stroma (Fig. 4.7, panels A & B). Epididymides and vasa
deferentia from males exposed to flutamide in utero (100 mgkg"1) continue to express AR in
both the stroma and epithelium, but this expression looks slightly reduced (Fig. 4.7, panels
C-F). Note that AR is expressed in the epithelium even in areas where the epididymis looks
abnormal both at the gross and histological level but it is no longer expressed in every
epithelial cell (Fig 4.7, panels E & F).
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Figure 4.7 Androgen receptor (AR) protein expression in postnatal epididymides from
control (A & B) and flutamide-exposed (100 mgkg'1, C-F) animals at pnd70. AR protein
(red) is expressed in most epithelial cells (cytoplasm immunostained green for cytokeratin;
arrow) and in some stromal cells (arrowhead) in the adult caput epididymis (A) and cauda
(B). Note that in some areas of the flutamide-exposed epididymis, the AR expression
pattern did not vary from the same region of the control epididymis (C compared to A and D
compared to B) while in areas where the epididymis has an abnormal phenotype (E - caput
and F -corpus) AR expression varied from controls. Sections were counterstained light blue
and the inner stromal smooth muscle layer is stained blue for smooth muscle actin.
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4.3.1.2 Oestrogen receptor expression in the fetal Wolffian duct
4.3.1.2.1 Oestrogen receptor a
Oestrogen receptor alpha (ERa) was immunolocalised to the efferent ducts, not the fetal
WD, in all reproductive tracts studied at el7.5-e21.5 (Fig. 4.8). This expression pattern did
not change in flutamide-exposed WDs.
Figure 4.8 Oestrogen receptor a (ERa) protein expression in the efferent ducts at
e21.5. Note that ERa is only expressed in the efferent duct epithelium (brown, arrow) and
was not detected in the Wolffian duct epithelium (arrowhead) or stroma. Scale bar -100 urn
4.3.1.2.2 Oestrogen receptor p
Oestrogen receptor p (ERP) was immunolocalised to both the stroma and epithelium in the
WD at all ages studied and showed no obvious variation with flutamide exposure (data not
shown).
4.3.1.2.3 5a-reductase type I and type II
5a-reductase type I and type II protein were not detected, by immunohistochemistry, in the
fetal WD (data not shown).
4.3.1.3 RXRcx
Retinoid X receptor a (RXRa), a member of the ligand-dependent retinoic acid receptor
transcription factor family, was immunolocalised to cell nuclei in both the stromal and
epithelial compartments of the WD at all ages studied (el7.5-e21.5). Immunoexpression was
less intense in WDs from fetuses exposed to flutamide in utero (Fig. 4.9) and was almost
absent in e2l.5 WDs exposed to 100 mgkg"1 flutamide (Fig. 4.9, panel F).
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Figure 4.9 RXRa expression in the developing rat Wolffian duct at e18.5 (A-C) and
e21.5 (D-F). Note that RXRa is expressed in both the stroma and the epithelium. At both
e18.5 and e21.5 RXRa expression is reduced in WDs from flutamide-exposed animals
(e18.5 B-50 mgkg'1 and C - 100 mgkg'1; e21.5 E -50 mgkg'1 and F - 100 mgkg'1) compared
to their age matched controls (A and C respectively).
4.3.2 Cell differentiation markers
4.3.2.1 Immunoexpression of basal epithelial marker p63
The basal epithelial cell marker p63 was not detected in the WD at any age studied (e21.5-
pndO) but was detected in the epithelium lining the neonatal urogenital sinus at pndO (Fig.
4.10). By pndl7, p63 was immunolocalised to the epithelium in WD-derived structures (Fig
4.11) and continued to be expressed throughout postnatal life. p63 was still
immunolocalised to the epithelium in postnatal males that had been exposed to flutamide in
utero, however this expression was reduced compared to age matched controls (Fig 4.11).
This reduction became more obvious in adults than in pre-pubertal males with p63 staining
only being evident in a few cells in some cross-sections of epididymis while in others there
was no obvious p63 expression at all. In some flutamide-exposed males, the epididymal
epithelium looked abnormal and was folded into crypt-like structures. In these areas, p63
staining appeared increased and not restricted to the basal cells (Fig. 4.12).














Figure 4.10 Immunoexpression of p63 in the neonatal reproductive tract (pndO). Note
that p63 was not expressed in the Wolffian duct epithelium (arrow) or stroma (A) but was
detected in the urogenital sinus epithelium (brown, arrowhead, B) from the same animal.
Scale bar -100 urn.
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Figure 4.11 Immunoexpression of p63 protein in the basal epithelial cells in the
postnatal epididymis (pnd17 - 70). Note that at pnd17, p63 is strongly expressed in basal
epithelial cells in the control epididymis (A) but this expression is slightly reduced in the
epididymis from flutamide-exposed animals (arrow, 100 mgkg'1,B). By adulthood (pnd70)
p63 continues to be strongly expressed in basal epithelial cells in the control epithelium in
the caput (C) and corpus (E) regions but expression is altered in flutamide-exposed
epididymides (100 mgkg1, D and F). Note that in the caput, p63 expression is reduced and
often absent in entire cross sections (arrow, D) whereas in the corpus, where the epididymis
had an abnormal phenotype, p63 is expression is increased (arrowhead, F). Scale bar =
100 urn
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Figure 4.12 Abnormal immunoexpression of p63 in adult epididymis from a male
exposed to flutamide (100 mgkg'1) in utero. Note the abnormal morphology of the
epithelium with folding into crypt-like structures and multilayers of cells. Note the strong p63
staining in basal cells and the less intense staining in the more apical cells. This was not
seen in control adult male epididymis.
4.3.2.2 Smooth muscle actin, a marker of WD stromal differentiation
4.3.2.2.1 Switching on of smooth muscle actin in control fetal WDs
Immunoexpression of smooth muscle actin (SMA), a marker of smooth muscle
differentiation, was first evident in the fetal rat WD at el8.5 (Fig. 4.13). SMA was only
detected in the stromal cells immediately adjacent to the epithelium, termed here as inner
stroma, not in the outer stromal compartment (Fig 4.13). This SMA expression was first
evident in the corpus segment of the WD at el8.5 (Fig. 4.13) and progressed towards the
caput and corpus by e20.5 (Fig 4.14).
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Figure 4.13 Immunoexpression of smooth muscle actin (SMA) in the fetal Wolffian
duct (WD) at e17.5-e21.5. Note that SMA is not expressed in the WD at e17.5 (arrowhead,
A) but switches on by e18.5 in the stroma immediately adjacent to the epithelium (brown,
arrow, B). SMA expression persists in the inner stroma at e19.5 (arrow, C) and e21.5
(arrow, D). Panel E highlights that SMA is first detected only in the corpus region at e18.5
(*), with expression in the caput and cauda regions by e20.5 (not shown). Scale bars -100
urn




Figure 4.14 Expression of smooth muscle actin (SMA) in the Wolffian duct (WD) at
e19.5 (A) and e20.5 (B) using whole mount immunohistochemistry. Note that at e19.5,
SMA was detected only in the corpus region (green, arrow, A) but by e20.5, SMA expression
had progressed towards the caput and cauda regions (arrowhead, B).
4.3.2.2.2 Evidence for earliest effects of flutamide treatment on the inner
stromal cells
As the data presented in chapter 3 (section 3.4.8) indicated an impact of flutamide treatment
on both stromal and epithelial tissues of the WD, evidence of stromal-specific effects was
sought using smooth muscle actin (SMA), a smooth muscle cell marker specifically
expressed in the inner stromal compartment. Immunostaining suggested a reduction in the
extent of this SMA positive layer in flutamide-exposed WDs compared to age matched
controls, though this varied considerably between WDs (Fig 4.15). This decrease was
confirmed quantitatively by Western blot analysis, which revealed a large reduction in SMA
protein expression from el8.5 (Fig. 4.15), a time-point at which no epithelial damage or
change in luminal length was detectable in flutamide-exposed animals (chapter 3). The
reduction in SMA expression continued throughout fetal life.
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Figure 4.15 Comparative expression of smooth muscle actin (SMA) at e19.5 in
Wolffian ducts (WDs) from controls (A) and animals exposed in utero to 50 mgkg-1 (B)
or 100 mgkg-1 flutamide (C). Note the reduction in SMA protein expression in WDs after
flutamide exposure. Panel D shows a representative Western blot for SMA protein in WDs
from control (C) and flutamide exposed animals (F - 50 mgkg'1; HF - 100 mgkg'1) at e18.5-
e21.5 (n= a pool of 3-5 WDs per age/treatment, from at least 3 different litters). Panel E
shows quantitative data expressed relative to SMA expression in control WDs at e19.5
(corrected for loading using /S-tubulin). Note the increase in SMA protein expression
between e18.5 and e19.5 in controls (solid blue bars) and the decrease in SMA expression
after flutamide-exposure (50 mgkg'1 chequered bars; 100 mgkg'1 striped bars), compared to
controls. * p<0.05, *** p<0.001, in comparison with respective control value. Values are
means ± S.E.M for 2-3 Western blots, each using a pool of 3 WDs per age/treatment, from at
least 3 litters).
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Analysis of SMA mRNA expression showed no consistent or significant difference in
mRNA expression with age or flutamide treatment (Fig. 4.16). The fluctuations seen in
mRNA expression are likely due to individual variation. It is worth mentioning that SMA
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Figure 4.16 Quantitative analysis of smooth muscle actin (SMA) mRNA expression in
Wolffian ducts at e18.5-e21.5 in control (solid blue bars) compared to flutamide-
exposed animals (50 mgkg'1chequered bars; 100 mgkg'1striped bars). Note that no
significant difference was seen in SMA mRNA expression with age/treatment, as determined
by Taqman QRT-PCR (means ± S.E.M, n=3-5 WDs per age/treament, each from different
litters). SMA mRNA expression was expressed relative to mRNA levels in control e21.5
testes (green bar, T) and compared to the internal positive control gene expression.
4.3.2.2.3 SMA expression in the postnatal epididymis
SMA can be localised to the stromal cells, immediately adjacent to the epithelium, in the
adult epididymis as in the fetal WD (Fig. 4.17). This thin layer of smooth muscle can be
seen along the full length of the epididymis, becoming thicker in the vas deferens (Fig. 4.17,
panel C and F). Exposure to flutamide in utero resulted in a thicker layer of smooth muscle
in the adult epididymis, but this varied between individuals and along the length of the
epididymis. In the vas deferens, a thin SMA negative layer can be seen between the
epithelium and the smooth muscle layer; this negative layer appears to be increased in males
exposed to flutamide in utero (Fig. 4.17).
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Figure 4.17 Smooth muscle actin immunoexpression (SMA, blue) in postnatal WD-
derivatives from control (A-C) and flutamide-exposed animals (100 mgkg'1, D-F) at
pnd70. Note that in the caput (A and D) and cauda (B and E) regions of the epididymis, a
layer of SMA is seen in the stroma adjacent to the epithelium (arrow) while in the vas
deferens (C and F), this SMA positive layer is slightly thicker and a thin SMA negative layer
can be seen between the epithelium and the SMA positive layer (*). Note that in the
epididymis, the SMA positive layer is slightly wider in the flutamide-exposed animals than in
controls. Green = cytokeratin, Red = androgen receptor
4.3.3 Integrity of the cytoskeleton and intermediate filaments in the WD
4.3.3.1 Cytokeratin
Simple columnar epithelia line the lumen of the fetal WD and its adult derivatives. In all
ages examined, cytokeratin was expressed in the cell boundary of this epithelium (Fig. 4.18)
and its expression did not obviously change with either age or flutamide treatment (50 or 100
mgkg"1). Immunostaining for cytokeratin highlighted abnormalities in the epithelial
compartment with cytokeratin still expressed in flattened, damaged epithelium even when it
was almost fibroblast-like (section 3.4.5). Cytokeratin localised to the epithelium in the
postnatal WD-derivatives, even those with an abnormal phenotype due to exposure to
flutamide during gestation (green staining in Fig. 4.16).















Figure 4.18 Cytokeratin expression (brown) at e21.5 in the Wolffian duct (WD)
epithelium from control and flutamide-exposed (50 and 100 mgkg1) fetuses. Note that
cytokeratin is still expressed in epithelia with an abnormal phenotype (arrow). Scale bars =
250 um
4.3.3.2 Desmin
Desmin protein was localised to the stromal compartment of the WD from at least el 5.5 (Fig
4.19) and continued to be expressed at all ages studied (el5.5-e21.5). Desmin was expressed
in both the inner and outer stromal compartments but was never detected in the epithelium.
There was no obvious change in desmin expression in flutamide-exposed WD stroma
determined by immunohistochemistry (Fig 4.19, C compared to D), and this was confirmed
quantitatively by Western blot (Fig. 4.20).
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Figure 4.19 Desmin protein expression in the fetal Wolffian duct (e15.5-e18.5). Desmin
is detected by e15.5 (brown, A) and continues to be expressed in the WD stroma throughout
fetal life (e18.5, B). Note that there is no obvious change in desmin expression in WDs from
flutamide-exposed fetuses (100 mgkg1, D) compared to age matched controls (C). Scale
bars =100 um
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Figure 4.20 Comparative expression of desmin protein at e17.5-21.5 in Wolffian ducts
(WDs) from controls and animals exposed in utero to 50 mgkg'1 or 100 mgkg'1
flutamide. Panel A shows a representative Western blot for desmin protein in WDs from
control (C) and flutamide exposed animals (F - 50 mgkg1; HF - 100 mgkg'1) at e17.5-e21.5
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(n- a pooI of 3 WDs per age/treatment, from at least 3 different litters). Panel B shows
quantitative data corrected for loading using p-tubulin (B-t). Note that no consistent change
was noted in desmin protein expression after flutamide-exposure (50 mgkg'1 chequered
bars; 100 mgkg1 striped bars), compared to controls. Values are means ± S.E.M.
4.3.3.3 Vimentin
Vimentin immunolocalised to the WD stroma of both control and flutamide exposed fetuses
at all ages examined (el7.5-e21.5; Fig. 4.21). Vimentin is also expressed in the basolateral
edges of epithelial cells in the distal corpus and cauda of the future epididymis. This
'spiking' was seen along the full length of the WD at el5.5 and el7.5 but by el9.5, epithelial
expression became mainly restricted to the cauda and was rarely seen in the caput epithelium
in control WDs (Fig. 4.21 and 4.22). Exposure to flutamide did not affect stromal vimentin
expression but altered the distribution of vimentin in the epithelium. In WDs from fetuses
exposed to flutamide in utero, vimentin 'spiking' was apparent in the caput of many WDs at
el9.5 and e21.5, as well as the cauda, and this spiking became more intense than in control
WDs (Fig. 4.22 and 4.23). No significant quantitative difference was seen in protein
expression in WDs from flutamide-exposed animals compared to age matched controls (Fig.
4.24).
Figure 4.21 Immunoexpression of vimentin in the caput region of control Wolffian
ducts (WD) at e15.5-e19.5. Note that vimentin (immunostained brown) is expressed in the
stroma at all ages but is only expressed in the epithelium (arrow) at e15.5 (A) and e17.5 (B),
not at e19.5 (C). Scale bar = 100 um













Figure 4.22 Immunoexpression of vimentin in control (left panel) and flutamide-
exposed (50 mgkg'1, right panel) WD at e19.5 and e21.5. Note that vimentin is expressed
in the stroma and did not vary with age or flutamide treatment (*, brown). Vimentin was also
detected in the epithelium (arrow) but only in the tail region of the epididymis and not in the
head region in control animals. Flutamide-exposure increased the prevalence of this
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vimentin 'spiking' in the epithelium and it became apparent in the head as well as in the
cauda. Scale bar = 100 urn
Figure 4.23 Co-expression of vimentin (green) and cytokeratin(red) in e21.5 Wolffian
ducts (WDs) from control (A and D) and flutamide-exposed (50 mgkg-1 B and E, 100
mgkg-1C and F) animals. Note that cytokeratin stains the epithelial cell boundaries red.
Note that vimentin (green) is not detected in the epithelium in the caput region of the control
WD (A) but is seen to co-express with cytokeratin in the cauda (yellow, D). This pattern is
altered in flutamide-exposed WDs with epithelial vimentin expression detected in both the
caput (B and C) and the cauda (E and F).
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*
el 7.5 el 8.5 e!9.5 e20.5 e2l.5
Chapter 4 Impact of interrupted androgen action on cellular compartments 146
Figure 4.24 Comparative expression of vimentin protein at e17.5-21.5 in Wolffian
ducts (WDs) from controls and animals exposed in utero to 50 mgkg-1or 100 mgkg-1
flutamide. Panel A shows a representative Western blot for vimentin protein (red) in WDs
from control (C) and flutamide exposed animals (F - 50 mgkg-1; HF - 100 mgkg-1) at e17.5-
e21.5 (n- a pool of 3 WDs per age/treatment, from at least 3 different litters). Panel B shows
quantitative analysis of vimentin expression, relative to e19.5 control levels and corrected for
loading using /3-tubulin (green band, B-t). Note that no consistent change was noted in
vimentin protein expression after flutamide-exposure (50 mgkg-1 chequered bars; 100 mgkg-
1 striped bars), compared to controls. Values are means ± S.E.M.
4.3.4 Integrity of the basement membrane in the WD after exposure to
flutamide
4.3.4.1 Laminin
Laminin was immunolocalised to the basement membrane in WDs at all ages studied (el8.5-
e21.5), forming a 'ring' between the epithelium and the stromal compartment (Fig. 4.25). In
WDs from flutamide exposed fetuses, the laminin 'ring' was interrupted in places and was
less defined (Fig. 4.25). In some WDs, the epithelial cells appeared to be sitting in the
laminin rather than sitting on the basement membrane.
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Figure 4.25 Immunoexpression of laminin in the basement membrane of control (A)
and flutamide exposed (B-F) WDs at e21.5. Note the defined 'ring' of laminin around the
base of the epithelium in the control WD (arrow, A). This 'ring' became less defined and
interrupted in WDs from flutamide-exposed litters (arrowhead, B-F). Scale bar = 100 urn
4.3.4.2 Fibronectin
Fibronectin is expressed around the basement membrane and the inner stroma of the WD at
all ages studied (el8.5-e21.5) with more intense immunoexpression in the cauda than the
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caput (Fig. 4.26). WDs from fetuses exposed to flutamide in utero showed an increase in
fibronectin expression, especially in areas where the epithelium looked abnormal (Fig, 4.27).
A B
Figure 4.26 Immunoexpression of fibronectin (brown) in an e21.5 control Wolffian
duct. Note that the staining is more intense in the cauda region (arrow, B) than the caput




Figure 4.27 Immunoexpression of fibronectin in control and flutamide-exposed WDs at
e21.5. Note that fibronectin is more intensely expressed in the flutamide-exposed WDs,
especially around abnormal epithelia (brown, arrow, C - 50 mgkg'1 and D - 100 mgkg'1) than
in age matched controls (arrowhead, A and B). Scale bar = 100 urn
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4.3.5 Degradation of the ECM
4.3.5.1 The role for MMP-2 in the degradation of flutamide-exposed WDs
MMP-2 was immunolocalised to the WD stroma immediately adjacent to the epithelium (Fig
4.28), but no significant difference was seen in immunoexpression or mRNA levels in
flutamide-exposed WDs compared to age matched controls (Fig. 4.29). However, this
represents both active and inactive forms of MMP-2 and specific analysis of active MMP-2
alone may provide more insight into the role for MMP-2 in the disruption of normal WD
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Figure 4.28 Immunoexpression of MMP-2 in an e21.5 control Wolffian duct. Note that
MMP-2 is expressed in the stroma (arrowhead) immediately adjacent to the epithelium
(arrow). Scale bar = 100 urn
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Figure 4.29 Quantitative analysis of MMP-2 mRNA levels in Wolffian ducts at e17.5-
e21.5 in control (solid blue bars) compared to flutamide-exposed animals (50 mgkg-1
chequered bars; 100 mgkg1 striped bars). Note that no consistent or significant
difference was seen in MMP-2 mRNA expression with age/treatment, as determined by
Taqman QRT-PCR (means ± S.E.M, n=3-5 WDs per age/treament, each from different
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litters). MMP-2 mRNA expression was expressed relative to mRNA levels in control e21.5
testes (green bar, T) and compared to the internal positive control gene expression.
4.3.5.2 Is the postnatal loss of WD segments and epithelium in flutamide-
exposed animals due to an immunological response?
Markers for macrophages (CD68), leukocytes (CD45) and neutrophils (neutrophil elastase)
were analysed in the postnatal epididymis by immunohistochemistry. No obvious influx of
leukocytes including macrophages or neutrophils was noted in either the control epididymis
or the flutamide-exposed epididymis at pndl7-pnd70 (data not shown).
4.3.6 The role for cell adhesion in WD development and its interruption by
flutamide-exposure
4.3.6.1 E-cadherin expression
E-cadherin was immunolocalised to the cell boundaries of the epithelium lining the WD at
all ages studied (Fig 4.30). Epithelia in flutamide-exposed WDs continued to express E-
cadherin protein in the same pattern (Fig 4.30). Quantification of this protein expression
highlighted no consistent or significant change in E-cadherin protein in WDs from
flutamide-exposed animals (Fig. 4.31).
Figure 4.30 Immunoexpression of E-cadherin in the epithelium of control (A) and
flutamide-exposed (100 mgkg'1, B-D) Wolffian ducts (WD) at e21.5. Note that E-cadherin
is expressed at the epithelial cell boundary in both control (brown, arrowhead, A) and
flutamide-exposed WDs, even when the epithelium is damaged and flattened (arrow, B-D).
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Figure 4.31 E-cadherin protein expression in control and flutamide-exposed Wolffian
ducts at e18.5-e21.5. Panel A shows a representative Western blot for E-cadherin (C -
control; F - 50 mgkg'1 flutamide; HF - 100 mgkg'1 flutamide). Panel B shows quantification
of E-cadherin protein levels in the Wolffian duct (WD) at e17.5 - e21.5 (mean ± SEM)
highlighting variation but no significant change in E-cadherin protein expression in WDs from
control (solid blue bars) compared to flutamide-exposed animals (checked bars - mgkg'1;
striped bars - mgkg'1). n-2 Western blots, each using a pool of 3 WDs per age/treatment,
from at least 3 litters. Protein expression was corrected for loading and expressed relative to
levels in e19.5 control WD. * p<0.05 compared to age matched control.
4.3.6.2 N-cadherin
N-cadherin was immunolocalised to the inner stromal compartment of an e21.5 WD,
immediately adjacent to the epithelium (Fig. 4.32). N-cadherin protein was weakly
expressed in WDs from control and low dose flutamide (50 mgkg"1) animals but was more
intensely immunoexpressed in WDs from high dose flutamide (100 mgkg"1) animals at e21.5
(Fig. 4.32).
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Figure 4.32 Immunolocalisation of N-cadherin to the stroma immediately adjacent to
the epithelium in the WD at e21.5. Note that N-cadherin is weakly immunoexpressed in
the WD from control (A) and low dose flutamide (B, 50 mgkg'1) animals while N-cadherin is
more intensely expressed in the WDs exposed to high dose flutamide (C, 100 mgkg'1). Note
that N-cadherin was not detected in the epithelium (arrow).
4.3.7 Hox gene expression in the fetal Wolffian duct
4.3.7.1 Hox A10
Hox A10 mRNA was detected in the fetal WD (el8.5-e20.5, Fig. 4.33) but its localisation
and protein expression could not be successfully determined due to technical difficulties with
antibodies and in situ hybridisation probes. There was an apparent increase in Hox A10
mRNA expression with age, but this was not quantified (Fig. 4.33).
pndO el9.5 Neg el8.5 el9.5 e20.5
UGT K WD WD WD
Figure 4.33 Hox A10 mRNA was detected in rat fetal Wolffian duct (WD) at e18.5-e20.5.
This expression was low in comparison to expression in the kidney (K) or urogenital tract as
a whole (UGT) but there was an apparent, increase in WD expression with age.
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4.4 Discussion
It was clear that gestational exposure to flutamide resulted in altered WD development at
both the gross and histological level (see chapter 3) but it was unknown what effect this had
at the molecular level or what was regulating the (mainly postnatal) loss of segments of the
WD.
It has been suggested that the pattern of androgen receptor (AR) expression reflects the
androgen responsiveness of the tissue (Bentvelsen et al, 1995). AR was mapped to the
epithelium from el7.5 and the stroma of the WD from el6.5, however epithelial AR
expression was less intense than in stromal cells, particularly before e20.5. This is in
agreement with other studies using antibodies demonstrating that ARs are expressed in the
nuclei of both the stroma and epithelial cells of the rat WD by el 7.5 (Bentvelsen et al, 1995;
Majdic et al, 1995). However, studies in mice using 3H-dihydrotestosterone steroid
autoradiography reported stromal expression from el3 but epithelial expression was not
detected until el9, much later than in rats (Cooke et al, 1991). This difference in timing of
expression may be due to species differences or different methodologies. The more intense
and earlier immunoexpression of AR in the stroma compared with the epithelium would be
consistent with the view that androgen effects on early WD development occur mainly
through stromal AR, and that androgens stimulate the stroma to signal to the epithelium to
indirectly control epithelial fate (Cunha et al, 1992). Flutamide exposure did not alter either
the onset of, or the intensity of, AR expression. Therefore WDs from flutamide-exposed
animals retained the potential for AR-mediated androgen action. This conclusion is in
contrast to findings by others who were unable to detect AR protein by
immunohistochemistry in WDs from e21.5 fetuses exposed to 100 mgkg"1 flutamide
(Bentvelsen et al, 1995). This difference is unexplained though it could be due to rat strain
difference or to the use of different anti-AR antibodies and immunohistochemistry
techniques.
AR continues to be expressed in the epithelium and stroma of the postnatal WD-derivatives,
in a similar pattern to that of the fetal WD. This highlights that WD-derived structures are
still capable of responding to androgens throughout life. As well as the androgen peak seen
during fetal life (Faiman, 1981; Fujieda et al, 1981; Habert and Picon, 1984), males are
exposed to another surge in testosterone levels during puberty (Swerdloff, 1981): this
testosterone surge may induce another phase of differentiation in the epididymis and vas
deferens, as occurs in the secretory epithelium of the seminal vesicles and prostate which
undergo functional differentiation around puberty (Cunha and Donjacour, 1987). Since there
was a dramatic increase in the prevalence of missing epididymides and/or vasa deferentia
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around the time of puberty in males that were exposed to flutamide in utero, it was
considered possible that these animals were no longer able to respond to androgens and so
did not further differentiate and even lost segments of the epididymis and/or vas deferens.
However, AR was still detected in the epididymis and vas deferens from postnatal animals
that had been exposed to flutamide in utero, even in areas that appeared highly damaged and
looked morphologically abnormal. This suggests that flutamide exposure during gestation
does not alter the pattern of AR expression in the WD and its adult derivatives and that the
adult structures still retain the potential for AR-mediated androgen action. This is consistent
with reports by previous researchers who showed that even after linuron exposure, AR was
still detected in WD-derived tissue at pnd7 (Turner et al, 2003). The mechanism behind the
increased loss of reproductive structures during puberty still therefore remains somewhat of
a mystery.
Testosterone can be metabolised by 5a-reductase to form the more potent androgen
dihydrotestosterone (DHT), or aromatised to oestradiol (George, 1994) but it is unlikely that
either of these hormones play a role in WD development. Oestrogen receptor a (ERa) was
not detected in the fetal WD, only in the efferent ducts but oestrogen receptor (3 (ERP),
which is highly expressed in many tissues throughout the body (Saunders, 1998), was
detected in the WD stroma and epithelium. However, aromatase could not be detected in the
fetal WD (unpublished findings) and oestrogen receptor knock out mice (ERKO) and
aromatase KO (ArKO) mice have epididymides present in adulthood (Robertson et al, 1999;
Hess et al, 2000) thus suggesting there is no essential role for oestrogens in fetal WD
development. It is also unlikely that DHT is required for fetal WD development as 5a-
reductase protein was not detected at any age studied (el7.5-e21.5). This is in agreement
with previous studies which showed that DHT was not detected in the WD until after
epididymal differentiation is complete (Wilson and Lasnitzki, 1971). Furthermore, 5a-
reductase deficient patients show normal WD differentiation (Imperato-McGinley and Zhu,
2002) while rats exposed to finasteride, a 5a-reductase inhibitor, show normal WD
development (Imperato-McGinley et al, 1992). This confirms that WD development is
dependent on testosterone action, rather than DHT or oestrogen.
In the WD, there are 2 main cellular compartments, the stroma and the epithelium. These
compartments are obvious in all ages studied (el5.5 - adult) and can be easily identified
histologically by the differences in cell morphology (see chapter 3). Flutamide does not alter
this compartmentalisation of the WD (discussed in chapter 3). Normal cellular organisation
and differentiation of these cellular compartments was assessed by examining expression of
cell differentiation markers specific to each compartment, namely smooth muscle actin
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(SMA) which demarcates the smooth muscle inner stromal layer, cytokeratin which is
specific to epithelial cells and p63 which marks basal epithelial cells. In the normal
developing WD, cytokeratin is expressed around the boundary of the epithelial cells from at
least el5.5 and continues to be expressed in epithelial cells through to adulthood.
Cytokeratin plays a role in controlling cell function, for example, epithelial growth and
apoptosis, by modulating signal transduction pathways (Paramio and Jorcano, 2002).
Cytokeratin expression is not obviously altered by flutamide exposure, and is even expressed
in the flat fibroblast-like epithelial cells in the fetal WD and in the abnormally arranged
epithelium in the adult epididymis. This suggests that flutamide does not cause epithelial
cells to lose their epithelial identity and function, even when the WD and/or epithelium looks
abnormal. This is consistent with previous studies which used cytokeratin as a marker that
the epithelial compartment was not altered by exposure to linuron (Turner et al, 2003;
Bowman et al, 2005). It has been suggested that epithelium can potentially regulate
patterning in an organ by forming barriers and regulating signal transduction (Shook and
Keller, 2003). Furthermore, epithelial sheets provide the organ with mechanical structure
and form the first line of defence against mechanical disruption. It is likely that the
epithelium will undertake these roles in the developing WD and any flutamide-induced
interruptions to the epithelium may interfere with these roles.
The basal epithelial cell marker p63 was not detected in the fetal WD but was expressed in
basal epithelial cells by pndl7. The timing and cell specific expression of p63 is vital for
normal development and functioning of the epithelium (Atanassova et al, 2005). Previous
studies have shown that p63 expression switches on in the vas deferens at pndlO and in the
epididymis at pndl4 (Hayashi et al, 2004; Atanassova et al, 2005) but this time point was
not examined in these studies. p63 is believed to be a marker of epithelial differentiation,
plays a role in epithelial cell proliferation and, through reciprocal signalling, promotes
proliferation and differentiation of the underlying mesenchyme (Levrero et al, 2000; Ince et
al, 2002; Lee and Kimelman, 2002). Previous studies have shown that p63 expression
switches on in a caudal-cranial direction with epididymal coiling occurring while p63 levels
are low and coiling ceasing once p63 levels reach adult level (Hayashi et al, 2004).
Expression of p63 was seen to continue throughout postnatal life and was still detected in the
epididymides of males exposed to flutamide in utero (pnd 17-70). However, p63 expression
was reduced in flutamide-exposed males with some cross-sections of epididymis having
reduced or even lacking p63 staining but this reduction was not quantified. This suggests
that the epididymal epithelium does not fully differentiate until postnatal life but that this
pattern is established by androgens during fetal life. Furthermore, this reduction in p63
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expression may explain the smaller epididymides and reduced cell proliferation in males
exposed to gestational flutamide since basal cells are known to influence behaviour of the
epithelium (Prins et al, 2001). This differs from the urogenital sinus in which p63 staining
was seen by pndO. It is thought that since p63 might regulate the cessation of WD coiling,
differences in p63 expression might account for the regional differences in WD morphology
(Hayashi et al, 2004) thus altered p63 expression might explain the abnormalities seen in
flutamide-exposed WDs. Previous studies have reported that mutation in p63 can result in
urogential developmental defects with p63 being essential for normal modelling of female
external genitalia (Ince et al, 2002). It was not examined if flutamide exposure in utero
delayed the onset of p63 expression thus highlighting delayed epithelial differentiation: this
therefore requires further investigation. Furthermore, in one adult male, the epididymal
epithelium appeared folded and stratified, unlike the simple epithelium in controls; this
epithelium had an increase in the number of p63 stained cells, which was no longer restricted
to the basal cells. This might explain the over-proliferation of the epithelium in this animal
as p63 is reported to play a key role in maintaining cell populations (Wang et al, 2001) and
over proliferation in adult prostates from males exposed neonatally to DES was believed to
be due to altered expression of p63 (Risbridger et al, 2001).
Unlike epithelial differentiation, smooth muscle stromal differentiation occurred during fetal
life with smooth muscle actin (SMA), an androgen responsive stromal differentiation marker
(Schlatt et al, 1993), detected in the stroma immediately adjacent to the epithelium in the
WD corpus by el8.5. It is not understood why SMA is first expressed in the corpus and
progresses towards the caput and cauda by e20.5, since the corpus is the segment of the WD
which coils last. SMA protein levels were seen to increase with age in control WDs: this
agrees with previous studies highlighting an increase in SMA between el7 and e21
(Hannema et al, 2006). Blocking androgen action by flutamide exposure impaired stromal
differentiation as indicated by reduced expression of SMA protein in the WD. This
reduction in smooth muscle differentiation may explain the reduction in WD coiling seen
after flutamide exposure (chapter 3). The flutamide-induced reduction in SMA expression
was noted as early as el9.5, before any obvious signs of impaired epithelial development
were apparent and before the epithelium undergoes differentiation even in the control
animals. This is consistent with previous studies in various organ systems which have shown
that the stromal cells, via paracrine interactions, play a critical role in controlling epithelial
proliferation, differentiation and development (Cunha et al, 1985; Donjacour and Cunha,
1991; Cooke et al, 1997; Arnold et al, 2001; Cunha et al, 2002; Marker et al, 2003).
However, in the seminal vesicles, it has been suggested that the thickness of the smooth
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muscle is determined by interactions with glandular epithelium during branching
morphogenesis (Marker et al, 2003), highlighting possible reciprocal interactions from the
epithelium to regulate differentiation of the stroma. The mechanisms underlying these
paracrine interactions are poorly understood but growth factors and/or extracellular matrix
components are likely to be involved; this therefore warrants further investigation.
The periductal smooth muscle layer persisted in the postnatal epididymis and vas deferens
and gestational exposure to flutamide appeared to increase the thickness of this layer. In the
vas deferens, a thick SMA negative layer is present between the epithelium and the smooth
muscle layer: this is believed to consist of undifferentiated fibroblast-like cells (Atanassova
et al, 2005). Exposure to flutamide results in an increase in this SMA negative layer.
Previous studies have also reported a widening of this layer and have suggested it may be
due to altered androgen-oestrogen balance (Chang et al, 1999; Atanassova et al, 2005). It is
also believed that thickening of this periductal fibroblast layer may act as a physical barrier
to interfere with normal signalling between the epithelium and stroma (Chang et al, 1999).
The extracellular matrix (ECM) surrounding cells is vital not only to provide mechanical
support for these cells but it also plays a role in controlling their behaviour and proliferation
and differentiation by regulating the availability of signals, such as growth factors, reaching
their cell surface (Streuli and Gilmore, 1999). ECM is composed partially of intermediate
filaments, such as desmin and vimentin, and previous studies have shown that various
components of the ECM increase with age in the developing WD (Hannema et al, 2006).
Desmin is one of the earliest markers of mesenchymal differentiation into muscle (Alberts,
1994) and was detected in the WD stroma at all ages studied (el5.5-e21.5). This again
highlights the early differentiation of the WD stroma. Desmin is still expressed in flutamide-
exposed WD stroma, showing no consistent change compared to age matched controls.
Intermediate filaments are required not only to support cells but are also involved in signal
transduction from the cell membrane to the nucleus; desmin may therefore play a role in
signal transduction in the developing WD.
Vimentin, an early mesenchymal intermediate filament, was also expressed in the fetal WD.
It was constituently expressed in the WD stroma at all ages studied (el8.5-e21.5) and this
was not obviously affected by flutamide-exposure. Vimentin is likely to be providing
mechanical support to the developing WD as well as possibly mediating signalling through
interactions with and organisation of the cytoskeleton (Alberts, 1994). Vimentin was also
expressed on the basolateral boundary of the epithelial cells: in control WDs this 'spiking'
was seen along the full length of the WD between el 5.5-18.5 but becomes restricted to the
caudal region by el9.5. It is thought that vimentin expression often precedes expression of
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other intermediate filaments during differentiation, for example desmin. Since vimentin is
initially expressed in the epithelium along the full length of the WD at el 5.5 and becomes
later restricted mainly to the cauda in control WDs by el9.5, it is likely that vimentin
expression in the epithelium is replaced by another intermediate filament in a cranio-caudal
direction as development proceeds. This hypothesis is substantiated by evidence from
studies in 8 week human fetuses in which both the MD and the WD co-express vimentin and
cytokeratin at the apical and basolateral edges of the epithelium while the surrounding
mesenchyme only expresses vimentin, not cytokeratin (Magro and Grasso, 1995). Epithelial
'spiking' of vimentin was detected along the full length of the epididymal segment of the
flutamide-exposed WD, rather than just in the cauda at e21.5. This could be due to failure of
the epithelial cells to differentiate and so fail to switch off epithelial vimentin expression and
thus epithelial cells retaining some mesenchymal-like properties. This might explain the
reduced epithelial cell height and loss of attachment to the basement membrane seen in
flutamide-exposed WDs. Vimentin is required for cell motility and increased vimentin
expression is seen in prostate cancer cells as they become more invasive (Singh et al, 2003).
It could therefore be hypothesised that these vimentin positive WD epithelial cells may be
gaining motility but there is no definitive evidence for this, and further investigation of
earlier and later time points might provide some insight. Studies in the equine endometrium
have shown that in cases of endometriosis, cytokeratin and vimentin become co-expressed in
the epithelium, which is hypothesised to be due to increased proliferation and a loss of cell to
cell contact (Aupperle et al, 2004). Other researchers have also shown that altered hormone
action could induce epithelial vimentin expression (Klymkowsky, 1989). These hypotheses
might explain the atypical expression of vimentin in flutamide-exposed WD epithelium.
The basement membrane, a thin tough sheet of ECM, plays an important role in mediating
epithelial cell adhesion, gene expression, proliferation and differentiation (Danen and
Yamada, 2001). Laminin was expressed in the WD basement membrane as a clearly
defined 'ring' around the base of the ductal epithelium. Flutamide exposure however
interrupted this laminin 'ring' resulting in a less defined and discontinuous basement
membrane. Laminin anchors epithelial cell surfaces to the basement membrane and
epithelial cells must attach to the appropriate ECM component in order to survive since loss
of contact with specific ECM components is recognised as a pro-apoptotic signal (Frisch and
Francis, 1994; Danen and Yamada, 2001). Therefore interruption to the basement membrane
could result in epithelial cells losing their attachment and so sloughing off or losing their
polarity and epithelial identity: previous studies have also highlighted this loss of basement
membrane in the regressing WD, resulting in possible mesenchymal transformation (Jirsova
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and Vernerova, 1993). It has also been suggested in the MD that epithelial cells can protrude
through breaks in the basement membrane and are phagocytosed, allowing neighbouring
cells to de-differentiate into mesenchymal cells and migrate off (Trelstad et al, 1982; Austin,
1995; Zhan et al, 2006). This might explain the loss of epithelia in sections of the WD and
the appearance of flattened mesenchymal-like cells (see chapter 3). This phenomenon is
apparent in the regression of the MD whereby the basement membrane becomes interrupted
and detached with apoptosis only evident in the mesenchyme after the basement membrane
has become discontinuous (Magro and Grasso, 1995); (Allard et al, 2000). It is believed that
the loss of cell contact with specific ECM components acts as a pro-apoptotic signal
resulting in regression of the MD (Allard et al, 2000).
Fibronectin accumulates along the interface between epithelium and mesenchyme and
attaches cells to a variety of extracellular matrices, except type IV matrices that involve
laminin as the adhesive molecule (Ruoslahti, 1981). Like many other cytoskeletal proteins,
fibronectin plays a role in regulating cell structure and behaviour and redistribution of
fibronectin can be associated with epithelial differentiation (Paranko et al, 1983).
Fibronectin was expressed in the inner stroma as a less defined 'ring' just below the
basement membrane in the fetal WD and is likely to be involved in regulating the attachment
of stromal cells to the surrounding ECM and mediating cell signalling. This expression was
more intense in the caudal segment of the future epididymis than in the caput: it is unclear
why there would be more fibronectin in the cauda. Fibronectin synthesis is an early sign of
smooth muscle differentiation so this increased expression in the cauda might represent
stromal differentiation (Paranko et al, 1984). Fibronectin expression was increased in
flutamide- exposed WDs, especially in areas where the epithelium looked abnormal and
flattened. This suggests increased adhesion of stromal cells to the surrounding ECM but it
remains something of a mystery why flutamide would induce this and the resulting effect on
WD morphology and function. This finding is in contrast to reports by Turner and
colleagues who saw no change in fibronectin expression in WDs after gestational exposure
to linuron (Turner et al, 2003). Our findings also contradict reports of reduced fibronectin
synthesis and discontinuous periductal expression seen during MD regression (Paranko et
al, 1984). Like epithelial cells, fibroblasts must adhere to the correct ECM in order to
survive and function normally (Danen and Yamada, 2001), therefore altered attachment to
the ECM could have a negative effect on stromal integrity and function. Changes in
fibronectin levels have been associated with altered epithelial cell proliferation in response to
hormones (Woodward et al, 2001), therefore flutamide-induced altered fibronectin
expression may play a role in reducing epithelial cell proliferation. Furthermore, fibronectin
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has been reported to increase MMP-2 activity and induce epithelial cell loss in hormone
withdrawal- induced mammary gland involution (Schedin et al, 2000). Therefore it is
possible that the increase in fibronectin in flutamide-exposed animals might play some role
in the loss of epithelium and entire segments of the WD.
E-cadherin was expressed around the boundary of epithelial cells in the WD and exposure to
flutamide did not consistently alter this expression whereas N-cadherin was expressed in the
inner stromal compartment and appeared to be more intensely expressed in WDs exposed to
high (100 mgkg"1), but not low doses of flutamide (50 mgkg"1). This increase may not reflect
a true increase in N-cadherin protein expression as it has been suggested that as N-cadherin
dissociates from the cell, it is more easily immunodetected. This may be true for WDs
exposed to 100 mgkg"' flutamide but would require further investigation by Western blot
analysis. Cadherins not only act as 'biological glue' but they also play a role in generating
signals at the cell surface that can influence cell function and appropriate expression of
cadherins is vital to maintain tissue integrity (Rowlands et al, 2000). It has even been
suggested that the manner in which cells respond to hormones is dependent on adhesive
interactions with other cells (Byers, 1993). It is possible therefore that E-cadherin and N-
cadherin are playing a role in maintaining normal tissue integrity in the WD and in
controlling how cells respond to androgens.
Taken together these results suggest flutamide-exposure can disrupt the formation and
maintenance of the cytoskeleton, intermediate filaments and basement membrane: this might
provide some explanation for the morphological effects of flutamide on the developing WD
(see chapter 3). It is unclear what is causing this disruption to the ECM and WD degradation
however it was hypothesised that MMPs may play a role since they are well known for
degrading the components of the ECM (Alberts, 1994). Analysis of MD regression in males
has shown that degradation of the ECM is evident and that MMP-2 plays a role downstream
of paracrine signalling (Roberts et al, 2002), thus it would be unsurprising if MMPs also
played a role in flutamide-induced WD abnormalities. Consistent with this, MMP-2 protein
was expressed in the inner stromal compartment of the WD but there was no consistent trend
in changes in MMP-2 mRNA expression in flutamide-exposed WDs compared to age
matched controls. This represents both inactive and active forms of MMP-2, therefore
further analysis is required using zymography to gain insight into this. This hypothesised
role for MMPs in WD abnormalities is further substantiated by data arising from gene array
studies examining changes in gene expression in control compared to linuron-exposed rat
WDs at pnd7. Linuron induced a decrease in T1MP3, an MMP inhibitor. T1PM3 is localised
to the epithelium and binds to the ECM thus locally regulating MMP activity in the ECM
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(Turner et al, 2003). Furthermore, Bowman and colleagues reported a trend for increased
MMP gene expression in the fetal WD after gestational exposure to DBP (Bowman et al,
2005). Taken together, these results suggest that MMPs might contribute to the
abnormalities seen in WD development. Previous studies in the endometrium have reported
that MMP-2 is synthesised by the stromal compartments but it requires a soluble epithelial
factor to be activated (Goffin et al, 2002). This might be true also in the WD and flutamide-
induced epithelial abnormalities may activate MMP-2 to degrade WD tissue. Alternatively,
it could be hypothesised that the disruption to the ECM and the subsequent loss of segments
of the WD may be due to an influx of immune cells. However, there was no obvious
immunological response seen in either flutamide-exposed fetal WDs or in the adult-
derivatives. This is in contrast to findings published showing that neonatal exposure to DES
can result in an influx of immune cells into the postnatal vas deferens with deleterious
consequences (Atanassova et al, 2005).
Retinoid X receptor alpha (RXRa) is a member of the retinoic acid receptor family and
functions as a ligand-dependent transcription factor. RXRs are expressed in a spatially
restricted pattern in the developing embryo and respond to high concentrations of RA.
RXRs can form dimers with the AR and, in the presence of ligand RXR can suppress AR
target genes while unliganded RXR can enhance AR transactivation (Chuang, 2005).
Similarly, AR can suppress RXR target genes thus preventing RXR binding to the response
element in target genes (Chuang, 2005). Other studies on going in the lab had shown
changes in RXR expression in the testis after exposure to anti-androgens therefore RXR
expression was examined in the WD. RXRa is expressed in the stroma and epithelium of the
WD at all ages studied (el7.5-21.5) and immunoexpression appeared reduced in flutamide-
exposed WDs. RXRa may play a role in regulating AR target gene expression in the WD
thus contributing to the normal development of the WD: the flutamide-induced reduction in
AR signalling may cause this decrease in RXRa expression. Further investigation is
required to interrogate fully the role for retinoid and their receptors in WD development.
Hox genes are known to play a role in fetal development, particularly in patterning and
segmentation (Favier and Dolle, 1997). It has been suggested that sex steroid hormones
might act to establish Hox gene expression (Block et al, 2000), for example, in the uterus
(Taylor et al, 1998; Taylor et al, 1999). Reproductive tracts in both males and females are
an example of developmental axes thought to be controlled by Hox genes. Notably, Hox
genes A9, A10, All and A13 are reported to be expressed along the length of Wolffian and
MDs with their expression persisting into adulthood (Podlasek et al, 1999; Block et al, 2000;
Bomgardner et al, 2001). Hox Al 1 is reported to be expressed in the mesenchymal cells of
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the developing Wolffian duct and in the stroma of the adult vas deferens but not in the
epithelial lining (Hsieh-Li et al, 1995) and Hox All homozygous mutants are sterile with
males presenting with small, abnormally coiled vasa deferentia (Hsieh-Li et al, 1995).
Furthermore, mice homozygous for targeted deletion of Hox A10 exhibit abnormal coiling of
the cranial portion of the vas deferens, again highlighting the role for Hox A10 in Wolffian
duct development (Benson et al, 1995; Podlasek et al, 1999). These studies suggest that Hox
A10 expression may delineate the boundary between the epididymis and vas deferens, and
that targeted deletion blurs the normal epididymis-vas boundary (Podlasek et al, 1999).
Current studies have shown that Hox A10 mRNA is expressed in the developing rat WD
from el7.5; however, technical difficulties have prevented any further progress in our
understanding of the role for Hox genes in the rat WD.
4.5 Conclusion
During WD development, AR expression is switched on early in the stroma then later in the
epithelium, around the time of morphological differentiation. This suggests that early
androgen action is mediated by the stromal cells. Flutamide-exposure did not alter AR
expression indicating that these WDs are still capable of AR mediated androgen action. The
fetal WD is divided into an epithelial and a stromal compartment in both control and
flutamide-exposed animals, however the differentiation of these cells types is altered by
flutamide-exposure. This is first evident in the stroma during fetal life and is not observed
widely or consistently in the epithelial compartment until postnatal life. Together this
evidence is consistent with the view that during male reproductive development, androgens
act on the stroma which in turn mediates epithelial development. Furthermore this evidence
suggests that the patterning of WD compartments and differentiation is established during
fetal life, even if abnormalities do not become apparent until adulthood.
The ECM is vital to provide cells with mechanical support as well as playing a role in
mediating cell signalling. Various extracellular matrices are present in the developing WD
including laminin, fibronectin and vimentin and exposure to flutamide interferes with their
normal expression pattern: the mechanisms involved in this ECM degradation are not yet
fully understood but MMPs may contribute. The flutamide- induced loss of an intact
basement membrane and ECM may be responsible for the loss of segments of the WD,
rather than the action of immune cells. Future studies will focus on understanding the timing
of androgen action in WD development as well as further investigating the mechanisms
behind androgen dependent WD development.
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5 Determination of the key time window of androgen action necessary
for WD development
5.1 Introduction
The results presented in chapters 3 and 4 confirmed the vital need for androgen action in WD
development, with WD differentiation apparently being more susceptible to reduced
androgen action than is stabilisation. These studies and those previously reported in the
literature have shown that androgens are necessary to mediate both stabilisation and
differentiation of the WD but these have not determined the actual window of androgen
action in WD development (Imperato-McGinley et al, 1992; Foster et al, 2001; Mclntyre et
al, 2002). It is generally presumed that androgen action is required during the window of
morphological differentiation, however this remains to be confirmed: the studies detailed in
this chapter were designed to answer this question and to establish the key window(s) of
androgen action in the developing WD.
One previous study has examined the effects of exposure to anti-androgens for short defined
periods during male reproductive development and compared this with exposure throughout
male reproductive development. Wolf and colleagues exposed pregnant rats to vinclozolin
for various 2 day windows during the period of fetal reproductive development and noted
that extended exposure to vinclozolin (400 mgkg"') between e 14-19 resulted in more severe,
and an increased prevalence of, reproductive tract abnormalities than did exposure for just 2
days (Wolf et al, 2000). They reported that different structures in the reproductive tract have
different windows of sensitivity. For example, AGD was significantly reduced in males
exposed to vinclozolin between e 16-17 and e 18-19 but not in males exposed to vinclozolin
earlier in fetal life (Wolf et al, 2000). The most sensitive period for exposure to vinclozolin
appeared to be between e 16-17, which resulted in abnormalities mainly in the external
genitalia, suggesting this to be the window of androgen action in external genitalia
development (Wolf et al, 2000). However, these studies did not provide insight into the
window of androgen action in WD development, as exposure to vinclozolin for just 2 days
between e 12-13, 14-15, 16-17, 18-19 or 20-21 did not result in any obvious abnormalities in
WD-derived structures in adulthood (Wolf et al, 2000). This is not surprising since in a
previous study Gray and colleagues (1994) saw no epididymal defects in rats exposed to
vinclozolin (200 mgkg"1) between el4-pnd3 suggesting that vinclozolin is insufficient at
blocking androgen action in the developing WD.
Another such study examining the effects of short term exposure to anti-androgens has been
undertaken in the mouse (Silversides et al, 1995). This study showed that exposure to
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hydroxyflutamide (30 mg) on el 1-15 resulted in smaller epididymides and infertility
whereas exposure on el 5-20 prevented normal prostate development: exposure to
hydroxyflutamide on el9-20 did not result in any obvious reproductive abnormalities or
infertility in adulthood (Silversides et al, 1995). These studies suggest that high levels of
androgens may not be essential later in WD development, during its morphological
differentiation, but none of the dosing regimes used by these researchers induced such gross
abnormalities as those seen in the studies presented in this thesis. This may be due to the use
of hydroxyflutamide by Silversides and colleagues therefore these studies are not directly
comparable to those in this thesis. Again, these studies do not address the precise window of
androgen action in WD development and insight into this may provide further understanding
of the mechanisms of androgen action, not just in the WD but in the entire reproductive tract.
5.1.1 Aims
To investigate the critical window of androgen action necessary for WD development.
To establish if androgens act during the period of morphological differentiation and/or
earlier in development.
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5.2 Methods
5.2.1 In utero treatments
As detailed in section 2.2, pregnant dams were randomly allocated to treatment groups and
dosed once daily by gavage with 1 mlkg"' maternal bodyweight of the following treatments.
Dams were dosed with 100 mgkg"1 flutamide either from the onset of androgen production
by the testis until birth (el5.5-21.5) or during critical windows to encompass the period of
WD stabilisation (el5.5-17.5, early exposure) or the period of WD morphological
differentiation (e 19.5-21.5, late exposure) (see Fig. 5.1).
Control: 1ml corn oil/2.5% DMSO (n=10 litters)
Flutamide: lOOmgkg"1 in 1ml corn oil/2.5% DMSO
el5.5-e21.5 - n=l 1 litters
el5.5-el7.5 - n=5 litters
el9.5-e21.5 - n=6 litters
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Figure 5.1 Summary of windows of flutamide exposure used
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This dose of flutamide was selected based on results previously reported in chapters 3 and 4
highlighting a high incidence of reproductive tract abnormalities.
Throughout this chapter, offspring from dams treated with flutamide while pregnant will be
referred to as "flutamide-exposed" or treated "in uteroThis does not mean that fetuses
were directly exposed to flutamide but were exposed indirectly via their mother.
5.2.2 Tissue collection
Dams were killed by inhalation of carbon dioxide and subsequent cervical dislocation and
fetuses were recovered at el8.5 and e21.5. Postnatal animals, older than pndlO, were killed
by inhalation of carbon dioxide and subsequent cervical dislocation. Fetuses (e21.5) and
postnatal animals were weighed and anogenital distance measured as described in section
2.3.
Fetuses were killed by decapitation before reproductive tracts were recovered by
microdissection and photographed using a Leica ICA camera (section 2.3.2.1). Reproductive
tracts and gonads were collected from postnatal animals and photographed as described in
section 2.3.2.2. Reproductive tracts were analysed microscopically, at the time of dissection,
for any gross morphological abnormalities and tissue was either fixed or frozen as detailed in
section 2.4.
5.2.3 Luminal length analysis
Differentiation of fetal WDs was quantified by digitally measuring the luminal length of the
epididymal segment ofWDs from control and treated animals, as described in section 2.8.
5.2.4 Epithelial height and width measurements
WD sections were immunostained for pan-cytokeratin as detailed in section 2.6.1 to label
clearly all epithelial cells. Sections were viewed using the x63 objective on an Olympus
BH-2 microscope fitted with a Prior automatic stage (Prior Scientific Instruments Ltd,
Cambridge, UK). Image-Pro Plus version 4.5.1 with Stereologer-Pro 5 plug-in software
(Media Cybernetics UK, Wokingham, Berkshire, UK) was utilized to measure epithelial cell
height and width. Using a x63 objective, epithelial cell height and width was measured in
every 5th epithelial cell in the future epididymal segment in a randomly selected section.
Height measurements were performed separately for the caput, corpus and cauda regions of
the future epididymal portion of the WD. Only epithelial cells in which the nucleus could be
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clearly identified were measured, thus excluding from analysis any epithelial cells from the
flutamide treatment groups that were severely flattened or disintegrating.
5.2.5 Immunohistochemistry
Immunohistochemistry was performed on isolated reproductive tracts fixed in Bouin's, using
standard avidin peroxidase protocols in order to highlight the location of proteins of interest,
as detailed in section 2.6.1.
Briefly, sections were cut from paraffin blocks and mounted on glass slides. Sections were
then dewaxed and rehydrated then pressure cooked in citrate buffer if required (Table 5.1).
Non-specific binding was blocked before adding the appropriate primary antibody overnight,
as detailed in Table 5.1. A biotin labelled secondary antibody was used that had been raised
against a species-specific sequence on the primary antibody. This biotinylated secondary
antibody signal was amplified by incubation with avidin-biotin conjugated with horseradish
peroxidase and the signal was localised using DAB. Sections were counterstained with
haematoxylin and mounted with glass coverslips. Further detailed protocols can be found in
section 2.6.1.
Table 5.1 Summary ofprimary antibodies used for immunohistochemistry
Target Antigen Source Dilution Retrieval Host Species
Androgen Receptor Santa Cruz 1:50 Citrate Rabbit
Smooth Muscle Actin Sigma 1:10000 None Mouse
Pan-cytokeratin Sigma 1:200 Citrate Mouse
Vimentin DAKO 1:1000 Citrate Mouse
Laminin Abeam 1:100 Citrate Rabbit
5.2.6 Western blots
Western blotting was carried out to separate a mixture of proteins according to their
molecular size, as detailed in section 2.6.2. Briefly, protein was extracted from frozen e2l.5
WDs using RIPA lysis buffer (section 2.6.2.1) and 15ug of each protein was loaded into an
SDS-page gel and subjected to electrophoresis at 100 V for l-2h. Proteins were electro-
transferred from the gel and immobilised onto a nitrocellulose membrane. Proteins were
subsequently detected on the membranes using specific antibodies (Table 5.2) as described
in section 2.6.2.5. An anti-6-tubulin antibody (Sigma) was used as a standardization loading
control, diluted 1:300 in TBST.
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Table 5.2 Summary of primary antibodies used for Western blotting
Target Antigen Source Dilution Host Species
Androgen Receptor Santa Cruz 1:300 Rabbit
Smooth Muscle Actin Sigma 1:10000 Mouse
5.2.7 RNA extraction
RNA was extracted from frozen WDs at el7.5-e21.5 using RNeasy Mini extraction kits
(Qiagen, Crawley, UK) and quantified using RNA 6000 Nano chips on an Agilent 2100
Bioanalyser (Agilent Technologies, Wockinghan. UK), as detailed in section 2.7.1-2.7.2.
5.2.8 Taqman QRT-PCR
Random hexamer primed cDNA was prepared using the Applied Biosystems TaqMan ®
reverse transcription kit (Applied Biosystems, Foster City, CA) (section 2.7.3.2) and
quantitative PCR was performed using the ABI Prism 7900 Sequence Detection System
(Applied Biosystems). Expression of AR mRNA was determined using the Assay-On-
Demand Gene Expression ™ system (Rn00560747, Applied Biosystems). Detailed
protocols can be found in section 2.7.5.
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5.3 Results
5.3.1 Effects of maternal exposure to flutamide during critical windows of
reproductive development
5.3.1.1 Non-reproductive effects of flutamide exposure
Consistent with previous studies (Mclntyre et al, 2001; Foster and Harris, 2005), exposure to
flutamide (100 mgkg"1) did not result in any toxicological effects to the dam with no obvious
problems with labour, no increase in fetal death or decrease in litter number (data not
shown). Furthermore, there was no significant decrease (p>0.05) in male bodyweight at
e21.5 between control fetuses and those from litters maternally exposed to flutamide (100
mgkg"1) either early (e 15.5-17.5) or late (e 19.5-21.5) in WD development (data not shown).
5.3.1.2 Effects of flutamide exposure on the reproductive tract
Maternal exposure to flutamide within critical windows of development (100 mgkg"1), as
expected, had no obvious effect on fetal female reproductive tract morphology but impacted
on normal masculinisation of fetal males. Normally, fetal sex can be determined externally
by the distance between external genitalia and the anus (anogenital distance; AGD), with
AGD significantly larger in control fetal males than in females (Fig 5.2, p<0.001). However,
maternal exposure to flutamide during the entire window of reproductive development
(el5.5-21.5) prevented normal masculinisation of fetal external genetalia, with AGD
significantly reduced (p<0.001) at e21.5 to a length similar to that of control females (as
discussed in section 3.4.3.2). Exposure to flutamide (100 mgkg"1) early in WD development
(el5.5-17.5) reduced AGD by the same extent as exposure to flutamide from el5.5-21.5
whereas maternal exposure to flutamide late in WD development (el9.5-21.5) did not result
in any significant change in male AGD at e21.5 (Fig. 5.2).
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Figure 5.2 Anogenitai distance (AGD) in e21.5 male (blue bars) and female (pink bars)
fetuses from control (solid bars) and high dose maternal flutamide (100 mgkg'1;
striped bars) litters. Note that AGD was significantly smaller in control female fetuses
(solid pink bar) than in males (solid blue bar): AGD in male fetuses exposed to flutamide
between e15.5-21.5 (blue striped bar) or between e15.5-17.5 (pale blue striped bar) was
reduced compared to control males and was comparable to female AGD. Exposure to
flutamide late in WD development (e19.5-21.5, dark blue striped bars) did not affect male
AGD. Maternal exposure to flutamide did not alter female AGD (pink bars, p>0.05). ***
p<0.001 compared to control male AGD. Values are means ± S.E.M for 6-23 animals.
Maternal exposure to flutamide (e 15.5-21.5 or el5.5-17.5) prevented normal prostate and
penis formation in males and resulted in the presence of a vaginal pouch (data not shown)
whereas exposure to flutamide late in reproductive development (el9.5-21.5) did not.
Testis descent was unaffected at e21.5 by maternal flutamide exposure (data not shown).
Consistent with previous reports (Mylchreest et al, 1999; Mclntyre et al, 2001; Foster and
Harris, 2005), these abnormalities were still evident postnatally (data not shown).
5.3.2 Effects on WD development of impaired androgen action during critical
windows of development
Exposure to flutamide (100 mgkg"1) between e 15.5-21.5 reduced WD development and
coiling compared to age matched controls, as detailed earlier (section 3.4.4.1.1). Exposure to
flutamide only between el5.5-17.5 (early flutamide) inhibited coiling by e21.5 to a similar
extent as did exposure from el5.5-e21.5, whereas coiling was still evident at e21.5 in WDs
exposed to flutamide between el9.5-21.5 (late flutamide) with little change compared to age
matched controls (Fig. 5.3). This difference was confirmed quantitatively (Fig. 5.4)
highlighting that there was no significant difference in luminal length between WDs from
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litters exposed to flutamide between e 15.5-21.5 and those exposed to flutamide only between
e 15.5-17.5. Exposure to flutamide late in WD development (e 19.5-21.5) did not
significantly reduce WD luminal length compared to age matched controls: this was
significantly different from WDs exposed to flutamide early in development (p<0.001).
V
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Figure 5.3 Representative Wolffian ducts (WD) at e21.5 from control and flutamide-
exposed (100 mgkg'1) fetuses. Note that exposure to flutamide between e 15.5-21.5 (B)
reduced WD coiling compared to controls (A). Exposure to flutamide between e15.5-17.5
(Early F100, C) reduced WD coiling to a similar extent to exposure to flutamide from e15.5-
21.5 (B) while exposure to flutamide only between e 19.5-21.5 (D) did not obviously reduced
WD coiling compared to age matched controls. * - efferent ducts Scale bar = 1mm
a
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Figure 5.4 Quantification of coiling (= luminal length) of e21.5 WDs from control and
flutamide-exposed litters. Note the significant reduction in WD luminal length in animals
exposed in utero to 100 mgkg'1 (blue striped bar) flutamide from e15.5-e21.5, when
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compared to controls (blue bar). Exposure to flutamide from e15.5-17.5 (Early F100; pale
blue striped bar) significantly reduced WD luminal length compared to controls. Note that
exposure to flutamide between e19.5-21.5 (late F100; dark blue striped bar) did not reduce
WD luminal length, compared to age matched controls. Values are mean ± S.E.M for 8-66
animals per group, ***p<0.001, in comparison to the respective control value, a p<0.001, in
comparison to exposure to flutamide from e15.5-21.5.
5.3.3 Androgen receptor expression
Exposure to flutamide either early (e 15.5-17.5) or late in WD development (el9.5-21.5) did
not prevent expression of androgen receptor (AR) in either the stroma or epithelium at e21.5
(Fig. 5.5, panels B and C, respectively). Further analysis of AR expression using Taqman
QRT-PCR confirmed that there was no significant difference either in AR mRNA expression
in control compared to flutamide-exposed WDs at e21.5 (Fig. 5.6). Variation was seen in the
levels of AR mRNA within each age/treatment however, this was not significant and
presumably represents variation between individual WDs.
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Figure 5.5 Expression of androgen receptor (AR) protein in the Wolffian duct (WD)
from control (A) and flutamide-exposed (B - 100 mgkg'1 e15.5-17.5, C - 100 mgkg'1
e19.5-21.5) rats at e21.5. Note that exposure to flutamide, either early (B) or late (C) in WD
development, does not alter AR expression in the stroma (*) or epithelium (arrow), compared
to age matched controls (A). Scale bar =100 urn.
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Figure 5.6 Quantitaive analysis of AR mRNA in the Wolffian duct at e21.5. No
significant difference was see in AR mRNA expression in WDs from control (solid blue bars)
and flutamide-exposed (striped bars -100 mgkg'1) rats, as determined by Taqman QRT-
PCR (means ± S.E.M, n=3-5 WDs per age/treament, each from different litters). mRNA
expression was corrected for loading and expressed relative to levels in the uterus.
5.3.4 Gross changes to the epithelial compartment
Examination ofWDs revealed no obvious histological differences in the epithelium of e21.5
WDs from control fetuses and fetuses exposed to 100 mgkg"1 flutamide late in WD
development (el9.5-21.5). However, as highlighted in Fig. 5.7, epithelial abnormalities
became apparent by e21.5 in WDs from fetuses exposed to 100 mgkg"1 flutamide early in
WD development (e 15.5-17.5) including loss of epithelium lining the lumen or flattening of
the epithelium compared to that of controls (Fig 5.7). The extent of this flattening varied
between WDs but was confirmed quantitatively at e21.5 (Fig. 5.8). These epithelial
abnormalities were similar to those observed in WDs from e21.5 fetuses exposed to 100
mgkg"1 flutamide between e 15.5-21.5 (section 3.4.5.1).
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Figure 5.7 Representative gross abnormalities seen in the epithelium of e21.5 WDs
(immunostained brown for cytokeratin) from control and flutamide-exposed (100
mgkg'1) litters. Note the apparent reduction in epithelial cell height (arrow) in WDs exposed
to flutamide early in development (e15.5-17.5, B & E) but not in WDs exposed to flutamide
later in WD development (e19.5-21.5, C & F), compared to age matched controls (A & D).
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Figure 5.8 Analysis of epithelial cell height in Wolffian ducts (WDs) at e21.5 from
control and flutamide-exposed animals. Note that epithelial cell height is significantly
reduced in males exposed to flutamide between e15.5-21.5 (blue chequered bar - 50 mgkg'1;
blue striped bar - 100 mgkg'1) and between e15.5-17.5 (Early F100, pale blue striped bar -
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100 mgkg'1) but not in males exposed to flutamide late in WD development (Late F100, dark
blue striped bar - 100 mgkg'1), compared to age matched controls (blue bar). Values are
means ± S.E.M, for 3-19 WDs per age/treament, each from different litters. ** p<0.01, ***
p<0.001 compared to e21.5 controls.
5.3.5 Flutamide-induced loss of Wolffian duct segments
As well as the reduction in coiling, exposure to flutamide from el5.5-21.5 resulted in some
WDs appearing incomplete at e21.5 with thinning of the epithelium and missing
corpus/cauda segments (detailed in section 3.4.4.1). This phenotype of missing segments
was not noted at e21.5 in fetuses exposed to flutamide during short windows either early
(el5.5-17.5) or late (e 19.5-21.5) in WD development (Table 5.3). However, by pnd42 40%
of males exposed to flutamide early in development had incomplete reproductive tracts with
missing or incomplete epididymides and/or vas deferentia. By adulthood (pnd70), 50% of
males exposed to flutamide early in WD development had incomplete epididymides and/or
vasa deferentia (Fig. 5.9). A further 25% of males had underdeveloped or abnormal
epididymides/vasa deferentia (Fig. 5.9). This phenotype was similar to that observed in
males exposed to flutamide throughout fetal reproductive development in which 83% of
males examined had incomplete WD-derived tissues (section 3.4.4.2). In contrast, males
exposed to flutamide late in development all had complete epididymides and vasa deferentia
at pnd42 and in adulthood (Fig. 5.9 and Table 5.3).
Table 5.3 Percentage of rats with an intact WD (e21.5) or WD-derived tissues (pnd17,







e21.5 100% 89% 100% 100%
Pndl7 100% 87% 100% 100%
Pnd42 100% 50% 60% 100%
Adult 100% 17% 50% 100%
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Figure 5.9 Wolffian duct-derived tissues in males from control and flutamide exposed
(100 mgkg'1) animals at pnd70. Note the thinning of the corpus (arrow), the vestigial caput
segment (arrowhead) and missing corpus (*) in epididymides from males exposed to
flutamide early in fetal development (e15.5-17.5), compared to age matched control males
(top row). In contrast, the WD-derived structures from animals exposed to flutamide late in
development (e19.5-21.5) were complete and appeared normal (bottom row).
5.3.6 Alterations to the basement membrane
In control animals, laminin was immunolocalised to the basement membrane in WDs,
forming a 'ring' between the epithelium and the stromal compartment (section 4.4.4.1).
Exposure to flutamide late in WD development (el9.5-21.5) did not alter laminin expression
but flutamide exposure early in WD development (e 15.5-17.5) resulted in interruptions to the
laminin 'ring' and it appeared less defined (Fig. 5.10).
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Figure 5.10 Immunoexpression of laminin in the basement membrane of control (A)
and flutamide-exposed (B & C) WDs at e21.5. Note the defined 'ring' of laminin around
the base of the epithelium in the control WD (arrow, A). This 'ring' becomes less defined and
interrupted in WDs exposed to flutamide early in WD development (e15.5-17.5, arrowhead,
B) but not in WDs exposed to flutamide late in WD development (e19.5-21.5, arrow, C).
Scale bar = 100 urn
5.3.7 Stromal cell differentiation
Immunostaining for smooth muscle actin (SMA), a smooth muscle cell marker specifically
expressed in the inner stromal compartment, suggested a reduction in the SMA-positive layer
in WDs from e21.5 fetuses that had been exposed to flutamide early in development,
compared to age matched controls (Fig. 5.11). No obvious change was noted in this SMA
positive layer in WDs from males exposed to flutamide during the late window (Fig. 5.11).
The SMA positive stromal compartment varied considerably in breadth between sections of
WDs so SMA protein expression in WDs was quantified by Western blot analysis (Fig.
5.12). This confirmed that SMA protein levels in WDs from males exposed to flutamide
early in development, but not those from late window flutamide fetuses, were significantly
different from that in age-matched controls (Fig. 5.12). This is consistent with the reduction
in SMA protein levels observed in WDs from fetuses exposed to flutamide (100 mgkg"1)
between e 15.5-21.5 (detailed in section 4.4.2.2.2).
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Figure 5.11 Comparative expression of smooth muscle actin (SMA, *) at e21.5 in
Wolffian ducts (WDs) from controls (A) and animals exposed in utero to 100 mgkg'1
flutamide between e15.5-21.5 (B), e15.5-17.5 (C) or e19.5-21.5 (D). Note the apparent
reduction in the depth of the SMA positive layer in WDs from animals exposed to flutamide
either between e15.5-21.5 (A) or e15.5-17.5 (C), but not in WDs from males exposed to
flutamide between e19.5-21.5 (D).
**
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Figure 5.12 Quantitative data comparing expression of smooth muscle actin (SMA)
protein at e21.5 in WDs from control (C) and flutamide-exposed animals. Note the
reduction in SMA protein expression in WDs from fetuses exposed to flutamide between
e15.5-21.5 (striped bar) or e15.5-17.5 (pale blue striped bar) while no obvious difference can
be seen in SMA protein expression in WDs from fetuses exposed to flutamide between
e19.5-21.5 (dark blue striped bar), compared to age matched controls (solid blue bar). n= a
pool of 3-5 WDs per age/treatment, from at least 3 different litters. Loading was corrected
using ({-tubulin protein expression.
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5.3.8 Vimentin expression
Vimentin protein was immunolocalised to the WD stroma of both control and flutamide-
exposed fetuses at e21.5 (Fig. 5.13). Vimentin was also detected at the basolateral edges of
epithelial cells in the distal corpus and cauda of the future epididymis in control WDs at
e21.5. Exposure to flutamide did not affect stromal vimentin expression but altered the
distribution of vimentin in the epithelium. In WDs from fetuses exposed to flutamide (100
mgkg"1) between el5.5-21.5 or between el5.5-17.5, vimentin 'spiking' was apparent in the
caput ofmany WDs at el9.5 and e21.5, as well as in the cauda (Fig. 5.13). This was rarely
seen in the caput ofWDs exposed to flutamide late in WD development (el9.5-21.5).
Figure 5.13 Immunolocalisation of vimentin protein in e21.5 Wolffian ducts from
control and flutamide-exposed animals. Note that vimentin expression in the stroma did
not vary with flutamide treatment (brown). Vimentin was also detected in the epithelium
(arrow) in the WD cauda (D), but not the caput (A), in control animals. This vimentin 'spiking'
in the epithelium became apparent in the caput (B) as well as in the cauda (E) in fetuses
exposed to flutamide between e15.5-17.5. This was not seen in the caput of WDs exposed
to flutamide late in development (C) but was still detected in the cauda (F).
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5.4 Discussion
In males, androgen action is believed to stabilise the Wolffian duct (WD) during fetal life,
allowing it to differentiate subsequently into its adult derivatives, the epididymis, vas
deferens and seminal vesicles (George, 1994; Huhtaniemi, 1994). In the female rat, the lack
of androgens results in the WD naturally regressing between el6.5 and el 8.5 (chapter 6).
This suggests that WD stabilisation occurs between el 5.5, the time of testosterone
production onset, and el8.5 while studies in our rat colony have shown that the window for
WD morphological differentiation is between el9.5 and birth, coinciding with the peak in
testosterone seen in male rats at el9.5 (chapter 3)(Warren et al, 1972).
Flutamide was used to interfere with androgen action as it has been shown to be a strong
competitive AR antagonist and exposure during fetal development interrupts male
reproductive development (Imperato-McGinley et al, 1992; Bentvelsen et al, 1995;
Mylchreest et al, 1999; Mclntyre et al, 2001; Hotchkiss et al, 2002). It is worth nothing that
flutamide is quickly cleared from the body and has a plasma half-life of 5-6 h in man (Neri
and Monahan, 1972) thus suggesting that fetuses are not exposed to flutamide for more than
24 h after the final gavage. Studies reported in chapter 3 have confirmed the role for
androgens in male fetal development since male fetuses from dams exposed to 100 mgkg"1
flutamide between el5.5-21.5 had no prostate, reduced AGD and impaired WD
development. These abnormalities persisted into adulthood confirming that the patterning
and establishment of the reproductive tract is set up in the fetus, and interfering with
androgen action during this period permanently alters reproductive tissues. It was assumed
that androgens are essential during the period of both WD stabilisation and morphological
differentiation: in order to test this hypothesis, fetuses were exposed to flutamide either
during the window of WD stabilisation (el5.5-17.5) or during WD morphological
differentiation (el9.5-21.5). Since exposure to 100 mgkg"1 flutamide between e 15.5-21.5 did
not prevent stabilisation of the male WD but impaired WD coiling, it was expected that
impaired androgen action late in development would allow 'rescue' of the WD but would
prevent initiation of WD coiling whereas exposure to 100 mgkg"1 flutamide early in
development would not have any major impact on the developing WD. Contrary to these
hypotheses, reduced androgen action early in male reproductive tract development (el 5.5-
17.5) resulted in a similar phenotype to exposure to flutamide during the entire window of
male fetal reproductive development (el 5.5-21.5) with males having a vaginal pouch instead
of a normal prostate, impaired WD development and with their AGD reduced to the length
found in normal females. This phenotype was not observed in male fetuses exposed to
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maternal flutamide later in development (el9.5-21.5). These results suggest that prostate
formation, WD patterning and masculinisation of AGD is established between el 5.5 and
el7.5, several days before any sign of WD morphological differentiation, and that high
levels of androgen action later in fetal development are not essential for maintaining this
male phenotype. This is in agreement with previous studies exposing pregnant rats to a
single dose of flutamide (50 mgkg"1) on el6, 17, 18 or 19 which showed that exposure to
flutamide on el6 or 17 resulted in missing epididymides in adults whereas exposure later in
development (el8 or 19) only resulted in smaller epididymides (Foster and Harris, 2005).
Furthermore, they highlighted that the peak incidence of abnormal prostate development was
noted in adults exposed to flutamide on el7 or 18, similar to our observations in males
exposed to flutamide between el5.5-17.5. Foster and Harris reported that exposure to a
single dose of flutamide resulted in a similar range of reproductive abnormalities as exposure
to flutamide throughout the period of reproductive development (el2-21) however, the
incidence was lower (Foster and Harris, 2005). This suggests that a single exposure to
flutamide can interfere with normal reproductive development but at a lower incidence and
even showing a less severe phenotype. This reduced incidence was not noted in our studies
since exposure to flutamide for 3 days early in development (el 5.5-17.5) resulted in a similar
number of adult males with reproductive tract abnormalities as exposure throughout
reproductive development. It was surprising that high levels of androgen action did not
appear to be essential during the window of morphological differentiation of the WD (el9.5-
21.5) but rather once the pattern of WD development was established by early androgen
exposure, the WD continued to development along the normal pathway, even if androgen
action was reduced by exposure to flutamide. It is worth noting that, as discussed in chapter
3, exposure to this level of flutamide does not completely block androgen action, therefore
we cannot completely rule out a role for low levels of androgens during this late window of
WD development (e 19.5-21.5). Studies carried out in the mouse have shown that exposure
to flutamide on el9 and 20 did not result in any obvious reproductive abnormalities or
infertility in adulthood whereas exposure on el 1-15 or el5-20 resulted in smaller
epididymides and infertility and lack of a prostate, respectively (Silversides et al, 1995).
These studies again confirm the long term deleterious effects of short-term androgen
blockade. It is not clear if androgens play any role late in fetal male reproductive
development and further investigation of more endpoints would be required in males from
litters exposed to flutamide between el 9.5-21.5.
Studies previously published (Silversides et al, 1995; Foster and Harris, 2005) and those
reported in this thesis, have shown that interfering with androgen action during defined
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windows of fetal development have varied effects on the male reproductive tract. Exposure
to flutamide (100 mgkg"1) during the entire window of male reproductive development
resulted in incomplete WDs in 11% of e21.5 males: the prevalence of this abnormality
increased around puberty to 50% of males and increased again in adults to 83%. This is in
agreement with previous studies showing that exposure to anti-androgenic compounds in
utero results in a high frequency of epididymal malformations in adult rats (Imperato-
McGinley et al, 1992; Mylchreest et al, 1999; Mclntyre et al, 2001; Turner et al, 2003;
Foster and Harris, 2005). The reasons for this increased prevalence as development proceeds
were unclear however it is hypothesised to be due to failure to establish normal patterning of
the WD in the fetus. Exposure to flutamide either early or late in WD development did not
result in incomplete WDs during fetal life in any fetuses examined, but this may be due to
the relatively low number of litters studied. Postnatal males exposed to flutamide late in
development (el9.5-21.5) did not show any signs of this phenotype with all reproductive
tracts studied appearing morphologically normal at all ages studied (pndl7, 42 and 70). On
the other hand, 40% of pubertal males (pnd42) examined that had been exposed to flutamide
early in WD development (el 5.5-17.5), had incomplete epididymides and/or vas deferentia.
This increased to 50%by adulthood. The slightly lower incidence of incomplete WD-derived
structures seen in animals exposed to flutamide early in development (el 5.5-17.5) compared
to the incidence noted in males exposed to flutamide throughout fetal reproductive
development (e 15.5-21.5), may be due to the lower number of litters examined in the early
exposure group: an increased percentage of incomplete reproductive tracts may be seen in
the early exposure group ifmore animals were examined. This data again confirms the role
for androgens early in WD development (el5.5-17.5) to establish the pattern of WD
development and highlights that interfering with this patterning during fetal life has long
term consequences for the adult male reproductive tract.
In order to confirm that the reduced WD development seen in animals exposed to flutamide
early in fetal development was due to similar mechanisms as that seen in animals exposed to
flutamide throughout reproductive development (see chapter 3 and 4), various endpoints
were examined. As discussed in chapter 4, exposure to flutamide did not alter expression of
the androgen receptor (AR) in the stroma or epithelium of the WD during fetal life.
Similarly, exposure to flutamide during either defined window (early or late) did not
interrupt AR expression, confirming that these WDs are still capable of responding to
androgens. This is in contrast to findings by Bentvelsen and colleagues who were unable to
detect AR protein by immunohistochemistry in WDs from e21.5 fetuses exposed to 100
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mgkg"1 flutamide (Bentvelsen et al, 1995). This difference may be due to differences in rat
strain or to the use of different anti-AR antibodies and immunohistochemistry techniques.
Furthermore, exposure to flutamide between el5.5-21.5 resulted in reduced epithelial cell
height and abnormal epithelial development in the WD by e21.5 (see chapters 3 and 4). This
was not found in WDs exposed to flutamide late in WD development (e 19.5-21.5) but was
seen in WDs exposed to flutamide early in development. These effects on the epithelium
were not evident until e21.5, thus suggesting that the epithelium initially forms normally in
flutamide-exposed animals but degenerates during differentiation, possibly due to impaired
androgen-driven signalling between the stroma and epithelium. Since no effect on epithelial
cell height or loss of epithelium was found after exposure to flutamide between el9.5-21.5,
only in animals exposed to flutamide between el 5.5-17.5, this again confirms the early role
for androgens in establishing the fate of the epithelial cells in WD development.
Another deleterious effect caused by flutamide exposure between el5.5-21.5 was
interruption of the basement membrane. Laminin forms a defined 'ring' around the base of
the epithelium and plays an essential role in anchoring epithelial cell surfaces to the
basement membrane (see chapter 4). Exposure to flutamide early, but not late, in WD
development also interrupted the basement membrane with the laminin 'ring' appearing
incomplete and less defined, as seen in WDs from animals exposed to flutamide between
el5.5-21.5. Interruption to the basement membrane might explain the abnormal epithelium
in sections of the WD and the appearance of flattened mesenchymal-like cells (as discussed
in chapter 4).
The early mesenchymal cell marker, vimentin, was constitutively expressed in the WD
stroma and was not altered by exposure to flutamide either throughout fetal reproductive
development (el5.5-21.5, see chapter 4) or flutamide-exposure only during defined
windows. In control animals, vimentin was also expressed on the basolateral boundary of the
epithelial cells along the full length of the WD at el 5.5 and becomes later restricted mainly
to the cauda by e21.5: this restriction of vimentin expression in the epithelium may reflect
vimentin being replaced by another intermediate filament in a cranio-caudal direction as
development and differentiation proceeds. Exposure to flutamide between el5.5-21.5
disrupts this cranio-caudal loss of epithelial vimentin reflecting the failure of the epithelium
to differentiate fully, as discussed in chapter 4. This pattern was again seen in WDs exposed
to flutamide between el 5.5-17.5 with vimentin still strongly expressed in the WD epithelium
in the caput as well as in the cauda, in contrast to controls. Conversely, vimentin was rarely
detected in the caput epithelium in WDs exposed to flutamide late in WD development.
These data provide further evidence for a key role for androgens between el5.5-17.5, rather
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than during WD morphological differentiation (el9.5-21.5), in mediating epithelial
differentiation and WD development. This might explain the reduced epithelial cell height
and loss of attachment to the basement membrane seen in WDs exposed to flutamide early,
but not late, in WD development.
Finally, as discussed in chapter 4, smooth muscle stromal differentiation occurred during
fetal life with SMA detected in the stroma immediately proximal to the epithelium in the
WD corpus by el8.5: this was impaired by exposure to flutamide between e 15.5-21.5. A
similar reduction was seen in the level of SMA protein expression in WDs recovered from
fetuses exposed to flutamide early in WD development (el5.5-17.5), but not in WDs from
fetuses exposed to flutamide in the late window (el9.5-21.5). This suggests that WD
development and smooth muscle differentiation are mediated by androgen action between
el 5.5-17.5, even thought the effects are not seen until several days later.
5.5 Conclusions
These studies highlighted that the pattern of WD coiling and its subsequent ability to develop
fully during postnatal life is established early in fetal life (el 5.5-17.5) as reduced androgen
action during this time-window inhibited coiling at e21.5 to the same extent as did exposure
from el 5.5-e21.5 and resulted in a similar high incidence of epididymal loss/abnormalities in
late puberty and adulthood. Exposure later in fetal life (e 19.5-21.5), the period in which WD
morphological differentiation occurs, did not impact on WD coiling at e21.5 or subsequent
epididymal development postnatally: this suggests that WD patterning is already established
by el 9.5 and is no longer dependent on high levels of androgen action. The critical window
for high levels of androgen action in establishing the pattern ofWD development is therefore
between el5.5-el7.5.
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6 Investigation of Wolffian duct stabilisation and its dependence on
androgens
6.1 Introduction
The studies presented so far in this thesis highlight that the pattern of WD coiling and its
subsequent ability to develop fully during postnatal life is dependent on androgen action and
is established early in fetal life (el5.5-17.5): patterning of WD differentiation has already
been established prior to any signs of morphological differentiation of the WD (i.e. el9.5-
20.5), and by this age, the WD is no longer dependent on high levels of androgen action.
Studies in chapter 3 suggested that patterning of WD differentiation is more susceptible to
reduced androgen action than is stabilisation. One interpretation of these studies is that the
dose of flutamide administered does not completely block androgen action and so does not
interfere with WD stabilisation and cause it to regress as occurs in the female. This suggests
that WD stabilisation is dependent on lower levels of androgen action than that required for
differentiation. Alternatively, WD stabilisation and differentiation could be regulated by
different mechanisms, thus highlighting WD development as a bi-phasic process. Insight
from models in which androgen action is more completely blocked may further our
understanding ofWD development.
Since the WD initially forms in the female then subsequently regresses due to the lack of
androgens, females offer a natural model in which to study the impact of a complete lack of
androgen signalling on the fetal WD (George, 1994). The female WD regresses in a cranio-
caudal direction and has almost completely regressed by el9 in the rat (Jirsova and
Vernerova, 1993). The mechanisms involved in the regression of the female WD are not
fully understood but similarities can be seen between the cellular processes suggested to be
involved and those reported in this thesis to be induced in the male WD by flutamide
exposure (chapter 4). Previous research has shown that the WD diameter decreases and the
epithelial cells lose their polarity and degenerate: it has been suggested that these epithelial
cells are lost due to apoptosis as well as a possible role for epithelial-mesenchymal
transformation (Inomata et al, 1989; Jirsova and Vernerova, 1993). This is similar to the
process observed in the regressing MD, in which the basement membrane is disrupted,
epithelial cell size decreases, the mesenchyme condenses and the epithelium subsequently
degenerates (Dyche, 1979; Ikawa et al, 1984; Inomata et al, 1989; Austin, 1995). This is
thought to be driven by paracrine mechanisms originating in the mesenchyme as a result of a
loss of ECM and results in apoptosis and possibly epithelial-mesenchymal transformation
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(Dyche, 1979; Inomata et al, 1989; Austin, 1995; Allard et al, 2000; Xavier and Allard,
2003).
It is presumed that the female WD is identical to the male WD and would develop in the
same way if exposed to androgens, however this is a presumption and has not been proven.
Testicular feminised (Tfm) mice provide a model in which to examine the effects of a
complete lack of androgens on male WD development since these mice have an X-linked
recessive mutation which causes a complete insensitivity to androgens due to a defect in AR
protein, not androgen production (Attardi and Ono, 1974; Gehring and Tomkins, 1974)
(section 1.5.2.1). Similar AR mutations can be identified in humans resulting in end-organ
androgen resistance termed androgen insensitivity syndrome (AIS) (Quigley et al, 1995;
Ahmed et al, 2000). Both of these models result in genetic males with normal testes and
testosterone production but with phenotypic female genitalia, though the clinical
observations in AIS patients can vary considerably depending on the degree and location of
the AR mutation (Lyon and Hawkes, 1970; Hughes and Patterson, 1994; Patterson et al,
1994; Hannema et al, 2004). Complete AIS (CAIS) patients and Tfm mice have no obvious
WD-derived structures in adulthood suggesting that the fetal WD is not rescued but, to the
best ofmy knowledge, current literature has not examined the status of the fetal WD in either
model. Furthermore, it has been noted by several researchers that rudimentary internal
genitalia can persist in some AIS individuals (Morris, 1953; Bale et al, 1992; Boehmer et al,
2001). This is believed to be due to the failure of the WD to completely regress. However,
Hannema and colleagues (2004) have shown the persistence of well developed epididymides
and vasa deferentia in some CAIS patients. These patients all had mutations in the AR
ligand binding domain and showed residual transcriptional activity in vitro, unlike ARs with
mutations in the DNA binding domain which completely lacked transcriptional activity
(Hannema et al, 2004). Together, these data suggest that WD development is more complex
than previously presumed and may not simply depend on the presence of androgens and a
functional AR: this therefore warrants further investigation to examine the mechanisms and
regulatory factors in WD stabilisation and differentiation.
These models provide systems in which to examine the complete loss of androgen action in
the male and female WD but exposure to mixtures of anti-androgenic compounds can
provide a tool with which to reduce further androgen action and so examine the dose-
dependent effects on male WD development (discussed in section 1.5.2.2). Maternal
exposure to anti-androgenic compounds during gestation results in varying degrees of
impaired masculinisation of the male offspring, some of which can be observed in the fetus
and others are not evident until adulthood. For example, maternal exposure to Di(n-butyl)
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phthalate (DBP) reduces testicular testosterone production in the male fetus thus interfering
with normal male reproductive tract development (Mylchreest et al, 1998; Mylchreest and
Foster, 2000; Mylchreest et al, 2000; Parks et al, 2000; Foster et al, 2001; Fisher et al,
2003). Conversely, flutamide exposure has no effect on androgen production but prevents
transcriptional activation of AR in target tissues (Peets et al, 1974). Therefore, maternal
exposure to flutamide dose-dependently prevents normal masculinisation of male fetuses
resulting in varying degrees of WD differentiation, maldescent of the testis, feminisation of
external genitalia and missing prostates in adulthood (Imperato-McGinley et al, 1992;
Mclntyre et al, 2001). Combined exposure to both these compounds would theoretically
result in a more complete reduction in androgen action by interfering with both androgen
production and action and therefore would provide a system in which to examine whether
WD development depends on a threshold of androgen action and whether WD regression
only occurs due to a complete lack of androgen action.
6.1.1 Aims
To investigate the pattern and timing ofWD regression in the female rat.
To compare the mechanisms of natural regression of the WD in the female with the
mechanisms of flutamide-induced WD abnormalities.
To investigate if functional inactivation of the AR (Tfm) results in complete regression of
the male WD, as occurs naturally in females.
To establish an In utero model to investigate more complete reduction in androgen action in
rats and investigate the subsequent impact on WD development. Does this further reduction
in androgen action result in regression of the WD as occurs naturally in females?
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6.2 Methods
6.2.1 Natural regression studies
In order to study the exact timing ofWD regression in females, matings were set up to allow
collection of fetuses at 6 hourly intervals between el 6.5 and el 8.5 (i.e. el 7.0, el 7.25, el 7.5,
etc). Time-matings were set up to allow accurate calculation of their mating within a 1 h
time window. One stud male and one female rat were paired together in grid bottom cages at
a precise time and monitored hourly for the presence of a vaginal plug. Detection of a
copulatory plug was taken as evidence of mating: this was defined as embryonic day 0.5
(e0.5). Once a positive mating was detected, the female was removed from the male rat.
Dams were killed by inhalation of carbon dioxide and subsequent cervical dislocation and
fetuses were recovered at 6 hourly intervals between el6.5-18.5 (n= 151 itters). Fetuses were
killed by decapitation before reproductive tracts were recovered by microdissection and
photographed using a Leica ICA camera (section 2.3.2.1). Reproductive tracts were
analysed microscopically at the time of dissection, for any gross morphological
abnormalities and tissue was fixed in Bouin's, as detailed in section 2.4.
6.2.2 In utero treatments
As detailed in section 2.2, pregnant dams were randomly allocated to treatment groups and
dosed once daily by gavage with 1 mlkg"1 maternal bodyweight of the various treatments
detailed below. Dams were dosed between el3.5-e21.5, or until the day prior to cull if this
was before e21.5. This window of exposure was selected to encompass the onset of
androgen action at el 5.5 and the period of fetal male reproductive development (el 5.5-21.5)
according to Warren et al (1972). This dose of flutamide was selected based on results
previously reported in chapters 3 and 4 highlighting that fetal exposure to flutamide induced
reproductive tract abnormalities in both fetal life and adulthood. The Di-n-butyl phthalate
(DBP) dose was selected based on studies in our lab investigating the effects of DBP on the
reproductive tract (Fisher et al, 2003; Mahood et al, 2005).
Control: 1ml corn oil/2.5% DMSO e 13.5-21.5, (n=6 litters)
Flutamide: lOOmgkg"1 in 1ml corn oil/2.5% DMSO, el5.5-21.5 (n=6 litters)
DBP: 500 mgkg"1 in 1 ml corn oil, el 3.5-e21.5 (n=9 litters)
Flutamide + DBP: lOOmgkg"1 flutamide in 1ml corn oil/2.5% DMSO, el5.5-21.5
500 mgkg"1 DBP in 1 ml corn oil, e 13.5-e21.5 (n = 3 litters)
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Figure 6.1 Summary of the maternal treatment regimes used.
6.2.3 Tissue collection
Dams were killed by inhalation of carbon dioxide and subsequent cervical dislocation and
fetuses were recovered at el8.5 and e2l.5. Fetuses were killed by decapitation before
reproductive tracts were recovered by microdissection and photographed using a Leica ICA
camera (section 2.3.2.1). Reproductive tracts were analysed microscopically, at the time of
dissection, for any gross morphological abnormalities and tissue was either fixed or frozen,
as detailed in section 2.4.
6.2.4 Luminal length analysis
Differentiation of e2l.5 WDs was quantified by digitally measuring the luminal length of the
epididymal segment ofWDs from control and treated animals, as described in section 2.8.
6.2.5 Testosterone analysis
Effects of In utero treatments on testosterone levels were quantified by measuring the levels
of testosterone in whole testis or ovary homogenates at el7.5. Protocols were already
established in house for these hormone assays (Atanassova et al, 1999).
6.2.5.1 Extraction of testosterone from whole organs
The whole tissue homogenates required an extraction step to free any testosterone bound in
the tissue to proteins such as albumin. Whole fetal testes or ovaries were homogenised in
0.5ml ice cold 0.1M PBS buffer and incubated on ice for 1 h: lOOpl of the homogenate was
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placed in a glass test-tube and vortexed for 5 min with 2 ml diethyl ether. The shaken tubes
were placed in a bath of methanol and dry-ice to freeze the aqueous portion, revealing the
unfrozen organic portion which was decanted into clean tubes. These tubes were left
overnight in a fume hood to enable the organic solvents to evaporate. The dry residue was
resuspended in 500 pi assay buffer and left for 30 min to solubilise: samples were then
stored at -20°C until ready to be quantified.
6.2.5.2 Radioimmunoassay (RIA) for testosterone
The radioimmunoassay was performed by Ian Swanson in the HRSU Assay lab, for which I
am extremely grateful. This method relies on competition between a known concentration of
radiolabeled antigen (testosterone with I125, APB Biotech, UK) against the unlabelled
endogenous testosterone present in the test sample. The more testosterone in the test sample,
the lower the level of binding by the labelled testosterone. Radiolabeled testosterone was
incubated with the test sample extract for 3 h at room temperature. The sample was then
incubated overnight at 4°C with a secondary antibody (Donkey-anti-sheep DAGS), raised
against the sheep IgG. The antibody binds to the testosterone to form a complex, resulting in
the formation of a stable precipitate. 2ml of wash buffer was added and the amount of
radiation in the precipitate was measured. The sample values were compared to a standard
curve of known antigen concentrations. A gamma counter (Multigamma 1261, LKB Wallac,
Turku, Finland) was used to measure residual I125. This assay is precise and sensitive with a
low intra-assay coefficient of variance (<10%). In each run, method blanks, quality control
(QC) samples (spiked buffer), and standards were analysed along with the samples. Data
were expressed as pg testosterone per 100 pi sample. Results were analysed using a
specifically designed computer programme (AssayZap, BioSoft, Cambridge, UK). For
presentation purposes, data were converted to ng/ml sample (= pg/lOOpl x 0.01).
6.2.6 Immunohistochemistry
Immunohistochemistry was performed on isolated rat reproductive tracts fixed in Bouin's,
using standard avidin peroxidase protocols in order to highlight the location of proteins of
interest, as detailed in section 2.6.1.
Briefly, sections were cut from paraffin blocks and mounted on glass slides. Sections were
then dewaxed and rehydrated then pressure cooked in citrate buffer if required (Table 6.1).
Non-specific binding was blocked before adding the appropriate primary antibody overnight,
as detailed in Table 6.1. A biotin labelled secondary antibody was used that had been raised
against a species-specific sequence on the primary antibody. This biotinylated secondary
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antibody signal was amplified by incubation with avidin-biotin conjugated with horseradish
peroxidase and the signal was localised using DAB. Sections were counterstained with
haematoxylin and mounted with glass coverslips. Further detailed protocols can be found in
section 2.6.1.
Table 6.1 Summary of primary antibodies used for immunohistochemistry
Target Antigen Source Dilution Retrieval Host Species
Androgen Receptor Santa Cruz 1:50 Citrate Rabbit
Smooth Muscle Actin Sigma 1:10000 None Mouse
Pan-cytokeratin Sigma 1:200 Citrate Mouse
Laminin Abeam 1:100 Citrate Rabbit
Desmin DAKO 1:400 Citrate Mouse
6.2.7 Immunostaining of mitotic cells
WD sections from control and DBP + flutamide-exposed rat fetuses at el8.5 and e2l.5 were
immunostained for phospho-histone H3 (Upstate Biotechnology, Dundee, UK), a mitotic
marker, using a Bond-X automated immunostaining machine (Vision Biosystems,
Newcastle, UK) and a polymer high contrast programme. Briefly, after high pressure
antigen retrieval, slides were peroxidase blocked for 5 min, incubated for 2 h with the
primary antibody diluted 1:1000 in the diluent supplied and then with the post-primary
reagent for 15 min. Control sections were incubated with diluent alone to confirm antibody
specificity. Sections were then incubated with the polymer reagent for 15 min to increase
sensitivity of detection prior to DAB detection for 10 min, counterstained in haematoxylin
for 5 min, dehydrated and mounted.
6.2.8 Analysis of apoptosis
Cleaved caspase 3 immunostaining was performed on WDs from control and treated rat
WDs using standard methods, as detailed in section 2.6.1, to stain for apoptotic cells. Very
few cleaved caspase 3 positive cells were detected, therefore a detailed stereological analysis
was not appropriate and all positive cells were manually counted in each WD using an
Axiolab microscope (Carl Zeiss Ltd, Hertfordshire, UK).
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6.2.9 Studies on Testicular feminised (Tfm) mice
Testicular feminised (Tfm) mice were generously supplied by Prof. Peter O'Shaughnessy,
for which I am extremely grateful (O'Shaughnessy and Murphy, 1993). Time-matings were
set up in Glasgow University Vet School animal facility by Dr Paul Baker.
The Tfm colony is maintained as a balanced stock, meaning the Tabby (Ta) gene is on one X
chromosome balanced against the Tfm gene on the other. Tfm mice were bred on a
C3H/HeH-101/H genetic background from stock animals obtained from the MRC
Radiobiologv Unit Harwell. Matings were set up between Ta females that carry the Tfm
deletion (XTa /XTfm) and sibling males (XTa/Y). This mating will produce Tabby males
(XTa /Y), Tfm males (XTfm/Y), Tabby females (XTa / XTa) and Tabby females carrying
the Tfm deletion (XTa /XTfm). The Tfm male mice do not carry the X-chromosome marker
genes (i.e. Tabby) therefore if allowed to mature, the young produced with female external
genitalia but with a normal coat are the XTfm/Y males, whereas females have a striped coat
because they carry one copy of the Ta gene or are homozygous Tabby with their distinct
phenotype (e.g. they have a waxy tail and bald patches behind the ears); XTa /Y males look
similar to the homozygous Tabby females. However, this Tabby X-chromosome marker did
not assist in differentiating between wild type female and Tfm male fetuses since fetal mice
have no coat as yet. Instead, a genetic allelic discrimination test needs to be optimized to
confirm fetal genotype. The appropriate controls used were normal males from the same
genetic background.
6.2.9.1 Dissections
Dams were killed by cervical dislocation and fetuses were recovered at e16.5 and e 18.5.
Fetuses were killed by decapitation before reproductive tracts were recovered by
microdissection and photographed using a Leica ICA camera (section 2.3.2.1). Reproductive
tracts were analysed microscopically for any gross morphological abnormalities and WDs
were fixed in Bouin's.
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6.3 Results
6.3.1 Natural regression
6.3.1.1 Timing and pattern of natural regression of the female rat WD
Figure 6.2 shows images of gonads and MD and/or WDs from e 16.5-18.5 fetuses. At el6.5,
the female WD is still evident, lying medial to the MD. This WD begins to regress in a
cranio-caudal direction and by el8.5, only the caudal portion of the female WD is evident.
In the male, the WD remains a simple straight duct throughout this period with the male MD
apparent at el6.5 but by el 8.5, the MD cannot be identified when examined microscopically
(Fig. 6.2).





Figure 6.2 Representative reproductive tracts from e16.5-18.5 male and female rat
fetuses highlighting the timing and pattern of Wolffian duct (WD) regression. Note that
at e16.5, the female WD (arrow) is obvious, lying medial to the MD (MD, arrowhead). By
e18.5, the female WD has almost completely regressed. Note also that the male MD is
evident at e16.5 but has regressed by e17.5. All images are at the same magnification. T -
testis O - ovary
6.3.1.2 Testosterone is not produced by the fetal rat ovary
Minimal testosterone levels were detected in the fetal ovary at el7.5, unlike the testis in
which more than 17 fold higher levels were found (Fig. 6.3).
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Figure 6.3 Testosterone (pg per sample) levels in the ovary and testis at e17.5. Values
are mean ± S.E.M for n=3. ** p<0.01, compared to testosterone levels in the testis
6.3.1.3 Androgen receptor is expressed in the regressing female rat
Wolffian duct
Androgen receptor (AR) protein was detected by immunohistochemistry in both the male
and female WD of rats at el7.5. In the male WD at el7.5, AR protein was intensely
expressed in the stroma while the epithelium showed weaker immunoexpression (Fig. 6.4,
panel A). In the el7.5 female WD, AR was detected in both the stroma and the epithelium:
this was seen in all female WDs examined (n=10) (a representative WD is shown in panel B,
Fig. 6.4).
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Figure 6.4 Immunoexpression of androgen receptor (AR) in the Wolffian duct (WD) in a
male and female rat fetus at e17.5. Note that AR (brown) is strongly expressed in the
stroma surrounding the male WD (arrow) but less intensely in the epithelium (A). Similarly,
AR is expressed in both the stroma and epithelium in the female WD (B). Note that the
female MD (arrowhead) is negative for AR protein by immunohistochemistry. Scale bar =
100 pm
6.3.1.4 Role for apoptosis in the regression of the female rat WD
Apoptotic cells, indicated by cleaved caspase 3 positive staining, were evident in the
epithelium of the female WD at el7.5 (Fig. 6.5). This is in contrast to the male WD from
either control el7.5 or flutamide-exposed (100 mgkg"1) el8.5 fetuses which were both
negative for cleaved caspase 3 by immunohistochemistry (Fig. 6.5). Note in the male, the
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remnant of the regressing MD could still be identified histologically at both el 7.5 and el 8.5
but no lumen was apparent.
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Figure 6.5 Frequency of apoptotic cells (immunopositive for cleaved caspase 3: brown
staining) in representative Wolffian ducts (WDs) from control and flutamide-exposed
(100 mgkg1) rat fetuses. Note that apoptotic cells were evident in the epithelium of the
regressing female WD at e 17.5 (arrow). Few apoptotic cells were seen in either male WDs
(arrow) from control e17.5 or flutamide-exposed e18.5 fetuses. Note also that apoptotic cells
were seen in the regressing MD (MD, arrowhead) in both control and flutamide-exposed
male fetuses. Scale bar -100 urn.
6.3.1.5 Cell proliferation is absent in the regressing female rat Wolffian
duct epithelium
Immunostaining for phospho-histone H3 showed mitotic cells were present in the stroma
surrounding the regressing female WD at el8.0 but they were rarely detected in the
epithelium (Fig. 6.6). This is in contrast to both control and flutamide-exposed male WDs in
which mitotic cells were evident in the stromal and epithelial cell compartments (Fig. 6.6).
Flutamide Male
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Figure 6.6 Frequency of mitotic cells (immunopositive for phospho-histone H3: brown
staining) in Wolffian ducts (WD) from male and female fetuses at e18.0-18.5 in the rat.
Note that cell mitosis was evident in the stroma surrounding the regressing female WD (A,
e18.0) (*) but not in the epithelium (arrow) whereas mitotic cells were obvious in both the
stroma (*) and epithelium (arrow) in control (B) and flutamide-exposed male fetuses at e18.5
(C, 100 mgkg'1). Note also that mitotic cells were seen in the epithelium of the female MD
(arrowhead, A). Scale bar -100 pm
6.3.1.6 Flattening of the epithelium in the regressing female rat Wolffian
duct
Upon visual inspection, epithelial abnormalities were noted in the regressing female WD at
all ages examined (el6.5-18.5), including an apparent reduction in epithelial cell height (this
was not quantified) and a narrowing of the lumen, often appearing absent (Fig. 6.7). This is
similar to the abnormalities seen in the male WD from fetuses exposed to flutamide (100
mgkg"1; see chapter 3). Note that in both the control and flutamide-exposed male, a remnant
of the MD was apparent at el 8.5, even though the MD could not be identified grossly at the
time of dissection.
Figure 6.7 Representative abnormalities in the epithelium of Wolffian ducts (WD;
immunostained for cytokeratin) from female and male fetuses at e18.0-18.5. Note the
reduction in epithelial cell height and narrowing of the lumen in the regressing female WD at
e18.0 (arrow) compared to the epithelium in control male WDs at e18.0 (arrow). This
epithelial flattening was also noted in the epithelium in WDs from flutamide-exposed fetuses
at e18.5 (arrow). Note also the reduction in epithelial cell height seen in the regressing MD
(MD) in the male fetus at e18.0 (arrowhead) compared to the control female MD
(arrowhead). Scale bar = 100 pm
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6.3.1.7 The basement membrane is interrupted in the regressing female
Wolffian duct
Immunostaining for laminin highlighted that the basement membrane around the WD
epithelium is interrupted and incomplete in the regressing female WD at el6.5 compared to
the defined 'ring' of laminin seen in the basement membrane in control male WDs (Fig. 6.8).
By el8.5, the female WD has almost completely regressed leaving patches of laminin
staining where the epithelium was once present (Fig. 6.8).
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Figure 6.8 Demarcation of the basement membrane in Wolffian ducts (WD) from male
and female fetuses at e16.5 and e18.5 in the rat. Note that laminin forms a defined 'ring'
at the basement membrane in control male WDs (arrow, e18.5). In contrast, in the female
WD at e16.5 (arrow) the basement membrane is interrupted in areas and by e18.5, the
epithelium is absent leaving patches of laminin staining (B, arrow). Note also the presence
of the female MD (arrowhead). All images are at the same magnification. Scale bar = 100
pm
6.3.1.8 Mesenchymal differentiation in the regressing female rat Wolffian
duct
As previously shown, desmin protein was localised to the stroma surrounding the male fetal
WD at all ages studied (e 15.5-21.5; section 4.4.3.2). Desmin was also expressed in the
stromal compartment surrounding the regressing female WD at all ages examined (el5.5-
18.5) in a similar pattern to that seen in the male WD (Fig. 6.9). Desmin expression was not
lost in the regressing female WD, even when the epithelium was flattened and the lumen was
no longer evident (Fig. 6.9, panel B). Desmin was never expressed in the epithelium in
either male or female WDs and was not detected in the stroma surrounding the MD in either
males or females.
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Figure 6.9 Desmin protein expression in the male and female rat WD at e17.5 and
e18.5. Note that desmin (immunostained brown) was detected in the stroma surrounding the
female WD (arrow) at e17.5 and e18.5 as well as that surrounding the male WD at e18.5.
Note also that desmin was not expressed in the stroma surrounding the MD (arrowhead)
from either male or female fetuses.
As reported in chapter 4, smooth muscle actin (SMA) was not expressed in the stromal
compartment surrounding the male WD until el8.5 therefore SMA was not examined in the
regressing female WD.
6.3.2 Wolffian duct regression in testicular feminised (Tfm) mice
In control mice, the female WD has almost completely regressed by el6.5 (Fig. 6.10) with
only the cauda evident in some animals.
At el6.5, all WDs from male fetuses from a proven Tfm carrier dam looked morphologically
similar (Fig. 6.10). By el8.5, there was an obvious morphological distinction between WDs
from wild-type littermates, which were already considerably coiled by el8.5, and those from
what were presumed to be Tfm males, which had no obvious WD with just a remnant,
mesenchymal-like structure present with no epithelium or lumen (Fig. 6.10). Final
confirmation of the genotype requires optimisation of the allelic discrimination assay.
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Figure 6.10 Representative Wolffian ducts (WD, arrow) from wild type (WT) and
testicular feminised (Tfm) mice at e16.5 and e18.5. Note that at e16.5, the female WD
has regressed and cannot be identified alongside the female Mullerian duct (arrowhead). At
e16.5, intact WDs were identified in all male fetuses (top row) whereas by e18.5, Tfm male
mice had only a remnant WD-iike structure (bottom middle). In contrast, WTmale WDs were
notably coiled by e18.5 (bottom right).
6.3.3 Wolffian duct regression after more complete reduction of androgen
action In utero in the rat.
6.3.3.1 Pattern of WD development after exposure to DBP + flutamide in
the rat
At el8.5, the WD remains a simple straight duct in both control and flutamide-exposed (100
mgkg"1) animals, as discussed in chapter 3. Combined exposure to DBP + flutamide did not
result in any gross differences in the appearance of the male WDs at el 8.5, compared to age
matched control male WDs (Fig. 6.11).
By e21.5, control male WDs were highly coiled and this was reduced by exposure to either
flutamide (100 mgkg"1) or DBP (500 mgkg'1) alone (Fig. 6.11 and Fig. 6.12). As well as
the reduction in coiling, some WDs from flutamide- or DBP-exposed fetuses appeared
incomplete at e21.5 (Table 6.2); this was never seen at el8.5 or in control WDs and affected
WDs always had a short lumen apparent at the caput end. As detailed in chapter 3, the
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incidence of incomplete WDs increased at around puberty in flutamide-exposed animals
resulting in the majority of adults having no WD-derived tissues. In contrast, the incidence
of incomplete WDs remained relatively constant in postnatal animals after fetal exposure to
DBP alone (Table 6.2).
Further reducing androgen action by combining exposure to DBP + flutamide resulted in an
almost complete loss of any WD structure in all fetuses examined at e21.5: a lumen was only
apparent in the caput segment of the WD, proximal to the efferent ducts (Fig. 6.11 and Table
6.2). This further reduction in luminal length was quantified, as shown in Fig. 6.12: it is
worth noting that since a lumen was only apparent at the caput in e21.5 WDs exposed to
DBP + flutamide, these luminal length measurements represent only this short lumen.














Figure 6.11 Representative Wolffian ducts (WD) in males from control, flutamide-
exposed (100 mgkg'1), DBP-exposed (500 mgkg'1) or DBP + flutamide-exposed litters
at e18.5 and e21.5. Note that at e18.5, all WDs were uncoiled but were complete, even
after exposure to flutamide or DBP + flutamide . By e21.5, control WDs were highly coiled.
Note that this coiling was reduced after exposure to flutamide or DBP alone (arrow). Note
that exposure to DBP + flutamide together resulted in severe abnormalities in the WD at
e21.5 with a loss of normal structure and no lumen apparent distal to the caput (arrowhead).
All images are at the same magnification. * - efferent ducts
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Figure 6.12 Quantification of coiling (= luminal length) of e21.5 WDs from control and
treated litters. Note the significant reduction in luminal length in WDs from animals
exposed in utero to 100 mgkg-1 flutamide (blue striped bar), DBP (solid green bar), or DBP +
flutamide (green striped bar), when compared to controls. Note also that exposure to DBP
reduced luminal length less than did flutamide-exposure while exposure to DBP + flutamide
decreased luminal length even more than flutamide alone. Values are mean ± S.E.M for
n=12-66 WDs, ***p<0.001, in comparison to the respective control value, a p<0.001
compared to F100 value.
Table 6.2 Percentage of rats with an intact Wolffian duct (WD, e18.5 and e21.5) or WD-
derived tissues (Pnd17 and adult) after treatment-induced impairment of androgen







el8.5 100%4 100% N/D5 100%
e21.5 100% 89% 86% 0%
Pnd 17 100% 87% 83% 0%
Adult 100% 17% 83% 0%
2
4
Note that 100% means that all WDs, or its derivatives, were complete while 0% means no
complete WDs were seen.
5 N/D - studies not yet done
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6.3.3.2 Androgen receptor expression in rat WDs after exposure to DBP +
flutamide
Androgen receptor (AR) protein was immunoexpressed intensely in the stroma surrounding
the WD but less intensely in the epithelium at el8.5 (Fig. 6.13). By e21.5, AR was intensely
immunoexpressed in both the epithelium and stroma (Fig. 6.13). AR protein expression was
not obviously altered by exposure to flutamide (Fig. 6.13 and section 4.4.1.1). Combined
exposure to DBP (500 mgkg1) + flutamide (100 mgkg1) did not obviously alter
immunoexpression of AR in the stromal compartment but AR was not detectable in the
epithelium at either el8.5 or e21.5 (Fig. 6.13). Exposure to DBP alone did not have any
obvious impact on AR expression in the WD (data not shown).
Note that at e21.5, little epithelium was observed in the WD from fetuses exposed to DBP +
flutamide with any persistent epithelium only identifiable in the caput region. In order to
highlight the effects of DBP + flutamide treatment on the epithelium, several WDs had to be
examined to identify any residual epithelium with many WDs showing no sign of any
obvious epithelium.
Figure 6.13 Immunoexpression of androgen receptor (AR) in representative rat
Wolffian ducts (WD) at e18.5 and e21.5. Note that AR protein is expressed in the stroma
(*) and epithelium (arrow) at e18.5 and e21.5 in both control and flutamide-exposed (100
mgkg'1) fetuses. Combined exposure to DBP (500 mgkg'1) + flutamide (100 mgkg'1) did not
alter AR expression in the stroma (*) but prevented AR expression in the epithelium
(arrowhead) at both e18.5 and e21.5. All images are at the same magnification.
Control F100 DBP + F100
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6.3.3.3 The role for apoptosis in the rat Wolffian duct after exposure to
DBP + flutamide
Apoptosis was not apparent in WDs from control, flutamide-exposed (100 mgkg'1) or DBP +
flutamide-exposed fetuses at e21.5 (data not shown). It is worth noting that by e21.5, little
epithelium was present in WDs exposed to DBP + flutamide together.
6.3.3.4 The presence of mitotic cells in the rat Wolffian duct after exposure
to DBP + flutamide
Cell mitosis was evident in both the stromal and epithelial cell compartments of WDs from
control and DBP + flutamide-exposed animals at all ages (Fig. 6.14). Immunostaining for
phospho-histone H3 suggested fewer mitotic cells were present in WDs from DBP +
flutamide-exposed fetuses compared to controls (Fig. 6.14) but this was not confirmed
quantitatively. This was particularly evident in the epithelium where mitotic cells were
rarely noted in WDs exposed to DBP + flutamide (Fig. 6.14). Note that in WDs from males
exposed to DBP + flutamide epithelium was only seen in the caput region.
DBP+ F100
Figure 6.14 Frequency of mitotic cells (immunopositive for phospho-histone H3;
brown staining) in representative Wolffian ducts (WDs) at e18.5 and e21.5 from control
and DBP + flutamide- exposed fetuses. Note the numerous mitotic cells in the stroma
(arrow) and epithelium (arrowhead) in control WDs. There is an apparent reduction in the
number ofmitotic cells in WDs from DBP + flutamide-exposed animals. Scale bar = 100 urn
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6.3.3.5 Impact of combined exposure to DBP + flutamide on the rat WD
epithelium
Histological examination of WDs revealed no obvious histological differences between WDs
from control and flutamide-exposed fetuses at el8.5 (data not shown). However, as seen in
Fig. 6.15, combined exposure to DBP + flutamide resulted in flattening of the epithelium,
even at el 8.5. The extent of this flattening varied between WDs: Fig. 6.15 shows examples
of WDs with relatively unaffected epithelium and WDs with significant collapse of the
epithelium. This flattening was not seen in controls or flutamide-exposed WDs at this age.
By e21.5, epithelial abnormalities were detected in WDs from fetuses exposed to flutamide
(100 mgkg"1), including flattening or even loss of epithelium lining the lumen and widening
or narrowing of the lumen (see Fig. 3.20). These abnormalities were again noted in any
persistent epithelium in WDs from fetuses exposed to DBP + flutamide: the majority of such
animals had very little epithelium evident, especially in regions distal to the caput and any
epithelium present was greatly flattened with an abnormal lumen (Fig. 6.15). Note that the
images depicted in Fig. 6.15 show rare persistent areas of epithelium in WDs from these
animals and these were only detected in the caput region of the WD from a few fetuses.
Control DBP/F100 DBP/F100
Figure 6.15 Representative abnormalities in epithelia (immunostained for cytokeratin)
of rat Wolffian ducts (WD) from e18.5 and e21.5 fetuses. Note the reduction in epithelial
cell height seen after exposure to DBP (500 mgkg'1) + flutamide (100 mgkg'1) at both e18.5
and e21.5 (arrowhead). Note also the widened lumen seen in some WDs (*) compared to
the flattened lumen in others. Scale bars = 100 urn
6.3.3.6 Combined exposure to DBP + flutamide interrupts the basement
membrane
Laminin was immunolocalised to the basement membrane in WDs at all ages studied and at
e21.5, this laminin expression was interrupted by exposure to flutamide (100 mgkg"1) (see
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section 4.4.4.1). Exposure to DBP + flutamide together did not interrupt laminin expression
in the basement membrane at el8.5 but by e21.5, laminin expression was less defined and
was often absent (Fig. 6.16).
Control DBP/F100 DBP/F100
Figure 6.16 Laminin protein expression (immunostained brown) in the basement
membrane in WDs at e18.5 and e21.5. Note the defined 'ring' of laminin around the base
of the epithelium in control WDs at e18.5 and e21.5 (arrow). Exposure to DBP + flutamide
did not alter this laminin expression at e18.5 (arrow) but by e21.5, combined exposure to
DBP + flutamide resulted in interrupted laminin expression (arrowhead). Scale bar = 100pm.
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6.4 Discussion
In females, the WD naturally regresses during fetal life: this is believed to be due to a lack of
androgens (Huhtaniemi, 1994). However, little is known about the timing of or mechanisms
controlling WD regression in female rats. In our rat colony, a full length WD can still be
identified in female fetuses at el6.5, lying medial to the developing MD and lateral to the
ovary. This WD begins to regress between el6.5 and el8.5 in a cranio-caudal direction with
only the caudal segment still evident by el8.5. These timings agree with those previously
published (Stinnakre, 1975; Inomata et al, 1989; Jirsova and Vernerova, 1993). In vitro
testosterone assays confirmed that at el7.5, testosterone was present in the fetal testis but
was barely detectable in the ovary at el7.5. This agrees with previous studies which have
shown that throughout fetal life, plasma testosterone levels are at least 4 time higher in male
fetuses than in females, where plasma testosterone levels remained very low (Habert and
Picon, 1984). Conversely, androgen receptor (AR) protein was detected in the female WD at
all ages studied, indicating that it is capable of responding to androgens if they were
available. This highlights the bipotential fate of the WD in males and females.
Histological analysis revealed that female WD regression is, at least partially, due to both
apoptosis and a lack of proliferation in the regressing epithelium. This is in contrast to
findings in male WDs from rats exposed to flutamide in utero, in which apoptosis was not
evident and mitotic cells were still identified in the WD epithelium (discussed in chapter 3).
This observation of apoptosis in the regressing female WD is in agreement with previous
studies (Dyche, 1979; Jirsova and Vernerova, 1993; Roberts et al, 1999; Allard et al, 2000)
and suggests that the WD is undergoing active cell death in the female rather than simply not
differentiating as appears to be the case in flutamide-exposed WDs (see chapter 3).
Contrastingly, mitotic cells were evident in the stromal compartment of the regressing
female WD at all ages studied (e 16.5-18.5), even when the epithelium was no longer
apparent. It has been suggested that the mesenchymal cells from the regressing male MD
may migrate and thereafter contribute to the mesonenphros (Austin, 1995): a similar
phenomenon may occur in the regressing WD and might explain the persistence of cell
mitosis during WD regression. The present findings highlight the differences in the cellular
mechanisms involved in the natural regression of the female WD compared to those which
result in the abnormalities seen in flutamide-exposed male WDs. These differences are
likely to be due to differences in the level of androgen blockade with females having no
androgen action while flutamide, at the doses used in these studies, is unlikely to cause a
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complete blockade of androgen action and the residual low levels of androgen action appear
to be sufficient to prevent WD regression.
Apoptosis was evident in the regressing rat WD and MD, as previously shown by Donohoe
et al (Price et al, 1977). However, it has been suggested that apoptosis alone is not sufficient
to cause regression of the MD, epithelial-mesenchymal transformation is also reported to be
involved (Xavier and Allard, 2003). By el7.5, abnormalities in both gross morphology and
histology were evident in the regressing female WD, including flattening of epithelial cells,
narrowing and subsequent disappearance of the lumen, and interruption and loss of the
basement membrane. These findings agree with previously published studies investigating
WD (Jirsova and Vernerova, 1993) and MD (Dyche, 1979; Inomata et al, 1989; Austin,
1995; Magro and Grasso, 1995) regression, ft has been suggested in the MD that the loss of
basement membrane allows epithelial cells to protrude through into the mesenchymal
compartment and de-differentiate into mesenchymal-like cells (Trelstad et al, 1982). These
abnormalities mirror those noted in the flutamide-exposed WD at e21.5 (detailed in chapter
4) and suggest that during female WD regression, epithelial cells lose their attachment to the
basement membrane and lose their polarity. It has been suggested that these changes may
even be the trigger for these cells to enter apoptosis (Xavier and Allard, 2003).
Smooth muscle actin (SMA), an androgen responsive stromal differentiation marker (Schlatt
et al, 1993), was not detected in the stroma of the male WD until el 8.5 (section 4.4.2.2.1)
and, therefore was not available as a marker for studying stromal development in the
regressing female WD. Desmin, one of the earliest markers of mesenchymal differentiation
into muscle, was detected in the male WD stroma at all ages studied (el5.5-e21.5). Since
intermediate filaments are required not only to support cells but are also involved in signal
transduction from the cell membrane to the nucleus, it was hypothesised that desmin may
play a role in signal transduction in the developing WD (Alberts, 1994). Desmin was
expressed in the regressing female WD at all ages studied (el6.5-18.5), even in areas where
no epithelium or lumen was evident. This is consistent with findings in male WDs, in which
flutamide did not induce a reduction in desmin expression. This suggests that the
mesenchymal differentiation into muscle is at least partially independent of androgen action
in both male and female WDs.
Studies in the female fetal rat have therefore confirmed that, in the absence of androgens the
WD regresses and has almost entirely degenerated by el8.5. In order to further investigate
WD regression, pregnant rat dams were exposed to both Di-n-butyl phthalate (DBP; 500
mgkg"'), another anti-androgenic compound with a different mechanism of action than
flutamide. DBP reduces fetal testicular testosterone production by 70-90% (Fisher et al,
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2003; Lehmann et al, 2004) and results in impaired WD coiling at e21.5 in a similar manner
to that observed in flutamide-exposed animals (discussed in chapter 3). This phenotype is
consistent with previous studies (Barlow and Foster, 2003; Bowman et al, 2005). It is
assumed that this reduction in WD coiling is due to the decrease in testicular testosterone
production however it cannot be ruled out that DBP could directly affect the WD,
independent of testosterone action. Coiling was reduced to a lesser degree by DBP exposure
than by exposure to flutamide (100 mgkg"'): this difference is likely to be due to the different
mechanisms of action by each compound. It is likely that the fetal testis produces
testosterone in excess of the levels required for masculinisation, with the result that DBP-
induced reduction in testosterone production may not reduce the levels of androgen action as
greatly as exposure to flutamide does. Flutamide prevents testosterone binding to the AR
and since there are a limited number of cells expressing AR in the developing WD, this
mechanism is likely to have a greater impact on androgen action than interfering with
testosterone production, which is not in such a limited supply.
Like flutamide exposure (discussed in chapter 3), exposure to DBP also resulted in
incomplete WDs with segments of the corpus missing in 14% of animals studied at e21.5.
However, contrary to the increased incidence noted in flutamide-exposed animals after
puberty, the incidence of missing segments remained relatively constant in DBP-exposed
animals at later ages. The increased prevalence of epididymal abnormalities noted in
animals exposed to flutamide in utero was hypothesised to be due to a failure to establish
normal patterning of the WD in the fetus thus resulting in irrecoverable malformation of the
reproductive tract and likely impairment of fertility. However, it is likely that the low level
of testosterone still available after DBP-exposure is sufficient to activate AR dependent gene
expression and thereby induce androgen-dependent WD patterning. The abnormalities
reported here are in agreement with previous studies showing that DBP exposure results in a
high incidence of epididymal abnormalities (Mylchreest et al, 1998; Mylchreest et al, 1999;
Foster et al, 2000; Mylchreest et al, 2000; Foster et al, 2001; Barlow and Foster, 2003;
Bowman et al, 2005).
In order to investigate WD regression further, an in vitro model was sought to allow further
reduction of androgen action than exposure to flutamide or DBP alone, since neither induced
WD regression as occurs naturally in the female. Pregnant rats were therefore exposed to
both DBP (500 mgkg"1) and flutamide (100 mgkg"1) in combination (DBP + F100), resulting
in a more complete blockade of androgen action. At el 8.5, WDs from all DBP + F100-
exposed animals were morphologically intact, suggesting that AR-mediated signalling was
still not completely blocked fetally, thus allowing the WD to be rescued. In contrast, by
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e21.5 the male WD had almost entirely regressed in all DBP + F100 fetuses leaving only a
small segment of epithelium at the caput. It is likely that this region survives as it is the
region that is closest to the testis and therefore will benefit from delivery of testosterone
down the WD lumen. It was surprising that the WD appeared normal at el8.5, an age when
the female WD has almost entirely regressed, but had almost completely degenerated by
e21.5.
In order to investigate this phenomenon further, studies were undertaken in testicular
feminised (Tfm) mice, which allowed study of the effects of complete blockade of androgen
action on male WD development (Gehring and Tomkins, 1974; Murphy and O'Shaughnessy,
1991). These mice also exhibit reduced serum testosterone levels in adulthood as they are
known to be deficient in 17 alpha-hydroxylase, a key enzyme in steroidogenesis (Murphy
and O'Shaughnessy, 1991; Jones et al, 2003): fetal testosterone levels have not been
reported, however, fetal Leydig cells appear normal (personal communication with Prof.
Peter O'Shaughnessy). Previously, identification of adult Tfm male rats has relied upon coat
colour and the absence of any WD-derived tissues, therefore a genotyping assay is required
to identify Tfm fetal males. I am currently optimising this assay, which will entail allelic
discrimination using Taqman PCR and this will be used to confirm the findings reported in
this thesis. Gross morphological analysis revealed that at el6.5, all male littermates had
intact but relatively uncoiled WDs. This is in contrast to the normal female mouse in which
the WD has almost completely regressed by el6.5, with a lumen only evident at the caudal
end. These observations are in agreement with timings previously published (Tsuji et al,
1992; Staack et al, 2003). By el8.5, within one litter WDs from some males are
considerably convoluted whereas other males had only a WD remnant with no obvious
lumen or normal structure: these are presumed to be Tfm males but this requires
confirmation. It is not immediately clear why the WD would regress slower in these Tfm
males, which are devoid of a functional androgen receptor (He et al, 1991; Murphy and
O'Shaughnessy, 1991), than in normal females. Proven Tfm carrier dams were used in the
matings therefore at least some of the male offspring should be Tfm.
These findings in Tfm mice and DBP + F100 exposed rats raise the question of whether, in
the absence of high levels of androgen action, some other mechanism may be trying to
compensate to rescue the fetal male WD. If so, it would seem that this mechanism alone is
not sufficient to maintain the WD long term since, in both models the male WD ultimately
undergoes degeneration before birth. Possible candidates involved in this compensatory
mechanism are oestrogens, inhibins and/or Insulin-like factor (Insl3). Insl3 is believed to
play a role in testis descent (Nef and Parada, 1999; Emmen et al, 2000; Kumagai et al, 2002;
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McKinnell et al, 2005) and lnsl3 and its receptor, LGR8, have been shown to be expressed in
the developing WD (unpublished data and personal communication with Bernard Jegou).
Insl3 knockout mice show normal WD development (Adham et al, 2000), however these
mice have normal androgen action, therefore it is unknown what effect a lack of both
androgen and Insl3 action would have on the developing WD: this phenomenon requires
further investigation.
Tfm mice are the mouse equivalent of complete androgen insensitivity syndrome (CA1S).
CAIS patients are XY males but with female external genitalia (Tsuji et al, 1991; Ahmed et
al, 2000; Brinkmann, 2001; McPhaul, 2002; Quigley, 2002). Most evidence from CAIS
patients is postnatal (Hannema et al, 2004) with no definitive evidence published detailing
the status of the human fetal WD. It is therefore unclear whether in CAIS patients the WD
fails to stabilise completely during fetal life, as occurs normally in females, or whether the
absence of WD structures in later life results from 'post-differentiation' degeneration of
WD-derived tissues, as occurs in rats exposed in utero to flutamide. These preliminary
findings in male Tfm mice support the latter view but require further investigation.
The androgen receptor (AR) is normally expressed in the WD epithelium and surrounding
stroma by el8.5 and this expression pattern is not altered by exposure to flutamide (detailed
in chapter 4). AR was expressed normally in the stromal compartment in animals exposed to
DBP + F100 but was not detected in the epithelium at either el8.5 or e21.5. This lack of
epithelial AR expression may explain the degeneration of the WD by e21.5 as, in other
systems, epithelial AR is believed to be vital for tissue morphogenesis (Lang et al, 2001;
Cunha et al, 2004). These results also suggest that epithelial AR expression is dependent on
AR signalling from the stroma whereas stromal AR expression appears to be either
dependent on much lower levels or even independent of androgen action. However, in the
regressing female WD, AR can be detected in both the stroma and the epithelium raising the
question of what controls epithelial AR expression and whether AR expression and/or WD
set up are different in the male and female: this again brings into question the long standing
belief that the decision for the WD to regress or develop is solely dependent on androgen
action.
Exposure to DBP + F100 resulted in similar histological abnormalities at e21.5 as those
observed in both the regressing female WD and in the flutamide-exposed male WD,
including flattening of the epithelium, narrowing and loss of lumen and interrupted basement
membrane. These observations suggest that a similar mechanism is operating in each of
these models whereby androgen action is reduced compared to age matched male controls.
However, these abnormalities were not noted at el8.5, again suggesting that exposure to
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DBP + F100 does not interfere with WD stabilisation at el8.5 but results in later
degeneration by e21.5. This further highlights the possibility for a role for another
compensatory mechanism in the early male WD if androgen action is low.
As in both the flutamide-exposed male and the naturally regressing female WD, the most
obvious explanations for the loss of WD tissue in DBP + F100 males are an increase in cell
apoptosis and/or a decrease in cell mitosis. Mitotic cells were evident in DBP + F100-
exposed WDs at both el 8.5 and e21.5, however, the number of mitotic cells appeared to be
reduced compared to age matched control WDs, especially in the small remnant of
epithelium. This reduction was more apparent in the corpus and cauda than in the caput
where a lumen and epithelium were still evident. This suggests that reduced cell
proliferation may contribute to the loss of WD tissue after exposure to DBP + F100. On the
other hand, cleaved caspase 3 positive cells were rarely observed in these WDs at either
el8.5 or e21.5. This suggests that apoptosis was not involved, however, at el8.5 the WD
looks normal and by e21.5 the majority of the WD has already degenerated thus suggesting
we are studying the wrong time points. It is possible therefore that apoptotic cells would be
seen in DBP+F100 WDs at el 9.5 or e20.5, especially since apoptotic bodies could be
identified in the degenerating WD at e21.5.
6.5 Conclusion
It can be seen from these studies that the female WD regresses in rats between el6.5-el8.5.
This regression is due to both apoptosis and a lack of proliferation in the WD epithelium.
This is in contrast to male WDs from fetuses exposed to flutamide in utero in which
apoptosis was not detected and proliferation is still apparent in both the epithelium and the
stroma, but at a reduced level compared to age matched controls. This again highlights that
flutamide does not induce regression of the male WD but prevents its subsequent
differentiation. Disruption to the ECM and basement membrane were evident in both the
naturally regressing female WD and in flutamide-exposed male WDs; it cannot easily be
distinguished whether these disruptions induce the abnormalities seen in the WD in both
these models or if they occur as a result of the disturbed WD development.
Studies in both Tfm mice and rats exposed to DBP and flutamide in combination (DBP +
F100) again highlight the essential role for high levels of androgen action in WD
stabilisation and development; however, since the early WD does not regress at the same age
as occurs naturally in the female, this raises the question of whether another factor may be
trying to compensate for the great reduction in or absence of androgen action. This
phenomenon warrants further investigation.
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7 Rescue of the female WD by exogenous testosterone exposure
7.1 Introduction
As discussed in chapter 6, regression of the female rat WD occurs between el 6.5-18.5 due to
a lack of androgens. However, the studies in Tfm mice and rats exposed to DBP + flutamide
in combination raised the question of whether androgens alone were acting to stabilise the
male WD or whether some other compensatory factor may play a role in rescuing the male
WD. The experiments detailed in this chapter will address this question and examine
whether exposure to exogenous androgens during gestation is sufficient to rescue the female
WD.
Evidence from clinical observations suggests that the female fetus is vulnerable to
masculinisation by androgen exposure (discussed in section 1.5.3.1). For example, fetuses
with congenital adrenal hyperplasia (CAH) have an increased production of adrenal
testosterone resulting in masculinisation of the external genitalia in the female fetus
(reviewed in Merke and Bornstein, 2005). However, it is worth noting that these patients do
not tend to have masculinised WD-derived structures: this is likely to be due to a lack of
sufficient levels of local androgens as these patients are exposed to systemic androgens
(section 1.5.3.1).
The ability of androgens to masculinise the female fetus is further substantiated by evidence
gained from experiments in which animals have been exposed to exogenous androgens
during fetal life (section 1.5.3.2). Exposure to exogenous androgens during gestation can
elicit varying degrees of masculinisation in the female offspring, depending on the level and
timing of exposure (Swanson and Werff ten Bosch, 1965; Ogawa and Nozawa, 1969; Jost et
al, 1973; Stinnakre, 1975; Wolf et al, 2002; Wolf et al, 2004). This is not surprising since
the regressing female UGT expresses ARs, highlighting its capability to respond to
androgens (Chapter 6; Bentvelsen et al, 1995). The timing of testosterone exposure is
critical for masculinisation of female fetuses: for example, in order to rescue the female WD,
testosterone exposure must commence prior to el8 in rats, by which time the female WD has
committed to regress (Swanson and Werff ten Bosch, 1965; Ogawa and Nozawa, 1969;
Stinnakre, 1975). Previous studies have suggested that the female external genitalia are the
most sensitive structures to the effects of testosterone with rescue and differentiation of the
female WD requiring higher levels of testosterone (Greene, 1939; Swanson and Werff ten
Bosch, 1965; Ogawa and Nozawa, 1969; Stinnakre, 1975; Wolf et al, 2002). However,
considerable variation can be seen in the dose of testosterone exposure required to rescue
and differentiate the female WD: Wolf and colleagues (2002) were unable to rescue the WD
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in female Sprague-Dawley rats, even with 10 mg/rat testosterone propionate between el4-19
(total dose 60 mg) whereas this dose caused masculinisation of the external genitalia.
However, Greene and colleagues (1939) noted that exposure to high doses of testosterone
(80-90 mg total dose) in Wistar rats was not only able to completely rescue the WD but
could stimulate some degree of coiling of the epididymis while lower testosterone doses
(13.5 - 40 mg total dose) could often only rescue the WD unilaterally with the adult derived
structures were often incomplete and lacked patent lumens. Unfortunately, the phenotype of
these rescued WDs is merely described without any quantitative data or images, so that
direct comparisons cannot be made with the normal male WD-derivatives. Further
investigation is therefore required to clarify the dose and timing of testosterone exposure
required to masculinise the female WD and the degree of differentiation that can be initiated.
7.1.1 Aims
To examine the impact of exogenous gestational testosterone exposure on fetal development.
To investigate if exogenous gestational testosterone exposure is sufficient to rescue and
differentiate the female WD in rats.
To investigate if testosterone acts during the same critical window to rescue the female WD
as it does to stabilise the male WD, as discussed in chapter 5.
To investigate it concomitant flutamide exposure can block the effects of exogenous
testosterone exposure.
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7.2 Methods
7.2.1 In utero treatments
As detailed in section 2.2, pregnant dams were randomly allocated to the various treatment
groups detailed below and dosed once daily according to maternal bodyweight between
el4.5-e2l.5, or until the day prior to cull if this was before e2l.5. This window of exposure
was selected to begin just before the onset of endogenous androgen production in fetal males
at el5.5 and the period of fetal male reproductive development (e15.5-21.5) according to
Warren et al (1972). The dose of flutamide was selected based on results previously
reported in chapters 3 and 4 highlighting that fetal exposure to flutamide induced
reproductive tract abnormalities in both fetal life and adulthood. The doses of testosterone
propionate (TP) used were selected based on previous results showing that doses above 1 mg
TP (per rat) increased female fetal testosterone by 80%, increased female anogential
distance (AGD) and rescued the seminal vesicles without a high incidence of toxicological
effects (Wolf et al, 2002).
Testosterone propionate (T5): 5 mgkg"1 TP in 0.4 ml corn oil, e 14.4-21.5 (n=6 litters)
subcutaneous injection at 0.4 mlkg"' maternal bodyweight
Testosterone propionate (T20): 20 mgkg"1 TP in 0.4 ml corn oil, subcutaneous (s.c) injection
Throughout this chapter, offspring from dams treated while pregnant will be referred to, for
example, as "testosterone-exposed" or treated "in utero". This does not mean that fetuses
were exposed directly but rather were exposed indirectly via their mother.
Preliminary studies and previous literature (Wolf et al, 2002; Wolf et al, 2004) suggested
that exposure to testosterone resulted in problems with labour and a high incidence of fetal
mortality. Therefore, if dams were to give birth to pups for postnatal examination, control
Control:
Flutamide:




lOOmgkg"' in 1ml corn oil/2.5% DMSO, el5.5-21.5 (n=10)
gavage at 1 mlkg"' dam bodyweight
lml corn oil/2.5% DMSO, el 5.5-21.5 by gavage
0.4 mlkg"' corn oil, el4.5-21.5 by s.c injection (n=4)
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pregnancies were mated on the same day to provide a foster mum for the testosterone-
exposed pups if the dam could not litter normally and required the fetuses to be removed by
caesarean section. In such instances the control pups were removed from the dam within
hours of birth and replaced with the testosterone-exposed pups. No obvious differences were
seen in the reproductive tracts of offspring reared by their biological mother compared to
those reared by a foster mother.























Figure 7.1 Summary ofmaternal treatment regimes
7.2.2 Tissue collection
Dams were killed by inhalation of carbon dioxide and subsequent cervical dislocation and
fetuses were recovered at el8.5 and e21.5 and killed by decapitation. Postnatal animals,
older than pndlO, were killed by inhalation of carbon dioxide and subsequent cervical
dislocation. Fetal and postnatal animals were weighed and AGD was measured using digital
callipers. Reproductive tracts were recovered by microdissection and photographed using a
Leica ICA camera (section 2.3.2.1). Reproductive tracts were analysed microscopically, at
the time of dissection, for any gross morphological abnormalities, and tissue was fixed in
Bouin's, as detailed in section 2.4. Fetal testes (e21.5) were weighed by members of Prof.
Richard Sharpe's lab group, for which I am grateful.
Chapter 7 Wolffian duct rescue by exogenous testosterone 215
7.2.3 Luminal length analysis
Differentiation of el8.5 and e21.5 WDs was quantified by digitally measuring the luminal
length of the epididymal segment of WDs from control and treated animals, as described in
section 2.8.
7.2.4 Immunohistochemistry
Immunohistochemistry was performed on isolated rat reproductive tracts fixed in Bouin's,
using standard avidin peroxidase protocols in order to highlight the location of proteins of
interest, as detailed in section 2.6.1. Briefly, sections were cut from paraffin blocks and
mounted on glass slides. Sections were then dewaxed and rehydrated then pressure cooked
in citrate buffer if required (Table 7.1). Non-specific binding was blocked before adding the
appropriate primary antibody overnight, as detailed in Table 7.1. A biotin labelled secondary
antibody was used that had been raised against a species-specific sequence on the primary
antibody. This biotinylated secondary antibody signal was amplified by incubation with
avidin-biotin conjugated with horseradish peroxidase and the signal was localised using
DAB. Sections were counterstained with haematoxylin and mounted with glass coverslips.
Further detailed protocols can be found in section 2.6.1.
Table 7.1 Summary of primary antibodies used for immunohistochemistry
Target Antigen Source Dilution Retrieval Host Species
Androgen Receptor Santa Cruz 1:50 Citrate Rabbit
Smooth Muscle Actin Sigma 1:10000 None Mouse
Pan-cytokeratin Sigma 1:200 Citrate Mouse
Desmin DAKO 1:400 Citrate Mouse
7.2.5 Analysis of apoptosis
Cleaved caspase 3 immunostaining was performed on WDs using standard methods, as
detailed in section 2.6.1, to stain for apoptotic cells. Very few cleaved caspase 3 positive
cells were detected, therefore a detailed stereological analysis was not appropriate and all
positive cells were manually counted in each WD using an Axiolab microscope (Carl Zeiss
Ltd, Hertfordshire, UK).
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7.3 Results
7.3.1 Effects of testosterone exposure
Due to time restraints and in an attempt to reduce the number of animals used, not all
endpoints were examined for all animal models discussed. All endpoints were examined
using WDs from litters exposed to high dose testosterone (T20, 20 mgkg"', el4.5-21.5) as
these WDs were most likely to highlight any low incidence phenotype, rather than those
exposed to lower dose testosterone or testosterone-exposure within shorter windows.
7.3.1.1 Effects of testosterone on dam weight
Exposure to low (T5 - 5 mgkg1) or high (T20 - 20 mgkg"1) doses of testosterone resulted in
a reduction in maternal weight gain at el8.5 and e21.5, compared to controls and relative to
bodyweight at el5.5 (Fig. 7.2): this reduction in dam weight gain was comparable in the high
and low dose testosterone groups. Exposure to flutamide (100 mgkg"1) also resulted in a
small, but non-significant, reduction in dam weight gain: this reduction was enhanced by
combined exposure to flutamide (100 mgkg"1) and testosterone (20 mgkg"1) but this was less
than that seen after exposure to testosterone alone suggesting that flutamide offers some
degree ofprotection against the growth restriction effects of testosterone (Fig. 7.2).
C FI00 T5 T20 C F100 T5 T20 T20 +
F100
e!8.5 e21.5
Figure 7.2 Maternal % weight gain at e18.5 and e21.5, relative to bodyweight at e15.5.
Note the reduction in weight gain in dams exposed to low (T5, 5 mgkg'1) or high (T20, 20
mgkg'1) doses of testosterone: this reduction was still seen in dams exposed to testosterone
(20 mgkg'1) and flutamide (100 mgkg'1) together. There was also a trend for reduced weight
gain in dams exposed to flutamide (100 mgkg'1) during pregnancy, but this was not
significant. Values are means ± S.E.M for 3-8 animals per group. * p<0.05, *** p<0.001,
compared to age matched controls.
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7.3.1.2 Effects of maternal testosterone exposure on pup weight
At e21.5, there was a significant decrease in fetal bodyweight after exposure to either low
(T5, 5 mgkg"1) or high (T20, 20 mgkg"1) doses of testosterone, compared to age matched
controls (p<0.01). This reduction in bodyweight was seen in both female and male fetuses
from litters exposed to testosterone throughout reproductive development (el4.5-21.5) or
during short defined windows early in WD development (el4.5-15.5 or el4.5-17.5)
(Fig.7.3). Fetuses exposed to flutamide (100 mgkg"1) and testosterone (20 mgkg"1) in
combination also had reduced bodyweight at e21.5, though thus reduction tended to be
slightly less than that observed in fetuses exposed to testosterone alone (Fig.7.3).
e14-15 el4-17 F100 el4-15 el4-17 F100
Male Female
Figure 7.3 Bodyweight at e21.5 in male (blue bars) and female (pink bars) fetuses from
control, high dose flutamide (100 mgkg'1), low dose testosterone (T5, 5 mgkg'1) or high
dose testosterone (T20, 20 mgkg'1) litters. Note that bodyweight was reduced in male and
female fetuses exposed to testosterone either alone or in combination with flutamide (T20 +
F100), compared to sex matched controls. Note also that bodyweight was reduced only in
male fetuses from litters exposed to flutamide (100 mgkg'1), not in female fetuses. Values
are means ± S.E.M for 9-28 animals per group. p<0.05, *** p<0.001, compared to sex
matched controls.
By pndl7, no significant difference was seen in bodyweight of males or females that had
been exposed to testosterone (20 mgkg"1) in utero, compared to age matched controls (data
not shown).
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7.3.1.3 Effects of maternal testosterone exposure on fetal reproductive
tract
7.3.1.3.1 Anogenital distance
Normally, fetal sex can be determined externally by the distance between external genitalia
and the anus (anogenital distance; AGD), with AGD significantly larger in fetal males than
in females (Fig. 7.4). Maternal exposure to either dose of testosterone (5 or 20 mgkg"1), had
no significant effect on anogenital distance (AGD) in male fetuses at e21.5 but increased
female AGD to a length similar to that seen in control male fetuses (Fig. 7.4). This increase
was noted in females exposed to testosterone throughout fetal reproductive development
(el4.5-21.5) and those exposed to testosterone only during a short early window in
development (el4.5-15.5 or el4.5-17.5) (Fig. 7.4). As discussed in chapter 3, exposure to
flutamide (100 mgkg"1) reduced male AGD to a length comparable to that of control females;
exposure to flutamide (100 mgkg"1) in combination with testosterone (20 mgkg"1; T20 +
F100) completely prevented the testosterone-induced increase in AGD in female fetuses and
induced a reduction in male AGD, equivalent it that seen after exposure to flutamide alone
(Fig.7.4).
C F100 T20 T20 T20 T20 + C F100 120 HO 120 T20 +
el4-15 el4-17 F100 el4-15el4-17 F100
Male Female
Figure 7.4 Anogenital distance (AGD) in e21.5 male (blue bars) and female (pink bars)
fetuses from control, high dose maternal flutamide (100 mgkg'1) and high dose
testosterone (20 mgkg'1) litters. Note that AGD was significantly smaller in control female
fetuses than in males. AGD was reduced in male fetuses exposed to flutamide alone or in
combination with testosterone (T20 + F100) compared to control males. AGD was increased
in females exposed to all doses of testosterone to a length comparable to control male AGD.
Note also that maternal exposure to flutamide did not alter female AGD (p>0.05), even in
combination with testosterone (T20 + F100). Values are means ± S.E.M for 5-23 fetuses. ***
p<0.001 compared to sex matched control AGD, a p<0.001 compared to control male AGD.
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AGD continued to be significantly smaller in control females than males at pndl7 (p<0.05):
exposure to testosterone (5 or 20 mgkg"1) during gestation permanently increased AGD in
both males (p>0.05) and females (p<0.001) resulting in testosterone-exposed female AGD
being comparable to that in a control male (p>0.05) (data not shown).
7.3.1.3.2 Prostate development after exposure to testosterone
Analysis of prostate morphology in these studies was guided by Dr Axel Thomson, for
which I am grateful. Due to time constraints, this was only analysed in animals exposed to
testosterone (5 or 20 mgkg"1) for the entire period of fetal reproductive development (el 4.5-
21.5).
The prostate begins to bud and develop in male rats at around el8.5: at this age prostatic
buds could be identified in females from testosterone-exposed litters (5 or 20 mgkg"') (data
not shown). These prostates were not highly developed and resembled prostates from el8.5
control males. At this age, a pad of inductive mesenchyme can be identified in control
females but no epithelial buds can be distinguished (Timms et al, 1995; Thomson et al,
2002).
In males, the dorsolateral lobe of the prostate develops first with the ventral prostatic lobe
budding later in fetal life. By e21.5, budding/branching could be seen in the dorsolateral
prostate in some low dose testosterone-exposed females: the extent of this development
varied between individuals with some prostates clearly branched while others showed no
sign of budding (data not shown). Contrastingly, all females from litters exposed to 20
mgkg"1 testosterone had highly masculinised prostates with budding evident in both the
dorsolateral and ventral prostates (Fig. 7.5). These female prostates were not as developed
as control male prostates at e21.5 and were estimated to be approximately 1-2 days behind
male development.
The prostates from e21.5 male fetuses from both low and high dose testosterone groups were
highly developed and masculinised: it is difficult to say objectively whether these prostates
were more developed than their age matched controls, but they were at the upper end of the
scale of normal development (data not shown).






Figure 7.5 Representative urogenital sinus region from an e21.5 female testosterone-
exposed (5 mgkg'1) fetus. Note the presence of seminal vesicles (s.v) and both dorsal and
ventral prostatic lobes. Note also the presence of epithelial budding in the dorsal prostate.
7.3.1.3.3 Testosterone exposure prevented normal vaginal development
By e21.5, the vagina develops in control females distal to the cervix, alongside the urethra
but females exposed to testosterone (5 or 20 mgkg"1) had no obvious vaginal opening (data
not shown). There were no obvious abnormalities in the uteri in these animals (data not
shown).
7.3.1.3.4 Development of seminal vesicles after testosterone exposure
Seminal vesicle development can be seen in male fetal rats around el 8.5 by the presence of a
mesenchymal bud. This was noted in females at el8.5 after exposure to both low (5 mgkg"1)
and high (20 mgkg"1) dose testosterone but no obvious epithelium was detected, as in age
matched males (data not shown). By e21.5, this seminal vesicle mesenchymal bud was still
apparent in testosterone-exposed females (5 or 20 mgkg"1) with epithelia evident in some
females, particularly from the high dose testosterone litters (Fig. 7.6). No obvious difference
was noted in the appearance of the seminal vesicles in testosterone treated males compared
to their age matched controls at el8.5 or e21.5 (data not shown).
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Figure 7.6 Representative urogenital tract from an e21.5 female testosterone-exposed
(20 mgkg'1) fetus. Note the presence of seminal vesicles (*) as well as both the MD
(arrowhead) and WD (arrow).
7.3.1.3.5 Testosterone exposure alters the position of the ovary
In control females, the ovary is located at the cranial/lateral edge of the kidney at both el 8.5
and e21.5. In testosterone-exposed females, the ovary was situated slightly lower at the
more caudal pole of the kidney compared to control females; however, the ovary did not
descend into the lower abdomen as the testis does by e21.5 in males (data not shown). This
apparent descent was not quantified.
7.3.1.3.6 Impact of testosterone exposure on the testis
Exposure to testosterone (20 mgkg"1) resulted in an average 25% reduction in testis weight at
e21.5 compared to age matched controls (p<0.0001). This is likely to be due to a reduction in
the number of Sertoli cells in these testes (data not shown).
7.3.2 Effects of testosterone exposure on WD development
7.3.2.1 Fetal Wolffian duct
At el8.5 the male WD is a simple straight duct which becomes highly coiled by e21.5
(Fig.7.7 and 7.8). Exposure to testosterone (5 or 20 mgkg"1) either during the entire window
of fetal reproductive development (el4.5-21.5) or during short defined periods early in WD
development (el4.5-15.5 or el4.5-17.5) had no obvious impact on male WD development at
either el8.5 or e21.5 (Fig. 7.7 and 7.8). As detailed in chapter 3, exposure to flutamide (100
mgkg"1) reduced the coiling normally seen in the male WD by e21.5 (Fig. 7.8) and exposure
to testosterone (20 mgkg"1) in combination with flutamide did not prevent this impaired
coiling in male WDs at e21.5 (Fig. 7.8).
Chapter 7 Wolffian duct rescue by exogenous testosterone 222
In normal females, the WD has almost completely regressed by el8.5, with only a small
remnant evident at the cauda (Fig.7.7 and section 6.4.1.1). At el8.5 and e21.5, WDs were
identified in many females exposed to both high (20 mgkg"') and low (5 mgkg"1) doses of
testosterone (Fig. 7.7 and 7.8): these complete WDs were noted in all e21.5 females exposed
to 20 mgkg"1 testosterone (Fig. 7.10) and even showed some degree of coiling, although this
was much less than that seen in control male WDs by e21.5 (Fig. 7.8). Variation was seen in
the female WD morphology after exposure to 5 mgkg"1 testosterone at both el8.5 and e21.5
(Fig. 7.7 - 7.10): in 25% of animals no WD was seen, in 53% of fetuses the WD could only
be identified at the caput while in the remaining 22% a full length WD was noted, with
coiling even evident at the caput and cauda (Fig. 7.7 - 7.10). Exposure to testosterone (20
mgkg"1) within short defined windows early in WD development (e 14.5-15.5 or el4.5-17.5)
also rescued the female WD in some animals and was even able to stimulate coiling by
e21.5, particularly at the caput (Fig 7.7 and 7.10). However, exposure to flutamide (100
mgkg"1) in combination with testosterone (20 mgkg"1) prevented this WD rescue and, in this
treatment group, no WD was identified in any female examined at e21.5 (Fig. 7.7 and 7.10).
Male





Figure 7.7 Representative WDs from e18.5 male and female control, flutamide-exposed
(F100, 100mgkg'1) and testosterone-exposed (T5, 5 mgkg'1 or T20, 20 mgkg'1) fetuses.
Note that no obvious difference can be seen in the male WD after exposure to flutamide or
testosterone (arrow, top row). Note also that no WD can be seen in the control female at
e18.5 whereas in testosterone-exposed females (arrow, T5 or T20) the WD can be clearly
identified lying medial to the MD (arrowhead). All images are at the same magnification. T
- testis, O - ovary
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Figure 7.8 Representative WDs from e21.5 male and female control, flutamide-exposed
(F100, 100mgkg'1) and testosterone-exposed (T5, 5 mgkg'1 or T20, 20 mgkg'1) fetuses.
Note that the male WD (arrow) was highly coiled at e21.5 and this was not affected by
exposure to either dose of testosterone within any time window. Flutamide exposure
inhibited this coiling in male WDs at e21.5 and testosterone was not able to rescue this effect
(T20 + F100). Note also that at e21.5, no WD was evident in the female but a full WD
(arrow) was evident medial to the MD (arrowhead) in females after exposure to testosterone.
Exposure to flutamide in combination with testosterone (T20 + F100) prevented this rescue





















Figure 7.9 Prevalence and morphology of WDs at e18.5 in male and female control and
testosterone-exposed (T5, 5 mgkg'1 or T20, 20 mgkg'1) fetuses. Note that a complete
WD was identified in all control males whereas in 25% of control female fetuses no WD was
identified, a complete WD was noted in 22% and in 53% an incomplete WD was seen. After
exposure to testosterone (T5 or T20), the majority of females had a complete WD. Values
are means for 3 litters per group.
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Figure 7.10 Prevalence and morphology of WDs at e21.5 in male and female control
and testosterone-exposed (T5, 5 mgkg'1 or T20, 20 mgkg'1) fetuses. Note that a
complete WD was seen in all control males but no WD was seen in any control female
examined. Exposure to 20 mgkg'1 testosterone between e14.5-21.5 rescued the WD in all
females whereas exposure to 5 mgkg' 1 only partially rescued the WD in some females.
Note however that WDs were only identified in some females after exposure to testosterone
(20 mgkg'1) between e14.5-15.5 or between e14.5-17.5. Note that exposure to flutamide
(100 mgkg'1) in combination with testosterone (T20 + F100) prevented the testosterone-
induced rescue of the female WD. Values are means for 3 litters per group.
These qualitative observations regarding the impact of testosterone exposure on the male
WD were quantified by measuring the length of the WD lumen. At el8.5, no significant
difference was noted in the luminal length of the male WD after exposure to flutamide (100
mgkg"1) or testosterone (T5, 5 mgkg"1 or T20, 20 mgkg"1), compared to age matched controls
(Fig.7.11). Furthermore, there was no significant difference in the luminal length of the
testosterone-exposed (20 mgkg"1) female WD compared to the male control WD (Fig.7.11).
Quantification of luminal length confirmed the reduction in WD coiling at e21.5 in males
exposed to flutamide (100 mgkg"1) alone or in combination with testosterone (T20 + F100,
20 mgkg"1) , compared to age matched controls (Fig. 7.12). Exposure to 5 or 20 mgkg"1
testosterone had no significant impact on male WD luminal length at e21.5 (Fig. 7.12). It is
worth noting that the luminal length of the female testosterone-exposed (20 mgkg"1) WD was
significantly reduced compared to both the control and testosterone-exposed male WD
(Fig.7.12).
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Figure 7.11 Quantification of coiling (= luminal length) of e18.5 WDs from control,
flutamide-exposed (100 mgkg'1) and testosterone-exposed (T5, 5 mgkg'1 or T20, 20
mgkg'1) male (blue bars) and female (pink bar) fetuses. Note that no significant
difference was seen in male or female WD luminal length after exposure to flutamide or
testosterone, compared to luminal length of male control WDs (solid blue bar). Values are
mean ± S.E.M for 10-21 WDs.
p<0.001
1.2-
Contol F100 TS T20 T20+F100 T20
Male Female
Figure 7.12 Quantification of coiling (= luminal length) of e21.5 WDs from control,
flutamide-exposed (100 mgkg'1) and testosterone-exposed (T5, 5 mgkg'1 or T20, 20
mgkg'1) male (blue bars) and female (pink bar) fetuses. Note that exposure to flutamide
alone (F100) of in combination with testosterone (T20 + F100) significantly reduced male
WD luminal length compared to control males. Exposure to 5 or 20 mgkg'1 testosterone (T5
or T20) had no impact on male WD luminal length. Note also that testosterone-exposed
female WD luminal length was significantly shorter than both control and testosterone-
exposed (20 mgkg'1) male WDs. Values are mean ± S.E.M for 11-30 WDs.* p<0.05, ***
p<0.001, compared to male control WD luminal length.
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7.3.2.2 Postnatal WD-derived tissues
The epididymis and vas deferens did not appear obviously different in the postnatal male
(pndl7, 42 or 70) after exposure to testosterone (5 or 20 mgkg"1) during gestation, compared
to age matched controls (data not shown).
Epididymides/vasa deferentia could still be clearly identified in many of the testosterone-
exposed (5 or 20 mgkg*1) postnatal females (pndl7, 42 and 70). Some degree of coiling
could be seen in many epididymides but they were considerably underdeveloped compared
to age matched control male epididymides and were incomplete in several females, (data not
shown).
Upon histological analysis, it was clear that these testosterone-rescued postnatal female WDs
were organised into the same compartments as those seen in the normal male WD (discussed
in chapter 4). Cross sections of epithelium were seen, highlighting the coiling seen in
regions of the female rescued WD: these were surrounded by rings of smooth muscle while
the stroma more distant to the epithelium was negative for smooth muscle actin (SMA) (Fig.
7.13).
Figure 7.13 Representative WDs from pnd17 females exposed to exogenous maternal
testosterone in utero (20 mgkg'1) immunostained for smooth muscle actin (SMA, blue),
cytokeratin (green) and androgen receptor (AR, red) to highlight the different cellular
compartments. Note in A that the WD (arrow) can be seen lying alongside the developing
uterus (arrowhead). Several cross sections of epithelium (immunostained green) can be
identified in panel B, highlighting the coiling seen in the caput of the female rescued WD.
Note also the smooth muscle ring in the stroma immediately adjacent to the epithelium in the
female testosterone-rescued WD.
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7.3.3 Histology of Wolffian ducts exposed to exogenous maternal
testosterone
7.3.3.1 Prevalence of apoptosis in testosterone-exposed WDs
As in control male WDs, apoptotic cells were rarely detected in either the epithelial or
stromal compartments ofWDs from male or female testosterone-exposed (20 mgkg"1) fetuses
at e21.5 (data not shown).
7.3.3.2 AR expression in testosterone-exposed WDs
The androgen receptor (AR) protein was immunolocalised to both stromal and epithelial cell
nuclei in the male WD at e21.5: this expression pattern was not obviously altered by
testosterone-exposure (Fig. 7.12). In the control female, AR was also immunolocalised to
the stroma and epithelium at el8.5 (section 6.4.1.3). It is not surprising therefore that AR
was expressed in the stroma and epithelium of the female testosterone-exposed WD at e21.5
but not in the MD (Fig. 7.14).
Control Male T20 Male T20 Female
Figure 7.14 Immunoexpression of androgen receptor (AR) in the WD of male and
female control and testosterone-exposed (T20, 20 mgk'1) fetuses at e21.5. Note the AR
expression (brown) in the epithelium (arrow) and stroma (*) in control male and testosterone-
exposed male and female WDs while the female MD (arrowhead) is immuno-negative for
AR. Scale bar = 100 pm
7.3.3.3 Presence of epithelium in testosterone-exposed female WDs
Immunohistochemistry for cytokeratin, an epithelial cell marker, highlighted the presence of
an apparently normal epithelium in the testosterone-exposed female WD at e21.5 (Fig. 7.15):
the presence of several epithelial cross sections in regions of these WDs was indicative of the
coiling seen during gross analysis (as discussed in section 7.3.1.4.2).




Figure 7.15 Representative e21.5 WDs from control and testosterone-exposed (T20, 20
mgkg'1) males and females immunostained for cytokeratin (brown). Note the presence
of epithelium in the testosterone-exposed female WD (arrow), lying medial to the MD
(arrowhead). This epithelium seemed comparable to that seen in both control and
testosterone-exposed male WDs (arrow).
7.3.3.4 SMA expression in testosterone-exposed WDs
Immunoexpression of smooth muscle actin (SMA), a marker of smooth muscle
differentiation, was evident in the stromal cells immediately adjacent to the epithelium in
control e21.5 male WDs: this expression was not altered in the male WD by exposure to
testosterone (20 mgkg"') (Fig. 7.16). SMA was similarly expressed in the stroma of female
testosterone-exposed WDs at e21.5 (Fig.7.16).
T20 FemaleT20 Female
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Control Male T20 Male T20 Female
Figure 7.16 Immunoexpression of smooth muscle actin (SMA) in the stroma in control
male and testosterone-exposed (T20, 20 mgkg'1) male and female WDs. Note that SMA
is strongly expressed in the stroma immediately adjacent to the epithelium in control and
testosterone-exposed male WDs as well as in female testosterone-exposed WDs (arrow).
Note however that the stroma surrounding the MD (arrowhead) is negative for SMA. All
images are at the same magnification.
7.3.3.5 Desmin expression
Desmin was expressed in the stromal compartment of the control male WD at el 5.5-21.e (as
discussed in section 4.4.3.2) and was detected by immunohistochemistry in the stroma of
both male and female testosterone-exposed (20 mgkg"1) WDs at e21.5 (Fig. 7.17).
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Figure 7.17 Desmin expression in control male and testosterone-exposed (20 mgkg'1)
male and female WDs at e21.5. Note that desmin in expressed in the WD (arrow) stroma
and is not obviously altered by exposure to testosterone. Note also that desmin can be
weakly immunolocalised to the stroma surrounding the MD (arrowhead).
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7.4 Discussion
As discussed in chapter 6, the female rat WD regresses between el6.5-18.5 and this is
believed to be due to the lack of androgens. However, studies in Tfm mice and rats exposed
to DBP and flutamide in combination raised the question of whether androgens alone were
acting to stabilise the male WD and whether some other compensatory factor may play a role
in rescuing the male WD. Studies were therefore undertaken to investigate whether
exposure to exogenous androgens during gestation was sufficient to rescue the female WD or
whether unknown testicular factors may also be required in male WD development.
Previous studies have shown that exposing pregnant rats to various doses of testosterone
masculinises the female offspring to varying degrees (Jost et al, 1973; Stinnakre, 1975; Wolf
et al, 2000; Wolf et al, 2002; Padmanabhan et al, 2006). However, little is known about the
ability of exogenous testosterone to rescue the female WD. Pregnant rats were exposed to
testosterone propionate (5 or 20 mgkg"1) throughout the period of fetal reproductive
development (e 14.5-21.5) and various endpoints were examined. The only obvious effect
noted in the male fetal reproductive tract was that fetal testes were significantly smaller at
e21.5, compared to age matched controls. This is in agreement with previous studies (Wolf
et al, 2002). Development and differentiation of the male WD was not dramatically affected
by exposure to exogenous testosterone, with coiling not initiated any earlier, suggesting
therefore that the initiation ofWD development is not dependent by the level of testosterone
available. Contrastingly, female fetal reproductive development was dramatically altered by
maternal exposure to exogenous testosterone. In testosterone-exposed female fetuses AGD
was increased to a length similar to control males, prostatic buds developed where the vagina
would normally develop, seminal vesicles were apparent, the WD was rescued, and the
ovary appeared slightly more descended. These findings agree with previous studies
highlighting that exogenous testosterone alone is capable of masculinising the female fetus
(Greene, 1939; Swanson and Werff ten Bosch, 1965; Ogawa and Nozawa, 1969; Stinnakre,
1975; Wolf et al, 2002; Manikkam et al, 2004; Wolf et al, 2004; Padmanabhan et al, 2006).
Furthermore, the WD was not only rescued in females exposed to maternal testosterone (5 or
20 mgkg"1) but some degree of differentiation and compartmentalisation occurred, as seen by
the initiation of coiling at the epididymal caput in particular by e21.5 while the prospective
vas deferens remained straight. By this age all normal female WDs had completely
regressed (discussed in chapter 6), therefore confirming that exposure to testosterone alone,
between e 14.5-21.5, is sufficient to stabilise and even partially differentiate the female WD.
It is worth noting however that coiling was never as dramatic in the testosterone-exposed
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female WD as that seen in control male WDs by e21.5. There are various explanations for
this. Firstly, it is possible that the doses of testosterone given in this study were not
sufficient to stimulate coiling fully and that dosing with an even higher level of testosterone
propionate, or even with the more potent androgen DHT, may result in more dramatic
coiling in the female rescued WD similar to that seen in the normal male. This hypothesis is
supported by results reported in chapter 3, highlighting that exposure to 100 mgkg"1
flutamide did not prevent stabilisation of the male WD but was able to inhibit its subsequent
coiling, thus suggesting that higher levels of testosterone were required for differentiation
than that needed for WD stabilisation in the male. Bentvelsen and colleagues (1995)
exposed pregnant rats to DHT and as expected this was able to rescue the female WD,
however, they do not mention the degree of coiling initiated in these studies. It is difficult to
compare the levels of testosterone used in many previous studies as they often express
testosterone doses per rat rather than by dam weight but it is fair to claim that the doses of
testosterone used in this thesis are not significantly different from previous studies. It is
worth noting however that Greene and colleagues (1939) reported that higher doses of
testosterone did elicit a greater degree of epididymal coiling but images are not provided to
allow comparisons with the coiling reported in this thesis.
Secondly, the female rescued WD may be physically prevented from fully coiling due to the
presence of the normal MD situated lateral to the WD in females. Alternatively, it may be
that testosterone needs to be directly delivered down the lumen of the WD, rather than via
systemic exposure. Male WDs are exposed to high levels of testosterone delivered directly
to the epithelium down the lumen from the testis, possibly resulting in the epithelium being
exposed to greater levels of testosterone than the more distal stroma. It is arguable that, in
testosterone-exposed female WDs, the stroma will be exposed to similar or even higher
levels of testosterone than the epithelium is, which may be sufficient to permit WD
stabilisation but has an impact on subsequent differentiation. This hypothesis is
substantiated by studies in Wnt4 knockout mice (Heikkila et al, 2005). These female mice
are born with complete WDs showing a considerable degree of coiling, although this coiling
is still not as dramatic as that seen in a newborn male WD (Heikkila et al, 2005). This
rescue and coiling of the WD is believed to be due to the production of testosterone by the
fetal ovary: this testosterone is likely to be delivered down the lumen of the female WD and
thus may explain why Wnt4 KO females have a greater degree of coiling than that seen in
these studies after exogenous maternal testosterone exposure. However, it is worth noting
that these females have no MD (Heikkila et al, 2005) as Wnt4 is required for its formation
thus it cannot be ruled out that the MD physically prevents the testosterone-exposed female
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WD from fully coiling. However, it should be pointed out that these studies are in mice,
rather than rats. No increase was noted in the level of plasma DHT in these KO females
compared to their wild-type littermates and levels remained considerably lower than that
detected in male mice (Heikkila et al, 2005). Furthermore, AGD and the external genitalia
were not masculinised in Wnt4 KO females suggesting that the levels of testosterone
produced by the ovary were insufficient to masculinise the more peripheral tissues, which
are dependent on the more potent DHT in males.
Studies reported in chapter 5 highlighted that stabilisation and patterning of the male WD
were established by androgens between el5.5-17.5 and high levels of androgen action were
less important later during differentiation of the WD. Exposing fetuses to exogenous
maternal testosterone further reinforces the hypothesis that this early time point is a critical
window of androgen action even in the female WD as exposure to testosterone (20 mgkg"1)
only between el4.5-l5.5 or between el4.5-17.5 was able to rescue the WD in many female
fetuses and even resulted in the initiation of coiling by e21.5. This is in agreement with
studies previously undertaken showing that injecting rats with 30mg testosterone propionate
between el5-17 resulted in females with well developed WDs while exposure between e8-10
had no effect on the female reproductive tract (Ogawa and Nozawa, 1969). It should be
noted, however, that testosterone propionate (TP) has long lasting effects and is reported to
increase circulating testosterone levels for 12-24 h in male rats after a single intramuscular
injection of 1 mg (Keating and Tcholakian, 1983). It is possible that testosterone propionate
may still be present in the mother's body a few days after the final exposure, so the window
of testosterone exposure cannot be tightly defined in these studies: it is assumed though, that
if the final exposure of testosterone was on el 5.5, the majority of testosterone will be cleared
from the dams by el8.5. Furthermore, since TP is aromatisable it is possible that some of
the testosterone injected into the pregnant dam will be converted into oestradiol in the
placenta (Padmanabhan et al, 2006), therefore the exact dose of testosterone that the fetus
was exposed to cannot be defined. Studies carried out by Wolf and colleagues showed that
injecting 1 mg testosterone propionate into a pregnant rat results in testosterone levels
increasing from 0.04 ng to 0.09 ng per female fetus while little difference was noted in male
testosterone levels (0.25-0.27 ng) (Wolf et al, 2004).
Examination of postnatal females that had been exposed to exogenous maternal testosterone
(5 or 20 mgkg"1) during gestation highlighted that the rescued female WD often persisted
into postnatal life, even though exposure to maternal testosterone ceased at birth. This
suggests that patterning of the fetal WD is established early in reproductive development
(el4.5-17.5) and, once stabilised, the female WD persists postnatally. This is in contrast to
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males exposed to flutamide in utero, in which WD-derivatives were present prior to puberty
but were often absent by adulthood (discussed in chapter 3). This contrast may highlight
fundamental differences between the male and female WD and the way in which they
respond to androgens during puberty or may simply be due to the low number of adult
testosterone-exposed females examined in this study and requires further investigation.
Histological analysis of the testosterone-rescued female WD revealed no obvious differences
in the histological organisation, compared to control male WDs. AR was expressed in both
the stroma and the epithelium in the fetal female WD, as seen in the male WD highlighting
its capability to respond to androgens. This is in agreement with previous studies showing
that exposure to DHT from el 1-20 rescued the female WD in female fetuses and resulted in
AR expression pattern similar to that of a male (Bentvelsen et al, 1995). The stromal and
epithelial compartments could easily be identified in the rescued female WD by the same
markers as in the control male WD (as discussed in chapter 4) with simple columnar
epithelial cells lining the lumen of the duct directly surrounded by a smooth muscle actin
(SMA) positive inner stromal compartment. Desmin, an early muscle differentiation marker,
was also detected in the stroma of the female WD, highlighting the normal differentiation of
the mesenchyme into muscle as seen in the male WD. These results highlight the normal,
but underdeveloped, morphological differentiation of the female rescued WD compared to
control male WDs; however it cannot be ascertained if the rescued female WD has
functionally differentiated.
In order to investigate the relative levels of testosterone exposure induced exogenously in
comparison to that required for normal male fetal development, pregnant dams were exposed
to both flutamide (100 mgkg"') and testosterone (20 mgkg"1) in combination. Male offspring
had WDs similar to those seen after exposure to flutamide alone (see chapter 3) while
females had no WD by e21.5. Furthermore, female AGD was unaffected by testosterone
exposure but male AGD was reduced to a length similar to control females. These results
suggest that 20 mgkg"1 testosterone was unable to prevent the effects of flutamide,
highlighting that even the high dose of testosterone used in these studies is relatively low
compared to endogenous male levels and yet it is still capable of masculinising female
fetuses. These results are comparable with studies examining the effects of combined
exposure to testosterone and vinclozolin in which it was shown that vinclozolin was able to
prevent testosterone-induced masculinisation of the female fetus (Wolf et al, 2004).
Furthermore, if Wnt4 KO mice are exposed to 100 mgkg"' flutamide in utero, no WD is seen
in the newborn female thus confirming that flutamide can antagonise the effects of
testosterone on the female WD (Heikkila et al, 2005).
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Exposure to testosterone alone resulted in reduced maternal weight gain and subsequent
reduced fetal bodyweight of both males and females at e21.5. This was noted in both low (5
mgkg"1) and high (20 mgkg"1) dose testosterone exposure groups as well as in fetuses only
exposed to testosterone within short defined periods (e 14.5-15.5 and e 14.5-17.5). The
effects of testosterone on fetal bodyweight are thought to be regulated though the mother,
rather than directly affecting the fetus as is believed to be the mechanism behind the
testosterone-induced alterations to the reproductive tract. It is known that inappropriate
steroid hormone signalling during fetal life can affect neonatal growth and testosterone-
induced intrauterine growth retardation (IUGR) has been reported previously (Wolf et al,
2002; Wolf et al, 2004; Steckler et al, 2005; Carlsen et al, 2006; Padmanabhan et al, 2006).
Examples of this hormone induced IUGR can also be seen in humans as patients with
polycystic ovarian syndrome (PCOS) have an increased prevalence of babies born small for
gestational age (Sir-Petermann et al, 2005). The effects of testosterone on fetal bodyweight
were not prevented by combined exposure to flutamide, unlike in the fetal reproductive
system. This is again consistent with studies showing that exposure to vinclozolin could not
prevent the testosterone induced decrease in fetal bodyweight (Wolf et al, 2004). It is not
immediately clear why flutamide or vinclozolin can antagonise the testosterone effects in the
reproductive tract but not the IUGR, but it may be due to the former being a direct effect of
testosterone on the fetus while the latter is a maternal effect. It is unknown, however
whether this is the result of testosterone action directly in the mother or the result of this
testosterone being converted into oestradiol since oestrogens are also known to cause a
decrease in maternal weight gain and fetal birth weight (Padmanabhan et al, 2006).
7.5 Conclusion
Exposure to maternal testosterone during late gestation did not obviously affect male
reproductive development however the female reproductive tract was masculinised. These
studies confirm that testosterone alone is capable of rescuing the fetal WD and any other
testicular factors are not essential for WD stabilisation if sufficient testosterone is available.
However, the rescued female WD never differentiated as fully as the male WD, possibly due
to insufficient levels of testosterone or differences in testosterone delivery between normal
males and testosterone-exposed females. As in normal males, testosterone is vital in the
female during the early phase of WD development (el4.5-17.5) in order to rescue the WD
and is even able to initiate some degree of coiling. Exposure to flutamide concomitantly
with testosterone was able to prevent the effects of testosterone on the female reproductive
tract.
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8 Final Discussion
Adult WD-derived organs are vital for the maturation and transport of sperm, therefore
normal development of these structures is fundamental for normal male fertility. It has been
previously shown by many researchers that impaired androgen action in the fetus interferes
with this developmental process. However, most researchers have examined the effects in
adult tissues, rather than in the fetus, and as yet the mechanisms involved are not understood.
The main objectives of this thesis were therefore: (1) to examine the role for androgen action
in fetal WD development, (2) to investigate the cellular and molecular mechanisms involved
in fetal WD development and their perturbation by anti-androgen treatment, (3) to
investigate the role for stromal-epithelial interactions in WD development.
8.1 The role for androgens in WD development
There have been several previous studies investigating the effects of interfering with
androgen action in the fetal reproductive tract using either AR knockout mice or exposure to
anti-androgenic compounds in utero (section 1.5.2.2). These studies reported that the
majority of these adult males lacked any WD-derived structures, but it was unknown
whether this was due to failure of WD stabilisation or due to 'post-differentiation'
degeneration. One of the main findings of this thesis is that the flutamide regime used in
these studies did not prevent stabilisation of the WD but impaired its subsequent convolution
and differentiation into its adult derivatives. This highlighted WD development as a bi-
phasic process with WD stabilisation apparently requiring lower levels of androgen action or
even acting by an alternative mechanism than that regulating WD differentiation. It was
puzzling why WD stabilisation was not affected by administration of a dose of flutamide,
which is approximately 4 fold higher than the dose required to prevent prostate formation
and induce feminisation of the external genitalia. Insight from models in which androgen
action is more completely blocked has furthered our understanding of this. The models used
in this thesis to study this were three-fold: natural WD regression in female rats, WD
regression in male Tfm mice, and WD development in male rats exposed to DBP + flutamide
(chapter 6).
Studies in the female provide a model in which to study the effects on the WD of a lack of
androgen action and this provided a unique opportunity to compare the impact on the WD of
artificially reducing androgen action in males (Chapter 6). In our rat colony, the female WD
regresses between el6.5-el8.5: there are similarities and differences in the cellular
mechanisms involved in the natural regression of the female WD compared to the
abnormalities induced in the male WD by flutamide exposure (Chapter 6). Few previous
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studies have undertaken detailed examination of the timing of, and mechanisms involved in,
WD regression in females, therefore these studies offer new insight. It is worth highlighting
that this model is limited in the study ofWD regression/development as it does not take into
account any fundamental differences there may be between the male and female WDs. It is
presumed that male and female WDs are identical and that masculinisation is solely
dependent on the presence of androgens but this has not been experimentally proven. The
testicular feminised (Tfm) mouse, the mouse equivalent of human CAIS in which the AR is
functionally inactive, offers an opportunity to investigate the impact of the complete absence
of androgen signalling on the male WD. Furthermore, in order to investigate the impact of
severely reduced androgen action on the male WD, rats were exposed to flutamide (100
mgkg"1) and DBP (500 mgkg"1) simultaneously. It was expected that in the complete or near
complete absence of androgen action in these animals, the male WD would degenerate at a
similar time and by a similar mechanism to that observed in the regressing female WD.
However, this was not the case. In both model systems, the male WD was still apparent and
looked relatively normal with a patent lumen at an age when the WD had completely
degenerated in the female littermates. By birth however, the male WD had degenerated and
only rudimentary tissue was observed in both Tfm mice and DBP + flutamide-exposed rats.
These studies further highlight the essentia! role for high levels of androgen action in WD
development, however since the early WD in androgen-deprived males does not regress at
the same age as in the female, this raises the question of whether another factor may be
trying to compensate for the severe reduction in, or absence of, androgen action. This may
also explain why the flutamide-exposed WD does not obviously differ from age-matched
control WDs at el7.5-19.5. It has always been presumed that androgens are the sole factor
mediating male reproductive tract development, therefore this phenomenon warrants further
investigation in order to characterise better factors that may contribute to this compensatory
role. Further studies in both Tfm mice and DBP + flutamide-exposed rats, examining WD
histology and gene expression may provide further insight into the mechanisms involved in
WD development.
A possible factor that may compensate for the lack of androgen action in Tfm mice and DBP
+ flutamide-exposed rats is Insl3. Like testosterone, Insl3 is secreted by the fetal Leydig
cells and therefore has the potential to be transported directly into the WD in a similar
manner to testosterone (Adham et al, 2000; McKinnell et al, 2005). Insl3 and its receptor,
LGR8, are expressed in the developing WD therefore there is a potential role for this
signalling pathway in WD development (unpublished data and personal communication with
Bernard Jegou). Insl3-/- mice do not show any obvious signs of impaired WD development,
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however testosterone production is normal in these animals and could be sufficient to
mediate normal WD development (Adham et al, 2000). It would be interesting to examine
the effect on the developing WD of ablating both androgen and Insl3 action. This could be
investigated by generating a double knockout mouse from Tfm and lnsl37" and examining
whether the male WD regresses at the same time as the female WD in these animals. These
mice have already been generated by Adham and colleagues (2000) but there are no reports
on the timing of WD regression in these male mice. Communication has been established
with Adham and colleagues to source these mice in order to undertake this investigation.
Another potential factor which may play a compensatory role in WD development in the
absence of androgen action is oestrogen. In the reproductive tract, testosterone has the
potential to be aromatised into oestradiol. Oestradiol could have a direct effect on the WD,
since the WD expresses ER(3, or alternatively oestrogens could act indirectly via the efferent
ducts which express ERa. In Tfm males, testosterone production is increased but there is no
functional AR for it to bind to, but this testosterone could be aromatised into oestradiol
which might contribute to why the male Tfm WD regresses later than does the normal
female WD. Lack of oestrogen action in the aromatase KO (ArKO) mice has no obvious
impact on WD development (Fisher et al, 1998) but as in the Insl3-/- mice, testosterone
action is unaffected in these animals therefore it would be interesting to examine the effects
of flutamide exposure in these ArKO mice to establish whether the WDs degenerate in the
male offspring at the same rate as that observed in the females.
Since the studies in Tfm mice and DBP + flutamide exposed rats (Chapter 6) raised the
question of whether androgens alone are controlling WD development, pregnant rat dams
were exposed to testosterone to investigate whether this was sufficient to stabilise the female
WD or whether during normal male WD development, some other testicular factor may also
be contributing (Chapter 7). Previous studies showed that exposing animals to exogenous
maternal testosterone could masculinise the female reproductive tract, however there was
considerable variation in the doses and timing of exposure reported to elicit this
masculinisation with little information available detailing the phenotype of the rescued WD
(section 1.5.3). In my studies, exposure to maternal testosterone (5 or 20 mgkg"1) between
el4.5-21.5 did not obviously affect male reproductive development but masculinised the
female reproductive tract: in these females the WD was not only stabilised but some degree
of differentiation was also initiated. Taken together with the results of the flutamide studies,
these results confirm that testosterone alone is capable of rescuing the fetal WD and any
other testicular factors are not essential for WD stabilisation if sufficient testosterone is
available. However, the rescued female WD never differentiated as fully as the male WD,
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possibly due to insufficient levels of testosterone or differences in testosterone delivery
between normal males and testosterone-exposed females. Further studies could be
undertaken exposing pregnant rats to higher concentrations of testosterone or to the more
potent DHT to examine whether this can stimulate male-like morphological differentiation in
the female WD. Furthermore, collaboration has recently been established with Dr. Matti
Poutanen to examine WD development in female mice that over-express 17(3-HSB which
results in increased androgen levels and genital masculinisation.
Previous studies have interfered with androgen action during the entire window of male
reproductive development (el4-21), therefore studies were designed to investigate the
precise window of androgen action in WD development by examining the effect of flutamide
exposure either during the initial window of stabilisation (el4-17) or during morphological
differentiation of the WD (el9-21) in the rat (Chapter 5). Surprisingly, exposure to
flutamide between el9.5-21.5 did not obviously alter WD stabilisation or morphological
differentiation. However, exposure to flutamide during the window of stabilisation
inhibited WD morphological differentiation to the same extent as did exposure from el 5.5-
e21.5. This is in agreement with studies undertaken by Foster and Harris, which were
published after my own studies had been undertaken, showing that exposure of pregnant rats
to flutamide (50 mgkg"1) on el6 or 17 resulted in missing epididymides in adulthood whereas
exposure later in development (el8 or 19) only resulted in smaller epididymides (Foster and
Harris, 2005). Furthermore, in my studies flutamide-exposure between el5.5-17.5 resulted
in a similar high incidence of epididymal loss/abnormalities in late puberty and adulthood as
did exposure throughout fetal reproductive development, highlighting that the pattern ofWD
coiling and its subsequent ability to develop fully during postnatal life is established early in
fetal reproductive development (el5.5-17.5) when the AR is only expressed in the stromal
cells. Care must be taken not to presume that androgens are not involved during the
subsequent window of WD differentiation since exposure to this dose of flutamide is
unlikely to be completely blocking androgen action. This could be further investigated in
transgenic mice in which the AR could be ablated during defined windows in development
thus allowing complete blockage of androgen action only during WD morphological
differentiation. Alternatively, rats could be exposed only during this later window of WD
morphological differentiation to a mixture of antiandrogenic compounds, which would
reduce androgen action more completely than that induced by flutamide exposure alone.
Furthermore, these results also shed light on studies undertaken in the first year of this PhD,
which are not reported in this thesis. An in vitro organ culture system was established in
order to manipulate WD development in a defined environment. This culture system was
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based on that reported by Tsuji and colleagues (1991) in which el5.5 male mouse urogenital
ridges containing WDs and MDs were cultured for 4 days with or without gonads in serum-
free medium. If the medium was supplemented with testosterone or DHT, coiling was
induced in the future epididymal segment of the WD and the effects of exogenous androgens
could be mimicked by co-culture with fetal testes. In my studies, WDs were recovered from
rat fetuses at el 8.5 or el9.5 and cultured for 3 or 4 days under similar conditions as used by
Tsuji and colleagues. It was decided to use el8.5 WDs as this was prior to the onset of
morphological differentiation (i.e. coiling) but after the regression of the male MD, therefore
removing this as an extraneous factor. WDs could be maintained in this culture system for
several days, however differentiation of these WDs could not be regulated by the addition of
androgens or anti-androgens. For example, in serum- and androgen-free media, some WDs
underwent considerable coiling while others collected from the same litter remained
relatively straight. At the time, these results gave cause for concern and it was assumed that
the culture system was not fully optimised. However, the studies detailed in chapter 5 of this
thesis exposing dams to flutamide either during WD stabilisation or differentiation highlight
that WD patterning is established by e 17.5 therefore WDs recovered at el8.5 would already
be patterned to differentiate and it is unlikely that this could be re-specified in vitro. Why
some WDs from the same litter coiled and others did not remains somewhat of a mystery.
Future studies could therefore utilise this in vitro culture system using WDs recovered at
el5.5 or 16.5 to further manipulate and understand WD development. This would allow the
study of not just androgen action in WD development but also the role for other factors that
cannot be examined in utero as they could interfere with normal pregnancy and result in
spontaneous abortion, such as growth factors.
A major puzzle arising from my flutamide studies reported in chapter 3 and 6 relates to why
the majority of flutamide-exposed fetal males have WDs which are complete (11%
incomplete at e21.5), but underdeveloped, whereas post-pubertally, in such animals the
majority of WD-derived structures are largely absent (63-83% animals) with entire segments
often missing. This data suggests that androgen action between el5.5-17.5 is essential to
establish patterning of the fetal WD but how this patterning is maintained to enable
differentiation into its different organ components, and the underlying molecular and
biochemical pathways involved remain unknown. This information would not only increase
our understanding of WD development but could also provide insight into how androgens
might regulate the development and function of other organ systems such as the prostate.
One obvious possible candidate for regulating WD patterning is the Hox gene family, which
are steroid responsive and are known to play a role in regulating patterning and segmentation
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of the reproductive tract (section 1.7.6.2). Investigations were undertaken to examine the
role for Hox genes in normal and flutamide-exposed WD development during this thesis hut
no definitive results were gained, primarily due to technical difficulties. Commercial and in-
house antibodies were used to localise Hox alO and al 1 in the rat WD, but these antibodies
did not yield convincing immunostaining. Localisation was further investigated using in situ
hybidisation but this was met with further complications as the mRNA sequence was not
known for rat Hox alO or 11 so the probe were designed based on mouse sequences. Like
the immunohistochemistry, the in situ hybridisations did not provide conclusive results as
staining was obtained from both the sense and anti-sense probes. Some Hox genes have
been shown to have both sense and anti-sense transcripts therefore this data may be correct:
probe specificity could be confirmed by performing a Northern blot prior to continuing these
studies. Altered Hox gene expression may contribute to the flutamide-induced WD
abnormalities therefore further investigation is required.
8.2 Cellular and molecular mechanisms in WD development
Studies were undertaken to investigate further the cellular and molecular effects of
flutamide-exposure in the developing WD in order to gain insight into the mechanisms
involved in WD patterning and development (Chapter 3 & 4). Somewhat surprisingly,
flutamide exposure did not induce apoptosis in the male WD but rather impaired WD
development by reducing cell proliferation in both the stromal and epithelial compartments.
Furthermore, various extracellular matrices are expressed by cells in the developing WD
including laminin, fibronectin and vimentin and exposure to flutamide interfered with their
normal expression pattern and interrupted the basement membrane. The mechanisms
involved in this ECM degradation are not yet fully understood but it is possible MMPs may
play a role: this mechanism may contribute to the degradation of segments of the WD.
These studies have not dramatically advanced our understanding of the molecular
mechanisms involved in WD development but have provided some insight into the cellular
mechanisms involved in normal and flutamide-perturbed WD development. These
molecular mechanisms could be further interrogated using gene array studies, for example
examining any differences in gene expression in the WDs from el6.5 flutamide-exposed
male rats compared to those from age-matched controls.
8.3 Role for stromal-epithelial interactions in WD development
In common with many structures in the reproductive tract, simple columnar epithelial cells
line the lumen of the WD with stromal cells surrounding this epithelium. In my studies, AR
was first expressed in the stroma surrounding the WD at el5.5 but was not detected in the
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epithelium until later, around el7.5. Throughout fetal life, this epithelial AR expression
remained less intense than that observed in the stroma. It is therefore proposed that the
stromal cells are the primary target for testosterone action and that testosterone regulates WD
development by acting indirectly on the epithelium to induce its differentiation via stromal-
epithelial interactions (Chapter 4). It became apparent that the epididymal epithelium does
not fully differentiate until postnatal life, since p63 (an epithelial differentiation marker) was
not expressed in the WD-derivatives until postnatal life, but that this was determined by
androgen action during fetal life (Chapter 4). Conversely, stromal differentiation, as seen by
smooth muscle actin expression, occurred during fetal life and was also impaired by
flutamide exposure. This stromal effect was noted as early as el9.5, before any obvious
signs of impaired epithelial development were apparent and before the epithelium underwent
differentiation even in the control animals. This is consistent with previous studies in various
organ systems which have shown that the stromal cells, via paracrine interactions, play a
critical role in controlling epithelial proliferation, differentiation and development (section
1.7).
The mechanisms behind these paracrine interactions are poorly understood but modification
of or, signalling via, the extracellular matrix and/or secretion of growth factors is likely to be
involved. Flutamide-exposure did not alter AR expression highlighting that these WDs are
still capable of AR-mediated androgen action. Reduced androgen action in flutamide-
exposed WDs is likely to interfere with this paracrine signalling, and this may be one of the
mechanisms involved in causing the flutamide-induced WD abnormalities seen in my
studies. Further investigation into flutamide-induced impairment of these stromal-epithelial
interactions is therefore required, especially the role for growth factors which have been
highlighted to play a role in WD development as well as in other androgen-dependent
processes. Previous studies have suggested a role for growth factors in reproductive tract
development (Section 1.7.6.1) but the mechanisms underlying this are still unknown.
Preliminary studies were undertaken during this thesis to investigate the role for EGF and
IGF signalling pathways in WD development, however due to time constraints and technical
limitations (namely availability of good antibodies for the rat) these studies did not yield any
conclusive data and so needs to be repeated with new reagents. Since my studies have
identified a more precise window of androgen action in the WD, the age to investigate their
impact is now defined. As methods have been established to separate the stromal and
epithelial compartments of various tissues (Cunha and Donjacour, 1987), primary WD cell
lines could be utilised to manipulate gene expression/signalling in vitro in each cell
compartment individually and so gain more insight into these stromal-epithelial interactions
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in the WD. There is potential to use these cells for co-culture studies such as, for example,
to investigate the effect of culturing AR negative stroma with control epithelium and
examine the effect on cell proliferation and/or gene expression. It is worth mentioning that,
in the past, stromal-epithelial co-culture experiments may not have provided hoped for
breakthroughs in our understanding of androgen action in the reproductive tract, but this is a
well-established technique that may yield some exciting results if utilised to examine genes
known to be involved in androgen-dependent WD development. The existence of transgenic
mice with a floxed AR gene (De Gendt et al, 2005) means that mice could be generated with
cell specific ablation of the AR in each of the cellular compartments of the WD.
8.4 The role for DHT verses testosterone
Testosterone and DHT are known to mediate the development and differentiation of different
structures in the male reproductive tract. This is unlikely to be due to different mechanisms
of action but rather due to a difference in the availability of testosterone in the male
reproductive tract since testosterone can mediate development of DHT-dependent tissues if it
is present in high enough concentrations (Wilson and Lasnitzki, 1971; Wilson, 1996). DHT
is a more potent androgen that dissociates less readily from the AR therefore activating
androgen signalling for longer than testosterone does. At the onset of this thesis, I presumed
that DHT-mediated tissues were more sensitive to the effects of androgen action and could
therefore be more easily affected by anti-androgen action. However, this seems to be an
oversimplification. The studies undertaken for this thesis and the evaluation of the literature
has highlighted various discrepancies in the ability of androgens and anti-androgens to
mediate testosterone- and DHT-dependent differentiation (summarised in Table 8.1). For
example, CAH female fetuses or animals exposed to exogenous maternal testosterone are
both able to masculinise DHT-dependent structures more readily than testosterone-dependent
(WD) tissues (discussed in section 1.5). Both CAH females and female fetuses exposed to
exogenous maternal testosterone depend on circulating testosterone, rather than testis-
derived local testosterone as occurs naturally in males. This might explain why the WD is
often not masculinised in these females as WD development appears to depend on high
levels of androgen action, unlike DHT-dependent structures. My studies showed that if
circulating testosterone levels are increase to sufficient concentrations, the WD can be
rescued. This further suggests that WD stabilisation is a dose dependent event. Conversely,
Wnt4"/_ female mice are exposed to local testosterone from the ovary, which can masculinise
the WD but has no effect on the external genitalia (discussed in section 1.5.3.2). This raises
the question of whether this difference is due to differences in the source of testosterone with
WD development depending on local testosterone exposure while DHT-dependent structures
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are masculinised by lower levels of circulating testosterone. However, this does not explain
why in Wnt4"'" female mice the levels of testosterone are capable of masculinising the WD
but are not able to masculinise the external genitalia. This puzzle can be further developed
using evidence from studies in which rats were exposed to various anti-androgens in utero.
For example, DBP and Linuron both decrease testicular testosterone production and as a
result, have a greater effect on WD-derived tissues than on DHT-dependent tissues
(Mylchreest et al, 1998; Foster et al, 2000; Lambright et al, 2000; Mclntyre el al, 2000;
Foster et al, 2001; Mclntyre et al, 2002). Conversely, flutamide and vinclozolin antagonise
the AR but have no effect on local testosterone production and are able to impair
masculinisation of DHT-dependent structures at lower doses than required to alter WD
development. It is likely that testosterone is concentrated enough locally to compete with
flutamide in the WD and so may explain why the WD is rescued in flutamide-exposed
animals while the external genitalia are feminised. However, none of these studies provided
definitive evidence for the differences in responsiveness of the different structures to
testosterone or DHT, and it is not immediately obvious how this could be done. Studies
would need to manipulate both the route of, as well as the dose of, androgen exposure in
order to resolve this issue.
Table 8.1 Summary of ability of androgens and anti-androgens to alter development of
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8.5 Conclusion
In conclusion, androgens alone appear to be sufficient for WD development, but in their
absence a compensatory mechanism may try to rescue the male WD. WD differentiation is
far more susceptible to blockade of androgen action than is its initial stabilisation and these
effects may be mediated by disruption of stromal-epithelial interactions. These findings
advance our understanding ofWD development as for the first time they have identified the
critical window for androgen action in the WD and thus have created an opportunity to study
the elusive mechanisms behind androgen action. Since androgens act on many other systems
in the body with many parallels existing between the male and female reproductive system,
the outcomes of these studies may therefore impact on our understanding of WD
development but also of other androgen-dependent processes such as the development,
function and diseases of other reproductive tissues. It is interesting to note however, that
over 25 years ago, Wilson and colleagues (1981) wondered how tissues develop the capacity
early in fetal life to respond to hormonal stimulation later in development and how the same
hormonal signal can be translated in different physiological effects in different tissues. Even
though the results presented in this thesis advance our understanding of WD development,
this question still remains largely unanswered today.
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Androgens play a vital role in Wolffian duct (WD) develop¬
ment, but the mechanisms that underlie this are unknown.
The present study used in utero exposure of pregnant rats to
the androgen receptor antagonist flutamide (50 or 100 mg/kg)
to explore possible mechanisms. Pregnant rats were treated
from embryonic d 15.5 (E15.5), and WDs were isolated from
fetuses from E17.5-E21.5 and from adults.WDmorphologywas
evaluated, and total length of the duct lumen was determined
in fetal samples. FetalWDswere immunostained for androgen
receptor and stromal (inner and outer) and/or epithelial-cell-
specific markers and analyzed for cell proliferation and ap-
optosis. In adulthood, most flutamide-exposed males lacked
proximal WD-derived tissues, whereas at E18.5-E19.5, a time
when the WD has completely regressed in females, a complete
normal WD was present in all flutamide-exposed animals. This
suggests that flutamide, at doses of50 or 100mg/kg, interferes
with WD differentiation, not stabilization. Consistent with
this, WD elongation/coiling increased in controls by 204% be¬
tween E19.5 and E21.5 but increased less significantly (103%)
in flutamide-exposed animals. This was associated with re¬
duced cell proliferation, but there was no increase in apopto-
sis or change in expression of androgen receptor mRNA or
protein. Flutamide treatment impaired differentiation of in¬
ner stromal cells, shown by decreased expression of smooth
muscle actin, before effects were noted in the epithelium, con¬
sistent with androgens drivingWD development via stromal-
epithelial interactions. In conclusion, WD differentiation is
farmore susceptible to blockade of androgen action than is its
initial stabilization, and these effects may be mediated by
disruption of stromal-epithelial interactions. (Endocrinology
147: 4820-4830, 2006)
DURING MAMMALIAN DEVELOPMENT, the urogen¬ital tract is identical in both sexes and is made up of
two duct systems, the Mullerian duct and the Wolffian duct
(WD) (1, 2). In males, Sertoli cells secrete anti-Mullerian
hormone, which causes the Mullerian duct to degenerate,
whereas Leydig cells secrete testosterone, which stabilizes
and rescues the WD (2, 3). In females, the lack of androgens
prevents stabilization of the WD, resulting in its degenera¬
tion (3). Once stabilized, the male WD begins to differentiate
to form its adult derivatives; the cranial portion of the WD
convolutes to form the adult epididymis, the central portion
remains a relatively simple straight duct and forms the vas
deferens, whereas the seminal vesicles bud off the distal
segment (4, 5).
It is widely accepted that WD development is under the
control of testosterone (2, 6), which is synthesized by the
Leydig cells of the testis (7) and is delivered directly from the
testis down the lumen of the WD (8). Testosterone secretion
begins at around E15.5 in the fetal rat with a peak at E19.5
(9). In some cells, testosterone can be metabolized by 5a-
reductase to form the more potent androgen dihydrotestos-
terone (DHT) or aromatized to form estrogens (2). However,
it is unlikely that either of these hormones are involved in
First Published Online June 29, 2006
Abbreviations: AR, Androgen receptor; DHT, dihydrotestosterone;
E0.5, embryonic d 0.5; NGS, normal goat serum; SMA, smooth muscle
actin; TBS, Tris-buffered saline; TBST, TBS containing 0.1% Tween 20;
WD, Wolffian duct.
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WD development because aromatase could not be detected
in the fetalWD (unpublished findings) and estrogen receptor
knockout mice and aromatase knockout mice have epidid¬
ymides present in adulthood (10,11). Furthermore, DHT has
not been detected in the WD until after epididymal differ¬
entiation is complete (12,13), and 5a-reductase-deficient pa¬
tients show normal WD differentiation (14), whereas rats
exposed to finasteride, a 5a-reductase inhibitor, show nor¬
mal WD development (15).
Androgen action is mediated via the androgen receptor
(AR), which is a member of the superfamily of ligand-acti-
vated steroid hormone receptors (16). The AR binds both
testosterone and itsmetabolite DHTwith high specificity and
affinity; however, DHT dissociates less easily from the AR
and is thus more effective at stabilizing the receptor in its
active conformation (2,17). Patients withmutations in the AR
affecting its activity and /or expression exhibit a range of
phenotypic abnormalities (18). In the case of complete an¬
drogen insensitivity, genetic XY males are bornwith a female
phenotype, intraabdominal testes, no prostate, and a lack of
WD-derived tissues (19-21).
Simple columnar epithelial cells line the lumen of the WD
with stromal cells surrounding this epithelium. The AR is
first expressed in the ratWD stroma at E16.5 and at low levels
in the epithelial cells by E17.5 (22, 23). Studies in both male
and female reproductive tracts show that mesenchymal cells
can determine the morphological fate of the overlying epi¬
thelium, possibly via local production of growth factors (24-
27). It has been proposed that stromal cells are the primary
target for androgen action and that testosterone may induce
proliferation and differentiation of epithelial cells through
stromal-epithelial interactions (24, 28).
4820
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Administration of the AR antagonist flutamide during
pregnancy has been shown to dose-dependently impair mas-
culinization. For example, treatment with 18 mg/kg flut¬
amide resulted in complete feminization of external genitalia
but normal WD differentiation (15). However, at doses above
100 mg/kg flutamide, the vas deferens was absent unilat¬
erally or bilaterally, and only small remnants of the epidid¬
ymis were present in adults (15). It is generally presumed
that the latter effect results from interference with WD sta¬
bilization but this has not been shown directly during fetal
life.
Although it is obvious that androgens play a role in WD
development, the molecular and cellular events that underlie
its stabilization and subsequent differentiation have received
little attention to date. To address this, we have used a model
system in which WD development can be altered, thus en¬
abling the investigation of WD stabilization and differenti¬
ation with the aim of elucidating the cellular mechanisms
responsible for androgen-dependentWD development. This
is the first report to have taken this approach, and itwas used
to address the following specific questions. 1) Does flut-
amide-induced blockade of androgen action affect stabiliza¬
tion of the male WD, as occurs naturally in females, and/or
its differentiation? 2) Do androgens control WD develop¬
ment by altering cell proliferation and/or apoptosis, and
does this preferentially target one cell compartment? 3) Does
altered expression of AR play a role in flutamide-induced
inhibition of WD development? 4) Are the effects of flut¬
amide treatment first detectable in the stromal compartment,
consistent with the view that epithelial development is me¬
diated by androgen effects on the stroma?
Materials and Methods
Animals
Wistar ratswere bred and maintained in our own animal house under
standard conditions according to United Kingdom Home Office guide¬
lines. Animals had access ad libitum to water and a soy-free breeding diet
(SDS, Dundee, UK). Time matings were set up, and the presence of a
vaginal plug was taken as evidence of mating; this was defined as
embryonic d 0.5 (E0.5).
In vivo treatment
Pregnant dams (n = 70) were randomly allocated to treatment groups
and dosed daily by oral gavage between 0830 and 1000 h with flutamide
(Sigma, Poole, UK) at 50 mg/kg (n = 30 dams) and 100 mg/kg (n = 18)
in 1 ml/kg corn oil/2.5% dimethylsulfoxide (Sigma) or vehicle alone
(n = 22). Dosing was undertaken from E15.5, the time at which the fetal
testis begins androgen synthesis, until the day before cull. Flutamide
doses were selected based on results previously reported (15). Dams
were weighed daily and checked for signs of toxicity.
Dams were killed by inhalation of carbon dioxide and subsequent
cervical dislocation. Fetuses were recovered at E17.5-E21.5, decapitated,
and placed in ice-cold PBS (Sigma). WDs were collected from male
fetuses by microdissection, examined with a Leica MZ6 dissecting mi¬
croscope (Leica Microsystems UK Ltd., Milton Keynes, UK) and pho¬
tographed using a Leica ICA camera. For each fetus, one WD was snap
frozen in liquid nitrogen, whereas the other was fixed in Bouin's for 1 h,
transferred into 70% ethanol, and processed for 17.5 h in an automated
Leica TP1050 processor. Fixed WDs were embedded horizontally in
paraffin wax and processed and sectioned onto coated slides using
standard procedures. Representative WDs from the aforementioned
litters were subsequently used for the studies detailed below; at least
three animals from at least three litters were studied per age/treatment
group. Only samples that were analyzable were studied; for example,
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WDs from flutamide-exposed animals with incomplete lumens (7% of
animals at E21.5) were not included in the analysis of luminal length.
Thus, results presented for luminal length are likely to underestimate the
overall effect of flutamide exposure.
Gross morphology and histological analysis
Reproductive tracts from control and flutamide-exposed males and
control females were analyzed microscopically, at the time of dissection,
for any gross morphological abnormalities. Considerable variation was
seen in the severity of malformation of the WDs after flutamide expo¬
sure; therefore, careful notewas taken of anymacroscopic abnormalities.
Reproductive tracts from control female fetuses were also recovered,
and the degree of regression of the WD was noted. Gross histological
analysis was performed on WD sections stained with hematoxylin and
eosin, using standard protocols.
WD luminal length measurement
Differentiation of WDs was quantified by measuring the luminal
length of the epididymal segment of WDs from control and treated
animals; a line was digitally drawn through the lumen of the WD image
taken at the time of dissection using the Image J program (National
Institutes of Health, Bethesda, MD). This line was drawn from the head
of the epididymis, where the efferent ducts end, to the tail of the epi¬
didymal section just before the start of the vas deferens. To ensure
reproducibility and to correct for individual variation, luminal length
was measured forWDs from 15-37 animals from at least three different
litters per treatment group.
Immunohistochemistry
Immunohistochemistry was performed onWDs recovered from con¬
trol and treated fetuses at E17.5-E21.5 using standard avidin peroxidase
protocols (see Ref. (29). For AR, pan-cytokeratin, and cleaved caspase 3,
antigen retrieval was performed using 0.01 m citrate buffer (pH 6.0).
Sections were pressure cooked for 5 min at full pressure, left to stand for
20 min, and then cooled under running water. Endogenous peroxidase
activity was blocked by washing sections in 3% H202 in methanol for
30 min at room temperature. All washes comprised two 5-min washes
at room temperature in Tris-buffered saline (TBS) (0.05 m Tris-HCl, pH
7.4, and 0.85% NaCl). Nonspecific binding sites were blocked by incu¬
bating sections in normal goat serum (NGS) (Autogen Bioclear UK Ltd.,
Wiltshire, UK) diluted 1:4 in TBS containing 5% BSA (Sigma). Sections
were incubated overnight at 4 C with primary antibodies diluted in
NGS/TBS/BSA: AR at 1:50 (Santa Cruz Biotechnology, Santa Cruz, CA),
smooth muscle actin (SMA, Sigma) at 1:10,000, pan-cytokeratin (Sigma)
at 1:200, and cleaved capsase 3 (Cell Signaling Technology, Beverly, MA)
at 1:200. Control sections were incubated with blocking peptide when
available or blocking serum alone to confirm antibody specificity. Sec¬
tions were incubated with the appropriate secondary antibody, either
biotinylated goat antirabbit orbiotinylated goat antimouse, diluted 1:500
in NGS/TBS/BSA for 30min at room temperature before incubation for
30 min with avidin-biotin conjugated with peroxidase diluted in 0.05 m
Tris-HCl (pH 7.4) according to the manufacturer's instructions (ABC-
HRP; Dako, Ely, UK). Antibody localization was determined using 3,3'-
diaminobenzidine (liquid DAB+; Dako) until staining was optimally
detected in control sections; the reaction was stopped by immersing the
sections in distilled water. Sections were counterstained in Harris's
hematoxylin and mounted using Pertex (Cell Path, Hemel Hempstead,
UK). Cellular sites of expression of AR, SMA, pan-cytokeratin, and
cleaved caspase 3 were determined and slides photographed using a
Provis AX70 (Olympus Optical, London, UK) microscope fitted with a
Canon DS6031 camera (Canon Europe, Amsterdam, The Netherlands).
Fluorescence immunohistochemistry
To delineate stromal and epithelial compartments, fluorescence im¬
munohistochemistry was used to colocalize three proteins in WDs re¬
covered from control and treated fetuses at E17.5-E21.5. Antigen re¬
trieval was performed as detailed above. All washes were two 5-min
washes at room temperature in PBS (Sigma). At each stage, control
sections were incubated with blocking serum without antibody to con-
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firm antibody specificity. Nonspecific binding sites were blocked by
incubating sections in NGS diluted 1:4 in PBS containing 5% BSA
(Sigma). Sections were incubated overnight at 4 C with anti-pan-cytok-
eratin antibody (Sigma) diluted 1:200 in NGS/PBS/BSA and was de¬
tected by incubating sections for 1 h with goat antimouse secondary
antibody directly conjugated with Alexa Fluor 488 (Molecular Probes,
Poort Gebouw, The Netherlands) diluted 1:200 in PBS to produce green
fluorescence. Sections were incubated for 30 min with mouse IgG
(Sigma) diluted 1:2000 in NGS/PBS/BSA to block any remainingmouse
IgG sites and prevent subsequent nonspecific binding. Nonspecific bind¬
ing sites were blocked again by incubating sections with NGS/PBS/BSA
for 30 min before incubating overnight at 4 C with anti-AR (Santa Cruz
Biotechnology) diluted 1:50 in NGS/PBS/BSA. AR immunostaining was
detected using biotinylated goat antirabbit IgG secondary antibody
(Dako) diluted 1:500 in NGS/PBS/BSA for 30 min followed by incu¬
bation for 1 h with streptavidin-conjugated Alexa 546 (Molecular
Probes), producing red fluorescence. Nonspecific binding sites were
blocked again with NGS/PBS/BSA for 30 min before incubating over¬
night at 4 C with anti-SMA antibody (Sigma) diluted 1:500 in NGS/
PBS/BSA. Sections were incubated for 1 h with goat antimouse labeled
with Cy5 (Amersham Biosciences, Little Chalfont, UK) diluted 1:60 in
PBS, producing blue fluorescence. Sections were counterstained for 10
min with a nuclear-specific blue fluorescent label, 4',6-diamidino-2-
phenylindole (Sigma), diluted 1:1000 in PBS and then mounted in
Mowiol mountingmedium (Calbiochem, Lutterworth, UK). Fluorescent
images were captured using a Zeiss LSM 510 Meta Axiovert 100M
confocal microscope (Carl Zeiss Ltd., Welwyn Garden City, UK).
To ensure reproducibility of results and allow accurate comparison
of immunostaining between treatment groups, sections of WDs from
control and treated animals were processed in parallel on at least three
occasions; sections of WDs from at least three animals in each treatment
group were run on each occasion. Appropriate negative controls were
included, whereby the primary antibody was replaced by blocking pep¬
tide or NGS alone, to ensure staining observed was specific; none of the
antibodies used showed other than minor nonspecific staining.
Apoptosis analysis
Cleaved caspase 3 immunostaining was performed on WDs from
control and flutamide-exposed fetuses using standard methods, as de¬
tailed above. Very few cleaved caspase-3-positive cells were detected;
therefore, a detailed stereological analysis was not appropriate and all
positive cells were manually counted in each WD using an Axiolab
microscope (Carl Zeiss Ltd.).
Frequency of cell mitoses in WDs
To determine whether cell proliferation in WD compartments was
affected by flutamide treatment, various cell cycle markers and analyt¬
ical methods were investigated. For technical reasons, it was considered
that determination of the proliferation index was impractical for the
densely packed stromal cell compartment. Instead, a method was de¬
vised to allow enumeration of the total number of mitotic cells in each
compartment, as outlined below.
WD sections from control and flutamide-exposed fetuses at E19.5-
E21.5 were immunostained for phospho-histone H3 (Upstate Biotech¬
nology, Dundee, UK) using a Bond-X automated immunostaining ma¬
chine (Vision Biosystems, Newcastle, UK) and a polymer high-contrast
program. Briefly, after high-pressure antigen retrieval, slides were per¬
oxidase blocked for 5 min and incubated for 2 h with the primary
antibody diluted 1:1000 in the diluent supplied and then with the post¬
primary reagent for 15 min. Control sections were incubated with di¬
luent alone to confirm antibody specificity. Sections were then incubated
with the polymer reagent for 15 min to increase sensitivity of detection
before DAB detection for 10 min, counterstained in hematoxylin for 5
min, dehydrated, and mounted as detailed above.
Phospho-histone H3-positive cells were counted in the epithelial
compartment and the inner and outer stromal layers of the WD using
the X20 objective on an Olympus BH-2 microscope fitted with a Prior
automatic stage (Prior Scientific Instruments Ltd., Cambridge, UK). Im¬
age-Pro Plus version 4.5.1 with Stereologer-Pro 5 plug-in software (Me¬
dia Cybernetics UK, Wokingham, UK) was used for analysis. Positive
cells were counted only in the future epididymal portion of the WD, not
in the efferent ducts or vas deferens. Because differences were noted in
the degree of coiling along the length of the future epididymal portion
of the WD, phospho-histone H3-positive cells were initially counted in
each region of the future epididymis individually, defined as in the adult
epididymis as caput, corpus, and cauda (5) (Fig. ID). However, no
consistent difference was seen in phospho-histone H3 staining between
the different regions of the epididymal portion of the WD; therefore,
proliferation was subsequently analyzed in the epididymal portion of
the WD as a whole.
Variation was noted in the length of the WD visible in each section
as well as the amount of epithelium visible per section; this was a result
of both treatment effects and the plane of sectioning. To correct for this
variation, the overall length of the WD and the length of epithelium
visible in each section were measured. The number of phospho-histone
H3-positive cells in the epithelial compartment was then divided by the
total length of epithelium visible in the section to calculate proliferation
per micron of epithelium. Because flutamide exposure reduces coiling
andWD luminal length, it was important to take this into account when
analyzing cell proliferation. The number of positive epithelial cells per
micron of epithelium was therefore multiplied by the luminal length for
that specific WD (calculated at the time of dissection, method detailed
above) to calculate total epithelial proliferation in the whole epididymal
portion of the WD, not just cell proliferation in the section being ana¬
lyzed. Similarly, the number of phospho-histone H3-positive cells in the
stromal compartment was divided by the length of WD epithelium
visible in the section to calculate stromal proliferation per micron of
stroma and hence correct for variation in the length of the WD. This was
then multiplied by the luminal length of the WD to calculate total
stromal proliferation in the whole epididymal portion of the WD. Sec¬
tions from eight to 14 fetuses from three to five separate litters were
analyzed from both control and flutamide-exposed animals at each age.
To confirm that this analysis was likely to reflect the cell proliferation/
mitotic index, the total number of phospho-histone H3-positive and
negative epithelial cells were counted (500-700 cells) in three control and
three F100 E21.5 WDs, and an epithelial mitotic index was derived
(percent phospho-histone H3-positive cells/total number of cells X
100%).
Epithelial cell height measurement
WD sections from six control fetuses and six fetuses from each of the
flutamide treatment groups at E21.5 were randomly selected and im¬
munostained for pan-cytokeratin as detailed above to clearly label all
epithelial cells. Using a X63 objective, epithelial cell height was mea¬
sured in every fifth epithelial cell per section, using the software and
stereological equipment noted above. Thiswas performed separately for
the caput, corpus, and cauda regions of the future epididymal portion
of the WD. Only epithelial cells in which the nucleus could be clearly
identified were measured, thus excluding from analysis any epithelial
cells from the flutamide treatment groups that were severely flattened
or disintegrating. In a subset of these animals, epithelial cell width was
also measured using the same method.
Quantitative RT-PCR
RNAwas isolated from frozenWDs using the RNeasyMini extraction
kit (QIAGEN, Crawley, UK) according to the manufacturer's instruc¬
tions. RNA was DNase treated during extraction using RNase-free
DNase on the column digestion kit (QIAGEN), and random hexamer
primed cDNA was prepared using the Applied Biosystems TaqMan RT
kit (Applied Biosystems, FosterCity, CA). Real-time PCRwas performed
with the ABI Prism 7900 Sequence Detection System (Applied Biosys¬
tems). Expression of AR mRNA was determined using the Assay-On-
Demand Gene Expression system for rat AR (Rn00560747_ml; Applied
Biosystems). The expression level of AR mRNA was corrected using an
internal control, 18S rRNA, and related to rat uterus expression levels.
Results shown are the mean of a minimum of three WDs per treatment
group performed in triplicate on at least two occasions.
Western blot analysis
Proteinwas harvested from frozenWDs using RIPA [1% Triton X-100,
15mM HEPES-NaOH (pH 7.5), 0.15mm NaCl, 1% sodium deoxycholate,
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Fig. 1. Age-dependent increase in coiling/elongation of
the WD between E18.5 and E21.5. Representative WDs
recovered from control fetuses (A and D) and fetuses
exposed to 50 mg/kg flutamide (B and E) or 100 mg/kg
flutamide(C and F) atE18.5 (top) and E21.5 (bottom) are
illustrated. Note the reduced coiling in WDs from flut-
amide-exposed animals at E21.5 (E and F) when com¬
pared with the age-matched control (D). Note the de¬
marcation of the epididymal regions of a control WD at
E21.5 (D) into the caput (Cap), corpus (Cor), and cauda
(Cau), as in the adult epididymis. Scale bar, 1 mm. E,
Prospective epididymis; ED, efferent ducts; V, prospec¬
tive vas deferens. The graph (G) illustrates quantifica¬
tion of coiling (luminal length) of the WDs. Note the
progressive increase in luminal length ofWDs from con¬
trols between E 18.5 andE21.5 (black bars). InWDs from
animals exposed in utero to either 50 mg/kg (white bars)
or 100 mg/kg (striped bars) flutamide, there was a sig¬
nificant reduction in luminal length at E20.5 and E21.5
when compared with controls, whereas at E18.5 and
E19.5, no difference was evident. Values are mean ± sem
for 15-36 animals per group. ***, P < 0.001 in compar¬
isonwith respective value for preceding day; a, P < 0.001
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0.1% SDS, 1 mm sodium orthovanadate, 10 him EDTA, and 0.5% protease
inhibitor cocktail (Sigma)] lysis buffer. WDs were homogenized in 75 pi
RIPA buffer and then incubated on ice for 1 h. Samples were centrifuged
at 2500 rpm for 10 min and the supernatant collected. The protein
concentration was determined using a Bio-Rad BCA protein assay kit
according to the manufacturer's instructions (Bio-Rad Laboratories,
Hemel Hempstead, UK). Proteins were denatured by boiling with SDS
loading buffer for 5min before loading 20 pg of each protein extract onto
a 7.5% polyacrylamide gel. Gels were subjected to electrophoresis at 100
V under reducing conditions for 2 h. The proteins were electrotrans-
ferred overnight at 20 V onto nitrocellulose membranes (Immobilon-P;
Millipore, Bedford, MA). Membranes were washed in TBS containing
0.1% Tween 20 (TBST) (Sigma) before incubating in TBST with 5% milk
for 1 h at room temperature to block nonspecific binding sites. Mem¬
branes were washed twice in TBST for 5 min and then incubated over¬
night at 4 C with anti-AR antibody (Santa Cruz Biotechnology) diluted
1:200 in TBST, anti-SMA antibody (Sigma) diluted 1:10,000, or an anti-
/3-tubulin antibody (Sigma) as a standardization control at 1:300 in TBST.
After washing with TBST, membranes were incubated for 1 h at room
temperaturewith antirabbit horseradish peroxidase or antimouse horse¬
radish peroxidase (SAPU, Carluke, UK), respectively, at 1:5000 in
TBST/5% milk. The signal was detected using ECL plus Western blot
detection reagents according to the manufacturer's instructions (Am-
ersham Biosciences). Signals were visualized using high-performance
chemiluminescence imaging film (Amersham Biosciences) and devel¬
oped using a Xograph compact X4 imaging system (Xograph, Tetbury,
UK). Antibody specificity was confirmed by the detection of only one
band at the expected size when visualizing each antibody. The intensity
of the bands was quantified using the Typhoon 9400 variable mode
imager (Amersham Biosciences). The expression level of protein was
corrected for loading using /3-tubulin and related to E19.5 control protein
levels. To ensure reproducibility of results, the Western blot was per¬
formed three to six times, and protein was isolated from at least three
WDs from three different litters each time.
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Statistical analysis
Values have been expressed as means ± sem. Data were analyzed
using one-way ANOVA followed by the Bonferroni post hoc test, using
GraphPad Prism version 4 (Graph Pad Software Inc., San Diego, CA).
Results
Normal development of the WD
Figure 1 shows images ofWDs isolated at E18.5 and E21.5.
At E18.5 (Fig. 1A), the epididymal portion of the WD is a
simple, straight uncoiled duct. Coiling first becomes evident
at the cranial and caudal ends of the future epididymal
portion of the WD at E20.5, whereas the corpus remains
relatively uncoiled (not shown). By E21.5, the full length of
the epididymal portion of the WD appears highly convo¬
luted, including the corpus (Fig. ID). This age-dependent
increase in coiling and development was confirmed quan¬
titatively by the demonstration of an increase in luminal
length (Fig. 1G). No significant increase (P > 0.05) in WD
luminal length was seen between E18.5 and E19.5, but a
highly significant increase was noted on consecutive days
thereafter.
Impact of flutamide treatment on gross WD morphology
Consistent with previous studies (30) that have blocked
androgen action in utero, considerable variation between an¬
imals was noted in the degree ofWD coiling after exposure
to flutamide; this was more apparent at later fetal ages
(E20.5-E21.5) when WDs are more differentiated in fetuses
from control mothers. To take account of this variability,
WDs were analyzed from 19-37 animals from at least three
litters per age/treatment group.
As in control WDs, an age-dependent increase was noted
in the degree of coiling and hence differentiation of WDs
from flutamide-exposed fetuses, but the degree of coiling
was reduced compared with age-matched controls (Fig. 1).
As in controls, no coiling was seen in WDs from flutamide-
exposed animals at E18.5 (Fig. 1, B and C). At E20.5 and E21.5,
but not at E18.5 or E19.5, flutamide-exposed animals showed
a highly significant reduction in WD coiling and luminal
length compared with controls (Fig. 1G). At E21.5, coiling
was more dramatically reduced in fetuses exposed to 100
mg/kg flutamide than those exposed to 50 mg/kg (Fig. 1, F
compared with E, respectively). As well as this reduction in
coiling, someWDs from flutamide-exposed fetuses appeared
incomplete at E21.5 with thinning of the epithelium and
missing corpus segments; this was not seen in control WDs.
Missing corpus segments were first noted at E21.5 whereby
5 and 11% ofWDs recovered from animals exposed to low-
and high-dose flutamide, respectively, had incomplete lumens
(Table 1). These fetuses were from the same litter within each
treatment group. Thiswas not seen inWDs at E18.5-E20.5 from
flutamide-exposed animals. This is in contrast to the natural
regression of WDs in females, in which by E18.5 the WD has
fully regressed and is no longer visible (Fig. 2B).
Impact of fetal exposure to flutamide on male reproductive
tract morphology
Exposure to either dose of flutamide prevented normal
masculinization of the fetal external genitalia, with anogeni-








E18.5 Control 0 10
Flutamide 50 mg/kg 0 21
Flutamide 100 mg/kg 0 21
E19.5° Control 0 37
Flutamide 50 mg/kg 0 47
Flutamide 100 mg/kg 0 35
E20.5 Control 0 25
Flutamide 50 mg/kg 0 68
Flutamide 100 mg/kg 2(7)" 29
E21.5 Control 0 24
Flutamide 50 mg/kg 2(5)" 39
Flutamide 100 mg/kg 4(H)6 34
Adults Control 0 18
Flutamide 100 mg/kg 10 (83)c 2
a At E19.5, the WD in control female rats has completely regressed.
6 Note that these WDs were all from the same litter (E20.5 F100,
one of three; E21.5 F50, one of six; and E21.5 F100, one of three).
c Note that these reproductive tracts were found in males from
three of three litters.
tal distance reduced in E21.5 flutamide-exposed males to a
length similar to that of control females (data not shown).
Flutamide-exposed E21.5 males had no prostate and a vag¬
inal pouch was present, but testis descent was largely un¬
affected (data not shown). Consistent with previous reports
(31-33), these abnormalities were still evident postnatally.
Considerable variation was noted in the degree of abnor¬
mality of WD-derived adult tissues, including underdevel¬
oped or incomplete epididymides, lack of vas deferens, and
underdeveloped or vestigial seminal vesicles (data not
shown). As in the fetus, the corpus segment of the epididymis
was often absent with 83% of epididymides studied being
incomplete (Table 1). In five animals, there was near-com¬
plete absence of all epididymal segments and the vas
deferens.
Histology
The WD is composed of two cellular compartments, sim¬
ple columnar epithelial cells lining the lumen of the duct and
stromal cells surrounding this epithelium, and this did not
Fig. 2. Natural regression of the WD in female rats between E17.5
(A) and E18.5 (B) in comparison with the effect of flutamide (100
mg/kg) treatment on WDs in the male (C). Note the presence of both
the Miillerian duct (arrow) and WD (arrowhead) in the female at
E17.5 (A), whereas the WD has regressed by E18.5 (B). In comparison,
in the flutamide-exposed male at E 18.5 (C), theWD is still present and
is comparable to its age-matched control (see Fig. 1A). Scale bar, 1
mm.
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vary along the length of the WD or with age. The mesen¬
chymal cells can be easily separated into two distinct pop¬
ulations, those directly surrounding the epithelial cells,
which are more densely packed and termed here as inner
stroma, and those that make up the rest of the body of the
WD, referred to here as outer stoma. This can easily be seen
by hematoxylin and eosin staining (Fig. 3A), but this dis¬
tinction was confirmed by staining for SMA, which is ex¬
pressed only in the inner and not the outer stromal cells of
the WD (Fig. 3B). SMA protein expression switched on in
these cells between E17.5 and E18.5 and increased dramat¬
ically between E18.5 and E19.5 (data not shown).
Examination of WDs revealed no obvious histological dif¬
ferences between WDs from control and flutamide-exposed
fetuses at E18.5 or E19.5 (data not shown). However, at E21.5
after flutamide exposure (high and low dose), the WD epi¬
thelium often looked abnormal compared with that of con¬
trols, appearing more flattened and sometimes fibroblast-
like. The extent of this flattening varied between WDs but
was not seen in controls or flutamide-exposed WDs at any
earlier age.
AR expression
AR was immunolocalized to cell nuclei throughout the
WD at all ages examined (E17.5-E21.5). Stromal cells directly
surrounding the epithelium showed the most intense im-
munostaining, whereas the epithelial cells showed weaker
staining (Fig. 4). WDs from flutamide-exposed animals dis¬
played a similar pattern of AR expression to controls at all
ages studied with AR expressed in the stroma by E16.5 and
epithelial expression switching on in some cells by E17.5
(data not shown). Additional analysis usingWestern blotting
and TaqMan quantitative real-time PCR confirmed that there
was no significant difference in either AR protein or mRNA
expression in control compared with flutamide-exposed
WDs at E17.5-E21.5 (Fig. 4, F and G). Variation was seen in
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Fig. 3. Demarcation oftheE21.5WD stroma into the inner and outer
stromal compartments (IS and OS, respectively). Note that the IS can
be identified as the more dense compartment immediately proximal
to the epithelium (arrow, A). This regionalization was confirmed by
immunostaining for SMA, which is expressed only in the inner stroma
(brown; B). Scale bar, 100 pm.
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the levels of AR mRNA and protein within each age/treat¬
ment; however, this was not significant and presumably
represents variation between individual WDs.
Role for apoptosis in flutamide-induced impairment of
WD development
Apoptotic cells were rarely detected (typically one cell per
section) in WDs from either control or flutamide-exposed
fetuses at any age studied (data not shown).
Frequency of cell mitoses in WDs
Cell mitosis was evident in all compartments ofWDs from
control and flutamide-exposed animals at all ages (Fig. 5, A
and B). Immunostaining for phospho-histone H3 suggested
fewer mitotic cells were present in WDs from flutamide-
exposed fetuses compared with controls, and this was con¬
firmed by quantitation that showed a significant reduction in
numbers ofmitotic epithelial and stromal cells perWD com¬
pared with controls (Fig. 5). This reduction was seen at all
ages studied; however, results are presented here only for
E21.5. Cell proliferation data are expressed as the overall
number of mitotic cells in the complete epididymal portion
of the WD rather than per 100 pm epithelium so as to take
into account the treatment-induced reduction inWD length.
If this correction was not applied, a similar treatment-in¬
duced reduction in cell mitosis was evident but was of
smaller magnitude.
Analysis of the epithelial mitotic index yielded compara¬
ble results, with epithelial mitosis reduced (P < 0.05) in
flutamide-exposed WDs (0.2 ± 0.03%, mean ± sem; n = 3),
compared with control WDs (0.3 ± 0.02%, mean ± sem; n =
3), indicating that the analytical method used reflects the
mitotic index.
Reduction in epithelial cell height after flutamide exposure
Upon visual inspection, areas of the epithelial compart¬
ment in some animals at E21.5 appeared abnormal after
flutamide exposure, with shorter epithelium, missing cells,
and widened lumens (Fig. 6B); this was not seen in controls
(Fig. 6A). This difference was confirmed quantitatively at
E21.5 as flutamide exposure reduced WD epithelial cell
height (Fig. 6C). This reduction was more dramatic in the
corpus and caudal portions of the WD and was most pro¬
nounced in animals exposed to 100 mg/kg flutamide. No
significant difference was noted in the width ofWDepithelial
cells in flutamide-exposed animals compared with controls
(data not shown).
Evidence for earliest effects of flutamide treatment on inner
stromal cells
Because the data presented above indicated an impact of
flutamide treatment on both stromal and epithelial tissues of
theWD, we sought evidence of stroma1-specific effects using
SMA, a stromal cell marker. Immunostaining suggested a
reduction in this SMA-positive layer in flutamide-exposed
WDs compared with age-matched controls, although this
varied considerably between WDs. This decrease was con¬
firmed quantitatively by Western blot analysis, which re-
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Fig. 4. AR expression in the different compartments of theWD caput
at E21.5. Note that the inner stroma is identified by SMA immuno-
staining {blue) and the epithelium by cytokeratin staining {green). No
obvious difference was seen in AR expression between WDs from
control animals (A) and animals exposed to 50 mg/kg (B) or 100 mg/kg
(C) flutamide. Image D shows AR only staining from Fig. 5A, high¬
lighting that AR protein was expressed {red) more intensely in the
stroma than in the epithelium {arrows) ofthe controlWD at E21.5 (D),
and flutamide treatment had no obvious effect on this pattern (B and
C). Scale bar, 50 pm. E, Representative Western blot for AR protein
expression in WDs at E17.5-E21.5 (n = 3 WDs per age/treatment)
with its loading control below. F, Quantitative analysis (mean ± sem)
ofAR protein from Western blots confirming no significant change in
AR expression in WDs at E17.5-E21.5 from control {black bars) and
flutamide-exposed {white bars, 50 mg/kg; striped bars, 100 mg/kg)
rats (n = 6 Western blots, each using a pool of three WDs per
age/treatment from at least three litters). Protein expression was
vealed that the biggest reduction was at E19.5 (Fig. 7), a time
point at which no epithelial damage or change in luminal
length was detectable in flutamide-exposed animals (Fig. 1).
Discussion
It is widely accepted that androgens play a vital role inWD
development, but little is known about the molecular and
cellular events that underlie this (2,34,35). The present study
set out to use an in utero model system in which epididymal
development can be altered to investigate the cellular mech¬
anisms responsible for androgen-dependent WD develop¬
ment and allow better understanding of the mechanisms
behind epididymal abnormalities in adults after reduced
fetal androgen action. The main findings of these studies are,
first, that in utero exposure to 50 or 100 mg/kg flutamide
inhibits development, elongation, and differentiation of the
WD but not its stabilization, contrary to previous interpre¬
tations. Second, these flutamide effects are mediated by ef¬
fects on cell mitosis, but not apoptosis, and do not involve
altered AR expression. Last, flutamide treatment appears to
impair/delay differentiation of inner stromal cells at a stage
in development before effects on the epithelium, consistent
with the view that androgens drive WD development via
stromal-epithelial interactions.
In males, the WD differentiates during neonatal life to
form the epididymis, vas deferens, and seminal vesicles (4).
In female rats, the WD regresses naturally between E16.5 and
E18.5; this is believed to be because of a lack of androgens,
whereas in males at this age, androgen action is believed to
stabilize the WD, allowing it to subsequently differentiate
into its adult derivatives (2, 3). In our rat colony, differen¬
tiation is first evident in the future epididymis by E20.5,
suggesting that the developmental window for WD differ¬
entiation is between E19.5 and birth, coinciding with the peak
in testosterone seen in male rats at E19.5 (9). This is in agree¬
ment with timings seen in previous studies (36).
It has been suggested that the pattern of AR expression
reflects the androgen responsiveness of the tissue (23). We
have mapped the AR to the epithelia from E17.5 and stroma
of theWD from El 6.5; however, epithelial AR expression was
less intense than in stromal cells, particularly before E20.5.
This is in agreement with other studies using antibodies
demonstrating that ARs are expressed in the nuclei of both
the stroma and epithelial cells of the rat WD by E17.5 (23).
However, studies in mice using [3H]dihydrotestosterone ste¬
roid autoradiography reported stromal expression from E13,
but epithelial expression was not detected until E19, much
later than in rats (37). This difference in timing of expression
may be because of species differences or different method¬
ologies. The more intense immunoexpression of AR in the
stroma compared with the epithelium would be consistent
with the view that androgen effects on early WD develop¬
ment occur mainly through stromal AR and that androgens
stimulate the stroma to signal to the epithelium to indirectly
corrected for loading and expressed relative to levels in E19.5 control
WD. G, No significant difference is shown in AR mRNA expression
between control and flutamide-exposed WD at E18.5—E21.5, as de¬
termined by TaqMan quantitative real-time PCR (means ± sem; n =
3-5 WDs per age/treament, each from different litters).
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Fig. 5. Frequency of mitotic cells (immunopositive for
phospho-histone H3; black staining) in representativeWDs
from a control (A) and an animal exposed in utero to 50
mg/kg flutamide (B) at E21.5. Note the numerous mitotic
cells in the inner stroma (arrows), outer stroma (arrow¬
head), and epithelium. Panel C shows the total number of
mitotic epithelial and stromal cells in the entire epididymal
segment of the WD at E21.5 in controls (black bars) and
animals exposed to 50 mg/kg (white bars) or 100 mg/kg
(striped bars) flutamide. ***, P < 0.001 in comparison with







control epithelial fate (24). Flutamide exposure did not alter
AR expression; therefore, WDs from flutamide-exposed an¬
imals retained the potential for AR-mediated androgen ac-
Caput Corpus Cauda
Fig. 6. Epithelial cell height at E21.5 in WDs from controls (A and
black bars in C) and animals exposed to 50 mg/kg (B and white bars
in C) or 100 mg/kg (striped bars) flutamide. Note that the epithelium
(immunostained for cytokeratin) is flatter in WDs in the flutamide-
exposed animal. Images in A and B are both from the caput region of
aWD, the segment of theWD where epithelial height is least reduced
by flutamide exposure. Scale bar, 25 pm. Panel C shows quantifica¬
tion of epithelial cell height in WDs from controls (black bars) and
from animals exposed to either 50 mg/kg (white bars) or 100 mg/kg
(striped bars) flutamide. Note that epithelial cell height is reduced
more in the corpus and caudal portions of the future epididymis after
flutamide treatment. *, P < 0.05; **, P < 0.01 in comparison with
respective control value. Values are means ± sem for five to seven
animals per treatment from at least three different litters.
Epithelia Inner Stroma Outer stroma
tion. This conclusion is in contrast to findings by others who
were unable to detect AR protein by immunohistochemistry
in WDs from E21.5 fetuses exposed to 100 mg/kg flutamide
(23). This difference is unexplained, although it could be
because of rat strain difference or to the use of different
anti-AR antibodies.
Previous studies have reported that flutamide exposure in
utero results in abnormal epididymides in adults, but in these
studies, it was not possible to identify whether the WD
formed and stabilized but segments were later lost during
differentiation or whether it failed to form and /or stabilize
(31-33). In the present studies, WDs from flutamide-exposed
males were present at E18.5 and E19.5 and appeared normal
in all animals, with no obvious morphological differences or
reduction in luminal length compared with their age-
matched controls. This suggests that flutamide-exposed
WDs initially form normally and are morphologically sta¬
bilized; however, it is unknown whether these WDs are
functional at the biochemical level, and this needs additional
investigation. In the regressing female WD, apoptosis is ap¬
parent, suggesting that the WD is dying rather than not
differentiating (unpublished findings) (38, 39). In contrast,
minimal cell apoptosis was detected inWDs from flutamide-
exposed males at any age studied. Together these findings
suggest that the doses of flutamide administered do not
completely block the AR and so may not reduce androgen
action sufficiently to impairWD stabilization and so cause it
to regress, as occurs in the female (38). This difference could
reflect the higher levels of testosterone reported to be avail¬
able at E18.5 when the WD is undergoing stabilization than
at E20.5 when the WD is differentiating (40), thus making it
more difficult for flutamide to block androgen action. Al¬
ternatively, WD stabilization may require relatively low lev¬
els of androgens, less than that required for differentiation,
or WD stabilization and differentiation may be regulated by
different mechanisms. This is the first report that we are
aware of highlightingWD development as a two-phase pro¬
cess, each of which may be differentially controlled. Insight
from patients with complete androgen insensitivity syn-
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Fig. 7. Comparative expression of SMA at E19.5 in WDs
from controls (A) and animals exposed in utero to 50 mg/kg
(B) or 100 mg/kg (C) flutamide. Note the reduction in SMA
expression in WDs after flutamide exposure. D, Represen¬
tative Western blot for SMA protein in WDs from control (C)
and flutamide-exposed animals (F, 50mg/kg; HF, 100mg/kg)
at E17.5-E21.5 (n = 3-5 WDs per age/treatment from at
least three different litters). Testes (T; E21.5) were used as
a positive control for SMA expression. E, Quantitative data
expressed lelalive to SMA cvprnnnion in control WDs at
E19.5 (corrected for loading using /t-tuhnlin) Note the in¬
crease in SMA protein expression between E18.5 and E 19.5
in controls and the decrease in SMA expression after flut¬
amide exposure (white bars, 50 mg/kg; striped bars, 100
mg/kg) compared with controls (black bars). *,P < 0.05; ***,
P < 0.001 in comparison with respective control value. Val¬
ues are means ± sem for two to three Western blots, each
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drome and testicular feminization mice might further elu¬
cidate this as AR signaling is blocked in each case. Reports
have shown that in both instances, adults lack any WD-
derivatives (41, 42), however, no definitive evidence is pub¬
lished regarding the status of the fetal WD.
In controls, WDs showed a significant age-dependent
increase in coiling and differentiation, as determined by
quantification of luminal length; this is believed to be an
androgen-dependent process. Unsurprisingly, flutamide in¬
terrupted this differentiation, thus confirming the vital role
for androgens in differentiation of the stabilized WD. The
most obvious explanation for this reduction in WD devel¬
opment could be an increase in cell apoptosis and/or a de¬
crease in cell mitosis. Because apoptosis wasminimal inWDs
from flutamide-exposed animals, it was considered likely
that altered cell proliferation was responsible. This is the first
study to report the impact of androgen blockade on cell
mitosis in the differentiating WD, showing androgen regu¬
lates both stromal and epithelial cell proliferation but that the
consequences of reduced AR signaling can be noted earlier
in the stromal compartment.
At E19.5, WDs from all flutamide-exposed animals were
morphologically intact, suggesting that AR-mediated signal¬
ing was incompletely blocked fetally, even at 100 mg/kg
flutamide, thus allowing WD rescue. Conversely, in adults
that had been similarly exposed to flutamide in utero, the
majority of the WD-derived tissues were largely absent. This
is in agreementwith previous studies showing that exposure
to antiandrogenic compounds in utero results in a high fre¬
quency of epididymal malformations in adult rats (15,31-33,
43). The contrast between WD abnormalities at E19.5 and in
adulthood in flutamide-exposed animals demonstrates that
the major effect of flutamide is on epididymal differentiation
rather than stabilization, contrary to what has been pre¬
sumed to occur by earlier researchers (15, 33). The increased
prevalence ofepididymal abnormalities as development pro¬
ceeds may be a result of failure to establish normal patterning
of the WD fetally. Interfering with androgen action within a
critical window of development can therefore impair WD
patterning and hence differentiation into its adult deriva¬
tives, resulting in irrecoverable malformation of the repro¬
ductive tract and likely impairment of fertility.
By E21.5, WDs from flutamide-exposed animals show ab¬
normalities in both gross morphology and histology, includ¬
ing shorter, flatter epithelia, occasional missing corpus seg¬
ments of the future epididymis, reduced coiling, and
incomplete lumens. This is not seen until E21.5; thus the
epithelium initially forms normally in flutamide-exposed
animals but degenerates during differentiation, possibly be¬
cause of interrupted androgen-driven signaling between the
stroma and epithelium. In multiple organ systems, it is be¬
lieved that steroid hormones control the fate of epithelial
Downloaded from endo.endojournals.org on October 25, 2006
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cells via interactions with the underlying stroma, and hor¬
mone withdrawal can result in epithelial-mesenchymal
transformation (24, 26, 44-46). Because the epithelium in
incomplete regions often appeared flattened with some cells
even looking more fibroblast-like, it may be that a lack of
androgen signaling resulted in dedifferentiation of some ep¬
ithelial cells intomesenchymal-like cells, thus contributing to
the impaired development of the WD. These missing seg¬
ments were noted only in the corpus segment, the region of
the WD that coils last and the segment of the adult epidid¬
ymis that is least coiled. The androgen signal may be weaker
in the corpus than in the caput or cauda, and thus flutamide
treatment could have more impact on its development. The
caput is closest to the testis and is therefore likely to be
exposed to high levels of locally delivered androgens, but it
is not obvious why the cauda should be less affected by
flutamide treatment than the corpus. It is possible that the
cauda may obtain testosterone from the blood as well as
directly from the testis. However, there is unlikely to be a role
for the more potent androgen DHT, because Wilson and
Lasnitzki (12) and Siiteri and Wilson (13) both reported that
DHT was not detectable in the WD until after epididymal
differentiation was complete.
Blocking androgen action by flutamide exposure impaired
stromal differentiation as indicated by reduced expression of
SMA, an androgen-responsive stromal differentiation
marker (47). This reduction in smooth muscle differentiation
may explain the reduction inWD coiling seen after flutamide
exposure. The flutamide-induced reduction in SMA expres¬
sion was noted as early as E19.5, before any obvious signs of
impaired epithelial development were apparent. This is con¬
sistent with previous studies in various organ systems that
have shown that the stromal cells, via paracrine interactions,
play a critical role in controlling epithelial proliferation, dif¬
ferentiation, and development (25, 26, 48-50). The mecha¬
nisms underlying these paracrine interactions are poorly un¬
derstood, but growth factors and/or the extracellular matrix
are likely to be involved.
There is substantial literature on the effects of reduced
androgen action on the male reproductive tract using knock¬
out mice and AR antagonists; however, most have studied
the effects in adult males, and few have looked at how this
impacts on development in fetal life. Because interferingwith
androgen action during fetal life, using 50 or 100 mg/kg
flutamide, did not prevent stabilization of the WD but im¬
paired its subsequent convolution and differentiation into its
adult derivatives, the current study has highlighted WD
development as a two-phase process with WD stabilization
apparently requiring lower androgen action than WD dif¬
ferentiation.Why WD stabilization is not affected by admin¬
istration of high doses of flutamide, approximately 5-fold
higher than levels that induce complete agenesis of the pros¬
tate and feminization of the external genitalia, is something
of a mystery and merits additional study. Future studieswill
also focus on using the present model system to investigate
possible signaling pathways involved inWD patterning and
differentiation. This should allow a clearer insight into the
mechanisms behind interrupted epididymal development
and function.
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The Critical Time Window for Androgen-Dependent
Development of the Wolffian Duct in the Rat
Michelle Welsh, Philippa T. K. Saunders, and Richard M. Sharpe
Medical Research Council Human Reproductive Sciences Unit,
Research Institute, Edinburgh, EH16 4TJ, United Kingdom
Androgens are thought to separately regulate stabilization
and differentiation of the Wolffian duct (WD), but the time
windows for these effects are unclear. To address this, fetal
rats were exposed to flutamide within either an early window
(EW) [embryonic day 15.5 (E15.5) to E17.5], when the WD de¬
generates in the female, or a later window (LW) (E19.5-E21.5),
when the WD morphologically differentiates in the male, or
during the full window ofWD development (FW) (E15.5-21.5).
WDs were examined for abnormalities during fetal (E21.5) or
postnatal life, and anogenital distance and prostate presence/
absencewere recorded. Exposure to FW- orEW-flutamide, but
not to LW-flutamide, induced comparable abnormalities in
the fetal WD at E21.5, namely reducedWD coiling, reduced cell
proliferation, reduced epithelial cell height, altered epithelial
vimentin expression, and reduced expression of smooth mus-
DURING MAMMALIAN DEVELOPMENT, before acti¬vation of SRY within the somatic cells of the genital
ridge, the urogenital tract is initially identical in both sexes,
comprising the Mtillerian duct (MD) and the Wolffian duct
(WD) (1, 2). In males, after differentiation of the different
somatic cell types in the fetal testis, the Sertoli cells secrete
anti-Miillerian hormone to induce MD degeneration,
whereas the Leydig cells secrete testosterone, which acts via
the androgen receptor (AR) to stabilize and rescue the WD
(2, 3). Conversely, in females, the ovaries do not synthesize
either androgens or anti-Miillerian hormone so the WD de¬
generates and the MD persists (1-3). In males, once the WD
is stabilized, it then differentiates to form its adult deriva¬
tives; the cranial portion of the WD convolutes to form the
adult epididymis, the central portion remains a relatively
simple straight duct and forms the vas deferens, whereas the
seminal vesicles bud off the distal segment (4,5). This process
is thought to be controlled by androgens because XY males
with inactivating mutations in the AR have a female phe-
notype with intraabdominal testes, no prostate, and a lack of
WD-derived tissues (6-9). In the rat, epididymal differenti¬
ation becomes evident between embryonic day 19.5 (E19.5)
to E21.5 and is characterized by transformation of the cranial
First Published Online April 12, 2007
Abbreviations: AGD, Anogenital distance; AR, androgen receptor; E,
embryonic day; EW, early window; FW, full window; LVV, late window;
MD, Mullerian duct; NGS, normal goat serum; PBST, PBS with 0.1%
Tween 20; PND, postnatal day; SMA, smooth muscle actin; WD, Wolf¬
fian duct.
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cle actin in the WD inner stroma. Exposure to EW- or FW-
flutamide, but not to LW-flutamide, resulted in incomplete/
absentWDs inmore than 50% ofmales by adulthood, although
such abnormalities were infrequent in fetal life. These find¬
ings suggest that androgen action during the EW is sufficient
to promote WD morphological differentiation several days
later. Because the androgen receptor is expressed in the WD
stroma but not in the epithelium during this EW, WD differ¬
entiation is likely to be dependent on androgen-mediated sig¬
naling from the stroma to the epithelium. In conclusion, the
critical window for androgen action in regulating WD devel¬
opment in the rat is between E15.5 and E17.5. This window is
also important forprostate formation and anogenital distance
masculinization. (Endocrinology 148: 0000-0000, 2007)
segment of the simple straight WD into an intensely coiled
structure (10). It is presumed that the patterning of this trans¬
formation is under the control of testosterone (11, 12), the
secretion of which begins at approximately E15.5 in the fetal
rat and peaks at E19.5 (13).
Previous researchers have shown that interferingwith an¬
drogen action during fetal life, using either AR mutant an¬
imals or exposure to antiandrogenic compounds, results in
abnormal reproductive tracts in adult males (for review, see
Refs. 14-21). Most studies have exposed rats to antiandro¬
genic compounds between E13 and E21, encompassing the
onset of testosterone production by the fetal testis and the
window of male reproductive development, and have then
examined the effects of this in adulthood. In such males, the
epididymis and/or vas deferens is often incomplete or ab¬
sent altogether. It has been presumed that this was attrib¬
utable to a failure of the male WD to stabilize early in fetal
development, as occurs naturally in females. However, we
demonstrated recently that exposure of pregnant rats to 100
mg/kg flutamide during the period E15.5-E21.5 did not in¬
duce regression of the male WD but did result in subsequent
impairment of WD morphological differentiation (10). These
studies and those reported previously in the literature sug¬
gest that fetal WD development may be a biphasic process,
with stabilization and differentiation possibly under differ¬
ential control. It has been presumed that androgen action is
vital for both early stabilization of the WD and the later
segmentation and differentiation of the WD into its adult
derivatives, but the precise window of androgen action in
WD development remains unknown.
One previous study in the mouse showed that exposure to
hydroxyflutamide from Ell to E15 resulted in smaller epi-
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didymides and infertility, whereas exposure to hydroxyflu-
tamide from E19 to E20 did not result in any obvious repro¬
ductive abnormalities or infertility in adulthood (22). A
similar study using rats examined the effects of maternal
exposure to a single dose of flutamide (50 mg/kg) on El 6,
E17, E18, or E19 and showed that this treatment resulted in
a similar range of reproductive abnormalities in adulthood
as did exposure to flutamide throughout the period of re¬
productive development (E12-E21) but at a lower incidence
(23). Exposure of pregnant rats to another antiandrogen,
vinclozolin (400 mg/kg), between E14 and E19 resulted in
malformations of the external genitalia, permanent nipples,
reduced anogenital distance (AGD), and reduced seminal
vesicle, ventral prostate, and epididymal weights. When vin¬
clozolin treatment was restricted to 2-d periods (e.g. E14-E15
or E18-E19), similar abnormalities were observed, but the
incidence and severity was reduced and no obvious abnor¬
malities were reported in adult WD-derived structures (24).
There is thus no consensus as to when androgens act to 1)
stabilize the WD and 2) induce its differentiation (i.e. epi¬
didymal coiling) and establish the patterning of the segmen¬
tation of the WD into its adult derivatives. It is also unclear
as to when a lack of fetal androgen action may result in loss
of part or all of the WD and precisely when this loss first
manifests because the studies to date have only examined
adults. To address this deficit in understanding, we used a
model system in which fetal rats were exposed to flutamide
specifically within either an early window (EW), when the
WD degenerates in the female (E15.5-E17.5), or in a later
window (LW), when the WD morphologically differentiates
in the male (E19.5-E21.5); the impact onWD development in
fetal (E21.5) and postnatal [postnatal day 17 (PND17),
PND42, and PND70] life was then studied. We previously
published evidence highlighting WD development as a bi-
phasic event with WD stabilization and differentiation de¬
pendent on either different levels of androgen action or on
different mechanisms (10). The present study sought to es¬
tablish the critical window of androgen action in both these
processes and has found, surprisingly, that androgen action
within the same early timewindow (E15.5-E17.5) is sufficient
to induce both rescue and latermorphological differentiation
of the WD.
encompassed the period of WD morphological differentiation, defined
by the appearance of coiling in the future epididymal segment of the WD
(E19.5-E21.5, LW-flutamide, n = 8 litters) (Fig. 1). Flutamide exposure
between E17.5 and E19.5 was not examined in this study because we
aimed to examine the role for androgens during WD stabilization or
during WD morphological differentiation rather than to investigate the
role for androgens during the entire period of reproductive
development.
To compare the effects of short window flutamide exposure with the
previously published effects of exposure to flutamide from the onset of
androgen production by the testis until birth [E15.5-E21.5, full window
(FW)-flutamide, n = 6 litters] (10), WDs from FW-flutamide exposed
males were included in all analyses. To reduce animal usage, theseWDs
were taken from both archived datasets (10) as well as from litters
generated specifically for this study; there were no obvious differences
between the archived (n = 8 litters) and newly generated datasets (n =
23 litters). Control dams (n = 10 litters) were gavaged daily with the
vehicle alone at 1 ml/kg corn oil/2.5% DMSO. Dams were checked daily
for signs of toxicity, and dam weights were recorded daily throughout
the dosing regimen. Male offspring were subsequently evaluated in late
fetal life (E21.5) or at PND17, PND42, or PND70.
For recovery of fetal animals, dams were killed by inhalation of
carbon dioxide and subsequent cervical dislocation. Pups were recov¬
ered, decapitated, and placed in ice-cold PBS (Sigma). Postnatal animals
(PND17, PND42, and PND70) were killed by inhalation of carbon di¬
oxide and subsequent cervical dislocation. Before recovery of repro¬
ductive tracts, AGD was measured in fetal (E21.5) and postnatal animals
using digital calipers (Faithfull Tools, Kent, UK), because it is widely
believed that AGD reflects the degree of masculinization of the animal
(for review, see Ref. 25). Female littermateswere also examined for AGD.
Our previous studies have shown that WD morphological differen¬
tiation is well established by E21.5, as evidenced by coiling in the future
epididymal segment of theWD (10). WDswere collected frommale pups
by microdissection, examined with a Leica (Nussloch, Germany) MZ6
dissecting microscope and photographed using a Leica ICA camera to
enable gross morphological evaluation and measurement ofWD lumi¬
nal length (see below). This study focused on the development of the
future epididymis and vas deferens (i.e. the upper portions of the WD)
rather than the seminal vesicles, which are believed to depend on both
testosterone and dihydrotestosterone. For each pup, the future epidid¬
ymis and vas deferens segments of one isolatedWD was snap frozen in
liquid nitrogen for subsequent RNA and protein analysis by Taqman
and Western blot, respectively, whereas the other was fixed in Bouin's
fixative for 1 h before being transferred into 70% ethanol and processed
for 17.5 h in an automated Leica TP1050 processor for later use in
histological analysis. Fixed WDs were embedded horizontally in par¬
affin wax, sectioned (5 /im), floated onto slides coated with 2% 3-amin-
opropyltriethoxy-silane (Sigma), and dried overnight at 50 C before
histological analysis (see below). Representative WDs from at least three
animals from at least three litters from the aforementioned treatment
groups were subsequently used for the studies detailed below.
Materials and Methods
Animals
WD Stabilisation WD Differentiation
Wistar ratswere bred and maintained in our own animal house under
standard conditions according to United Kingdom Home Office guide¬
lines. Animals had access ad libitum to water and a soy-free breeding diet
(SDS, Dundee, UK). Time matings were established, and the presence of
a vaginal plug was taken as evidence ofmating; thiswas defined as E0.5.
Treatment and collection of tissues and measurement of
AGD
A total of 36 pregnant dams were used for this study, with dams
randomly allocated to treatment groups. Dams were dosed daily by oral
gavage between 0830 and 1000 h with flutamide (Sigma, Poole, UK) at
100 mg/kg in 1 ml/kg corn oil/2.5% DMSO (Sigma); these doses were
selected based on previously reported results (10, 17). Dosing was un¬
dertaken during critical windows that either 1) encompassed the period
ofWD stabilization, defined by the timing ofWD regression in females



















Fig. 1. Summary of duration of flutamide exposure in relation to key
events in reproductive development and testosterone (T) levels in the
fetal male testis (4, 13, 38, 39).
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To recover postnatal reproductive tracts, the abdomen of the supine
male rat was opened, and testes, epididymides, and vas deferens were
pulled out of the scrotal sac by the fat pad and removed from the animal.
Gross morphology and histological analysis
Reproductive tracts from control and flutamide-exposed males at
E21.5 or PND17, PND42, and PND70 were analyzed microscopically, at
the time of dissection, for any gross morphological abnormalities. His¬
tological analysis was performed on WD sections stained with hema¬
toxylin and eosin, using standard protocols. Note was taken of any
histological abnormalities, including swollen lumens and epithelial
malformation.
WD luminal length measurement
Differentiation of WDs at E21.5 was quantified by measuring the
luminal length ofWD from control and treated animals on photographs
taken of WD at the time of dissection, as detailed previously (10). A line
was digitally drawn through the lumen of the WD image taken at time
of dissection using theNIH Image J program. To ensure reproducibility,
luminal length was measured for WDs from 15-30 individuals from at
least three different litters per treatment group.
Immunohistochemistry
Immunohistochemistrywas performed on Bouin's-fixed WDs recov¬
ered from control and treated fetuses at E21.5 using previously pub¬
lished standard avidin-peroxidase protocols (10). The antibodies used
for immunohistochemistry, their dilutions, and sources are listed in
Table 1. Cellular sites of expression of AR, smooth muscle actin (SMA),
and pan-cytokeratin were determined, and slides were photographed
using a Provis AX70 (Olympus Optical, London, UK) microscope fitted
with a Canon DS6031 camera (Canon Europe, Amsterdam, The Neth¬
erlands). To ensure reproducibility of results and allow accurate com¬
parison of immunostaining between treatment groups, sections of WDs
from control and treated animals were processed in parallel on at least
three occasions; sections of WDs from at least three animals in each
treatment group were run on each occasion. Appropriate negative con¬
trols were included, whereby the primary antibody was replaced by
normal goat serum (NGS) alone, to ensure that any staining observed
was specific; none of the antibodies used showed other than minor
nonspecific staining.
Double-fluorescence immunohistochemistry for cytokeratin
and vimentin
Sections from Bouin's-fixed WDs were deparaffinized and rehy-
drated, and antigen retrieval was performed as detailed previously (10).
Nonspecific binding sites were blocked by incubating sections in NGS
(Autogen Bioclear UK Ltd., Wiltshire, UK) diluted 1:4 in PBS containing
5% BSA (Sigma) for 1 h and then incubated overnight at 4 C with
anti-pan-cytokeratin antibody (Sigma) diluted 1:200 in NGS/PBS/BSA.
This signal was detected by incubating sections for 1 h with goat anti-
mouse secondary antibody directly conjugated with Alexa Fluor 546
(Invitrogen, Carlsbad, CA) diluted 1:200 in PBS to produce red fluores¬
cence. Sections were washed well in PBS before blocking in NGS/PBS/
BSA for 1 h. Because the anti-vimentin antibody (DakoCytomation, Ely,
UK) and the pan-cytokeratin antibody were both raised in mice, the
anti-vimentin antibody was directly labeled with Alexa Fluor 488 using
an Alexa Fluor 488 labeling monoclonal antibody labeling kit (Invitro¬
gen). This antibody was diluted 1:15 in NGS/PBS/BSA and incubated
on sections for 2 h at room temperature. Because no secondary antibody
detection was required, sections were counterstained for 10 min with a
nuclear-specific blue fluorescent label (4',6'-diamidino-2-phenylindole;
Sigma) diluted 1:1000 in PBS and then mounted in Mowiol mounting
medium (Calbiochem, Lutterworth, UK). Fluorescent images were cap¬
tured using a Zeiss (Welwyn Garden City, UK) LSM 510 Meta Axiovert
100M confocal microscope.
Frequency of cell mitoses in WDs
One randomly selected section fromWDs recovered from control and
flutamide-exposed fetuses at E21.5 was immunostained for phospho-
histone H3 (Upstate Biotechnology, Dundee, UK) using a Bond-X au¬
tomated immunostaining machine (Vision Biosystems, Newcastle, UK)
as published previously (10). Phospho-histone H3-positive cells were
counted in the epithelial compartment and the inner and outer stromal
layers of the WD using an Olympus Optical (Tokyo, Japan) BH-2 mi¬
croscope fitted with a Prior automatic stage (Prior Scientific Instruments,
Cambridge, UK). Image-Pro Plus version 4.5.1 with Stereologer-Pro 5
plug-in software (Media Cybernetics, Wokingham, Berkshire, UK) was
used as detailed previously (10). Positive cells were counted only in the
future epididymal portion of the WD, and the number of positive cells
was then related to the amount of epithelium seen in section and the total
length of the WD lumen (10). Sections from 4-14 fetuses from three to
five separate litters were analyzed from both control and flutamide-
exposed animals.
Epithelial cell height measurement
WDs (E21.5) from six control fetuses and four to six fetuses from each
of the flutamide treatment groups were sectioned and immunostained
for pan-cytokeratin as detailed above to clearly label all epithelial cells.
The software and stereological equipment noted above were used. Using
a X63 objective, epithelial cell height was measured in every fifth ep¬
ithelial cell per section. This was performed separately for the caput,
corpus, and caudal regions of the future epididymal portion of the WD
(10). Only epithelial cells inwhich the nucleus could be clearly identified
were measured, thus excluding from analysis any epithelial cells from
the flutamide treatment groups that were severely flattened or
disintegrating.
Western blot analysis
Protein was harvested from frozenWDs using radioimmunoprecipi-
tation assay lysis buffer as published previously (10). Protein concen¬
tration was determined using a Bio-Rad (Hemel Hempstead, UK) bicin-
choninic acid protein assay kit according to the instructions of the
manufacturer, and 20 /xg of each protein extract was loaded onto a 7.5%
polyacrylamide gel. Gels were subjected to electrophoresis at 100 V
under reducing conditions. The proteins were then electrotransferred
overnight at 20 V onto nitrocellulose membranes (Immobilon-P; Milli-
pore, Bedford, MA). Membranes were washed in PBS before incubating
in Odyssey blocking buffer (LI-COR, Lincoln, NE) diluted 1:1 in PBS for
1 h at room temperature to block nonspecific binding sites. Membranes
were incubated overnight at 4 Cwith anti-SMA antibody (Sigma) diluted
1:10,000 and anti-j3-tubulin antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) diluted 1:300 in Odyssey blocking buffer/PBS. The LI-COR
buffer allows detection of more than one antibody at a time; therefore,
both antibodies could be added at once as long as their host species
differed, so they could be discriminated by secondary antibodies of
different specificities. The anti-/3-tubulin antibody was used as a stan¬
dardization loading control. Residual primary antibody was washed off
with PBS with 0.1% Tween 20 (PBST) (Sigma) for 5 min (three times).
Membranes were then incubated for 1 h at room temperature with the
TABLE 1. Antibodies: source, dilution, retrieval, and species
Antibody Source Dilution Retrieval Species raised in
AR Santa Cruz Biotechnology 1:50 Citrate Rabbit
SMA Sigma 1:10000 None Mouse
Pan-cytokeratin Sigma 1:200 Citrate Mouse
Phospho-histone H3 Upstate Biotechnology 1:1000 Citrate Rabbit
Vimentin DakoCytomation 1:1000 Citrate Mouse
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secondary antibodies diluted 1:5000 in Odyssey blocking buffer/PBST.
Goat antirabbit secondary antibody conjugated with IRDye 800 (Rock¬
land, Gilbertsville, PA) was used to detect /3-tubulin, whereas goat
antimouse secondary antibody conjugated with Alexa Fluor 680 (In-
vitrogen) was added to detect SMA. Membranes were again washed in
PBST for 5 min (three times) and then PBS (one time) to remove any
residual Tween 20, before detecting the signal. The membrane was
scanned using the LI-COR buffer, according to the instructions of the
manufacturers.
Antibody specificity was confirmed by the detection of only one band
at the expected size when visualizing each antibody. The intensity of the
bands was then quantified, with the area of exposure equating to the
amount of labeled protein present in the sample. Protein expression level
was corrected for loading using /3-tubulin. To ensure reproducibility of
results, the Western blot was performed at least twice, and protein was
isolated from at least three WDs from two to three different litters each
time.
Statistical analysis
Values have been expressed as means ± sem. Data were analyzed
using one-way ANOVA, followed by the Bonferroni's post hoc test, using
GraphPad Prism version 4 (GraphPad Software, San Diego, CA).
Results
Effects of flutamide exposure on AGD and the reproductive
tract
Maternal exposure to flutamide during the entire window
of reproductive development (E15.5-E21.5, FW-flutamide)
prevented normal masculinization of fetal external genitalia,
with AGD significantly reduced (P < 0.001) at E21.5 and
PND17 to a length comparable with that of control females.
Exposure to flutamide (100 mg/kg) early in WD develop¬
ment (E15.5-E17.5, EW-flutamide) reduced AGD by the
same amount as did FW-flutamide exposure, whereas ma¬
ternal exposure to flutamide late inWD development (E19.5-
E21.5, LW-flutamide) did not result in any significant change
in male AGD at E21.5 or PND17 when compared with age-
matched control males (Fig. 2).
Maternal exposure to FW-flutamide (E15.5-E21.5) or EW-
flutamide (E15.5-E17.5) prevented normal prostate and pe¬
nis formation in males and resulted in the presence of a
vaginal pouch, whereas exposure to LW-flutamide (E19.5-
E21.5) had no such effects (data not shown).
Effects on fetal and postnatal WD development of impaired
androgen action during critical windows of development
Fetal. Exposure to FW-flutamide reduced WD development
and coiling compared with age-matched controls, as pub¬
lished previously (10). Exposure to EW-flutamide inhibited
coiling (WD differentiation) at E21.5 to a similar extent as did
FW-flutamide exposure, whereas exposure to LW-flutamide
had no obvious effect onWD coiling at E21.5 compared with
age-matched controls (Fig. 3). This difference was confirmed
quantitatively (Fig. 3), highlighting that there was no signif¬
icant difference in luminal length between WDs from litters
exposed to FW-flutamide and those exposed to EW-flut¬
amide. Exposure to LW-flutamide did not significantly re¬
duce WD luminal length compared with age-matched
controls.
As well as the reduction in coiling, exposure to FW-flut-
amide resulted in some WDs appearing incomplete at E21.5
(Table 2), with thinning of the epithelium and missing cor-
pus/cauda segments, as reported previously (10). This phe-
notype ofmissing segments was not noted at E21.5 in fetuses































Fig. 2. AGD in males and females from control and flutamide-exposed litters at E21.5 and PND17. Note that AGD was significantly smaller
in control females than in males; AGD in males exposed to flutamide between E15.5 and E21.5 (FW; white bars) or between E15.5 and E17.5
(EW; striped bars) was reduced compared with control males and was comparable with female AGD. Exposure to LW-flutamide (E19.5-E21.5;
checkered bars) did not affect male AGD. ***, P < 0.001 compared with control male AGD. Values are means ± sem for 6-23 animals.
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Postnatal. Consistent with our findings in the fetus and with
previous reports (23, 26, 27), FW- or EW-flutamide exposure
resulted in abnormal morphology of the adult male reproduc¬
tive tract with underdeveloped or incomplete epididymides,
lack of a vas deferens, and underdeveloped or vestigial seminal
vesicles. At PND17 (early puberty), all males exposed to either
EW- or LW-flutamide treatment had complete epididymides
and vasa deferentia, but, by late puberty (PND42), 40% of males
exposed to EW-flutamide had incomplete reproductive tracts
with missing or incomplete epididymides and/or vas defer¬
entia (Table 2). By adulthood (PND70), 50% of males exposed
to EW-flutamide had incomplete epididymides and/or vasa
deferentia (Table 2); an additional 25% of such males had un-
Control FW EW LW
I I
flutamide
derdeveloped or abnormal epididymides/vasa deferentia
(data not shown). This phenotype was similar to that observed
in males exposed to FW-flutamide, in which 83% of males
examined in adulthood had incomplete WD-derived tissues
(Table 2). In contrast, males exposed to LW-flutamide all had
complete epididymides and vas deferens at PND42 and in
adulthood (Table 2).
AR expression
Androgens act through the AR; therefore, it was important
to establish whether flutamide exposure affected AR expres¬
sion. In control animals, AR expression was initially re-
TABLE 2. Percentage of rats with an intact WD (E21.5) or epididymis and vas deferens {i.e. WD-derived tissues, PND17, PND42, adult)
after exposure to flutamide (100 mg/kg) during specific time windows in fetal life
Fig. 3. Representative WDs at E21.5 from control and
flutamide-exposed fetuses. Note that coiling is evident in
the future epididymal segment ofthe controlWD (A) and
that exposure to flutamide between E15.5 and E21.5
(FW; B) reduced this coiling. Exposure to flutamide be¬
tween E15.5 and E17.5 (EW; C) reduced WD coiling to
a similar extent as did exposure to FW-flutamide (B). In
contrast, exposure to LW-flutamide (E19.5-E21.5; D)
did not obviously reduce WD coiling compared with age-
matched controls. * indicates efferent ducts. Scale bar,
1 mm. E shows quantification ofcoiling (luminal length)
of E21.5 WDs from control and flutamide-exposed lit¬
ters. Note the significant reduction in WD luminal
length in animals exposed in utero to FW-flutamide
{white bar) or EW-flutamide (striped bar) when com¬
pared with controls {black bar). Exposure to LW-flut-
amide {checkered bar) did not reduceWD luminal length.
Values are mean ± sem for 15-30 animals per group.
**, P < 0.01 compared with exposure to flutamide from





Control (%) FW-flutamide (%) EW-flutamide (%) LW-flutamide (%)
E21.5 100 (34 of 34) 89 (34 of 38) 100 (30 of 30) 100 (19 of 19)
PND17 (early puberty) 100 (32 of 32) 87 (7 of 8) 100 (3 of 3) 100 (5 of 5)
PND42 (late puberty) 100 (12 of 12) 37 (3 of 8) 60 (4 of 6) 100 (4 of 4)
Adult 100 (18 of 18) 17 (2 of 12) 50 (4 of 8) 100 (3 of 3)
Values are for at least three litters per treatment/age, and the number of animals is shown in parentheses.
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Fig. 4. Immunoexpression of AR in
the developing WD from control ani¬
mals at E15.5-E21.5. AR (immuno-
stained brown) was confined to the WD
stroma at E15.5 (A, B). AR was first
detected in a few epithelial cells at
E 17.5 (C, D) andwas strongly expressed
in the epithelium by E19.5 (E, F). AR
was intensely expressed in both the
stroma and the epithelium by E21.5 (G,
H). Scale bars, 50 pm.
stricted to the WD stroma at E15.5 (Fig. 4) and E16.5 (data not
shown), but, by El 7.5, a few epithelial cells were weakly
immunopositive for AR (Fig. 4). AR was expressed in many
epithelial cells by E19.5 and in the majority of epithelial cells
by E21.5 (Fig. 4). Exposure to either EW- or LW-flutamide did
not alter AR expression in either the stroma or the epithelium
at E21.5 or PND17 (data not shown). Additional analysis of
AR expression using Taqman quantitative RT-PCR con¬
firmed that there was no significant difference in AR mRNA
expression in flutamide-exposed WDs at E21.5 compared
with controls (data not shown). This is in agreement with
results reported previously, showing that FW-flutamide ex¬
posure did not alter AR expression in the fetal WD (10) or
postnatally (our unpublished data).
Frequency of cell mitoses in WDs
Cell proliferation was detected in all compartments of
WDs from both control and flutamide-exposed animals at
E21.5. Immunostaining for phospho-histone H3 detected
fewer proliferating cells in WDs from pups exposed to FW-
or EW-flutamide compared with age-matched controls, but
there was no apparent change in WDs exposed to LW-flu-
tamide (data not shown). This was confirmed quantitatively
(Fig. 5). Cell proliferation data were expressed as the overall
number of proliferating cells in the complete epididymal
portion of the WD rather than per 100 pm epithelium, so as
to take into account any treatment-induced changes in WD
length.
Reduction in epithelial cell height after flutamide exposure
Exposure to FW-flutamide resulted in epithelial abnor¬
malities in some areas of the WD in some animals at E21.5,
for example, shorter epithelium, missing cells, and widened
lumens, as reported previously (10). These abnormalities
were also evident in WDs from animals exposed to EW-
flutamide, but histological examination revealed no obvious
abnormalities in the epithelium ofWDs from fetuses exposed
to LW-flutamide compared with age-matched controls (Fig.
6). These differences in WD epithelial cell height at E21.5
were confirmed quantitatively (Fig. 6).
Vimentin expression
Vimentin protein expression was examined in control and
flutamide-exposed WDs because vimentin is an early mes¬
enchymal intermediate filament, the expression of which is
lost as cells undergo differentiation; aberrant expression of
vimentin can result in abnormal cell behavior (28, 29). Vi¬
mentin was immunolocalized to the WD stroma of both
control and flutamide-exposed fetuses at all ages examined
(Fig. 7). Vimentin was also detected at the basolateral edges
of epithelial cells in the WD at E17.5; this "spiking" was seen
along the full length of the WD at E15.5 (data not shown) and
E17.5 (Fig. 7A). In contrast, at E19.5 and E21.5, vimentin
expression was rarely seen in the epithelium of the caput
region in control WDs (Fig. 7, B and C), although it was still
evident in the epithelium of the caudal region at both E19.5
and E21.5 (data not shown). Exposure to flutamide did not
affect expression of vimentin in the stroma but affected its
distribution in the epithelium (Fig. 7). For example, vimentin
spiking was apparent in the epithelium at the caput region
as well as in the caudal region (Fig. 7) in WDs from E21.5
fetuses exposed to FW- or EW-flutamide; this spiking was
rarely seen at the caput region ofWDs from fetuses exposed
to LW-flutamide (Fig. 7) butwas still noted in the epithelium
wmmm
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Fig. 5. Total number of mitotic epithe¬
lial and stromal cells in the entire epi-
didymal segment of the WD at E21.5
from control and flutamide-exposed fe¬
tuses. Note the significant reduction in
the number ofmitotic cells in WDs from
animals exposed to either FW-flutamide
(white bars) or EW-flutamide (striped
bars) compared with controls (black
bars); this was apparent in all cellular
compartments. Note also that exposure
to LW-flutamide (checkered bars) did not
affect WD cell proliferation at E21.5
compared with age-matched controls;
these values were significantly higher
than those from EW-flutamide WDs.
*, P < 0.05 compared with respective
EW-flutamide value; ***, P < 0.001 com¬
pared with respective control value. Val¬
ues are means ± sem for 3-16 animals
per group.
of the caudal region, as in age-matched controls (data not
shown).
Evidence for flutarnide effects on inner stromal cells
Immunostaining for SMA, which is expressed in the inner
stromal compartment and believed to be androgen depen¬
dent (10, 30), revealed a reduction in the SMA-positive layer
in WDs from E21.5 fetuses that had been exposed to FW- or
EW-flutamide compared with age-matched controls (Fig. 8).
No obvious change was noted in this SMA-positive layer in
WDs from males exposed to LW-flutamide (Fig. 8D). The
SMA-positive stromal compartment varied considerably in
breadth between sections of WDs, so the reduction in SMA
protein expression in WDs recovered from fetuses exposed
to FW- or EW-flutamide was confirmed quantitatively by
Western blot analysis (Fig. 8E). This confirmed that SMA
protein levels inWDs from EW- and FW- treatments, but not
those from LW-flutamide fetuses, were significantly differ¬
ent from that in age-matched controls (Fig. 8E).
Discussion
It is widely accepted that androgens play a critical role in
WD development. A recent study published by our group
confirmed the role for androgens in male fetal reproductive
development and highlighted WD development as a bipha-
sic process, with fetal exposure to flutamide (100 mg/kg)
inhibiting development, elongation, and differentiation of
the WD but not its earlier stabilization (10). Abnormalities in
WD-derived structures persisted and worsened by adult¬
hood, confirming that the patterning of the reproductive tract
is established in the fetus and that interfering with androgen
action during this critical period permanently impairs re¬
productive tissues. It has been assumed that androgen-
driven gene activity is essential during the period of bothWD
stabilization and morphological differentiation, but the pre¬
cise time window within which androgens act in males to
mediateWD stabilization and/or differentiation remains un¬
clear. In the present study, we used an in utero model system
inwhich fetal rats were exposed to flutamide on eitherE15.5-
E17.5 (EW), to interfere with androgen action during the
"stabilization window" when the WD is degenerating in the
female, or E19.5-E21.5 (LW), during the "differentiation win¬
dow" when WD morphologically differentiates into the ep¬
ididymis in the male. The impact of these treatments onWD
morphology and functional differentiation in fetal (E21.5)
and postnatal (PND17, PND42, and PND70) life was also
investigated.
The main findings of these studies are, first, that androgen
action during the early time window (E15.5-E17.5), which is
several days before any sign of WD morphological differ¬
entiation, is sufficient to promote later WD segmentation and
development (coiling/functional differentiation). Second,
exposure to EW-flutamide was able to induce similar gross
and histological abnormalities in the fetal and adult WD as
those observed after exposure to FW-flutamide. Because the
AR is expressed in the WD stroma but not in the epithelium
during this "early" window, this suggests that AR-depen-
dent androgen action must signal via the stroma to pattern
laterWD development and differentiation. Finally, exposure
to flutamide during the "late" window (E19.5-E21.5), the
period in which WD morphological differentiation actually
occurs, did not result in any obvious gross or histologicalWD
abnormalities at this or later times, thus suggesting that the
pattern ofWD segmentation is already established by E19.5
and that its morphological differentiation is no longer de¬
pendent on high levels of androgen action. The critical win¬
dow for high levels of androgen action in establishing the
pattern of WD development in rats is therefore between
E15.5 and E17.5.
Because exposure to FW-flutamide did not prevent stabi¬
lization of the maleWDbut impaired WD differentiation (i.e.
coiling) between E19.5 and E21.5 (10), we anticipated that
reducing androgen action duringWD morphological differ¬
entiation would allow WD "rescue" but would prevent sub¬
sequent WD differentiation, whereas exposure to EW-flut¬
amide would not have any major impact on WD coiling or
functional differentiation. Contrary to these expectations,
reduced androgen action early in male reproductive tract
development (E15.5-E17.5) resulted in a similar phenotype
to that documented after exposure to FW-flutamide, with
males having a vaginal pouch instead of a normal prostate,
impaired WD development, and an AGD the same as that in
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normal females. This phenotype was not observed in male
fetuses exposed to LW-flutamide. These results suggest that
prostate formation, WD patterning, and masculinization of
AGD is established between E15.5 and E17.5, several days
before any sign of morphological differentiation of any of
these tissues, and that high levels of androgen action later in
fetal development are not essential for maintaining this male
phenotype. These findings support and extend those of a
recent study in which pregnant rats were exposed to a single
dose of flutamide (50 mg/kg) between E16 and E19, and the
impact on male phenotype of adult rats was examined. The
results revealed that exposure to flutamide on E16 or E17
resulted in missing epididymides in adults, whereas expo¬
sure on E18 or E19 only resulted in smaller epididymides
(23). These authors highlighted that the peak incidence of
abnormal prostate developmentwas noted in adults exposed
to flutamide on E17 or E18, similar to our observations in
males exposed to flutamide between E15.5 and E17.5 (23).
Furthermore, they noted that exposure to a single dose of
flutamide on any one day between E16 and E19 resulted in
a similar range of reproductive abnormalities as did expo¬
sure to flutamide throughout the period of reproductive
development (E12-E21), although the incidence was lower
(23). We also noted a reduced incidence of reproductive
abnormalities after exposure to EW-flutamide compared
with that observed in animals exposed to FW-flutamide in
animals examined at a range of different ages.
It was surprising that high levels of androgen action did
not appear to be essential during the window of morpho¬
logical differentiation of the WD (E19.5-E21.5). Instead, it
appears that, once the pattern ofWD segmentation has been
established by earlier androgen exposure, the WD continues
to develop normally, even if androgen action is reduced
during the period of morphological differentiation. It is
worth noting that, as reported previously (10), exposure to
this level of flutamide may not completely block androgen
action; therefore,we cannot completely rule out a role for low
levels of androgens during this LW of WD development
(E19.5-E21.5). Flutamide was used to interfere with andro¬
gen action because it has been shown to be a strong com¬
petitive AR antagonist and exposure during fetal develop¬
ment interrupts male reproductive development (17, 26, 27,
31, 32). Flutamide is believed to be cleared from the body
relatively quickly and has a plasma half-life of 5-6 h in man
(33), suggesting that fetuses are not exposed to flutamide for
more than 24 h after the final gavage. Studies in the mouse
have shown that exposure to flutamide on E19 and E20 did
not result in any obvious reproductive abnormalities or in¬
fertility in adulthood, whereas exposure on E11-E15 or E15-
E20 resulted in smaller epididymides and infertility or lack
of a prostate, respectively (22). These studies again confirm
the long-term deleterious effects of EW short-term androgen
blockade. It remains unclear what role, if any, androgens
play late in fetal male reproductive development, and ad¬
ditional investigation of more endpoints would be required
in males from litters exposed to flutamide between E19.5 and
E21.5.
In the present study and as reported previously (10), ex¬
posure to flutamide during the FW of male reproductive
development (E15.5-E21.5) resulted in incomplete WDs in
11% of males at E21.5, 50% of males at PND17, and 83% of
adult males. This is in agreement with previous studies
Fig. 6. Representative gross abnor¬
malities seen in the epithelium ofWDs
(immunostained brown for cytokeratin)
from control (A) and flutamide-exposed
(B-D) fetuses at E21.5. Note the appar¬
ent reduction in epithelial cell height
(arrow) in WDs from males exposed to
FW-flutamide (B) or EW-flutamide (C)
compared with age-matched controls (A).
This was not obvious in WDs from males
exposed to LW-flutamide (D). Scale bars,
100 /xm. E shows quantification of epi¬
thelial cell height in WDs at E21.5 from
males exposed to FW-flutamide (white
bar) or EW-flutamide (striped bar) or
LW-flutamide (checkered bar) compared
with age-matched controls (black bar).
Values are means ± sem for 3-19 WDs
per age/treatment, each from different
litters. *, P < 0.05 and ***, P < 0.001
compared with E21.5 controls.
Control FW EW LW
I
flutamide
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Fig. 7. Coexpression of vimentin
(green) and cytokeratin (red) protein in
the caput region of WDs from control
and flutamide-exposed animals. Note
that vimentin was expressed in the
stroma at E17.5 (A), E19.5 (B), and
E21.5 (C-F) and did not vary with flu-
tamide treatment (D, FW-flutamide; E,
EW-flutamide; F, LW-fhitamide) Vi¬
mentin was also detected at the baso-
lateral edges of the WD epithelium (ar¬
row) at E17.5 (A) but was absent by
E19.5 (B) and E21.5 (C) in control ani¬
mals. However, vimentin spiking in the
epithelium was still apparent in the ca¬
put region of the WD at E21.5 in fetuses
exposed to FW-flutamide (D) or EW-flu¬
tamide (E) but was not evident in WDs
exposed to LW-flutamide (F).
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showing that exposure to antiandrogenic compounds in utero
results in a high frequency of epididymal malformations
when studied in adulthood (17, 23, 26, 27, 34). Exposure to
LW-flutamide did not result in incomplete WDs at any time
point studied. In contrast, EW-flutamide did not show evi¬
dence of loss of WD during fetal life, but 40% of pubertal
males (PND42) and 50% of adults had incomplete epididy¬
mides and /or vasa deferentia. This has provided compelling
evidence that androgen action early in WD development
(E15.5-E17.5) is essential to establish the pattern of WD de¬
velopment and that interfering with this has long-term con¬
sequences for the adult male reproductive tract. However, it
remains to be shown why completion of puberty should
result in delayed degeneration or loss of WD-derived tissues
in animals exposed to EW- or FW-flutamide.
To confirm that the disturbances inWD development seen
in animals exposed to flutamide during the early treatment
window involved similar mechanisms to those seen in ani¬
mals exposed to flutamide throughout reproductive devel¬
opment (10), various endpointswere examined (summarized
in Table 3). As we reported previously (10), exposure to
flutamide between E15.5 and E21.5 did not alter expression
of the AR in the stroma or epithelium of the WD at any age
during fetal life or postnatally (our unpublished data). Sim¬
ilarly, in the present study, exposure to flutamide during
either defined window (early or late) did not interrupt AR
expression in the fetus or at PND17, confirming that these
WDs are still capable of responding to androgens; because
AR is expressed in the postnatal (PND17, PND42, and
PND70) WD derivatives from animals exposed to flutamide
between E15.5 and E21.5 (our unpublished data), it is un¬
likely that exposure to flutamide during the EW or LW
would alter AR expression. This is in contrast to findings by
Bentvelsen et al. (31), who were unable to detect AR protein
by immunohistochemistry in WDs from E21.5 fetuses ex¬
posed to 100 mg/kg flutamide. This difference may be at¬
tributable to differences in rat strain or to the use of different
anti-AR antibodies and immunohistochemistry techniques.
Exposure to FW-flutamide resulted in reduced epithelial cell
height and abnormal epithelial development in the WD by
E21.5 (10). The same epithelial disturbance was not found in
WDs from males exposed to LW-flutamide but was seen in
WDs from males exposed to EW-flutamide. These effects on
the epithelium were not evident until E21.5, suggesting that,
although the epithelium initially forms normally, flutamide
exposure results in subsequent abnormalities during differ¬
entiation, possibly attributable to impaired androgen-driven
signaling between the stroma and epithelium. As well as the
impact of flutamide exposure on epithelial differentiation,
we reported previously that exposure to flutamide between
E15.5 and E21.5 impaired WD stromal cell differentiation, as
evidenced by a reduction in SMA protein expression at
E19.5-E21.5 (10). In the present studies, a similar reduction
was noted inWDs from fetuses exposed to flutamide during
the EW but not the LW of WD development, highlighting the
a role for androgens between E15.5 and E17.5 in regulating
stromal cell differentiation as well as epithelial cell
differentiation.
Vimentin, an early mesenchymal intermediate filament,
was expressed in the WD stroma at all ages studied (E15.5-
E21.5), and its expression in the stroma was not obviously
affected by flutamide exposure. This stromal vimentin is
likely to be providing mechanical support to the developing
WD and may also mediate signaling through interactions
with and organization of the cytoskeleton (35). Vimentin was
also expressed on the basolateral boundary of the epithelial
cells in some regions of the developingWD. It is thought that
vimentin expression often precedes expression of other in¬
termediate filaments during differentiation, for example
desmin. Vimentin is initially expressed in the epithelium
along the full length of the WD at E15.5 but becomes pro¬
gressively more restricted such that, by E21.5, it is confined
to the caudal region in control WDs. This may mean that
vimentin expression in the epithelium is replaced by another
intermediate filament in a craniocaudal direction as devel¬
opment proceeds. At E21.5, epithelial spiking of vimentin
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Fig, 8. Comparative expression of
SMA at E21.5 in WDs from controls (A)
and animals exposed to FW-flutamide
(B), EW-flutamide (C), or LW-flutamide
(D). Note the apparent reduction in
SMA immunoexpression (brown) in
WDs from fetuses exposed to FW- or
EW-flutamide but not in WDs from fe¬
tuses exposed to LW-flutamide. E
shows quantitative data from Western
blot analysis comparing expression of
SMA protein at E21.5 in WDs from con¬
trol (C) and flutamide-exposed animals.
Note the reduced levels of SMA protein
in WDs from fetuses exposed to FW-
flutamide (white bar) or EW-flutamide
(striped bar), although no obvious dif¬
ference can be seen in SMA protein ex¬
pression inWDs from fetuses exposed to
LW-flutamide (checkered bar) com¬
pared with age-matched controls (black
bar), n = 3-5 WDs per age/treatment,
from at least three different litters.





was detected along the full length of the epididymal segment
ofWDs from fetuses exposed to FW- or EW-flutamide rather
than just in the cauda. This pattern is in contrast toWDs from
fetuses exposed to LW-flutamide, which were similar to con¬
trols. The alteration in epithelial vimentin expression could
be attributable to failure of the epithelial cells to differentiate
and thus to switch off epithelial vimentin expression and
may mean that these epithelial cells retain some mesenchy-
mal-like properties. This might explain the reduced epithelial
cell height and loss of attachment to the basement membrane
seen in flutamide-exposedWDs. Vimentin is required for cell
motility, and increased vimentin expression is seen in pros¬
tate cancer cells as they become more invasive (28). It could
therefore be hypothesized that these vimentin-positive WD
epithelial cells may be gaining motility but there is no de¬
finitive evidence for this, and additional investigation of
earlier and later time points might provide some insight.
Studies in the equine endometrium have shown that, in cases
of endometriosis, cytokeratin and vimentin become coex-
pressed in the epithelium, and it has been suggested that this
could be attributable to increased proliferation and a loss of
cell to cell contact (36). Other researchers have also shown
that altered hormone action could induce epithelial vimentin
expression (37).
It is concluded that the pattern of WD coiling and its
subsequent ability to develop fully during postnatal life is
established by androgen action early in fetal reproductive
development (E15.5-E17.5) and that, by E19.5, androgen-
dependent WD patterning is already established and is no
longer dependent on high levels of androgen action. Re¬
duced androgen action during this early time window in¬
hibited coiling at E21.5 to the same extent as did exposure
from E15.5 to E21.5 and resulted in a similar high incidence
of epididymal loss/abnormalities in late puberty and adult¬
hood. Exposure later in fetal life (E19.5-E21.5), the period in
whichWDmorphological differentiation actually occurs, did
not impact on WD coiling at E21.5 or on subsequent ep¬
ididymal development postnatally. The critical window
for high levels of androgen action in establishing the pat¬
tern of WD development is therefore between E15.5 and
El 7.5 in the rat.
TABLE 3. Summary of endpoints affected by exposure to flutamide during specific time windows in fetal life compared with controls at
E21.5
Treatment
Endpoint FW-flutamide EW-flutamide LW-flutamide
AGD 1 1
WD coiling 1 <->
AR expression
Cell proliferation 1
Epithelial cell height 1 I
SMA expression 1 i
Vimentin caput epithelial expression T t
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